Total Synthesis of Aspidosperma Family Indole Alkaloids through the iORC Domino Process by Wagnières, Olivier
POUR L'OBTENTION DU GRADE DE DOCTEUR ÈS SCIENCES
acceptée sur proposition du jury:
Prof. N. Cramer, président du jury
Prof. J. Zhu, directeur de thèse
Dr T. Gaich, rapporteuse 
Prof. H.-U. Reissig, rapporteur 
Prof. J. Waser, rapporteur 
Total Synthesis of Aspidosperma Family Indole Alkaloids 
through the iORC Domino Process
THÈSE NO 6607 (2015)
ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
PRÉSENTÉE LE 3 JUILLET 2015
À LA FACULTÉ DES SCIENCES DE BASE
LABORATOIRE DE SYNTHÈSE ET PRODUITS NATURELS
PROGRAMME DOCTORAL EN CHIMIE ET GÉNIE CHIMIQUE 
Suisse
2015
PAR
Olivier WAGNIÈRES

Il faut toujours connaître les limites du possible.
Pas pour s’arrêter, mais pour tenter l’impossible
dans les meilleurs conditions
— Roman Gary

Acknowledgements
I feel the need to write this section in a comprehensive more than succinct way, as it is the
best opportunity for me to express my gratitude, in writing, to all the people who supported
me and helped me duringmy graduate career.
First of all, I would like to thank my PhD supervisor Jieping for accepting me to his
group and having the confidence in me to be a good chemist. It was a fascinating experience
to work on these challenging projects with his support and supervision. I am also inspired
and impressed by Jieping, by his enthusiasm for chemistry, his spirit to challenge some of the
hardest problems, his sharing of great ideas, and his hard-working attitude. I wish I would be
an excellent chemist as him in the future. I appreciate his patience with me, his advices and
his constant support for me.
Next, I want to express my gratitude to Professor Reissig, Professor Gaich, Professor
Cramer and Professor Waser for taking time to review my PhD work and for serving on my
graduate committee.
I would also like to thank Qian for her valuable guidance of my work, her kindness
to help me under any circumstances and her rigor in the attention to detail. Her positive
attitude and professional dedication set up amodel for us to follow.
I certainly could not accomplish my PhDwork without the assistance of my wonderful
colleagues. First goes to JB, with whom I started my academic studies ten years ago in EPFL.
He is a generous friend and great companion with a dark humor but shining personality. We
have gone though so many great moments together, from our Bachelor, while playing video
games, to our PhD defence, with all the great lunches and coffee breaks and the mutual sup-
port during the tough days where nothing was working. I will always keep with me part of
his wisdom, as his famous quote "Si tu penses que la violence ne résout rien, c’est que tu n’as
pas frappé assez fort". I am also grateful for his patience and help in proofreading my papers
and correcting my English. And now I am lucky enough to have him as my best man on my
most important day.
I have to thank Thomas, who has been an amazing colleague to me. I enjoyed dis-
cussing with him about chemistry as well as life, his silly jokes and optimistic vision could
v
Acknowledgements
light up my days.
I want to expressmy appreciation to Solène, from the neighbouring lab, for her support
though my entire PhD work. I have known her since our master studies in EPFL and always
admire her positive outlook and her ability to smile despite the situation. She is always a
great friend tome and I think fondly of time having lunch with her, discussing and gossiping,
or having a drink in the Great Escape.
I am always thankful to my former colleague but forever mate Nick, for his unique
humor and his wisdom. We not only go out together for the music festival and brunches, but
also have insightful discussions about chemistry and support each other though the darkest
times. He also contributes significantly to my PhD thesis as proofreader and later on to my
wedding as my best man.
The following person I would express my appreciation is Claire, who brought fresh air
to the lab even though she only stayedwith us for ninemonths. She is so friendly and cheerful,
and could always light up our days by her particular “GoodMorning” greetings alongwith her
smile. Besides, she is amongst fewpeoplewho truly understandmy silly jokes and always give
me a great laughter instead of a pity look. I believe short times are gone, but more fun times
will come.
Next, I would like to thankDylan andAntonin, who are talented chemists and very cool
guys. I had as much fun in the lab with them as in the bars drinking and dancing. They have
been so supportive to me and share their insights about chemistry and life with me.
I am also grateful to Viktoria, a smart and interesting girl with who I always love to talk.
She has her special philosophy of life and she taught me not to let the stress take the best of
me. We shared great laugh in the lab during the past four years, and hopefully in the future
too.
I would like to dedicate a special thanks to Zhengren and Shuo, the two excellent post-
docs who had fundamental influence on me. Zhengren who is currently doing another post-
doc in the United States inspired me with his efficiency, professional, enthusiastic, and his
dedication to chemistry work. He is my primary resource to solve scientific confusions and
was helpingme thoughmy PhD time. Besides, ZhengrenwasmyChinese teacher who always
kindly correctsmyChinese. Shuowhoworked next tomemotivatedmewith her support, her
kindness and sweetness. She had always been there forme when I had questions and tried to
help me out.
Certainly, I owemy thanks to allmy remarkable co-workers. It is a great pleasure forme
to work with Cyril, Tu and Nico, who I valued all the lovely discussions and enjoyed sharing
vi
Acknowledgements
great afternoon coffee time; Weiwu and Yang, who I appreciate their help and nice discus-
sions; Xu, who is always been friendly to me; and Bo, who shared his good ideas with us.
There are more colleagues in my PhD time I would like to thank to, who are not only
great helpers for my PhD work but also lovely friends in my life: Ioulia, for her constant sup-
port, her insightful advice, and the greatest tricks of all as the “emergency chocolate”; Giulia,
for her smile and her encouragement tomywork; Stephan, for his “keep calm, work hard and
party harder” spirit which inspired me to enjoy life; Hugo, for his classic humor that always
brought me smiles; Yann, for his generous sharing of his own experience; Martina, for her
kindness and friendliness; and Ala, for the unique spirit she passed on us which brought a
brand new perspective in our lives. And lastly, a special thanks to all the young promising
chemists in our lab who I had the pleasure to work with: Marion, Mathias, Samuel, Raphael,
Sjaak, David, Balázs and Johan.
Particularly, I would like to express my gratitude to Monique, our secretary, for her
kindness and patience, as well as all the administration work she did for us.
In the past four years, I was honoured to meet and work with some brilliant scientists
who inspired and motivated me all the time. Sandrine, my Mentor, who was a role model as
a researcher and teacher; Davide, who I admire his fashion style as well as his time manage-
ment skills and multitasking capability; Francoise, who I cherish her laughter and her free
spirit; Slavo, who I adore his working attitude; Francois, who I like his living style; and Pascal,
who always surprises me with his wide knowledge. There are also so many other awesome
scientists from the LCSA and LCSO, withwhom I have the luck to share greatmoments during
Barbecues and Aperos and got to know them.
My PhD work could certainly not have gone well without the assistance of the techni-
cal teams of ISIC. I would thank the NMR service (Anto, Pascal and Martial), for their effort
to maintain the machines; the Mass Service (Laure, Daniel and Francisco), for their fast, effi-
cient and accurate analysis of our samples; Luc, for his hardwork in developing all the fantas-
tic informatics tools to help us; the Magasin (Giovanni, Annelise, Gladys, and Benjamin), for
their efficiency in providing us requested new chemicals and equipments; the Mechanical
workshop, for designing personalized spare parts for our machines; and finally Patrick, for
his patience in solving our various hardware problems.
Besides mywork, family and friends are the best part ofmy life. I could not successfully
finish my PhD work without their continuous support. I would express my greatest appreci-
ation to my beloved family: my parents, Philippe and Dominique, who taught me to be a
gentleman and always support my decisions; my dear brother Raphaël, who is the coolest
and best brother everyone wishes to have. Also, I would like to thank my life-long friends
who grew up with me and mean so much to me, especially Simon, Marc, Laurence, Laura,
vii
Acknowledgements
Valentine and Amaniel, for always cheering me up and giving me a hand when I needed the
most. I cherish the love and friendship you constantly give to me.
The best outcome in the past four years is not only finish my PhD, but more impor-
tantly find my lifelong soul mate Huiwen. She has been a true and great supporter since we
are together and always has faith in me. She cheered me up in the depressing time, worked
along with me in the lab until 3am, and shared life responsibilities with me in tough period
and happy days. I am the luckiest man to have her onmy side andwill love her from now and
forever.
Lausanne, June 8, 2015 O.W.
viii
Abstract
This thesis describes a unified strategy for the synthesis of monoterpene indole alkaloids
of the Aspidosperma family. These syntheses feature two key steps: (1) a palladium-
catalyzed decarboxylative vinylation that provides quick access to cyclopentene interme-
diates containing all of the carbons present in the natural products and (2) an integrated
oxidation/reduction/cyclization (iORC) sequence for skeletal reorganisation that converts
the cyclopentenes to the corresponding pentacyclic structures of the natural products. By
incorporation of a geometric constraint to the iORC substrates, both the chemoselectivity
(C7 versus N1 cyclization) and the stereoselectivity (trans- versus cis-fused ring system) of
the cyclization process can be controlled. Using this method, we achieved the total syn-
thesis of racemic aspidospermidine and dehydroaspidospermidine in seven steps; both of
which feature a cis-fused ring system. We then accomplished a ten-steps synthesis of kop-
sihainanine A featuring a trans-fused ring system. The work towards the total synthesis of
aspidoalbidine and kopsinitarine E using the same two key steps was attempted, but was not
completed in the time provided. This PhD will also cover our synthetic efforts towards the
alkaloid minfiensine, featuring a domino reduction/cyclization sequence performedprior to
the development of the iORC process.
Keywords: natural product, indole alkaloids, domino reaction, iORC, total synthesis, min-
fiensine, aspidospermidine, dehydroaspidospermidine, vincadifformine, aspidoalbidine,
kopsihainanine A, kopsinitarine E.
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Résumé
Cette thèse décrit une stratégie unifiée pour la synthèse d’alcaloïdes indoliques monoterpe-
niques de la famille des Aspidosperma. Ces synthèses présentent deux étapes clés : (1) une
vinylation décarboxylante catalysée au palladium, qui fournit un accès rapide aux intermé-
diaires cyclopentèniques contenant tous les carbones présents dans les produits naturels ci-
blés et (2) une séquence domino d’oxidation/réduction/cyclisation intégrée (ORCi) permet-
tant une réorganisation du squelette des cyclopentènes en leurs structures pentacycliques
équivalentes. Par incorporation d’une contrainte géométrique aux substrats de l’ORCi, tant
la chimiosélectivité (cyclisation en C7 ou N1) que la stéréosélectivité (systèmes cycliques fu-
sionnés en trans ou en cis) du procédé de cyclisation peuvent être contrôlées. En utilisant
cette méthode, nous avons achevé la synthèse totale racémique de l’aspidospermidine et
de la déhydroaspidospermidine en sept étapes ; les deux présentant un système cyclique fu-
sionné en cis. Nous avons ensuite accompli la synthèse totale racémique de la kopsihaina-
nine A en dix étapes et présentant un système cyclique fusionné en trans. Le travail vers la
synthèse totale de l’aspidoalbidine et la kopsinitarine E utilisant ces deux étapes clés ont été
tentées,mais ne furent pas complétées dans le temps imparti. Ce doctorat couvre aussi nos ef-
forts de synthèse de la minfiensine, utilisant une séquence domino de réduction/cyclisation
antérieure au développement du procédé ORCi.
Mots-Clés : produit naturel, alkaloïde indolique, réaction domino, ORCi, synthèse totale,
minfiensine, aspidospermidine, dehydroaspidospermidine, vincadifformine, aspidoalbidine,
kopsihainanine A, kopsinitarine E.
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General Introduction
The Aspidosperma family is one of the largest family of monoterpene indole alkaloids com-
prising over 250 members. This group of alkaloids can be foundmostly in plants of the Apoc-
ynaceae family, essentially present in tropical forest. These monoterpene indole alkaloids
fascinate the scientific community due to their congested polycyclic structures, high substi-
tution patterns, andmultiple stereocenters. These challenging features inspired chemists for
decades, and pushed them to develop new methodologies toward the synthesis of complex
heterocycles. One of the main research areas of our group is the development of domino
reactions, and their use in the construction of substituted indoles. So far many palladium-
catalysed syntheses as well as multicomponent reactions for the formation of substituted
indoles were developed by our group. In a continuation of this work, we are always looking
for newways to build in a late-stage the indole polycyclic core of indole alkaloids via domino
processes.
This thesis focuses on the use of a domino reaction called an integrated
oxidation/reduction/cyclization (iORC) process to reach various members of the aspi-
dosperma family of monoterpene indole alkaloids, specifically the natural products 1-7.
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Our idea was to start from stable and easily accessible 1-(2-nitrobenzyl)-cyclopentene
derivative 8. After an oxidative cleavage of the double bond and reduction of the nitro group,
we should obtain putative diaminodicarbonyl intermediate 9 that should spontaneously cy-
clize into iminium indole intermediate 10.
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We can notice that 10 has two nucleophilic positions: the N1 and C7 position. It is well
known that the C7 position is more nucleophilic than the N1. Nevertheless, if C7 is already
substituted with a bulky R1 group, the attack should occur from the nucleophilic nitrogen
N1 and give tetracyclic aminal 11 bearing a cis-fused [6,6] ring system. This example, a total
synthesis of (±)-Goniomitine has been done previously in our lab, and will be detailed in
1.3.1.
To force the attack from the C7 position, we envisaged two solutions. i) A structural
constrain, such as a tether between R1 and R2 would help force the regioselectivity and give
the cis-fused [6,6] ring system 12. ii) By removing all sterical hindrance in R1, the regiose-
lectivity for the C7 attack could be high, allowing us to reach tetracyclic structure 13. In this
example, we would like to address in more details the diastereocontrol of the iORC, as we
plan to force the cyclization in a trans-fused [6,6] ring system.
It is important to note that stereogenic centre C7 temporarily becomes sp2 hybridized
during the iORC and therefore, loses all stereochemical information. Therefore, the C20 qua-
ternary centre will control the diastereoselectivity of the cyclization.
This thesis will start with a brief summary and state of the art of the topics related to
this work, namely indole alkaloids, the use of domino process in their total synthesis, and
an introduction to the iORC, along with the other syntheses done using this domino process
(Chapter 1).
2
Afterward, this thesiswill cover thework done toward the total synthesis ofminfiensine
1, which used an early version of the iORC, lacking the oxidation step (Chapter 2).
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The next two chapters cover the synthesis of aspidospermidine 3, dehydroaspidosper-
midine 2 and vincadifformine 4 (Chapter 3), and our approach toward the synthesis of aspi-
doalbidine 5 (Chapter 4) by using the iORC and taking advantage of structure-induced strain
to promote the C7-C21 bond formation as key step.
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The next chapter investigates more into detail the regio- and stereoselectivity of the
unrestrained iORC, and of their use in the total synthesis of kopsihainanine A 6 (Chapter 5).
N
H
N
H
O
HO
(±)-Kopsihainanine A
NO2
Domino
Oxidation/
Reduction/
Cyclization
(iORC)
N
H
N
H
O
NH
O
6
The last chapter covers our approach toward the synthesis of kopsinitarine E 7 using
the iORC on a much more complex substrate (Chapter 6).
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CHAPTER1
Background
The chemistry of natural products has captivated the scientific community for hundreds
of years. Since the first reported isolation of an alkaloid (morphine) in 1805 by Sertürner,1
chemists have fought many intellectual battles trying to reproduce the wonders of Nature in
their flasks. Nature provides us with unlimited numbers of organic compounds, with a large
spectrum of molecular masses, of complexity, of heteroatoms, and of many more features,
each of them being an intellectual challenge. It is a fascinating field, that contains many so-
phisticated aspects. The starting point of all this is of course the isolation of the products
from various biological media, such as bark of trees, algae, bacteria, or evenmammals.
Every compound produced by a biological entity has a specific purpose. The direct
consequence of this is the numerous biological effects caused bymany of these natural prod-
ucts. These biological properties will often be a strong driving force for the synthetic study of
a given natural product. Themost potent compounds are often present in negligible quantity
inside the biological entity. Therefore the study of such compounds is near impossible due to
the tremendous amount of biomass which would be needed to extract a sufficient amount of
said compound. This is without mentioning the difficulty to gain access to such a quantity of
biomass. A relevant examplewould be the polyketide (+)-discodermolide, whichwas isolated
in 1990 by Gunasekera and co-workers.2 This natural product was isolated from the deep-sea
sponge Discodermia dissoluta, who grows only at more than 33m deep in the Caribbean sea.
In addition to the difficult access to the biomass, the quantity of (+)-discodermolide present
within is small. Only 7mg of compound per 434g of sponge was found. It is therefore easy
to imagine why the synthesis of such compounds is so attractive, allowing scientists to have
easier access to the product in sufficient amounts. It will also give the chemists the ability to
make derivatives of a given product, in the optic of increasing some of its biological effects,
such as anti cancer or antimicrobial properties.
1Sertürner, F. J. Pharm. Aerzte. Apoth. Chem. 1805, 13, 229–243
2Gunasekera, S. P.; Gunasekera, M.; Longley, R. E. J. Org. Chem. 1990, 55, 4912–4915
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The total syntheses which constitute the body of this work are monoterpene indole al-
kaloids. Therefore, the first section of this chapter will gomore into detail on indole alkaloids
and their biosynthesis. As our synthetic strategy revolve around a domino reaction for the
late-stage formation of the indole core of these natural products, we will give some exam-
ples of the synthesis of indole alkaloids which involved a key domino sequence. We will then
introduce our iORC per se as well as the other work done with this method.
1.1 Monoterpene Indole Alkaloids
Alkaloids are natural products that can be extracted from the alkaline aqueous phase result-
ing from treatment of the corresponding biomass, as most of the time they present a basic
nitrogen atom. They are produced by a large variety of biological entities and are classified
by their skeleton structure. Amongst these alkaloids, we will focus on the products contain-
ing an indole moiety.3 A large number of them were discovered by extracting plants or fungi,
which were known to have some beneficial effect in traditional medicine. For example the
plants of the Strychnos genus are a major source of numerous alkaloids, these plants have
been used in traditional and conventional medicine for ages. A famous example is the poi-
son strychnine, extracted from the specie Strychnos nux vomica, it has been used since the
ancient Chinese era. The beneficial effects of plant extracts from the Strychnos genus were
also exploited in different traditional medicines. Naturally, the biological properties of these
plants attracted the attention of chemists which led to the isolation of strychnine by Pelletier
and Caventou in 1819.4 This was the first monoterpene indole alkaloid isolated. Since then,
more than 2000 monoterpene indole alkaloids were discovered. Due to their potent biologi-
cal activities,5 and their challenging polycyclic structure, numerous laboratories have spent
years extracting, identifying or synthesizing these alkaloids.
As a result of this strong interest from the scientific community, a large number of re-
views and books on indole alkaloids already exist.6 Therefore, instead of making a full ac-
3For a review on indole alkaloids, see for example Grundon,M. F.; Saxton, J. E. In The Alkaloids, Grundon,M. F.,
Ed.; The Alkaloids, Vol. 6; Royal Society of Chemistry: Cambridge, 1976; Chapter 10, pp 189–251
4Pelletier, P. J.; Caventou, J. B. Ann. Chim. Phys. 1819, 10, 142–177
5For relevant examples, see a) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H.
Molecules 2013, 18, 6620–6662; b) Kutchan, T. M. In Alkaloids Chem. Biol. 1998; Vol. 50; Chapter 7, pp 257–316; c)
Frederich,M.; Hayette, M.-P.; Tits, M.; DeMol, P.; Angenot, L. Antimicrob. Agents Chemother. 1999, 43,
2328–2331; d) Leclercq, J.; De Pauw-Gillet, M.-C.; Bassleer, R.; Angenot, L. J. Ethnopharmacol. 1986, 15, 305–316;
e) Gong, Z.; Sun, L.-r.; Cao, X.; Li, S.-j.; Zhu, X.-h.; Gao, T.-m. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28, 2121–2125;
f) Baliga, M. S.; Jagetia, G. C.; Ulloor, J. N.; Baliga, M. P.; Venkatesh, P.; Reddy, R.; Rao, K. V. N. M.; Baliga, B. S.;
Devi, S.; Raju, S. K.; Veeresh, V.; Reddy, T. K.; Bairy, K. L. Toxicol. Lett. 2004, 151, 317–326
6For reviews onmonoterpene indole alkaloids, see: a) Saxton, J. E. The Alkaloids 1998, 51, 343–376; b) Higuchi, K.;
Kawasaki, T.Nat. Prod. Rep. 2007, 24, 843–868; c) Lopchuk, J. M. Prog. Heterocycl. Chem. 2011, 23, 1–25; d)
Hájícˇek, J. Collect. Czechoslov. Chem. Commun. 2012, 76, 2023–2083
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count on the topic of the synthesis of indole alkaloids, wewill only introduce the biosynthesis
of this class of natural products.
1.1.1 Biosynthesis ofmonoterpene Indole Alkaloids
The biosynthetic pathway of most monoterpene indole alkaloids are already established and
well studied.7 Secologanine 14 and tryptamine 15 are the core building blocks to most, if
not all, of the monoterpene indole alkaloids (Scheme 1.1). They are synthesised respectively
from 1-deoxy-D-glucose 5-phosphate 16 and tryptophan 17. After an enzymatic Pictet Spen-
gler reaction between these two products, strictosidine 18 is obtained. After removal of the
glucose, some rearrangements lead to 4,21-dehydrogeissoschizine 19. This ammonium salt
can lead to the Yohimbinoid Family, or be reduced into geissoschizine 20, which is a precur-
sor of the Ajmalicine family. The Cinchona alkaloids are also derived from strictosidine 18.
From strictosidine 18 and geissoschizine 20 is derived the uniform numbering system
of indole alkaloids proposed by Taylor and Le Men in 1965.8 We will use this numbering for
the attribution of the NMR spectra as soon as an intermediate bearing all the carbons of the
natural products is reached.
From geissoschizine 20 to aspidosperma alkaloids, the mechanism is less understood.
Many enzymes involed in the process haven’t been isolated or identified. Nevertheless, there
are a few theories and some isolated intermediates that allowed chemists to hypothesise a
mechanism (Scheme 1.2).7,9
After an oxidation, geissoschizine 20 could cyclise to intermediate 21, an akuammiline
precursor, that could rearrange into preakuammicine 22 (a precursor of akuammicine alka-
loids). Then, the iminium would be reduced to afford stemmadenine 23. From this alkaloid,
an isomerisation of the double bond, followed by opening of the macrocycle through enzy-
matic dehydroxylation would afford Iboga precursor 24. This intermediate could undergo
a Diels-Alder cycloaddition into tabersonine 25. A simple reduction into vincadifformine 4
gives an entrance into the vinca, aspidosperma, strychnos alkaloids and few other families.
7O’Connor, S. E.; Maresh, J. J.Nat. Prod. Rep. 2006, 23, 532–547
8Le Men, J.; Taylor, W. I. Experientia 1965, 21, 508–510
9; a) Scott, A. I.; Qureshi, A. A. J. Am. Chem. Soc. 1969, 91, 5874–5876; b) Wenkert, E.; Wickberg, B. J. Am. Chem.
Soc. 1965, 87, 1580–1589
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Scheme 1.1 – Biosynthetic pathway to geissoschizine from tryptamine and secologanine
1.2 The Domino Process in Total Synthesis of Indole Alkaloids
Using domino reactions10 has diverse advantages in organic synthesis mostly less work-up
and purification steps, meaning cheaper and faster reaction sequences. It is then not sur-
prising if a myriad of groups applied them in total synthesis. A tremendous number of to-
tal syntheses using domino reactions already exist (and it would take many books to cover
them).
Domino processes by themselves are not new. Many classical chemical reactions, like
Mannich reactions11 are by definitions domino processes. Therefore, it is easy to imagine
the tremendous amount of examples of domino reactions accessible in the literature. The
10Tietze, L. F. Chem. Rev. 1996, 96, 115–136
11Mannich, C.; Krösche, W. Arch. Pharm. (Weinheim). 1912, 250, 647–667
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Scheme 1.2 – Biosynthetic pathway to vincadifformine from geissoschizine
fascination of chemists for these processes lies in the elegance and almost artistic fashion to
perform chemical transformations. The simple reasoning to not just quench the resulting
intermediate into a given product A, but instead having it reacting with another substrate
toward a more complex product B is somewhat appealing. Lots of work were already done
in this field, and multiple reviews on the use of domino reaction in total synthesis already
exist.10,12 Wewill only present some selected total syntheses of indole alkaloids that are using
domino reactions as key steps.
12Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. Angew. Chem. Int. Ed. 2006, 45, 7134–7186
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1.2.1 Corynanthe Type Indole Alkaloid Synthesis by Tietze
In 1992, Tietze and co-worker reported a synthesis of the tetracyclic core of corynanthe al-
kaloids by the use of a domino Pictet-Spengler/intramolecular ene reaction (Scheme 1.3).13
Intermediate 26 submitted to acidic mediumwent through a Pictet-Spengler cyclization into
tricycle 27. This intermediate could be isolated in 66% yield. If SnCl4 was added to the reac-
tion mixture, an intramolecular ene reaction occurred to give racemic corynanthe core 28.
N
H
N
CO2MeMeO2C
N
H
N
CO2MeMeO2C
H
H
H
TFA
20 °C
N
H
N
CO2MeMeO2C
SnCl4
42%
26 27 28
Scheme 1.3 – Domino Pictet-Spengler/intramolecular ene reaction for the synthesis of corynanthe family
indole alkaloids
It is an interesting example of an ene reaction in a domino process. The ene reaction
hasmost of the time a high activation energy, whichmakes it more difficult to be included in
a domino process (often in the presence of other reagents or reactive intermediates).
1.2.2 Strictosidine Analogues Synthesis by Tietze
Between 1994 and 1997, Tieze published the syntheses of strictosidine type structure us-
ing a Domino Knoevenagel/hetero-Diels-Alder pathway (Scheme 1.4).14 After a Knoeve-
nagel condensation of aldehyde 29 with dimethylbarbituric acid 30 or Meldrum’s acid 31, a
hetero-Diels-Alder with as dienophile (E)-((but-1-en-1-yloxy)methyl)benzene produced the
two strictosidine analogues 32 and 33 respectively. These products were converted into cory-
nanthe alkaloid 34 or valesiachotamine alkaloid 35 by hydrogenolysis of the Cbz and Bz
groups.
These examples illustrate the principle of a divergent strategy, where from the same
starting material and different reagents, different alkaloids (here corynanthe alkaloid and
valesiachotamine alkaloid) can be reached.
13Tietze, L. F.; Wichmann, J. Angew. Chem. Int. Ed. 1992, 31, 1079–1080
14a) Tietze, L.-F.; Bachmann, J.; Schul, W. Angew. Chem. Int. Ed. 1988, 27, 971–973; b) Tietze, L. F.; Bachmann, J.;
Wichmann, J.; Burkhardt, O. Synthesis 1994, 26, 1185–1194; c) Tietze, L. F.; Bachmann, J.; Wichmann, J.; Zhou, Y.;
Raschke, T. Liebigs Ann. 1997, 881–886
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Scheme1.4 –DominoKnoevenagel/hetero-Diels-Alder reaction for the synthesis of strictosidine type indole
alkaloid
1.2.3 Corey’s Total Synthesis of (-)-Aspidophytine
In 1999, Corey and co-workers reported the use of a dominoMannich/allylation sequence to
reach aspidophytine 36 (Scheme 1.5).15 Starting from indole 37 and dialdehyde 38, an acid-
catalyzed condensation into iminium 39 took place. The indole moiety of this reactive in-
termediate cyclized on the iminium, forming indolenium salt 40. This intermediate cyclized
again into pentacycle 41. In situ isomerization of the enamine into an iminium, followed by
reduction with NaBH3CN afforded pentacycle 42 in 66% yield from the starting amine and
dialdehyde. This intermediate was converted to (-)-aspidophytine 36 in 6 steps. This synthe-
sis is an elegant example of using indole reactivity to perform multiple cyclizations in one
domino process.
1.2.4 Boger’s Total Synthesis of (-)-Vindorosine
Boger and co-workers reported in 2006 a total synthesis of (-)-vindorosine 43 via an inverse
electron demand Diels–Alder reaction (IEDDA)/(1,3)-dipolar cycloaddition domino process
(Scheme 1.6).16 From intermediate 44, an IEDDA between the electron-rich dienophile and
the 1,3,4-oxadiazole moiety afforded intermediate 45. Subsequent elimination of nitrogen
furnished dipolar intermediate 46 that underwent a (3+2) cycloaddition into ether-bridged
15He, F.; Bo, Y.; Altom, J. D.; Corey, E. J. J. Am. Chem. Soc. 1999, 121, 6771–6772
16Elliott, G. I.; Velcicky, J.; Ishikawa, H.; Li, Y.; Boger, D. L. Angew. Chem. Int. Ed. 2006, 45, 620–622
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Scheme 1.5 – Domino Cyclizations for a total synthesis of (-)-aspidophytine
product 47. Both enantiomers of 47were separated, and (-)-vindorosine 43was then reached
in 7 additional steps.
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Scheme 1.6 – Domino IEDDA/(1,3)-dipolar cycloaddition for a total synthesis of (-)-vindorosine
Diels-Alder and retro Diels-Alder reactions are often used in domino reactions, as they
often display good regio and diastereoselectivity and the resulting olefin can undergo subse-
quent transformations.
1.2.5 Qin’s Total Synthesis of (±)-Minfiensine
Qin and co-workers illustrated in 2008 the efficiency of a cyclopropanation/retro-
Mannich/cyclization domino sequence towards total synthesis of minfiensine
12
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(Scheme 1.7).17 Starting directly with indole structure 48 (obtained in 3 steps from
tryptamine with 70% yield), they obtained diazo ketone 49. It then cyclized in the presence
of copper triflate through a one-pot cyclopropanation/ring opening/ring closing cascade
reaction to form intermediate 50. (±)-Minfiensine 1was then reached in 9 more steps.
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Scheme 1.7 – Domino cyclopropanation/retro-mannich/cyclization process in Qin’s total synthesis of (±)-
minfiensine
The release of the ring strain of a cyclopropane is a good driving force for developing a
process that does not require harsh conditions. It allows more flexibility in the development
of one-pot procedures.
1.2.6 Danishefsky’s Total Synthesis of (-)-Phalarine
Danishefsky reported in 2010 a total synthesis of the furanobisindole alkaloid (-)-phalarine
(Scheme 1.8).18 Starting from aminoester derivative 51, their reaction sequence beganwith a
Pictet Spengler reactionwith formaldehyde into iminium salt 52. Subsequent attack from the
C3 position of the indole gave indolenium intermediate 53. This was followed by a Wagner-
Meerwein rearrangement into carbocation 54. The carbocation was then trapped by the phe-
nol moiety affording 55 in 91% yield as a single diastereoisomer. Ten more steps were neces-
sary to reach enantiopure (-)-phalarine 56.
1.3 The iORC Process and Related Total Syntheses
The Michael and Mannich additions are amongst the most powerful tools for C-C bond for-
mation. Despite being well established reactions, Michael and Mannich reactions are still
17Shen, L.; Zhang,M.; Wu, Y.; Qin, Y. Angew. Chem. Int. Ed. 2008, 47, 3618–3621
18Trzupek, J. D.; Lee, D.; Crowley, B. M.; Marathias, V. M.; Danishefsky, S. J. J. Am. Chem. Soc. 2010, 132, 8506–8512
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Scheme 1.8 – Domino Pictet-Spengler/Cationic cyclization pathway in a total synthesis of (-)-phalarine
being studied and improved every year.
Intramolecular Mannich reactions between indole derivatives and imine or iminium
species are well described systems.19 Nonetheless, the one-pot sequential condensations
of on one hand a 2-aminophenylacetyl ketone moiety to form the indole and on the other
an amine and carbonyl group to form an activated imine followed by reaction of these two
species in situhaven’t been exploited to the best of our knowledge. The reason is the difficulty
to obtain a stable intermediate with amines and carbonyles groups without prior unwanted
condensation or polymerization. The first concept of the iORCwas to form these two amines
and carbonyl groups in situ in a domino process (Scheme 1.9). From stable and easily acces-
sible 1-(2-nitrobenzyl)-cyclopentene derivative 8, an oxidative cleavage of the double bond20
and reduction of the nitro group,21 afforded putative diaminodicarbonyl intermediate 9 that
should spontaneously cyclize into iminium indole intermediate 10 (cf. General Introduc-
tion).
We can notice that 10 has two nucleophilic positions: the N1 and C7 position. It is well
known that the C7 position is more nucleophilic than the N1. Nevertheless, as C7 is already
substituted with a bulky alkyl group, the attack occured from the nucleophilic nitrogen N1
and gave the tetracyclic aminal 11 bearing the desired cis-fused [6,6] ring system.
19Shiri, M. Chem. Rev. 2012, 112, 3508–3549
20a) Criegee, R. Angew. Chem. Int. Ed. 1975, 14, 745–752; b) Van Ornum, S. G.; Champeau, R. M.; Pariza, R. Chem.
Rev. 2006, 106, 2990–3001
21Ono, N., The Nitro Group in Organic Synthesis; Feuer, H., Ed.; JohnWiley & Sons, 2003: 2001
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Scheme 1.9 – General pathway of the iORC domino process for the total synthesis of goniomitine
1.3.1 Total Synthesis of (±)-Goniomitine
In 2013, Zhu and co-workers published the total synthesis of goniomitine using the iORC
domino sequence (Scheme 1.10).22 This synthesis was the proof of concept for this domino
process.
From easily accessible potassium salt 57 and vinyl triflate 58, a palladium-catalyzed
decarboxylative coupling followed by in situ deprotection of the silyl group afforded the alco-
hol 59. After a Mitsnobu reaction to form the azide 60, the key step could be attempted. As
planned, the bulky CH2CH2OBn chain blocked the attack from the C7 position and only the
attack from the nitrogen was observed with full diastereocontrol. After ozonolysis and sub-
sequent reduction of both nitro and azide groups, O-benzylgoniomitine 61 was isolated as
the only product in 80% yield. Deprotection of the benzyl group under standard conditions
afforded racemic goniomitine 62 in 65% yield.
1.3.2 Total Synthesis of leuconolam–leuconoxine–mersicarpine
In the end of 2013, our group published a domino sequence similar to the iORC process in
order to reach the leuconolam–leuconoxine–mersicarpine skeleton (Scheme 1.11).23 In this
case, the domino sequence is not anymore an iORC, because the oxidation of the olefin was
performed as a separate operation, and the reduction/cyclization sequence was refined to
incorporate a lactamization and further oxidation steps. Nonetheless, the reaction pathway
22Xu, Z.; Wang, Q.; Zhu, J. Angew. Chem. Int. Ed. 2013, 52, 3272–3276
23Xu, Z.; Wang, Q.; Zhu, J. J. Am. Chem. Soc. 2013, 135, 19127–19130
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Scheme 1.10 – Total Synthesis of goniomitine 62 using an iORC domino process
has strong similarities with our former iORC.
From boronic acid 63 and iodoenone 64, a Suzuki-Miyaura coupling afforded 65, then
an ozonolysis affordedmethyl ester 66. Following the idea of the iORC, the following stepwas
the reduction of both the nitro group and the azide, giving the two amines needed for the cy-
clizations. A careful optimization allowed for selectivity between pathways a and b. Following
pathway a, the alkyl amine 67 cyclized on the aryl ketone, to afford a 1H-3-aminoindole. This
intermediate underwent lactamization of the ester by the indole nitrogen promoted by KOH,
followed by in situ oxidation with oxygen and reduction with Me2S to yield (-)-mersicarpine
68which was isolated with 75% yield.
When acetic anhydridewas used during the first reduction step (path b), the azidemoi-
ety was converted into an acetamine group (69). After two consecutive cyclizations, interme-
diate 70 was isolated in 50% yield. This intermediate is a precursor to scholarizine G, but is
lacking the C6-C7 bond (the acetyl did not cyclize on the 3-oxindole). Submitting this inter-
mediate to a strong base afforded (-)-scholarisine G 71 in 73% yield. Further transformations
of this natural product allowed our laboratory to reach (+)-meoldinine E 72, (-)-leuconoxine
73 and (-)-leuconolam 74.
This work demonstrates the high versatility of the iORC process. Its potency to reach a
large variety of families of monoterpene indole alkaloid is quite exceptional.
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Scheme 1.11 – Total Synthesis of (-)-mersicarpine 68, (-)-scholarisine G 71, (+)-melodinine E 72, (-)-
leuconoxine 73 and (-)-leuconolam 74
17

CHAPTER2
Approach Towards the Total Synthesis of
Minfiensine
In 1989, Massiot and co-workers discovered an indole alkaloid named (+)-minfiensine 1,
which possess an unprecedented pentacyclic structure. They isolated this new alkaloid from
the African plant Strychnos minfiensis (Figure 2.1).24
NN
H
HO
N
OH
N
H
N
H
N
OH
N
H
N
OH
(+)-Minfiensine 1
Figure 2.1 – Different representations of the indole alkaloid minfiensine 1
This strychnos indole alkaloid raised the attention of the scientific community due to
its highly congested pentacyclic ring system that presents an interesting synthetic challenge.
In addition, different members of the strychnos indole alkaloid family have shown interest-
ing anticancer activities.25 The pentacyclic core of this alkaloid was unique until 2012, when
Morita and co-workers found in the Alstoniaplant an indole alkaloid with a similar polycyclic
system named (+)-alsmaphorazine C (Figure 2.2).26 The challenge of this quite unique con-
gested skeleton encouraged many laboratories to search for a synthetic route and, until now,
five laboratories have achieved the total synthesis of minfiensine.
24Massiot, G.; Thépenier, P.; Jacquier, M. J.; Le Men-Olivier, L.; Delaude, C. Heterocycles 1989, 29, 1435–1438
25a) Leewanich, P.; Tohda, M.; Matsumoto, K.; Subhadhirasakul, S.; Takayama, H.; Aimi, N.; Watanabe, H. Eur. J.
Pharmacol. 1997, 332, 321–326; b) Leewanich, P.; Tohda, M.; Matsumoto, K.; Subhadhirasakul, S.; Takayama, H.;
Watanabe, H. Biol. Pharm. Bull. 1996, 19, 394–399; c) Maier, A.; Maul, C.; Zerlin, M.; Grabley, S.; Thiericke, R. J.
Antibiot. 1999, 52, 952–959
26Koyama, K.; Hirasawa, Y.; Nugroho, A. E.; Kaneda, T.; Hoe, T. C.; Chan, K.-L.; Morita, H. Tetrahedron 2012, 68,
1502–1506
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Figure 2.2 – The indole alkaloid (+)-alsmaphorazine C
To the best of our knowledge, no biosynthetic pathway of minfiensine is reported. It is
reasonable to postulate thatminfiensine 1 originates frompreakuammicine 22 (Scheme 2.1),
as minfiensine’s structure is closely related to some members of the akuammiline indole al-
kaloid family. The first step is probably a decarboxylation, leading to tetrahydrovincanine 75.
This structure is closely related to 18-desoxy-Wieland-Gumlish aldehyde 76 isolated from the
same plant as minfiensine 1. From here, the remaining steps to go from tetrahydrovincanine
75 tominfiensine 1 are the cleavage of the N1-C2 bond and the formation of the N1-C3 bond.
Unfortunately, there are no explanation so far on the enzymatic pathway leading to minfien-
sine 1.
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Scheme 2.1 – Hypothesis of biosynthetic pathway for akuamiline alkaloid minfiensine 1
2.1 Previous Syntheses
16 years after the isolation of minfiensine 1, Overman and co-workers reported the first syn-
thetic pathway to enantiopure alkaloid 1 in 21 steps and 3.2% overall yield,27 which has since
27Dounay, A. B.; Overman, L. E.; Wrobleski, A. D. J. Am. Chem. Soc. 2005, 127, 10186–10187
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thenbeen improved in 2008 to 15 steps and 6.5% overall yield.28 Qin and co-workers reported
in 2008 a synthesis of the racemic alkaloid in 18 steps and 0.4% overall yield (See 1.2.5).17 A
major breakthrough came from the MacMillan group the year after, who obtained the enan-
tiopure alkaloid in only 9 steps and 21% yield.29 Finally the group of Padwa and Qiu synthe-
sized (±)-minfiensine in 2011, the former in 11 steps and 3.3% overall yield30 and the latter
in 10 steps and 6.2% overall yield31 respectively.
2.1.1 Overman’s Synthesis of (+)-Minfiensine
Overman’s group published the first synthesis of (+)-minfiensine 1 starting from 77
(Scheme 2.2). Five steps were needed to convert this amine into enamine intermediate
78. Then by using a catalytic asymmetric Heck-iminium ion cyclization sequence, indoline
derivative 79was obtained. Acidification of the reaction mixture resulted in the N4 attack of
the C3 position, closing the aminal ring, affording 80. Ninemore steps were required to reach
(+)-minfiensine 1.27,28
NH2
OTIPS
N
OTf
MeO2C
8
N
CO2Me
7
N
MeO2C
3
N
Boc
4
N
OH
N
H
5 steps
47% overall
NHBoc
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85%, 99% ee
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99%ee
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TFA,
DCM
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PPh2 N
O
t-Bu
L*
78
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1
77 79
80
Scheme 2.2 – Overman’s Synthesis of (+)-minfiensine 1
Using the Pfaltz ligand for the formation of 79, they were able to form the quaternary
center on the C7 with full enantiocontrol, which then dictated the stereoselectivity of the
aminal formation.
28Dounay, A. B.; Humphreys, P. G.; Overman, L. E.; Wrobleski, A. D. J. Am. Chem. Soc. 2008, 130, 5368–5377
29Jones, S. B.; Simmons, B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2009, 131, 13606–13607
30a) Bobeck, D. R.; France, S.; Leverett, C. A.; Sánchez-Cantalejo, F.; Padwa, A. Tetrahedron Lett. 2009, 50,
3145–3147; b) Li, G.; Padwa, A.Org. Lett. 2011, 13, 3767–3769
31Liu, P.; Wang, J.; Zhang, J.; Qiu, F. G. Org. Lett. 2011, 13, 6426–6428
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2.1.2 MacMillan’s Synthesis of (+)-Minfiensine
In 2009, a short enantioselective synthesis was published by MacMillan and co-workers.29
Their synthesis of (+)-minfiensine 1 startedwith protected tryptamine 81, synthesizing diene
82 in three steps (Scheme 2.3). This diene reacted with propionaldehyde after activation by
a chiral organocatalyst. The resulting Diels-Alder product spontaneously cyclized with the
Boc-protected amine to afford 83with good yield and ee.
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Scheme 2.3 – MacMillan’s Synthesis of (+)-Minfiensine 1
After protection of the alcohol and alkylation of the amine (84), a radical 6-exo-dig
cyclization closed the last ring of the natural product and form the allene 85. A palladium
catalyzed hydrogenation afforded the E alkene with high selectivity. Finally, deprotection
gave (+)-minfiensine 1.
2.1.3 Padwa’s Synthesis of (±)-Minfiensine
The strategy of Padwa and co-workers is shown in Scheme 2.4.30 Starting from 87, ob-
tained in 4 steps from 86, they decided to build the indole moiety using a domino cross-
coupling/Diels-Alder/rearrangement process to reach 88. After this, Boc deprotection with
MgI2 with spontaneous cyclization to form the aminal moiety, palladium-catalyzed deallyla-
tion, and N-allylation afforded 89. Finally, a Heck-type reaction closed the last ring of the
racemic natural product and (±)-minfiensine 1 was obtained in 4 more steps via functional
group interconversions.
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Scheme 2.4 – Padwa’s synthesis of (±)-minfiensine 1 using a domino Cross-coupling/Diels-
Alder/rearrangement process
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Scheme 2.5 – Qiu’s total synthesis of (±)-minfiensine
2.1.4 Qiu’s Synthesis of (±)-Minfiensine
In Qiu’s strategy (Scheme 2.5),31 the indole is formed using the Fisher indole synthesis as
the first step. The quaternary carbon at the C7 position was then installed with a palladium
catalyzed allylation to reach intermediate 90. Protection of the indoleninemoiety followed by
a two-step oxidative cleavage of the terminal olefin and reductive amination of the resulting
aldehyde afforded 91. It was then cyclized at the C3 position to form aminal 92. A Heck-
type reaction allowed them to close the last ring of the pentacyclic core to reach racemic
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minfiensine 1 after functional group interconversions.
2.2 Synthetic Studies of Minfiensine
These strategies, elegant as they are, all form the indole in an early stage, or start from an
indole derivative (tryptamine). As far as we know, nobody has yet attempted to form both C-
N bonds of the aminal in one step. This approach could be a powerful tool for the formation
of indole alkaloids. With this in mind, we undertook the synthesis of minfiensine 1 featuring
our domino process.
From a retrosynthetic point of view (Scheme 2.6), (±)-minfiensine 1 can be easily ob-
tained from 93, following a similar Heck-type reaction as described in other syntheses.32
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H N
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N
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I
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H
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N
H
CO2Me
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NH2
CO2Me
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N3
(±)-1
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95
Scheme 2.6 – Retrosynthetic analysis of (±)-minfiensine
The key step would be the formation of 94 through a reduction/cyclization sequence.
To the best of our knowledge, such strategywas not yet described to reach this type of alkaloid.
We planed to use a reductive domino double cyclization sequence in which the aminal was
formed from a ketone and two latent amine functions (95). This reaction had the great advan-
tage of creating the two amino functions in situ, avoiding excessive protection/deprotection
steps. We can consider this domino process as an early version of our iORC process, that did
not include the oxidation step.
We can notice the presence in the key intermediate of the quaternary center in what
32a) Martin, D. B. C.; Vanderwal, C. D. J. Am. Chem. Soc. 2009, 131, 3472–3473; b) Zu, L.; Boal, B. W.; Garg, N. K. J.
Am. Chem. Soc. 2011, 133, 8877–8879
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would be the C7 position of the future alkaloid structure. This stereocentre should direct the
diastereoselectivity of the different cyclisations. As our first plan was to reach intermediate
95 and study the feasibility of the key reaction of our synthesis, we decided not to focus on the
chirality of this stereocentre for the moment, but to dedicate our efforts to a racemic version
of the synthesis with the possibility to develop subsequently an enantioselective version.
2.2.1 Key Intermediate Formation: Intramolecular RCM Strategy
We pursued several strategies to obtain intermediate 95. Our first idea (Scheme 2.7) was to
perform an alkylation and an allylation on methyl 2-(2-nitrophenyl)acetate 96. Alkylation
with 97, would afford ester 98. Subsequent allylation with 99 would generate 2,2-disubsti-
tuted arylacetate 100. With this straightforward approach it was, in theory, possible to reach
allyl ketone 101 frommethyl ester 100 and then form highly functionalized cyclohex-3-en-1-
one derivative 95 by ring closing metathesis (RCM).
Cs2CO3
DMF, 
16h, 60°C
73%
N3I
NO2
CO2Me
NO2
N3
+ CO2Me
CO2Et
Br
Cs2CO3
DMF
24h, 40°C
17%
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N3
CO2Me
EtO2C
NO2
N3
EtO2C
O
CO2Et
ONO2
N3
Allylation RCM
96 97 98
99
100
101 95
Scheme 2.7 – First pathway to the key intermediate
The α position of the ester has a low pKa value due to the strong electron withdrawing
effect of the o-nitrophenyl group. This makes the anion a poor nucleophile. Furthermore,
after the first addition, this position becomes quite hindered which makes the attack on the
electrophile more difficult. The formation of this quaternary center was therefore a major is-
sue in this strategy. When we inverted the sequence and started by adding 99, which worked
well, the anion from this allylated product was not sufficiently nucleophilic to add onto 97
and no desired compound 100 was obtained. The more reactive methacrylate derivative 99
had therefore to be added in the second step. After careful screening of diverse bases and
temperature, the yield of the first additionwas pushed to a promising 73%, but the second ad-
dition to form 100 was more tedious. Even after optimizing the base (amines, lithium bases,
alcoholates, carbonate bases with or without crown ether), the solvent and the temperature,
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the yield never exceeded 17%. This reaction resulted either in recovering the starting mate-
rial, or decomposition if the temperature was too high or the base too strong. We attempted
to modify the nucleophile, using an azidophenyl acetate 102 instead of the nitrophenyl ac-
etate 96, but all alkylations tried on this substrate resulted in degradation of the reagent and
a messy reaction mixture. It is noteworthy that such alkylation on 2-(2-azidophenyl)acetyl
acid derivatives were never reported. We also attempted to form malonate compound 105.
Sadly, the poor reactivity of the anion was again troublesome and the quaternary carbon was
unreachable by alkylation (from 104) or SNAr (from 106) regardless of our efforts. Reactions
with similar substrates are known, but only on less bulky substituents, or withmore activated
electrophiles.33 The conversion after 24h was less than 10% in the best conditions.
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Scheme 2.8 – Attempts on malonate derivatives or azidophenyl derivative
At this stage, we reasoned we could not afford such a poor yield for the formation of
this quaternary centre. We needed a way to force the anion to react and increase the yield.
It was decided to attempt the cross-metathesis first, and then form the quaternary centre
intramolecularly.
2.2.2 Key Intermediate Formation: Cross Metathesis
For this strategy, we needed at first to change the ester of 98 to an allyl ketone. Several path-
ways were attempted. The results are shown in Scheme 2.9. We first saponified ester 98 to
33Only example of SNAr reaction of α-alkyl substitutedmalonate with 2-fluoronitrobenzene, see: a) Ueno, M.;
Yonemoto, M.; Hashimoto, M.; Wheatley, A. E. H.; Naka, H.; Kondo, Y. Chem. Commun. 2007, 2264–2266; For
examples of alkylation on α-arylmalonate, see also b) Selvakumar, N.; Reddy, B. Y.; Azhagan, A. M.; Khera, M. K.;
Babu, J. M.; Iqbal, J. Tetrahedron Lett. 2003, 44, 7065–7069; c) Hong, S.; Jung,M.; Park, Y.; Ha, M. W.; Park, C.;
Lee, M.; Park, H. G. Chem. Eur. J. 2013, 19, 9599–9605; d) Hong, S.; Lee, J.; Kim, M.; Park, Y.; Park, C.; Kim, M. H.;
Jew, S. S.; Park, H. G. J. Am. Chem. Soc. 2011, 133, 4924–4929; e) Hirschhäuser, C.; Parker, J. S.; Perry, M. W. D.;
Haddow, M. F.; Gallagher, T. Org. Lett. 2012, 14, 4846–4849
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acid 109, and tried to synthesize allyl ester 107. We first considered performing a C-acylation
with but-3-enoyl chloride to form 108, followed by a palladium-catalyzed decarboxylation of
the allyl ester. Unfortunately the steric hindrance and low nucleophilicity of allyl ester 107
made the synthesis of 108 impossible. Only degradation or no conversion was observed.
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Scheme 2.9 – Formation of homoallylic alcohol 112 or allyl ketone 110
We decided to avoid this problem by direct allylation of the acid chloride derived from
109, or through allylation of Weinreb amide 113 to allylketone 115 used as model substrate.
Numerous Lewis acids were tried in combination with allyltrimethylsilane, as well as differ-
ent allyl-metal derivatives, but then resulting only in verymessy reactions without anymajor
compound being formed. We observed that the nitro group on the aromatic ring was sen-
sitive to Grignard-type reagents. Nitroaryls are known to react with organometals as in the
Bartoli indole synthesis.34 The azido group is also known to react strongly with Lewis-acids,
resulting in side-reactions.35 In our case, almost every Lewis acid tried resulted in degrada-
34a) Bartoli, G.; Bosco, M.; Dalpozzo, R. Tetrahedron Lett. 1985, 26, 115–118; b) Bartoli, G.; Marcantoni, E.;
Bosco, M.; Dalpozzo, R. Tetrahedron Lett. 1988, 29, 2251–2254
35a) Takeuchi, H.; Maeda, M.; Mitani, M.; Koyama, K. J. Chem. Soc. Chem. Commun. 1985, 287–289; b)
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tion of the startingmaterial. The desired allyl ketone 110was never observed.
We therefore decided to try different types of allylations. In an attempt to make the
reaction smoother, we planed to use an aldehyde instead of an acyl chloride. Here again, ally-
lation of aldehyde 111was not trivial. Numerous Lewis acids were tried in combination with
allyltrimethylsilane, or different allyl-metal species. These attemps resulted only in degrada-
tion, except for allyl cerium complexes, formed in situ from cerium chloride and allylmagne-
sium bromide36 afforded the desired product, though the yield remained low (<20%). After
many trials, we finally found that Brown Allylation of aldehyde 111with an allylboronic acid
pinacol ester worked well to afford homoallylic alcohol 112 in good yield as a mixture of two
diastereoisomers.37 From this intermediate, formation of both TES-protected alcohol 114
and allyl ketone 110 proceeded smoothly.
With allyl products 110, 112 and 114 in our hand, we could attempt the cross metathe-
sis with different acrylates (Scheme 2.10).38 Unfortunately, all possible combinations of the
three acrylates 99, 116, 117 with unprotected alcohol 112, TES-protected alcohol 114 or the
oxidized allyl ketone 110 did not provide the desired olefin when using either Grubbs II or
Hoveyda-Grubbs II. Only starting material and degradation was observed. An attempt was
made after tethering the two olefins by esterification, but resulting compound 119 also failed
to undergo the RCM to 120. This behaviour might be due to the presence of an azide group.
Some ruthenium catalysts are known to react with azides39 and the phosphine in the Grubbs
II catalyst could also reduce the azide group. Examples of metathesis with substrates bearing
an azide moiety are sparse and are often described as troublesome, giving low yields, espe-
cially if the azide group is close to the olefin.40
Since the metathesis proved unfruitful, we planned to screen conditions for a Baylis
Hillman reaction38,41 on aldehyde 128 (Scheme 2.11), but only degradation was observed.
Takeuchi, H.; Shiobara, Y.; Kawamoto, H.; Koyama, K. J. Chem. Soc. Perkin Trans. 1 1990, 321–327
36Imamoto, T.; Takiyama, N.; Nakamura, K.; Hatajima, T.; Kamiya, Y. J. Am. Chem. Soc. 1989, 111, 4392–4398
37a) Brown, H. C.; Racherla, U. S.; Pellechia, P. J. J. Org. Chem. 1990, 55, 1868–1874; b) Krafft, M. E.; Cheung, Y. Y.;
Abboud, K. A. J. Org. Chem. 2001, 66, 7443–7448
38Aouzal, R.; Prunet, J.Org. Biomol. Chem. 2009, 7, 3594–3598
39a) Caselli, A.; Gallo, E.; Ragaini, F.; Ricatto, F.; Abbiati, G.; Cenini, S. Inorganica Chim. Acta 2006, 359, 2924–2932;
b) He, J.; Yamaguchi, K.; Mizuno, N. J. Org. Chem. 2011, 76, 4606–4610; c) Risse, J.; Scopelliti, R.; Severin, K.
Organometallics 2011, 30, 3412–3418
40a) White, J. D.; Blakemore, P. R.; Korf, E. A.; Yokochi, A. F. T. Org. Lett. 2001, 3, 413–415; b) Yang, H.; Carter, R. G. J.
Org. Chem. 2010, 75, 4929–4938; c) Chang, C. W.; Chen, Y. N.; Adak, A. K.; Lin, K. H.; Tzou, D. L. M.; Lin, C. C.
Tetrahedron 2007, 63, 4310–4318; d) Kanemitsu, T.; Seeberger, P. H.Org. Lett. 2003, 5, 4541–4544; e) Rai, A. N.;
Basu, A.Org. Lett. 2004, 6, 2861–2863; f) Busscher, G. F.; van den Broek, S. B. A. M. W.; Rutjes, F. P. J. T.;
van Delft, F. L. Tetrahedron 2007, 63, 3183–3188; g) Chaudhari, V. D.; Ajish Kumar, K. S.; Dhavale, D. D.Org. Lett.
2005, 7, 5805–5807; h) Barrett, A. G. M.; Beall, J. C.; Braddock, D. C.; Flack, K.; Gibson, V. C.; Salter, M. M. J. Org.
Chem. 2000, 65, 6508–6514; i) Randl, S.; Blechert, S. J. Org. Chem. 2003, 68, 8879–8882
41Basavaiah, D.; Rao, P. Tetrahedron 1996, 52, 8001–8062
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Scheme 2.10 – Attempts to perform themetathesis before the formation of the quaternary center.
Horner–Wadsworth–Emmons reaction with ethyl 2-(diethylphosphono)acrylate 125 and an
external nucleophile did not afforded 126.42 Attempts without external nucleophile to reach
directly cyclized 127 has proven unsuccessful.
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Scheme 2.11 – Morita-Baylis-Hillman or Horner–Wadsworth–Emmons reaction for the formation of 127
After encountering so many problems at this stage of the synthesis, we decided to
change our strategy in order to reach our key intermediate. We reasoned that because it con-
tains a cyclohexenone ring, we could probably attempt to form it via a Diels-Alder reaction.
42Semmelhack, M. F.; Tomesch, J. C.; Czarny, M.; Boettger, S. J. Org. Chem. 1978, 43, 1259–1262
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2.2.3 Key Intermediate Formation: Cycloaddition Strategies
Our first cycloaddition strategy relied on an IEDDA reaction (Scheme 2.12). Starting from
aldehyde 111, formation of a silyl enolate43 followed by cycloaddition with 2-buta-1,3-
dienoate ethyl ester should afford desired cyclohexene 130. The diene needed for the re-
action proven not to bo stable, but could be formed in situ by heating sulfonene 131.
CO2Et
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N3
NO2
N3
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ON
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CO2Et
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+
CO2Et
CO2Et
O
CO2Et
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2. 
,
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H
Y
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132 133 134
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131
131
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Scheme 2.12 – IEDDA to the key intermediate andmodel reaction for the cycloaddition on an enamine
This diene precursor is easily synthesised44 and is well described in IEDDA reactions
with electron rich dienophiles to afford structures with the desired regioselectivity.45 Unfor-
tunately, all our attempts at forming 130were unsuccessful and only resulted in degradation.
Instead, we envisaged to perform the cycloaddition using a base (enolate formation) or an
amine (enamine formation). After a few unsuccessful trials with aldehyde 111, we decided
to use a model substrate to continue studying this reaction. We decided to use the commer-
cially available N-morpholinocyclohex-1-ene as enamine for this cycloaddition.46 The main
difficulty encountered during this reaction was the easy polymerization of both starting ma-
terials. Product formation could only be observed undermicrowave assisted conditions. But
the best yield which could be obtained was 30% of cis-fused cycloadduct 132, along with sig-
43a) Takasu, K.; Tanaka, T.; Azuma, T.; Takemoto, Y. Chem. Commun. 2010, 46, 8246–8248; b) Yu, J.; Wang, T.;
Liu, X.; Deschamps, J.; Flippen-Anderson, J.; Liao, X.; Cook, J. M. J. Org. Chem. 2003, 68, 7565–7581
44a) Trost, B. M.; Huang, X. Chem. Asian J. 2006, 1, 469–478; b) McIntosh, J. J. M.; Sieler, R. R. A. J. Org. Chem. 1978,
43, 4431–4433; c) McIntosh, J. M.; Sieler, R. A. Can. J. Chem. 1978, 56, 226–231; d) Leonard, J.; Hague, A. B.; Jones,
M. F.; Ward, R. A. Synthesis 2000, 32, 507–509; e) Johnson, J. W.; Evanoff, D. P.; Savard,M. E.; Lange, G.; Ramadhar,
T. R.; Assoud, A.; Taylor, N. J.; Dmitrienko, G. I. J. Org. Chem. 2008, 73, 6970–6982; f) Andrade, G. S.; Berkner, J. E.;
Liotta, C. L.; Eckert, C.; Schiraldi, D. A.; Andersen, A.; Collard, D. M. Synth. Commun. 2003, 33, 3643–3650
45a) Vasil’ev, A. A.; Serebryakov, E. P. Russ. Chem. Rev. 2001, 70, 735–776; b) Lathbury, D. C.; Parsons, P. J.; Pinto, I. J.
Chem. Soc. Chem. Commun. 1988, 81–82
46a) Pottie, I. R.; Nandaluru, P. R.; Benoit, W. L.; Miller, D. O.; Dawe, L. N.; Bodwell, G. J. J. Org. Chem. 2011, 76,
9015–9030; b) Backvall, J.-E.; Rise, F. Tetrahedron Lett. 1989, 30, 5347–5348
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nificant amount of side-product 133 and a large amount of diene dimer 134 (described as an
important competitive reaction).47 The addition of a Lewis acid to this reaction resulted in a
higher polymerization rate. Attempts to tune the electron density of diene by modifying the
ester moiety of the sulfolene were done. But other sulfolene derivatives were too unstable to
handle.
We therefore decided to rely on another cycloaddition for the formation of this cyclo-
hexene derivatives (Scheme 2.13). Cycloaddition between electron-poor triple bonds and
electron rich dienes are well described in the literature.48 We chose two vinyl ketones (135
and 137) as potential precursor to the diene needed for the reaction. We believed that the
corresponding enolates, enamines or silyl enol ethers of these methyl enones would be suit-
able partners for a Diels-Alder reaction with methyl propiolate as dienophile. Resulting cy-
cloadducts 136 or 138, thus obtained, should be easily transformed into key intermediate
95.
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Scheme 2.13 – New cycloaddition strategy to reach key intermediate
The regioselectivity of this type of cycloadditions is known to match the one required
for our strategy.48c,49 The electron demand seems to be good in our case, having an elec-
47a) Spino, C.; Pesant, M.; Dory, Y. Angew. Chem. Int. Ed. 1998, 37, 3262–3265; b) Alanine, A. I.; Fishwick, C. W.;
Jones, A. D.; Mitchell, M. B. Tetrahedron Lett. 1989, 30, 5653–5654
48a) Yates, P.; Gomes, A.; Burnell, D.; Cong, D.; Sawyer, J. Can. J. Chem. 1989, 67, 37–47; b) Olsen, R. K.; Feng, X.
Tetrahedron Lett. 1991, 32, 5721–5724; c) Inanaga, K.; Takasu, K.; Ihara, M. J. Am. Chem. Soc. 2004, 126,
1352–1353; d) Ackland, D. J.; Pinhey, J. T. J. Chem. Soc. Perkin Trans. 1 1987, 2689–2694
49a) Ghosh, A.; Chakraborty, I.; Adarsh, N. N.; Lahiri, S. Tetrahedron 2010, 66, 164–171; b) Lahiri, S.; Yadav, S.;
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tron deficient dienophile and an electron-rich diene. Themain risk was that the nitrophenyl
group would diminish the electron density of the diene. However we believed a correct cata-
lyst should help us overcome this difficulty.
In the forward synthesis, intermediates 135 and 137 could be rapidly obtained as
shown in Scheme 2.13, 2-(2-nitrophenyl)acetic acid could be converted to enone 135 using
a Dakin-West reaction50 followed by a Knoevenagel Condensation.51
Wefirst attempted to reach alcohol 140 in one step by opening tulipane,52 but this reac-
tion proven to bemessy and resulted in a low yield. We returned to using bromomethacrylate
99 (obtained in 2 steps); Homologation with formaldehyde and indium gave the desired al-
cohol 140 in good yield. Azidation and reduction into aldehyde 139 proceeded smoothly.
Unfortunately, our attempts toward converting the aldehyde to methyl ketone 137 showed
no desired product in all our attempts, resulting only polymerization of the acrolein moiety.
The results of a model study (see below) prompted us to change our strategy before we could
optimize the formation of 137.
From compound 135, we attempted to form the diene using a base (formation of an
enolate), a silyl enolate (TBS or TMS enolate), or methylbenzylamine (as organocatalyst) fol-
lowed by cycloaddition with methylpropiolate. Only starting material or decomposition was
observed. Modification of the reactions conditions (Temperature, solvent, Lewis-acids) only
changed the speed of decomposition. A more active dienophile such as prop-2-ynal29 was
used without anymore success. Desired compound 136 was never observed. Probably the
electron-withdrawing effects of the nitrophenyl substituent decreased too strongly the elec-
tron density of the diene making it unreactive towards Diels-Alder reaction. Another reason
could be the steric clash between the aryl and the silyl group. This steric repulsion would
increase the energy required to pass from the unreactive s-trans to the reactive s-cis interme-
diate.53
When 3-methylbut-3-en-1-one was used as a diene precursor (model substrate of 137,
Scheme 2.14), the desired product 141a could only be observed in low yield, as an insepara-
ble mixture with isomers 141b and 141c.48b Considering how poor the regioselectivity was,
and how easily the double bond in 141a could migrate to 141b, we decided not to pursue
Chanda, M.; Chakraborty, I.; Chowdhury, K.; Mukherjee, M.; Choudhury, A. R.; Guru Row, T. N. Tetrahedron Lett.
2005, 46, 8133–8136; c) Yadav, S.; Banerjee, S.; Maji, D.; Lahiri, S. Tetrahedron 2007, 63, 10979–10990; d)
Maiti, B. C.; Lahiri, S. Tetrahedron 1997, 53, 13053–13062; e) Xiao, T.; Dong, X.; Tang, Y.; Zhou, L. Adv. Synth.
Catal. 2012, 354, 3195–3199; f) Smith, D. L. L.; Chidipudi, S. R.; Goundry, W. R.; Lam, H. W.Org. Lett. 2012, 14,
4934–4937; g) Takasu, K.; Inanaga, K.; Ihara, M. Tetrahedron Lett. 2008, 49, 4220–4222
50a) Danheiser, R Tetrahedron 1983, 39, 935–947; b) Tran, K.-V.; Bickar, D. J. Org. Chem. 2006, 71, 6640–6643
51Okuro, K.; Gurnham, J.; Alper, H. J. Org. Chem. 2011, 76, 4715–4720
52Mendgen, T.; Scholz, T.; Klein, C. D. Bioorg. Med. Chem. Lett. 2010, 20, 5757–5762
53Sauer, J Angew. Chem. Int. Ed. 1967, 6, 16–33
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Scheme 2.14 – Test of cycloaaddition
further this synthetic pathway.
Our last attempt was with the Diels-Alder reaction shown in Scheme 2.15. From
dienophile 142, a cycloaddition with either described 2H-pyran-2-one or the comercially
available methyl furane-2-carboxylate could be considered. Similar bridged bicyclic struc-
tures are known to be easy to open.54 The opening of our cycloadduct should afford interme-
diate 143.
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142143
Scheme 2.15 – New cycloaddition pathway
The pyranone is known to react with electron poor dienophiles,55 and the regioselec-
tivity can vary according to literature. But in comparison with the work of Markó and co-
workers,56 the possibility of having a good regioselectivity was high despite the need for high
pressure and harsh reaction conditions. As for the furane, some examples exist, even if most
of the Diels-Alder reaction used in similar molecules are intramolecular, like in the work of
Padwa and co-workers57 or Kitagawa and co-workers.58
To synthesise dienophile 142, we first substituted the ester 96 with iodoalkane 144 to
54a) Markó, I. E.; Seres, P.; Swarbrick, T. M.; Staton, I.; Adams, H. Tetrahedron Lett. 1992, 33, 5649–5652; b)
Posner, G. H.; Suh, B. C.; Petersen, K. S.; Dolan, P.; Agoston, E. S.; Kensler, T. W.; Koh, J. T.; Peleg, S. J. Steroid
Biochem. Mol. Biol. 2007, 103, 213–221; c) Posner, G. H.; Ishihara, Y. Tetrahedron Lett. 1994, 35, 7545–7548; d)
Shin, I. J.; Choi, E. S.; Cho, C. G. Angew. Chem. Int. Ed. 2007, 46, 2303–2305
55Pfaff, E.; Plieninger, H. Chem. Ber. 1982, 115, 1967–1981
56Swarbrick, T. M.; Markó, I. E.; Kennard, L. Tetrahedron Lett. 1991, 32, 2549–2552
57Padwa, A.; Crawford, K. R.; Straub, C. S.; Pieniazek, S. N.; Houk, K. N. J. Org. Chem. 2006, 71, 5432–5439
58Nakamura, M.; Takahashi, I.; Yamada, S.; Dobashi, Y.; Kitagawa, O. Tetrahedron Lett. 2011, 52, 53–55
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afford ester 145 (Scheme 2.16). After a reduction, we obtained alcohol 146. Mesylation of
alcohol 146 followed by elimination under basic conditions only afforded side-product 147
instead of olefin 142. Iodination of 146 resulted only in traces of desired iodine 148, the
reaction yielding mostly overiodinated products and degradation. To our delight, tosylate
149was stable enough to prevent the cyclization and was readily eliminated to olefin 142 in
the presence of DBU and NaI.
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Scheme 2.16 – Synthesis of the dienophile 142
Unfortunately, no reaction was observed when using lewis acids, high temperatures
(up to 200 °C. Above, degradation was observed) and high pressures (up to 200bar) for the
pyranone or furane substrates. This lack of reactivity toward Diels-Alder reaction was proba-
bly due to steric hindrance of the dienophile.
After considering the strategies already reported and the length of our current strate-
gies, the decision was taken to suspend our efforts toward the synthesis of minfiensine and
to change targets.
2.3 Conclusion
In summary, the total synthesis of minfiensine was attempted using a reduction/cyclization
domino sequence as a key step. The key intermediate needed for this domino sequence was
never reached due to the steric hindrance around the quaternary center and the easy isomer-
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ization of the olefine. Multiple strategies were attempted (summarized in Scheme 2.17). Our
lack of success with these strategies, combined with the efficient syntheses published pre-
viously and the growing number of steps required to overcome the problems encountered
convinced us to suspend our efforts towards this natural product, and change targets.
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Scheme 2.17 – Summary of the different strategies used in this chapter
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CHAPTER3
Dehydroaspidospermidine and
Aspidospermidine
During the synthetic studies of minfiensine, our laboratory developed the iORC process to
target goniomitine (cf. Section 1.3). As shown in Scheme 3.1, the C7 position of iORC
iminium intermediate 10was too hindered, and only cyclization via the nucleophilic N1 was
observed, giving (±)-O-benzylgoniomitine as the sole product. The diastereoselectivity was
controlled by the quaternary center C20.
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Scheme 3.1 – Cyclization to (±)-aspidospermidine and (±)-dehydroaspidospermidine
In this new project, we wanted to apply the iORC domino process to reach
aspidospermidine-type alkaloids. We postulated that a tether between the N4 iminium and
the C7 (150) would force the cyclization to take place between C7 and C21 carbons. The
installation of this connection would not be redundant steps, as this tether exists in the
aspidospermidine-type natural products. As first target, we chose the dehydroaspidospermi-
dine 2 and aspidospermidine 3. The pentacyclic skeleton of aspidospermidine has received
attention as a testing ground for the evaluation of new reactions and synthetic strategies. It
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was then natural to start from this alkaloid to investigate our iORC sequence, before moving
to more complicated structures (cf. Chapter 4 and 6).
3.1 Aspidospermidine, Background
(+)-Aspidospermidine 3 was first isolated by Biemann and co-workers in 196159 during a
mass spectrometry study of the indole alkaloids from the bark of Aspidospera Quebracho-
Blanco. In this same paper, they also observed (+)-1,2-dehydroaspidospermidine 2 and re-
duced it to (+)-aspidospermidine 3 using zinc. From a biosynthetic point of view, this alka-
loid comes from (+)-vincadifformine 4 (cf. Section 1.1.1), where a simple decarboxylation
would afford (+)-dehydroaspidospermidine 2, and further reduction would give aspidosper-
midine 3. The pentacyclic structure of the aspidosperma family is an interesting synthetic
challenge that pushed many chemists to pursue this synthesis. As a result, more than thirty
total syntheses of aspidospermidine 3 are published so far. Most of them could be divided
into three categories: Starting from an indole derivative, from a tryptamine derivative, or the
syntheses where the indole is formed during the synthesis.
3.1.1 Previous syntheses from tryptamine derivatives
Wenkert and co-workers in 198360 made the tryptamine derivative 151 and used it in an in-
tramolecular cycloaddition reaction to form (after oxidation with lead tetraacetate) interme-
diate152 (Scheme 3.2). In 1991, they published the route to the natural product from in-
termediate152.61 Tosylation followed by diastereoselective alkylation afforded intermediate
153. Further reductions gave racemic aspidospermidine 3.
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Scheme 3.2 – (±)-Aspidospermidine syntheses fromKunesch and co-workers
Two similar enantiospecific total syntheses are shown in Scheme 3.3, from Fuji and
co-workers in 1990 and Tomioka and co-orkers in 2009.
59Biemann, K.; Friedmann-Spiteller, M.; Spiteller, G. Tetrahedron Lett. 1961, 2, 485–492
60Wenkert, E.; Orito, K.; Simmons, D. P.; Kunesch, N.; Ardisson, J.; Poisson, J. Tetrahedron 1983, 39, 3719–3724
61Le Menez, P.; Kunesch, N.; Liu, S.; Wenkert, E. J. Org. Chem. 1991, 56, 2915–2918
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Fuji’s group published in 1987 and 199062 a synthesis using the Pictet-Spengler reac-
tion between tryptamine and acetal derivative 154 to reach intermediate 155. From here, an
acid catalyzed ring closing/rearrangement sequence followed by reduction with LiAlH4 gave
(+)-aspidospermidine 3. The intermediate 154 was also synthesized by Wee and co-workers
in 2001 in a synthesis of other Vinca alkaloids.63
The group of Tomioka used a similar strategy.64 Condensation of tryptamine with lac-
tone 156 afforded intermediate 157. Intramolecular Pictet-Spengler reaction followed by
LiAlH4 reduction allowed them to reach the natural product.
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Scheme 3.3 – (+)-Aspidospermidine syntheses from Fuji and Tomioka
MacMillan and co-workers recently published an enantioselective total synthesis of as-
pidospermidine 3 (Scheme 3.4),65 where the route toward the natural product started with
tryptamine derivative 158. A new cascade reaction featuring a cycloaddition of 158with pro-
piolaldehyde using an imidazolidinone catalyst, followed by 5-exo-trig cyclization with the
internal secondary amine afforded 159 in good yield and excellent ee. A Wittig reaction,
N-Boc deprotection and N-allylation provided indoline derivative 160. A Heck cyclization
closed the last ring to afford 161, which upon reduction provided (+)-aspidospermidine 3.
3.1.2 Previous syntheses from indole derivatives
Many groups developed methodologies to functionalize or substitute the indole moiety, and
the development of total syntheses using these new reactions is frequent. Here are some rel-
evant examples of syntheses of aspidospermidine 3 starting from an indole derivative other
62a) Node, M.; Nagasawa, H.; Fuji, K. J. Am. Chem. Soc. 1987, 109, 7901–7903; b) Node, M.; Nagasawa, H.; Fuji, K. J.
Org. Chem. 1990, 55, 517–521
63Wee, A. G. H.; Yu, Q. J. Org. Chem. 2001, 66, 8935–8943
64Suzuki, M.; Kawamoto, Y.; Sakai, T.; Yamamoto, Y.; Tomioka, K. Org. Lett. 2009, 11, 653–655
65Jones, S. B.; Simmons, B.; Mastracchio, A.; MacMillan, D. W. C. Nature 2011, 475, 183–188
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Scheme 3.4 – MacMillan’s total synthesis of (+)-aspidospermidine
than tryptamine.
Bach’s group published in 2012 a total synthesis of (±)-aspidospermidine 3
(Scheme 3.5),66 using a newly developed palladium-catalyzed 2-alkylation of indoles, allow-
ing them to build precursor 162. Allylation followed by hydroboration of the newly installed
double bond afforded intermediate 163. Oxidation of the alcohol, reductive amination and
reduction of the amide afforded hemiaminal 164. Under acidic conditions, this hemiami-
nal was dehydrated to iminium 165which underwent a Mannich-type reaction to afford 166.
The last ringwas closed in one step, affording (±)-dehydroaspidospermidine 2, that was then
reduced with NaBH4 to (±)-aspidospermidine 3.
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Scheme 3.5 – Bach’s strategy, starting from indole
A similar strategy to close the last ring of aspidospermidine 3 was used by Rubiralta’s
group in 1996 (Scheme 3.6).67 Rubiralta synthesized aspidospermidine 3 starting from dithi-
ane 167. 1,4-addition on enone 168 afforded racemic 169. A reduction/cylclization protocol
66Jiao, L.; Herdtweck, E.; Bach, T. J. Am. Chem. Soc. 2012, 134, 14563–14572
67Forns, P.; Diez, A.; Rubiralta, M. J. Org. Chem. 1996, 61, 7882–7888
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was performed to reach intermediate 170. Closing the last ring by a nucleophilic substitution,
and subsequent reduction of the dithiane afforded a mixture of (±)-aspidospermidine 3 and
(±)-dehydroaspidospermidine 2.
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Scheme 3.6 – Rubiralta’s synthesis of aspidospermidine
Andrade and co-workers reached (+)-aspidospermidine 3 in 2013 (Scheme 3.7).68
Starting from chirla N-sulfinyl indole 171, a domino Michael/Manich/N-alkylation afforded
172 with good diastereoselectivity. Intermediate 173 was then reached in 6 steps from the
N-sulfinyl derivative 172. The sequence include a reduction of the ester into an aldehyde, a
Wittig reaction and a RCM to close the azacyclohexene ring. Finally, a Bosch-Rubiralta spiro-
cyclization69 closed the last ring, and a reduction afforded the natural product.
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Scheme 3.7 – Andrade’s synthesis of (+)-aspidospermidine
Wenkert in 198870 decided to reach (+)-dehydroaspidosermidine 2 and (+)-
aspidospermidine 3 from aminal lactone 174 (Scheme 3.8). Acidic treatment of 174 with in-
dole afforded 175 as a single diastereoisomer. Cyclization of 175 into 176 in phosphoric acid
proceeded with 61% yield. Reduction of amide and double substitution with ethylene bro-
mide afforded dehydroaspidospermidine, that was converted into aspidospermidine with
68Zhao, S.; Andrade, R. B. J. Am. Chem. Soc. 2013, 135, 13334–13337
69Rubiralta, M.; Diez, A.; Bosch, J.; Solans, X. J. Org. Chem. 1989, 54, 5591–5597
70Wenkert, E.; Hudlicky, T. J. Org. Chem. 1988, 53, 1953–1957
41
Chapter 3: Dehydroaspidospermidine and Aspidospermidine
LiAlH4. Waser and co-workers reached Wenkert’s intermediate 176 in a formal synthesis of
aspidospermidine 3 using a homo-Nazarov reaction on an aminocyclopropane derivative.71
N
H
N
H
N
H
HN
O
N
H
HN
CO2H
HN
O
O
1. LiAlH4, dioxane
    , 97%
2. K2CO3,
    BrCH2CH2Br
    140 °C, 
    32%, 80% BRSM
3. LiAlH4, Et2O, 70%
H3PO4
90 °C
61%
Indole, HCl
AcOH/dioxane
80 °C, 89%
(+)-174 175 176 3
Scheme 3.8 – Wenkert’s synthesis of (+)-aspidospermidine
3.1.3 Syntheses of aspidospermidine with formation of the indole ring
The most common way to synthesize the aspidospermidine 3 was first described by Stork
and co-workers in 1963 in a total synthesis of aspidospermine,72 and applied later on by Aubé
and co-workers for aspidospermidine.73 Tricycle 177was used in a Fisher indole synthesis to
afford dehydroaspidospermidine. Reduction of indolenine moiety gave aspidospermidine 3.
Many groups targeted intermediate 177 for the total synthesis74 or the formal synthesis75 of
aspidospermidine 3.
N
O NH
N
H
Fisher-Indole Synthesis
1. Ph-NHNH2, PhH, 
2. AcOH, 
3. LiAlH4, THF, 
51% (3 steps)
3177
Scheme 3.9 – Aubé’s indole synthesis of aspidospermidine
71a) De Simone, F.; Gertsch, J.; Waser, J. Angew. Chem. Int. Ed. 2010, 49, 5767–5770; b) De Simone, F.; Waser, J.
Synlett 2011, 22, 589–593; c) De Simone, F.; Waser, J. Chimia 2012, 66, 233–236
72Stork, G.; Dolfini, J. E. J. Am. Chem. Soc. 1963, 85, 2872–2873
73Iyengar, R.; Schildknegt, K.; Aubé, J. Org. Lett. 2000, 2, 1625–1627
74a) Callier-Dublanchet, A.-C.; Cassayre, J.; Gagosz, F.; Quiclet-Sire, B.; Sharp, L. A.; Zard, S. Z. Tetrahedron 2008,
64, 4803–4816; b) Sharp, L. A.; Zard, S. Z.Org. Lett. 2006, 8, 831–834; c) Gnecco, D.; Vázquez, E.; Galindo, A.;
Terán, J. L. J.; Orea, L.; Bernès, S.; Enríquez, R. G. Arkivoc 2003, 185–192; d) Guérard, K. C.; Sabot, C.;
Beaulieu, M.-A.; Giroux, M.-A.; Canesi, S. Tetrahedron 2010, 66, 5893–5901; e) Burrell, A. J. M.; Coldham, I.;
Watson, L.; Oram, N.; Pilgram, C. D.; Martin, N. G. J. Org. Chem. 2009, 74, 2290–2300; f) Cho, H.-K.; Tam, N. T.;
Cho, C.-G. Bull. Korean Chem. Soc. 2010, 31, 3382–3384; g) Coldham, I.; Burrell, A. J. M.; White, L. E.; Adams, H.;
Oram, N. Angew. Chem. Int. Ed. 2007, 46, 6159–6162; h) Ishikawa, T.; Kudo, K.; Kuroyabu, K.; Uchida, S.;
Kudoh, T.; Saito, S. J. Org. Chem. 2008, 73, 7498–7508; i) Iyengar, R.; Schildknegt, K.; Morton,M.; Aubé, J. J. Org.
Chem. 2005, 70, 10645–10652; j) Sabot, C.; Guérard, K. C.; Canesi, S. Chem. Commun. 2009, 2941–2943
75a) Banwell, M. G.; Smith, J. A. J. Chem. Soc. Perkin Trans. 1 2002, 2613–2618; b) Huang, J.-Z.; Jie, X.-K.; Wei, K.;
Zhang, H.; Wang, M.-C.; Yang, Y.-R. Synlett 2013, 24, 1303–1306; c) Pearson, W. H.; Aponick, A.Org. Lett. 2006, 8,
1661–1664
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In 1994, Angelo and co-workers76 reached the natural compound from 178
(Scheme 3.10). Copper-assisted cyclization created the indole ring, and a few functional
group interconversions afforded 179. Reduction of the carbonyl group, followed by
Staudinger reduction and N-acylation provided 180. Acidic treatment allowed them to elim-
inate the alcohol, and cyclize the amine on the C21 position. Subsequent oxidation of the
thioether to sulfoxide followed by a Pummerer rearrangement afforded 181. Desulfurization
and reduction of the amide and enaminemoieties afforded the natural product.
N
N
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O
N
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O
N
H
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H
N
H
1. W2-Raney Ni,
    DMF/EtOH
    56%
2. LiAlH4, THF, 
    0 °C to RT
    68%
1. NaBH4
    EtOH, RT, 92%
2. PPh3, THF
3. PhSCH2COCl
    NaOH, DCM
62% (2 steps)
1. NaH, CuI
    HMPA, 120 °C
    84%
2. LiBH(Et)3, THF
    -40 °C, 88%
3. MsCl, Et3N
    DMAP, DCM/THF
4. NaN3, DMF, 80 °C
5. NaOH, MpsCl,
    n-Bu4NHSO4
    DCM,
74% (3 steps
N
Mps
NH
O
PhS
OH
1. TFA, DCM
    0 °C, then PhCl
    135 °C, 94%
2. NaIO4, THF/MeOH
3. TFA, DCM
    then PhCl, 
89% (2 steps)
Mps
(+)-
178 179
180
181 3
Scheme 3.10 – Angelo’s synthesis of (+)-aspidospermidine with formation of the indole ring
Murphy and co-workers published in 199977 a synthesis of (±)-aspidospermidine
(Scheme 3.11), using their previously developed tetrathiafulvalene (TTF)-mediated radical-
polar crossover reaction.78 This reaction extruded nitrogen from 182 and formed the aryl
radical. A cyclization on the double bond gave benzylic radical that was oxidized to the ben-
zylic cation and trappedwith water. The formed alcohol was oxidized with PCC to afford 183.
This intermediate was transformed into 184 in six steps. A Heck-type reaction on 184 closed
the last ring. Reduction and deprotection of 184 afforded aspidospermidine 3.
One year after, Murphy’s group reached the same precursor 184 from alcohol 185.79 A
five step procedure converted 185 into 186. Azidation of primary alcohol afforded 187. An
iodoazide radical cascade cyclization closed both 5 membered rings, and N-allylation with
(Z)-3-bromo-1-iodopropene afforded 184.
Another interesting example is the racemic synthesis of (±)-rhazinilam and
76Desmaeele, D.; D’Angelo, J. J. Org. Chem. 1994, 59, 2292–2303
77Callaghan, O.; Lampard, C.; Kennedy, A. R.; Murphy, J. A. J. Chem. Soc. Perkin Trans. 1 1999, 995–1002
78Fletcher, R.; Kizil, M.; Lampard, C.; Murphy, J. A.; Roome, S. J. J. Chem. Soc. Perkin Trans. 1 1998, 2341–2352
79Patro, B.; Murphy, J. A.Org. Lett. 2000, 2, 3599–3601
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Scheme 3.11 – Murphy’s Syntheses of (±)-aspidospermidine with formation of the indole ring
its subsequent transformation into (±)-aspidospermidine 3 by Gaunt and co-workers
(Scheme 3.12).80 Using the pyrrol derivative 188, a palladium-catalyzed C-H alkenylation
reaction afforded the intermediate 189. Reduction of the vinyl group and the nitro group,
followed by macrolactamization using 2-chloro-1-methylpyridinium iodide (CMPI) as cou-
pling reagent afforded 2-methoxycarbonyl-rhazinilam 190. From here, a three-steps reduc-
tive transannular cyclization process afforded (±)-aspidospermidine 3.
N
H
N
HN
H
N
O
N
MeO2C
NO2
CO2TSE
N
MeO2C
NO2
CO2TSE
Available in 6 steps
Pd(OAc)2, 
t-BuONa, 
O2, DMF, 
PivOH, 110 °C, 
60%
1. Pd/C, H2,
    MeOH
2. AlCl3, H2O
3. Et3N, CMPI,
    DCM
70% (3 steps)
MeO2C
1. Superhydride, 
    DCM, -78 °C
    then Pyridine, 
    Ac2O, -10 °C
2. TFA, DCM,
     then NaBH3CN
3. TFA, DCM
47% (3 steps) (±)-
188 189
190 3
Scheme 3.12 – Gaunt’s Synthesis of (±)-aspidospermidine with formation of the indole ring
In 2002, Marino finished a total synthesis of (+)-aspidospermidine81 with a late-stage
closing of the indole ring (Scheme 3.13). Starting from the chiral sulfoxide 191, a ketene
lactonization with trichloroacetyl chloride (TCAC), followed by reduction and deprotection
80McMurray, L.; Beck, E. M.; Gaunt, M. J. Angew. Chem. Int. Ed. 2012, 51, 9288–9291
81Marino, J. P.; Rubio, M. B.; Cao, G.; de Dios, A. J. Am. Chem. Soc. 2002, 124, 13398–13399
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of the acetal provided lactone 192. Lactone opening with pyrrolidine, afforded aldehyde 193.
Subsequent aldol condensation and amidation provided 194. Intramolecular aza-Michael
addition followed by cyclization of the resulting enolate on the alkyl chloride and Saegusa
reaction gave enone 195. Boc deprotection followed byWolff-Kishner reduction afforded (+)-
aspidospermidine 3.
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Op-TolS
O
OO
NBoc2Sp-Tol
O
1. Zn(Cu), TCAC, 
    THF, -45 °C, 78%
2. Bu3SnH, Et3B, 
    PhH, , 92%
3. p-TsOH, 
    acetone, RT, 96%
pyrrolidine, 
PhH, RT,
86%
N
H
O
ONBoc2
1. pyrrolidine, 
    i-PrOH, AcOH
2. i-BuOCOCl, 
    Et3N, 
    Cl(CH2)3NH3Cl, 
    THF, 0 °C, 
64% (2 steps)
NBoc2
O
O
O
N
Cl
(+)-
191 192 193
194 195 3
Scheme 3.13 –Marino’s Syntheses of (+)-aspidospermidinewith formation of the indole ring
Banwell in 2005 started from precursor 196 for a racemic synthesis of aspidospermi-
dine 3 (Scheme 3.14).82 An Ullmann cross-coupling with o-nitroiodobenzene followed with
saponification of the acetate and azidation of the resulting alcohol afforded 197. Reflux-
ing this azide in benzene forced an azacyclopropanation to afford 198. Acidic treatment of
this cyclopropane gave the chloride derivative 199. Subjecting this intermediate to reduc-
ing conditions like TiCl3/NH4OAc, followed by N-acylation with 2-chloroacetyl chloride af-
forded indole 200. Halogen exchange, followed with cyclization and reduction afforded (±)-
aspidospermidine 3 (3-step protocol developed by Toczko and Heathcock)83 in high yield.
Rawal in 200284 reported a catalytic enantioselective Diels-Alder reaction between di-
ene 201 and ethylacrolein using antimonate salt of Jacobsen’s chiral CrIII-salen complex85
(Scheme 3.15). The resulting aldehyde 202was submitted to a Wittig reaction and RCM reac-
tion to afford bicyclic structure203. (o-Nitrophenyl)phenyliodonium fluoride (NPIF) reagent
arylated the silyl enolate and provided the nitrophenyl derivative 204. A reduction of the ni-
tro function provided indole derivative 205. Deprotection of the amine with trimethylsilyl
iodide followed by N-alkylation with 2-bromoethanol, mesylation of the alcohol and cycliza-
tion gave 1,2,14,15-tetrahydroaspidospermidine 206. Reduction of both double bonds gave
82a) Banwell, M. G.; Lupton, D. W. Org. Biomol. Chem. 2005, 3, 213–215; b) Banwell, M. G.; Lupton, D. W.;
Willis, A. C. Aust. J. Chem. 2005, 58, 722–737
83Toczko, M. A.; Heathcock, C. H. J. Org. Chem. 2000, 65, 2642–2645
84Kozmin, S. A.; Iwama, T.; Huang, Y.; Rawal, V. H. J. Am. Chem. Soc. 2002, 124, 4628–4641
85Martinez, L. E.; Leighton, J. L.; Carsten, D. H.; Jacobsen, E. N. J. Am. Chem. Soc. 1995, 117, 5897–5898
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Scheme 3.14 – Banwell’s Synthesis of (±)-aspidospermidine with formation of the indole ring
(+)-aspidospermidine 3 in good yield.
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Scheme 3.15 – Rawal’s synthesis of (+)-aspidospermidine with formation of the indole ring
3.2 Dehydroaspidospermidine
Dehydroaspidospermidine 2was isolated from the same tree as aspidospermidine 3. It is the
oxidized version of aspidospermidine, having an indolenine ring instead of an indoline.
Most of the syntheses of aspidospermidine pass by dehydroaspidospermidine with a
subsequent reduction, and few papers synthesized aspidospermidine and oxidized it into de-
hydroaspidospermidine. Hence they were already discussed in the previous section. One of
the few groups who synthesized dehydroaspidospermidine 3 without involving aspidosper-
midine 3 was Ban and co-workers in 198186 (Scheme 3.16). They reported an effective pho-
86a) Ban, Y.; Yoshida, K.; Goto, J.; Oishi, T. J. Am. Chem. Soc. 1981, 103, 6990–6992; b) Ban, Y.; Yoshida, K.; Goto, J.;
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Scheme 3.16 – Ban’s synthesis of (±)-dehydroaspidospermidine
toisomerization of amine 207 into amine 208 that spontaneously cyclize into the amide 209.
With just a few protections, alkylations and deprotections, they achieved the synthesis of (±)-
dehydroaspidospermidine 2 in seven steps and 17% overall yield.
Other syntheses of aspidospermidine and dehydroaspidospermidine are reported. But
the syntheses above are amongst the most relevant ones.87
3.3 Synthetic Studies of Aspidospermidine and Dehydroaspi-
dospermidine
We could see that forming the indole moiety of aspidospermidine in a late-stage fashion is
an interesting idea, as it reduces the sensitivity of the substrate toward acidic media, and
diminishes the need for protecting groups. In addition, exploiting the reactivity of the indole
during its formation, as a domino process could be a powerful tool to cyclize other rings.
These are the power of our iORC process we wished to emphasis.
From a retrosynthetic point of view, 1,2-dehydroaspidospermidine 2 could be reached
from iminium 150 (Scheme 3.17). The cyclization of this intermediate could only happen be-
tween the C7 and C21 due to the tether N4-C5-C6-C7. This intermediate contains an enam-
ine and an iminium group. These functional groups could arise from their respective amino
and carbonyl groups (intermediate 210). The anilinemoiety could arize from a nitrobenzene,
and the secondary amine from a protected amino group (Intermediate 211). We chose a ni-
trophenylsulfonamide protecting group due to the mild deprotection conditions that were
Oishi, T.; Takeda, E.; Ishigamori Tetrahedron 1983, 39, 3657–3668
87See also a) Harley-Mason, J.; Kaplan, M. Chem. Commun. 1967, 915–916; b) Mandal, S. B.; Giri, V. S.; Pakrashi,
S. C.Heterocycles 1988, 27, 11–12; c) Mandal, S. B.; Giri, V. S.; Sabeena, M. S.; Pakrashi, S. C. J. Org. Chem. 1988,
53, 4236–4241; d) Wenkert, E.; Liu, S. J. Org. Chem. 1994, 59, 7677–7682; e) Kawano, M.; Kiuchi, T.; Negishi, S.;
Tanaka, H.; Hoshikawa, T.; Matsuo, J.-i.; Ishibashi, H. Angew. Chem. Int. Ed. 2013, 52, 906–910; f) Li, Z.; Zhang, S.;
Wu, S.; Shen, X.; Zou, L.; Wang, F.; Li, X.; Peng, F.; Zhang, H.; Shao, Z. Angew. Chem. Int. Ed. 2013, 52, 4117–4121;
g) Xia, G.; Han, X.; Lu, X. Org. Lett. 2014, 16, 2058–2061; h) Jiao, L.; Bach, T. Synthesis 2014, 46, 35–41
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Scheme 3.17 – Retrosynthesis of dehydroaspidospermidine
compatible with our iORC sequence.88
The aldehyde 211 could result from an ozonolysis of 212. This macrocycle is the key
intermediate we planned to use for our key step. From this intermediate to dehydroaspi-
dospermidine, we hope the whole sequence would be performed in a one pot fashion.
We planned tomakemacrocycle 212 from 213 by N-alkylation orMitsunobu reactions
with H2NNs. This monoprotected diol could be the result of a decarboxylative coupling be-
tween potassium salt 215 and vinyl triflate 214. This palladium-catalyzed decarboxylative
coupling between potassium 2-(2-nitrophenyl)acetate derivatives and vinyl triflates was de-
veloped by Zhu and co-workers in 2013.22 This reaction is a key point of our iORC strategy, as
it allows us to build a large variety of precursors for our key domino process. A remarkable
feature of this coupling is its ability to assemble intermediates bearing all the carbons needed
in the natural product.
3.3.1 Key Intermediate Formation
The two partners of the decarboxylative coupling are easy to access. First, the potassium salt
215 had to be synthesised (Scheme 3.18). Starting from ester 145 (already synthesized in
Section 2.2.3), we saponified the methyl ester with KOH, and treated the resulting acid 216
with equimolar amount of potassium tert-butoxyde to reach potassium salt 215.
Then, the vinyl triflate needed for the decarboxylative coupling had to be synthesized
(Scheme 3.19). Starting from the commercially available 217, the enone 218 was obtained
88Fukuyama, T.; Jow, C.-K.; Cheung,M. Tetrahedron Lett. 1995, 36, 6373–6374
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Scheme 3.18 – Synthesis of the potassium salt
after 1,2-addition of a Normant-type Grignard reagent,89 followed by strong acidic work-up
to eliminate ethanol. Silylation of the primary alcohol gave either TES-protected 219 or TBS-
protected 220. These enone derivatives could undergo a copper-assisted 1,4 addition, fol-
lowed by the trapping of the enolate with Comins’ reagent, to give the corresponding vinyl
triflate 214 or 58. Deprotection of this last one afforded free alcohol 221.
O O
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MeMgBr
Mg
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then HCl
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DMF, RT
60-61% (2 steps)
: R = TES
: R = TBS
EtMgBr
CuBr·Me2S
THF, -40°C
then Comins' 
reagent
82%
: R = TES
: R = TBS
: R = H
AcCl
MeOH
quant.
HO
O
RO
O
RO
TfO
217 218 219
220
214
58
221
Scheme 3.19 – Synthesis of vinyl triflates
It is noteworthy that the only important stereocenter of thenatural product, i.e. the one
that will control the diastereochemical outcome of the iORC is formed in a copper-assisted
1,4-addition. We naturally envisioned to make this addition enantioselective using reported
procedures.
Copper-catalysed enantioselective 1,4-addition on enone are well described in the lit-
erature. Nevertheless, most examples are reported on linear or unstrained cyclic enones. The
enantioselective conjugate addition of nucleophiles to cyclopentenones is a challenging pro-
cess that has rarely been achieved. The main examples are from Copper-catalyzed addition
of organomagnesium nucleophiles,90 silver catalized organoaluminium nucleophiles91 and
palladium-catalyzed conjugate addition of arylboronic acid.92
The route toward our vinyl triflate was already optimized and seemed to work well
with copper-assisted 1,4-addition. Wewere hoping Alexakis’ N-heterocarbene (NHC) ligands
89Cahiez, G.; Alexakis, A.; Normant, J. Tetrahedron Lett. 1978, 19, 3013–3014
90See Germain, N.; Schlaefli, D.; Chellat, M.; Rosset, S.; Alexakis, A.Org. Lett. 2014, 16, 2006–2009
91See May, T. L.; Brown,M. K.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2008, 47, 7358–7362
92See Gottumukkala, A. L.; Matcha, K.; Lutz, M.; De Vries, J. G.; Minnaard, A. J. Chem. Eur. J. 2012, 18, 6907–6914
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with catalytic amount of copper could work in our synthesis.93 The trials were done on our
enone 220 (Scheme 3.20). The newly formed cyclopentanone 222 was benzoylated in order
tomeasure the ee (UV detector). Despite our efforts, the copper catalyzed conjugate addition
using Alexakis ligand afforded 222with a maximum of 5% ee.
O
OTBS
O
OTBS
Cu(OTf)2, L*
EtMgBr
Et2O
N N
OH
PF6
L*
O
OBz
1. AcCl, MeOH
2. BzCl, Pyridine
ee=5%
220 222 223
Scheme 3.20 – Asymmetric 1,4-addition trials
The lack of stereoselectiviy might come from the size of the alkyl chain. Most of the
examples described in the development of this ligand were done on simple cyclopentenone
with small substituents (Me, Et). Therefore, we synthesized the allylcyclopentenone 22494
and used the same conditions (Scheme 3.21). The ketone 225was obtained in good yield, but
after cross metathesis to 226 (for UV activity), the measured ee was 10%. An improvement
not good enough to continue with this catalyst.
O
OCu(OTf)2, L*
EtMgBr
Et2O
N N
OH
PF6
L*
O
Ph
Styrene,
Grubbs II
DCM
ee=10%
224 225 226
Scheme 3.21 – Asymmetric 1,4-addition trials
Wewanted to pursue the 1,4-addition withHoveyda’smethodology, using AlEt3 and his
silver-catalyst. The substrate 227 (Scheme 3.22) was chosen to be optimal, due to the chelat-
ing effect of ester. Homoallylation of 217 afforded substituted enone 228. Selective ozonol-
ysis of terminal double bond afforded ester 227. After discussion with Professor Hoveyda, a
sample of 227 was sent to his group for preliminary trials on enantioselective addition. The
results were promising, but showed some trouble for the one-pot triflation of the enolate. A
higher temperature is needed to form the enol triflate, and Dieckmann condensation would
occur. no further work was done for an enantioselective synthesis, as we focused our effort
on the racemic synthesis.
Continuing with racemic vinyl triflates, we performed the decarboxylative cou-
pling with potassium salt 215 following the conditions optimised in our laboratory
93Germain, N.; Magrez, M.; Kehrli, S.; Mauduit, M.; Alexakis, A. Eur. J. Org. Chem. 2012, 5301–5306
94Moore, S. P.; Coote, S. C.; O’Brien, P.; Gilday, J.Org. Lett. 2006, 8, 5145–5148
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Scheme 3.22 – Substrate preparation for asymmetric 1,4-addition trials
(Scheme 3.23).22 We planned to reach diol 229 and monoprotected diol 213. It was previ-
ously observed that this decarboxylative coupling produce had as major side-product the
protodecarboxylation product 230, and reduced triflate 231. The formation of these side-
products was increased if the free alcohol 221was used. In order to improve the yield of 213,
we opted for the TES-protected vinyl triflate 214 as it could be removed selectively, and used
1.2-1.5 equivalent of potassium salt 215.
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Scheme 3.23 – Macrocyclisation attempts
From the diol 229, we performed multiple attempts on double N-alkylation with o-
nitrophenylsulfonamide, as described in the literature.95 Double SN2 on the diiodine 232 or
95a) Zaimoku, H.; Nishide, H.; Nishibata, A.; Goto, N.; Taniguchi, T.; Ishibashi, H. Org. Lett. 2013, 15, 2140–2143; b)
Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, H.; Fukuyama, T. J. Am. Chem. Soc.
2002, 124, 2137–2139; c) Sumi, S.; Matsumoto, K.; Tokuyama, H.; Fukuyama, T. Tetrahedron 2003, 59, 8571–8587;
d) Sumi, S.; Matsumoto, K.; Tokuyama, H.; Fukuyama, T. Org. Lett. 2003, 5, 1891–1893; e) Shimada, N.; Abe, Y.;
Yokoshima, S.; Fukuyama, T. Angew. Chem. Int. Ed. 2012, 51, 11824–11826; f) Schneider, C. Angew. Chem. Int.
Ed. 2002, 41, 4217–4219; g) Pan, G.; Williams, R. M. J. Org. Chem. 2012, 77, 4801–4811; h) Kaburagi, Y.;
Tokuyama, H.; Fukuyama, T. J. Am. Chem. Soc. 2004, 126, 10246–10247; i) Yang, Y.-R.; Lai, Z.-W.; Shen, L.;
Huang, J.-Z.; Wu, X.-D.; Yin, J.-L.; Wei, K. Org. Lett. 2010, 12, 3430–3433
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the dimesylate 233 were tried. Unfortunately, the double N-alkylation process has proven
ineffective, showing lack of reactivity and easy degradation our substrate.
The double Mitsunobu of diol 229 was also troublesome.96 During the Mitsunobu
(Scheme 3.24), triphenylphosphine and DEAD first react to form intermediate 234. In the
presence of alcohol, this intermediate is in equilibrium with reactive species 235 and unre-
active intermediate 236.97 The mechanism of the Mitsunobu reaction has been well studied
and it was shown that intermediate 234 is in some cases an inhibitor of the reaction.98 This
may explain why an excess of the alcohol is often needed to improve the yield, as the equi-
librium will be pushed in favor of 235 and 236. Since the alcohol is sometimes difficult to
obtain (as in our case, the alcohol is our substrate, and the nucleophile is commercially avail-
able), is would be interesting if it could be used as limiting reagent. In this purpose, Walker
in 199598 showed that using neopentyl alcohol could push the equilibrium away from 234.
As neopentyl alcohol is hindered, the SN2 reaction of 235 where R = neopentyl will be too
slow compared to the substrate, and the only reactive specie will be the intermediate 235
with desired substrate R-OH, leading to an improvement of the yield. In our case, when try-
ing the double Mitsunobu on 229, one possibility would be that intermediate 236 was too
favorable, and the reaction was slow. Yet, it is known that sulfonamide, like H2NNs or H2NTs
could react in the presence of PPh3 and DEAD (or DIAD) to give undesired 237.
96e,99 This
side-reaction would compete with the desired Mitsunobu and consume the starting mate-
rial. If the presence of the two alcohols on the molecule slow down the Mitsunobu reaction,
this side-reaction would become the fastest one, and low conversion was achieved, as all the
phosphine and aminewere consumed. Even (cyanomethylene)tributylphosphorane (CMBP)
described to prevent formation of 23796d showed no good reactivity with our substrate.
In order to obtain the macrocycle 212, we decided to go through the monoprotected
alcohol 213 and perform a two step procedure (Scheme 3.25). Having only one alcohol on
themolecule seems to accelerate theMitsunobu reaction and allow the product to be formed
before the side product 237. Deprotecting the TBS in a one-pot fashion, we could obtain the
amino alcohol 239 in good yield using a variation of Walker’s conditions.98 Themacrocyclisa-
tion was again performedwith aMitsunobu reaction. Optimization of the stoichiometry and
concentration allowed us to push the cyclization yield up to 81%. We also attempted tomesy-
96For reviews andmechanistic studies onMitsunobu, see: a) Ahn, C.; Correia, R.; DeShong, P. J. Org. Chem. 2002,
67, 1751–1753; b) Camp, D.; Jenkins, I. D. J. Org. Chem. 1989, 54, 3045–3049; c) Crich, D.; Dyker, H.; Harris, R. J. J.
Org. Chem. 1989, 54, 257–259; d) Sakamoto, I.; Nishii, T.; Ozaki, F.; Kaku, H.; Tanaka, M.; Tsunoda, T. Chem.
Pharm. Bull. 2005, 53, 1508–1509; e) Tsunoda, T.; Yamamoto, H.; Goda, K.; Itô, S. Tetrahedron Lett. 1996, 37,
2457–2458; f) Camp, D.; Hanson, G. R.; Jenkins, I. D. J. Org. Chem. 1995, 60, 2977–2980; g) Dodge, J. A.; Trujillo,
J. I.; Presnell, M. J. Org. Chem. 1994, 59, 234–236; h) Hughes, D. L. Org. Prep. Proced. Int. 1996, 28, 127–164
97Varasi, M.; Walker, K. A. M.; Maddox, M. L. J. Org. Chem. 1987, 52, 4235–4238
98Walker, M. A. J. Org. Chem. 1995, 60, 5352–5355
99Pomerantz, M.; Chou, W. N.; Witczak, M. K.; Smith, C. G. J. Org. Chem. 1987, 52, 159–163
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Scheme 3.24 – Mitsunobumechanism
late the alcohol and perform an intramolecular N-alkylation reaction, but it proved inferior
to Mitsunobu conditions.
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Scheme 3.25 – Macrocyclisation toward 212
During the study of macrocycle 212, we were able to obtain a monocrystal of one of
the diastereoisomer, and obtained an X-ray structure (Figure 3.1). One can observe the bent
structure of the bridged olefin, showing the strain present in this structure (in solid state).100
3.3.2 IORC sequence and endgame
With macrocycle 212 in hand, we could start studying its reactivity toward our iORC domino
sequence (Scheme 3.26). Our original plan was to use ozonolysis for the cleavage of the
olefin. The advantage of this reaction was of course the possibility to remove the oxidant
(ozone) by bubbling argon or nitrogen through the solution, making it the perfect tool for
a one-pot processes. There are a few conditions known to influence ozonolysis. The main
modifications in an ozonolysis are the solvent (DCM or MeOH are the most common ones),
with or without Na2CO3, and quenching the ozonide with Me2S or PPh3. We found that the
cleanest reaction condition with our substrate was the standard one, in DCM without base
100Wagnières, O.; Xu, Z.; Wang, Q.; Zhu, J. J. Am. Chem. Soc. 2014, 136, 15102–15108
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Figure 3.1 – X-Ray structure of one diastereoisomer of the key intermediate 212
and by quenching the reaction withMe2S. The aldehyde intermediate 211 could be observed
after work-up, but was not stable on silicagel. We decided then to continue with the one-
pot procedure. Deprotection of the nosyl group appeared to have a rate dependent on the
solvent. When the reaction mixture was kept in DCM, the deprotection took 24h to reach
completion. However, if MeCN was added, the reaction was finished in 2h. Unfortunately,
the intermediate at this stage was impossible to analyse. No product could be obtained af-
ter an aqueous work-up. Simple filtration and evaporation afforded a crude mixture, which
NMR showed to have some aldol condensation between the C7 and the C21 (240). At that
stage, we attempted to have the cyclized adduct 241. After the deprotection, the screening
of Brønsted acids, Brønsted bases, Lewis acids, solvents and temperatures were done, but no
desired product was ever observed. We expected the cyclization to be easier on the indole
moiety, and decided to continue with the one-pot procedure.
The reduction step was the main problem of the iORC. Many reduction conditions
exist for reducing nitroaryl groups,101 but the reducing conditions should not touch any
iminium/imine/aldehyde/enamine intermediates. The conditions should be slightly acidic
to promote the cyclizations, and the intermediates as well as final product should be stable
enough in the reaction conditions to avoid degradation. As hydrogenations gave no reactions
of degradations, activated zinc powder with HCl 0.5M gave (±)-dehydroaspidospermidine 2,
but only in low yield. All other attempted combinations of Zinc or Iron with various acids
101For some examples of nitroaryl reductions, see: a) Banwell, M. G.; Kelly, B. D.; Kokas, O. J.; Lupton, D. W.Org.
Lett. 2003, 5, 2497–2500; b) Bunce, R. A.; Nammalwar, B. J. Heterocycl. Chem. 2009, 46, 172–177; c) Cardwell, K.;
Hewitt, B.; Ladlow, M.; Magnus, P. J. Am. Chem. Soc. 1988, 110, 2242–2248; d) Heller, G.; Lauth, H.; Buchwaldt, A.
Berichte der Dtsch. Chem. Gesellschaft 1922, 55, 483–489; e) Ho, T. T.-L.; Wong, C. M. C. Synthesis 1974, 6, 45–45;
f) Iwama, T.; Birman, V. B.; Kozmin, S. A.; Rawal, V. H. Org. Lett. 1999, 1, 673–676; g) Raucher, S.; Koolpe, G. A. J.
Org. Chem. 1983, 48, 2066–2069; h) Royer, D.; Wong, Y.-S.; Plé, S.; Chiaroni, A.; Diker, K.; Lévy, J. Tetrahedron
2008, 64, 9607–9618; i) Sachs, F.; Kantorowicz, H. Berichte der Dtsch. Chem. Gesellschaft 1906, 39, 2754–2762; j)
Snape, T. Synlett 2008, 19, 2689–2691; k) Tan, S. H.; Banwell, M. G.; Willis, A. C.; Reekie, T. A.Org. Lett. 2012, 14,
5621–5623
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Scheme 3.26 – iORC sequence
resulted in full degradation. To our delight, reduction using TiCl3
101e-g,i afforded the de-
sired natural product with up to 50% yield after tuning of the stoichiometry, pH of the so-
lution (NH4OAc as buffer) and reaction time. By quenching the excess of TiCl3 with aqueous
NaHCO3, and adding excess of NaBH4 in a one-pot fashion, (±)-aspidospermidine 3 would
be isolated with similar yield.
3.4 Vincadifformine
Vincadifformine 4 was isolated in 1962,102 from the leaves of the tree Vinca Difformis. It is
an indole alkaloid of the Aspidosperma family. Its biosynthesis is fully detailed in 1.1.1. Its
first total synthesis was from Kutney and co-workers in 1968.103 Since then, numerous total
syntheses were achieved.68,104 The synthetic connection between dehydroaspidospermidine
102Djerassi, C.; Budzikiewicz, H.; Wilson, J.; Gosset, J.; Men, J. L.; Janot, M.-M. Tetrahedron Lett. 1962, 3, 235–239
103Kutney, J. P.; Chan, K. K.; Failli, A.; Fromson, J. M.; Gletsos, C.; Nelson, V. R. J. Am. Chem. Soc. 1968, 90, 3891–3893
104a) Barsi, M.-C.; Das, B. C.; Fourrey, J.-L.; Sundaramoorthi, R. J. Chem. Soc. Chem. Commun. 1985, 88–89; b) J.-Y.
Laronze, P.; Laronze-Fontaine, J.; Lévy, J.; Le Men, J. Tetrahedron Lett. 1974, 15, 491–494; c) Kalaus, G.; Greiner, I.;
Kajtar-Peredy, M.; Brlik, J.; Szabo, L.; Szantay, C. J. Org. Chem. 1993, 58, 1434–1442; d) Kalaus, G.; Kiss, M.;
Kajtár-Peredy, M.; Brick, J.; Szabó, L.; Szántay, C.Heterocycles 1985, 23, 2783–2787; e) Kobayashi, S.; Peng, G.;
Fukuyama, T. Tetrahedron Lett. 1999, 40, 1519–1522; f) Kuehne, M. E.; Bandarage, U. K.; Hammach, A.; Li, Y.-L.;
Wang, T. J. Org. Chem. 1998, 63, 2172–2183; g) Kuehne, M. E.; Huebner, J. A.; Matsko, T. H. J. Org. Chem. 1979,
44, 2477–2480; h) Kuehne, M. E.; Matsko, T. H.; Bohnert, J. C.; Kirkemo, C. L. J. Org. Chem. 1979, 44, 1063–1068;
i) Kuehne, M. E.; Podhorez, D. E. J. Org. Chem. 1985, 50, 924–929; j) Kuehne, M. E.; Roland, D. M.; Hafter, R. J.
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2 and vincadifformine 4 was already known in both directions65,105 (Scheme 3.27). Using
Mander’s reagent, dehydroaspidospermidine was converted into vincadifformine with 50%
yield.65
N
N
N
H
N
CO2Me
Lévy, 1984
Sévenet, 1994
n-BuLi
NCCO2Me
THF, -78 °C
50%
Ban, 1985
MacMillan, 2011
2 4
Scheme 3.27 – Synthetic connection between vincadifformine and dehydroaspidospermidine
3.5 Quebrachamine
Quebrachamine 242 is an Aspidosperma alkaloid highly related to dehydroaspidospermidine
2 (Scheme 3.28). It was first isolated by Hesse in 1882106 but no structure was given. In 1951,
Gellert found a new alkaloid called kamassine107 but found out it was quebrachamine 242
one year later.108 Its correct structure was hypothesized by Witkop in 1960,109 before it was
confirmed by Biemann one year after.110 Since then, more than twenty syntheses (total and
formal) were published.62,70,72,74g,84,86b,111
Org. Chem. 1978, 43, 3705–3710; k) Kuehne, M. E.; Wang, T.; Seaton, P. J. J. Org. Chem. 1996, 61, 6001–6008; l)
Lewin, G.; Bernadat, G.; Aubert, G.; Cresteil, T. Tetrahedron 2013, 69, 1622–1627; m) Pandey, G.; C, P. K. Org. Lett.
2011, 13, 4672–4675
105a) Yoshida, K.; Nomura, S.; Ban, Y. Tetrahedron 1985, 41, 5495–5501; b) Hugel, G.; Lévy, J. Tetrahedron 1984, 40,
1067–1073; c) David, B.; Sevenet, T.; Thoison, O.; Awang, K.; Pais, M.; Wright,M.; Guenard, D. Bioorg. Med. Chem.
Lett. 1997, 7, 2155–2158
106Hesse, O. Justus Liebig’s Ann. der Chemie 1882, 211, 249–282
107Schlittler, E.; Gellért, E.Helv. Chim. Acta 1951, 34, 920–923
108Gellért, E.; Witkop, B.Helv. Chim. Acta 1952, 35, 114–115
109Kny, H.; Witkop, B. J. Org. Chem. 1960, 25, 635–637
110Biemann, K.; Spiteller, G. Tetrahedron Lett. 1961, 2, 299–304
111; a) Ziegler, F. E.; Kloek, J. a.; Zoretic, P. a. J. Am. Chem. Soc. 1969, 91, 2342–2346; b) Kutney, J. P.; Abdurahman, N.;
Gletsos, C; Le Quesne, P.; Piers, E.; Vlattas, I. J. Am. Chem. Soc. 1970, 92, 1727–1735; c) Takano, S; Hatakeyama, S;
Ogasawara, K J. Am. Chem. Soc. 1976, 98, 3022–3023; d) Giri, V. S.; Ali, E.; Satyesh, C. J. Heterocycl. Chem. 1980,
17, 1133–1134; e) Takano, S.; Chiba, K.; Yonaga,M.; Ogasawara, K. J. Chem. Soc. Chem. Commun. 1980, 616–617;
f) Ban, Y.; Yoshida, K.; Goto, J.; Oishi, T. J. Am. Chem. Soc. 1981, 103, 6990–6992; g) Takano, S.; Yonaga, M.;
Ogasawara, K. J. Chem. Soc. Chem. Commun. 1981, 1153–1155; h) Wenkert, E.; Halls, T. D.; Kwart, L. D.;
Magnusson, G.; Showalter, H. Tetrahedron 1981, 37, 4017–4025; i) Temme, O.; Taj, S.-A.; Andersson, P. G. J. Org.
Chem. 1998, 63, 6007–6015; j) Wee, A. G.; Yu, Q. Tetrahedron 1998, 54, 13435–13448; k) Amat, M.; Lozano, O.;
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3.6. Conclusion
One possible biosynthetic pathway of quebrachamine 242 is from dehydroaspidosper-
midine 2. Biemann already suggest a possible connection between these two alkaloids in his
structure determination of the aspidospermidine.59 Previous studies by Schmid,112 Trotte113
andRawal84 have reported the possible synthetic connection between these twonatural com-
pounds, going from aspidospermidine and dehydroaspidospermidine to quebrachamine
and vice versa (Scheme 3.28). The reaction should pass by the same iminium intermediate
150 used in our iORC.
N
H
N
N
H
N
N
N
(-)-Quebrachamine(+)-Dehydroaspidospermidine
Hg(OAc)2
or KMnO4
PtO2, H2
-H+
+H+
H
150 2422
Scheme 3.28 – Possible biosynthetic pathway of quebrachamine
Iminium intermediates similar to 150 have already been reported for the synthesis of
quebrachamine.87c Therefore, we planed to intercept iminium 150 in our domino sequence
by using stronger reducing conditions to obtain quebrachamine 242 instead of dehydroaspi-
dospermidine 2. Unfortunately, the formation of quebrachamine has proven unsuccessful
using the iORC domino process. Only dehydroaspidospermidine or degradation were ob-
served.
3.6 Conclusion
In summary, the total syntheses of (±)-aspidospermidine 3, (±)-dehydroaspidospermidine
2 and (±)-vincadifformine 4 were accomplished (Scheme 3.29).100 From the potassium car-
bonate 215 and vinyl triflate 214, a decarboxylative coupling developed in our laboratory
allowed us to build intermediate 213 bearing all the carbons needed in the natural product.
Two consecutiveMitsunobu reactions afforded themacrocyclic key intermediate212 in good
yield. Our key iORC sequence did a full skeleton reorganization in a diastereoselective fash-
ion, allowing us to reach either (±)-dehydroaspidospermidine 2 or (±)-aspidospermidine 3.
A known procedure allowed us to reach (±)-vincadifformine 4 in 50% yield.
Escolano, C.; Molins, E.; Bosch, J. J. Org. Chem. 2007, 72, 4431–4439; sl) Bajtos, B.; Pagenkopf, B. L. Eur. J. Org.
Chem. 2009, 1072–1077; m) Sattely, E. S.; Meek, S. J.; Malcolmson, S. J.; Schrock, R. R.; Hoveyda, A. H. J. Am.
Chem. Soc. 2009, 131, 943–953; n) Nidhiry, J. E.; Prasad, K. R. Tetrahedron 2013, 69, 5525–5536; o) Hsu, S. W.;
Cheng, H. Y.; Huang, A. C.; Ho, T. L.; Hou, D. R. Eur. J. Org. Chem. 2014, 3109–3115; p) Liu, Y.; Liniger, M.;
McFadden, R. M.; Roizen, J. L.; Malette, J.; Reeves, C. M.; Behenna, D. C.; Seto, M.; Kim, J.; Mohr, J. T.; Virgil, S. C.;
Stoltz, B. M. Beilstein J. Org. Chem. 2014, 10, 2501–2512
112Bycroft, B. W.; Schumann, D.; Patel, M. B.; Schmid, H.Helv. Chim. Acta 1964, 47, 1147–1152
113Camerman, A.; Camerman, N.; Kutney, J.; Piers, E.; Trotter, J. Tetrahedron Lett. 1965, 6, 637–642
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Scheme 3.29 – Summary of the total synthesis of aspidospermidine, dehydroaspidospermidine and vincad-
ifformine
These syntheses showed the power of our iORC domino sequence, and the simple syn-
thesis of precursor 212motivated us to pursue other natural products with similar key steps.
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CHAPTER4
Approach Towards the Total Synthesis of
Aspidoalbidine
(+)-Aspidoalbidine (or (+)-fendleridine) 5 is an aspidosperma alkaloid isolated in 1966 by
Burnell and co-workers from the seeds of Aspidosperma fendleri (Figure 4.1). The name
fendleridine was based on the name of the tree.114 Although in 1963, Brown isolated (+)-N-
acetylaspidoalbidine 244,115 they gave the name "aspidoalbidine" to the postulated simplest
member by analogy to aspidospermidine, discovered by Biemann two years before.59 While
both names seemed to be used nowadays for this natural product, we will use aspidoalbidine
as it relates better to the aspidosperma family to which it belongs.
N
H
N
O
H
N
N
O
H
Ac
N
H
21
N
4
H OH
(+)-Limaspermidine (+)-Aspidoalbidine (+)-N-Acetylaspidoalbidine243 5 244
Figure 4.1 – Structures of limaspermidine 243, aspidoalbidine 5 and N-acetylaspidoalbidine 244
The biosynthesis of this alkaloid seems to arize from limaspermidine (18-
hydroxyaspidospermidine) 243 via oxidation of the N4-C21 bond and cyclization.
4.1 Previous Syntheses of Aspidoalbidine
Few syntheses of both aspidoalbidine 5 and N-acetylaspidoalbidine 244 are reported. Most
of them followed the biosynthetic pathway. They reached first limaspermidine, oxidized the
N1-C21 bond and the alcohol group cyclized spontaneously on the iminium moiety. This
114Burnell, R. H.; Medina, J. D.; Ayer, W. A. Can. J. Chem. 1966, 44, 28–31
115Brown, K.; Budzikiewicz, H.; Djerassi, C. Tetrahedron Lett. 1963, 4, 1731–1736
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last oxidation step required the protection of the indole moiety, which is the main reason
whymost of the groups targeted N-acetylaspidoalbidine.
4.1.1 Ban’s Syntheses of (±)-N-Acetylaspidoalbidine and (±)-Aspidoalbidine
In 1975, Ban and co-workers reported the first total synthesis of (±)-N-acetylaspidoalbidine
244,116 and one year later reported the first total synthesis of (±)-aspidoalbidine 5
(Scheme 4.1).117 Starting from pentacyclic intermediate 245 . Michael addition with ketene
thioacetal monoxide provided intermediate 246. Hydrolysis of thioacetal group followed
by reduction with LiAlH4 provided alcohol derivative 247. Selective acetylation of indole
afforded 248. Hydrogenation on both 247 and 248 with Adams’ catalyst afforded (±)-
limaspermidine 243 and (±)-N-acetyllimaspermidine 249 respectively. Final oxidation of
N1-C21 bond with mercury acetate in acidic medium afforded (±)-aspidoalbidine 5 or (±)-
N-acetylaspidoalbidine 244.
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Scheme 4.1 – Ban’s synthesis of (±)-N-acetylaspidoalbidine and (±)-aspidoalbidine
In 1987, Ban and co-workers reported a formal synthesis of (±)-N-acetylaspidoalbidine
244 (Scheme 4.2).118 From the indole-protected precursor 250, addition of methyl ox-
alate, Wolff-Kishner reduction and esterification afforded methyl ester derivative 251.
Reduction gave hemiaminal derivative 252. Under acidic conditions, the THP was
cleaved and the hemiaminal was dehydrated to form iminium salt 253, which cy-
116Ban, Y.; Ohnuma, T.; Seki, K.; Oishi, T. Tetrahedron Lett. 1975, 16, 727–730
117Ban, Y.; Honma, Y.; Ohnuma, T.Heterocycles 1976, 5, 47–51
118Yoshida, K.; Sakum, Y.; Ban, Y.Heterocycles 1987, 25, 47–50
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clized into (±)-dehydrolimaspermidine 254. Reduction and acetylation afforded (±)-N-
acetyllimaspermidine 249 as the precursor of (±)-N-acetylaspidoalbidine 244
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Scheme 4.2 – Ban’s formal synthesis of (±)-N-acetylaspidoalbidine
4.1.2 Overman’s Formal Synthesis of (±)-N-Acetylaspidoalbidine
In 1991, Overmanpublished a formal synthesis of (±)-N-acetylaspidoalbidine involving a tan-
dem aza-Cope rearrangement/Mannich cyclization sequence as a key step (Scheme 4.3).119
Addition of 255 on ketone 256 followed by intramolecular acylation afforded lactone 257
in 76% yield. Wittig reaction followed by lactone opening gave key intermediate 258. The
key-step started with formation of iminium 259. Oxy-cope rearrangement gave enol inter-
mediate 260 and Mannich cyclization afforded ketone derivative 261, that condensed into
indolenine 262. A four steps sequence allowed Overman and co-workers to reach (±)-N-
acetyllimaspermidine 249.
4.1.3 Boger’s Synthesis of (±)-Aspidoalbidine
Boger and co-workers reported in 2010 a total synthesis of (±)-aspidoalbidine120 using their
emblematic domino IEDDA/(1,3)-dipolar cycloaddition sequence (also presented for their
total synthesis of vindorosine in Section 1.2.4). From intermediate 263 (Scheme 4.4), a ther-
mal IEDDA occured and afforded intermediate 264. Release of nitrogen resulted in dipolar
intermediate 265. A (1,3)-dipolar cycloaddition afforded polycyclic structure 266 in 71% yield
from 263. Conversion of the ester to the primary amide followed by dehydration to the nitrile
and deprotection of silyl ether with HF resulted in the cyclized aspidoalbidine-core 267. Six
steps were needed to reach aspidoalbidine 5. Separation of enantiomers four steps before
the end allowed them to reach the enantiopure form of the natural product.
119Overman, L. E.; Robertson, G. M.; Robichaud, A. J. J. Am. Chem. Soc. 1991, 113, 2598–2610
120Campbell, E. L.; Zuhl, A. M.; Liu, C. M.; Boger, D. L. J. Am. Chem. Soc. 2010, 132, 3009–3012
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Scheme 4.3 – Overman’s Formal Synthesis of (±)-N-acetylaspidoalbidine
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Scheme 4.4 – Boger’s Total Synthesis of aspidoalbidine
4.1.4 Banwell’s Synthesis of (±)-N-Acetylspidoalbidine
In 2012, Banwell and co-workers published a total synthesis of (±)-N-acetylaspidoalbidine
244 (Scheme 4.5).101k Nitrile derivative 268 was converted in four steps into the enone in-
termediate 269. A domino reduction/cyclization sequence using Raney-Cobalt and TsOH
afforded tertacyclic intermediate 270. Alkylation of the amine gave 271, and cyclization pro-
vided the pentacyclic structure 272. (±)-Limaspermidine 243was obtained after reduction of
the amide, and Ban’s procedure117 allowed them to reach (±)-N-acetylaspidospermidine 244.
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Attempts to reproduce Ban’s conversion of (±)-limaspermidine 243 into (±)-aspidoalbidine
5 (without protection of indole) were not successful.
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Scheme 4.5 – Banwell’s Total Synthesis of (±)-N-acetylaspidoalbidine
4.1.5 Shao’s Formal Synthesis of (+)-Aspidoalbidine
Shao and co-workers published in 2013121 a formal synthesis of (+)-N-acetylaspidoalbidine
similar to Banwell’s work (see above). Having developed a palladium-catalyzed decarboxyla-
tive allylation, they used this methodology to build indole precursor 273 (Scheme 4.6). Re-
ductive cyclization of the cyano group on the ketone, followed by oxidation resulted in alde-
hyde 274. Reduction of aldehyde with LiAlH4, followed by benzyl deprotection and alco-
hol protection afforded intermediate 275. Following Banwell’s route, alkylation of amine
afforded 276, which was cyclized in two steps into protected (+)-dehydrolimaspermidine
277. Reduction of 277 with LiAlH4 afforded (+)-limaspermidine 243 as precursor of (+)-
aspidoalbidine.
4.1.6 Canesi’s Formal Synthesis of (±)-N-Acetylaspidoalbidine
In 2012, Canesi and co-workers developed an oxidative 1,3-alkyl shift process and used it in
the formal synthesis of (±)-N-acetylaspidoalbidine (Scheme 4.7).122 From alkyne 278, their
1,3-alkyl shift process afforded alkene 279 in good yield. Diiodination gave olefin 280 as a
mixture of isomers. Amination and intramolecular 1,4-addition provided intermediate 281
in low yield, as only one isomer of 280 had the correct conformation to favor the cyclization.
121Zhang, S.-X.; Shen, X.-L.; Li, Z.-Q.; Zou, L.-W.; Wang, F.-Q.; Zhang, H.-B.; Shao, Z.-H. J. Org. Chem. 2013, 78,
11444–11449; Correction in Zhang, S.-X.; Shen, X.-L.; Li, Z.-Q.; Zou, L.-W.; Wang, F.-Q.; Zhang, H.-B.; Shao, Z.-H. J.
Org. Chem. 2014, 79, 829–829
122Guérard, K. C.; Guérinot, A.; Bouchard-Aubin, C.; Ménard, M. A.; Lepage, M.; Beaulieu, M. A.; Canesi, S. J. Org.
Chem. 2012, 77, 2121–2133
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Scheme 4.7 – Canesi’s Formal Synthesis of (±)-N-acetylaspidoalbidine
Mesylation of the alcohol followed by cyclization afforded tricyclic structure 282.
Hydrogenolysis of the iodide and hydrogenation of the two olefins afforded intermediate
283. From this intermediate, six steps (deprotection of the aldehyde moiety and its re-
duction into alcohol, Fischer indole synthesis, reduction and acetylation) provided (±)-N-
acetyllimaspermidine 249.
4.1.7 Qiu’s Total Synthesis of (±)-N-Acetylaspidoalbidine
In 2014, Qiu and co-workers reported aDiels-Alder cycloaddition between tryptamine deriva-
tive 284 and propynal (Scheme 4.8).123 The resulting cycloadduct 285 was transformed
to 286 by a three steps sequence. Reduction of the aminal followed by oxidation of alco-
hol afforded aldehyde 287. Domino Michael addition gave pentacyclic intermediate 288.
123Jin, J.; Qiu, F. G. Adv. Synth. Catal. 2014, 356, 340–346
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Wittig reaction followed by functional group manipulations afforded (±)-limaspermidine
243. Qiu and co-workers attempted to change the oxidation conditions to reach (±)-N-
acetylaspidoalbidine 244. Nevertheless, most reported conditions for tertiary amine oxida-
tion suffered from irreproducibility and non completion of the reaction. Iodine oxidation of
tertiary amine (reported on alkaloids by Szántay in 2001)124 gave the final product in 21%
yield.
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Scheme 4.8 – Qiu’s Total Synthesis of (±)-N-acetylaspidoalbidine
4.2 Synthetic Studies of Aspidoalbidine
Considering the close relation between aspidospermidine and aspidoalbidine, we decided to
pursue the total synthesis of this Aspidosperma alkaloid. As most previous syntheses passed
by 18-hydroxyaspidospermidine (limaspermidine), then oxidize the C21-N4 bond into its
iminium form, we wanted to see if similar iminium intermediates were not readily accessi-
ble through our iORC process.
From a retrosynthetic analysis perspective (Scheme 4.9), (±)-aspidoalbidine 5 could
arise from (±)-dehydroaspidoalbidine 289. Disconnecting the aminal ether would give the
iminium 290. Following the iORC disconnection (cf. Chapter 3), we can consider the discon-
nection of the iminium moiety and indolenine moiety to the putative diamino-dicarbonyl
124Moldvai, I.; Szántay, C.; Szántay, C.Heterocycles 2001, 55, 2147–2155
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intermediate 291. This intermediate could result from the reduction of a nitro group, the de-
protection of a secondary amine, and intramolecular Dieckmann condensation frommacro-
cycle 292. If we compare this intermediatewith aldehyde 211 in Scheme 3.17, the only differ-
ence in the key step would be to perform the ozonolysis from 293 with a work-up leading to
the methyl ester instead of aldehyde. Cyclopentene derivative 293 is again closely related to
the key intermediate 212 used for aspidospermidine. Taking inspiration from the aspidosper-
midine synthesis presented in theprevious chapter, we could reach this 10-membered ringby
twoMitsunobu reaction and a hydroboration from precursor 294. This precursor could arise
from our palladium-catalyzed decarboxylative coupling between potassium carboxylate 215
and vinyl triflate derivative 295.
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Scheme 4.9 – Retrosynthetic analysis of aspidoalbidine
4.2.1 Key intermediate synthesis
The synthesis of potassium carboxylate 215 was already detailed in 3.3.1. For the vinyl tri-
flate derivative 295, we decided to follow the same strategy as for triflate derivative 214 (with
ethyl instead of vinyl, see 3.3.1). We planned that the presence of the vinyl group instead of
an ethyl moiety would not interfere with the synthetic route used in the total synthesis of as-
pidospermidine. Starting from TES-protected enone 219 (Scheme 4.10). A copper-assisted
1,4-addition of vinylmagnesium bromide, followed by trapping of the enolate with Comins’
reagent afforded triflate derivative 295. To our delight, the palladium-catalyzed decarboxyla-
tive coupling between potassium carboxylate 215 and vinyl triflate derivative 295 afforded
product 294 as a mixture of diastereoisomers in 58% yield.
From monoprotected diol 294, Mitsunobu reaction with nosylamine afforded pro-
tected aminoalcohol 296 (Scheme 4.11). Deprotection with catalytic amount of HCl in
methanol gave aminoalcohol 297. A second Mitsunobu afforded desired macrocycle 298.
The results of this cyclization was different from the aspidospermidine case. In large scale,
66
4.2. Synthetic Studies of Aspidoalbidine
NO2
TBSO OH
NO2
OTBS
OTES
CO2K
TfO
OTES
O
CH2=CHMgBr
CuBr·Me2S
THF, -40 °C
then Comins' 
reagent
73%
+
OTES
TfO
[Pd(allyl)Cl]2
X-Phos
Diglyme
100 °C
then TBAF, 0 °C
58% dr 1:1
219 295
215 295 294
Scheme 4.10 – Synthesis of triflate and decarboxylative coupling
dimerization of 297 appeared as major side-product (60%). To avoid this side-reaction,
higher dilution had to be used in the scale up of this intramolecular Mitsunobu reaction. Se-
lective anti-Markovnikov hydroxylation of terminal double bond in the presence ofmore hin-
dered olefins were already described in the literature, using hindered borane like Cy2BH,
125
thexylborane126 or 9-BBN.127 In our case, attemptswith these boranes aswell as simpler ones
were performed. Only 9-BBN afforded alcohol 299 with good yield. Finally, protection with
TBSCl gave 293.
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Scheme 4.11 – Mitsunobu cyclization
125Jiao, L.; Lin, M.; Zhuo, L. G.; Yu, Z. X.Org. Lett. 2010, 12, 2528–2531
126Nagaoka, H.; Shibuya, K.; Yamada, Y. Tetrahedron 1994, 50, 661–688
127a) San Feliciano, A.; Medardea, M.; Toméa, F.; Caballeroa, E.; Hebreroa, B.; del Corrala, J. M. M.; Barrerob, A. F.
Tetrahedron 1989, 45, 1815–1822; b) Hoveyda, A. H.; Lombardi, P. J.; O’Brien, R. V.; Zhugralin, A. R. J. Am. Chem.
Soc. 2009, 131, 8378–8379; c) Yu, M.; Ibrahem, I.; Hasegawa, M.; Schrock, R. R.; Hoveyda, A. H. J. Am. Chem. Soc.
2012, 134, 2788–2799
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4.2.2 iORC Study
Our first ozonolysis attempts were on free alcohol 299 (Scheme 4.12). Many conditions were
reported on ozonolysis to afford a methyl ester instead of aldehyde.128 If an ozonolysis is
performed in the presence of methanol and a mild base, peroxide 300 should be formed.
Quenching this peroxide into methyl ester 301 is a well described procedure, commonly per-
formed by treatment with acids,129 hypochlorites,130 Ac2O/Et3N
131 or Ac2O/pyridine.
132 If
the base used during ozonolysis is strong (NaOH, or sodium methanolate), direct formation
of methyl ester 301 should be observed. In our case, all attempts gave dirty mixture of perox-
yde 302 and lactone 303 with poor mass balance. Methyl peroxide 300 or methyl ester 301
were never observed. The reason could be that the intramolecular cyclization was faster than
the attack of the solvent, or methyl ester was formed, but lactonization happened under the
reaction conditions. It is also possible that methyl peroxide degraded before conversion to
methyl ester. In any case, if lactonization was easy, removing the methanol in the reaction
mixture should favor it, and in fact reaction was much cleaner without methanol. Unfortu-
nately, using Ac2O and Et3N provided large amount of peroxide 302 and low conversion into
lactone 303. Amongst all the conditions tried, only Ca(OCl)2 afforded lactone 303 cleanly
with good yield (70%).
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Scheme 4.12 – Ozonolysis mechanism
Now that ozonolysis was optimized, we looked into the rest of the domino sequence
(Scheme 4.13). Large scale ozonolsis of 299 afforded lactone 303with reproducible yield. We
128Lee, D. G.; Chen, T. In Compr. Org. Chem. V7 Oxidations, Trost, B. M., Fleming, I., Eds.; Pergamon, Oxford: 1991,
pp 541–591
129Keul, H.; Griesbaum, K. Can. J. Chem. 1980, 58, 2049–5054
130Fisher, T. J.; Dussault, P. H. Tetrahedron Lett. 2010, 51, 5615–5617
131Schreiber, S. L.; Claus, R. E.; Reagan, J. Tetrahedron Lett. 1982, 23, 3867–3870
132Lee, S.-g.; WooLim, C.; EuiSong, C.; HanPark, D. Synth. Commun. 1996, 26, 4623–4631
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first attempted direct Dieckmann cyclization using organic or inorganic bases, in different
solvents at various temperature. It was possible to observe which conditions could deproto-
nate substrate 303 (DBU, > 50 °C), as the reaction was performed on each diastereoisomer
separately and epimerization could be observed when deprotonation at C7 occurred. How-
ever, no cyclization into 304was observed.
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Scheme 4.13 – Study of key step
Deprotection of nosyl group afforded an unstable crudemixture of amine 305 and pre-
sumably enamine 306. The deprotection wasmuch cleaner if performed in acetonitrile com-
pared to DCM. Cyclization attempts into 307 were attempted with various bases, acids or
Lewis acids, but without success. We thought that as the C7 position of 305 needed to be
activated, it would be beneficial to already reduce the nitro group, in order to form the in-
dole. The position C7 would then be nucleophillic with milder activation conditions. Un-
fortunately, only degradation was observed no matter the reduction conditions tried or the
acidity of the solution. Never any dehydroaspidoalbidine 289was observed.
One of the problems may come from the conformation of the lactone moiety that dis-
favors any type of cyclization. We decided then to use the TBS-protected precursor 293 to
avoid lactone formation (Scheme 4.14).
The work toward the total synthesis of aspidoalbidine is unfortunately not finished at
the moment. Preliminary results showed that synthesis of methyl ester 292 was less clean
than lactone 303. From ester 292 Dieckamnn condensation to 304 has proven unsuccess-
ful under Brønsted acid, Brønsted base or Lewis acid conditions. When stronger conditions
were used, degradation appeared. Deprotection of 308 gave unstable amine derivative 308
that could not be converted into tricyclic intermediate 307 or dehydroaspidoalbidine 289.
The ozonolysis of 293 into acid 309 is still ongoing. We planned to activate acid 309 via the
corresponding acid chloride to facilitate the Dieckmann cyclization.
69
Chapter 4: Approach Towards the Total Synthesis of Aspidoalbidine
NO2
N
Ns
OTBS
O
NNO2
Ns
CO2Me
OTBS
O
N
OH
O
NO2
Ns
O
N
H
NO2
CO2Me
O
N
O
NO2
N
N
O
O3, NaHCO3
-78 °C to 0 °C
then Ca(OCl)2
0 °C to RT
DCM
PhSH, NaHCO3
DCM or MeCN
O
NNO2
Ns
CO2H
OTBS
OTBS
(COCl)2
then base 
or acid
acid,
base,
or LA
acid,
base,
or LA
Reduction
Cyclization
Ongoing
Work
293
292
304
308 307289
309
Scheme 4.14 – Study of key step
4.3 Conclusion
By changing the ethyl into a vinyl group, we could synthesize vinyl triflate 295 with similar
route as for aspidospermidine (Scheme 4.15). Decarboxylative coupling with potassium salt
215 afforded intermediate 294. Two successive Mitsunobu reactions allowed us to reach ten-
membered ring 298. Hydroboration followed by silyl protection gave the key intermediate
293 needed for our iORC process. Unfortunately, this key domino process proceeded less
easily than for the previous examples. The Dieckmann condensation was difficult, or the
product too unstable to be observed. The study of our key step is still ongoing.
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Scheme 4.15 – Summary of the synthetic efforts towards aspidoalbidine
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CHAPTER5
Kopsihainanine A
The Apocynaceae is a family of tropical or subtropical floral plants, which most of the mem-
bers are poisonous and produce milky latex. The Kopsia genus of this family is wildely dis-
tributed in Asia and Australia and is rich in alkaloids. From the leaves of Kopsia hainanensis,
a plant used in chinese medicine, Gao and co-workers in 2011 isolated two monoterpene
indole alcaloids, (+)-kopsihainanine A 6 and (+)-kopsihainanine B 310 (Figure 5.1).133 (+)-
Kopsihainanine A 6 possess a unusual 6/5/6/6/6 pentacyclic structure.
CO2
10
11
12
13
8
9
N
H
1 2
7
18
19
20
21 15
14
3
N
4
17
6
16
O
HO
H
10
11
12
13
8
9
N
H
1 2
7
6
18 19
20
21 15
14
3H
N
45
H 17
6
O
(±)- +)-Kopsihainanine A (+)-Kopsihainanine B6 310
Figure 5.1 – (+)-kopsihainanine A 6 and (+)-kopsihainanine B 310
Gaoand co-workers suggested the biosynthesis of kopsihainanineA6 fromkopsihaina-
nine B 310 (Scheme 5.1). Decarboxylation and retro-Michael gave vinylketone structure 311.
An oxidation of the terminal olefin afforded glyoxal intermediate 312. This intermediate
should condense into the hemiaminal 313, and has keto-enol equilibrium with diol 313 and
kopsihainanine A 6.
Even without any reported biosynthesis of kopsihainanine B 310, we could postulate a
biosynthetic pathway (Scheme 5.2). From vincadifformine 4, an oxidation into minovincine
315 occurred. Kutney postulated in 1971 that this oxidation is more likely to happen at this
stage instead of happening on an earlier intermediate.134 We postulated that an intramolec-
ular conjugated addition of minovincine 315 could afford 316. Similar cyclizations were de-
133Chen, J.; Chen, J.-J.; Yao, X.; Gao, K. Org. Biomol. Chem. 2011, 9, 5334–5336
134Kutney, J. P.; Beck, J. F.; Eggers, N. J.; Hanssen, H. W.; Sood, R. S.; Westcott, N. D. J. Am. Chem. Soc. 1971, 93,
7322–7324
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Scheme 5.1 – Sugested biosynthesis of kopsihainanine A 6 from kopsihainanine B 310
scribed during the biomimetic synthesis of kopsijasminilam135 and pauciflorine A and B by
Kuehne and co-workers.136
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Scheme 5.2 – Postulated biosynthesis of kopsihainaine B
Reduction of the ketonewould afford kopsinine 317. From this alkaloid, the cyclization
of C6 on C22 is required. Kuehne and co-workers showed similar transformation in acidic
135Kuehne, M. E.; Li, Y. L.; Wei, C. Q. J. Org. Chem. 2000, 65, 6434–6440
136Kuehne, M. E.; Li, Y. L.Org. Lett. 1999, 1, 1749–1750; Corrections in Kuehne, M. E.; Li, Y. L. Org. Lett. 2000, 2,
97–97
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media in 1985.137 Such cyclization would convert kopsinine 317 into kopsanone 318. The
selectiveα-keto hydroxylation of C16 carbon is needed to reach kopsine 319. Such hydroxyla-
tion was performed on similar substrate in 10 steps byMagnus in a racemic total synthesis of
kopsine in 1989.138 From kopsine 319, acyloin rearrangement could afford α-hydroxyketone
320.139 This α-hydroxyketon structure is also present in the alkaloid dasyrachine, found in
Kopsia dasyrachis by Kamand co-workers.140 They found in the same plantmethyl chanofru-
ticosinate 321,141 which is closely related to kopsihainanine B 310. Therefore we suggested
an oxidative cleavage of the α-hydroxyketone moiety of 320 to reach kopsihainanine B 310
5.1 Previous Syntheses of Kopsihainanine A
N
H
N
O
HO
H
N
O
Bn
CONH2N
O
Bn
CN
O
O
N
O
Bn
N
HN
Bn
O
H
1. BH3·THF
    THF, -20 °C
    then NaBO3
    73%
2. MsCl, Et3N
    DCM, 0 °C
3. NaH, DMF
    0 °C to RT
58% (2 steps)
N
N
O
H
Bn
1. LDA, O2, Na2SO3
    THF, 0 °C to RT
    85% (dr > 6:1)
2. AlCl3
    Anisole, 100 °C
    64%
LiAlH4
THF, -20 °C
then 2N HCl
98%
t-BuOK
vinyl-CN
THF/t-BuOH
0 °C to RT
78%
N
O
Bn
CN
HCO2H
quantitative
racemic synthesis
racemic
N
O
Bn
CN
>92% ee
Pd2dba3
L*
PhMe, 50 °C
> 90%
HCO2H
quantitative
enantioselective
synthesis
N
O
t-Bu
PPh2
L*
(+)-
322
323
323
324325
326 327 6
Scheme 5.3 – Previous syntheses of kopsihainanine A 6
Up to date, four total synthesese were published. The first three are shown in
Scheme 5.3. The difference between these three syntheses resides on the rout towards cyano
137Kuehne, M. E.; Seaton, P. J. J. Org. Chem. 1985, 50, 4790–4796
138Magnus, P.; Katoh, T.; Matthews, I. R.; Huffman, J. C. J. Am. Chem. Soc. 1989, 111, 6707–6711
139Govindachari, T. R.; Nagarajan, K.; Schmid, H.Helv. Chim. Acta 1963, 46, 433–444
140Kam, T. S.; Subramaniam, G.; Chen, W. Phytochemistry 1999, 51, 159–169
141Kam, T. S.; Choo, Y. M.; Chen, W.; Yao, J. X. Phytochemistry 1999, 52, 959–963
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intermediate 323. The first one was a racemic total synthesis by She and co-workers in
2012.142 Starting from ketone 322, conjugate addition afforded racemic cyano derivative 323.
In 2013, Lupton and co-workers143 and Shao and co-workers87f published at the same time a
palladium-catalyzed decarboxylative allylation of precursor 325 using PHOX-type ligand to
reach one enantiomer of 323.
From this intermediate, hydrolysis of the cyano group into primary amide derivative
324 followed by reductionwith LiAlH4 afforded cyclized intermediate 326. Anti-Markovnikov
hydroxylation of allyl group followed by mesylation and cyclization afforded protected 16-
dehydroxykopsihainanine A 327. Oxidation of α position of amide followed by deprotection
gave alkaloid 6. It is interesting to report that She did obtain an aluminum complex of kopsi-
hainanine A due to the last deprotection step. The product they obtained was not soluble in
CDCl3, in opposition to the isolated natural product. Shao, using the same last step for the
synthesis (deprotection of the N-Benzyl protected indole using AlCl3) observed the same sol-
ubility issue. But after treatment of the natural product with Rochelle’s salt, the free natural
product was obtained.
Last year, Mukai and co-workers reported a new strategy for a total synthesis of (+)-
kopsihainanine A 6.144 From precursor 328, a similar palladium-catalyzed decarboxylative
allylation gave 329 with excellent ee. Deprotection of both Boc and Bz group afforded inter-
mediate 330. Bischler-Napieralski reaction followed by NaBH4 reduction converted 330 into
331. Boc and Cbz protection followed by dihydroxylation gave diol intermediate 332. Cbz
deprotection and oxidation with IBX afforded α-ketonamide intermediate 333. Reduction
with NaBH4 and Boc deprotection afforded the natural product (+)-6.
5.2 Retrosynthetic Study
In our previous uses of our iORC domino process, we showed that with bulky group in the
position 3 of indole, the intermediate 10 would cyclize from N1 to afford protected (±)-
goniomitine 61 (Scheme 5.5). With a tether, we could force the cyclization from 150 to (±)-
dehydroaspidospermidine 2 and (±)-aspidospermidine 3. However, both cyclizations gave
cis-fused [6,6] ring systems. By targeting (±)-kopsihainanine A 6, we planned to address
two questions: (1) Will the cyclization of 334 (without tether) still be highly regioselective
for the C7 attack? And (2) How to force the trans-fused [6,6] ring systems needed for (±)-
kopsihainaine A 6?
142Jing, P.; Yang, Z.; Zhao, C.; Zheng, H.; Fang, B.; Xie, X.; She, X. Chemistry 2012, 18, 6729–6732
143Gartshore, C. J.; Lupton, D. W. Angew. Chem. Int. Ed. 2013, 52, 4113–4116
144Mizutani, M.; Yasuda, S.; Mukai, C. Chem. Commun. 2014, 50, 5782–5785
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Scheme 5.4 – Mukai’s synthesis of (+)-kopsihainanine A 6
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Scheme 5.5 – iORC cyclization: Diastereoselectivity issue
The regioselectivity should not be troublesome, as other similar transformation hap-
pened with good yields, but almost all the examples gave cis-selectivity. Which mean the
diastereoselectivity will be a problem. If we manage to control these two factors, we would
obtain intermediate 335, which could be transformed in few steps into the racemic alkaloid
(±)-6.
On a retrosynthetic perspective, (±)-kopsihainanine A 6 could be obtained from 336
in a similar way as the previous syntheses (Scheme 5.6). To force the trans-selectivity, we de-
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cided to already have the amide bond on iminium intermediate 337. This way, the cyclization
in trans should be favoured. This amide formation is not a redundant step for the synthesis,
as it is present in the natural product. Following our iORC procedure, this iminium could
arise from the putative dicarbonyl intermediate 338. As the previous cases, forming the ani-
line from a nitrophenyl moiety, and the two carbonyl by an ozonolysis resulted in synthon
339. A Staudinger lactamization from the azide and a carboxylic acid leads us to precursor
340. This precursor could be reached via the same palladium-catalyzed decarboxylative cou-
pling as the aspidospermidine, using slightly different startingmaterials.
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Scheme 5.6 – Retrosynthesis of kopsihainanine A 6
5.3 Synthetic studies of Kopsihainanine A
In order to reach precursor 340, we planned to start from 220 (cf. Chapter 3). A chain
with a carboxylic acid precursor should be added (Scheme 5.7). Our first attempt was with
Normant-type Grignard reagent,89 which did not gave desired product 341 but only yielded
1,2-adduct 342. Organozinc generated either from methyl 3-iodopropanoate145 or from (1-
Ethoxycyclopropoxy)trimethylsilane146 resulted in messy reactions or degradations. Desired
1,4-adduct 343was never observed.
To avoid these difficulties, we chose to perform a 1,4 homoallylation using similar con-
ditions as before and oxidize the olefin on a late stage. Trapping of the enolate with Comins’
reagent gave vinyl triflate 344. Our palladium-catalyzed decarboxylative coupling between
145a) Charette, A. B.; Beauchemin, A.; Marcoux, J. F. J. Am. Chem. Soc. 1998, 120, 5114–5115; b) Wang, J.-X.; Fu, Y.;
Hu, Y.; Wang, K. Synthesis 2003, 35, 1506–1510; c) Tamaru, Y.; Gavryushin, A.; Knochel, P. In e-EROS Encycl.
Reagents Org. Synth. JohnWiley & Sons, Ltd: 2009
146Nakamura, E.; Kuwajima, I. Tetrahedron Lett. 1986, 27, 83–86
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Scheme 5.7 – attempts of direct 1,4-Addition
triflate 344 and potassium salt 345 afforded compound 346 in good yield. We could observe
the improvement of the yield compared to our previous syntheses due to the low steric hin-
drance of this potassium salt. One-pot azidation of the alcohol gave intermediate 347.
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Scheme 5.8 – Synthetic studies of kopsihainanine A 6
At this stage, an oxidation of the terminal olefin of 347 into themethyl ester is required.
The presence of the second olefin made this oxidation quite challenging (Scheme 5.9).
Ozonolysis under non-reductive conditions (Ac2O/Et3N) gave directly the methyl ester 349
with 25% yield. When a Lemieux-Johnson or Lemieux Von-Rudloff oxidation were at-
tempted,147 we could notice that a catalytic amount of osmium or manganate was not suf-
ficient, no mater how much of the co-catalyst was used. No conversion was observed un-
til more than 1.0 equivalent of the metal was added. And as soon as the stoichiometry was
passed, the reaction occurred. This findingwasunexpected and suggested that the first equiv-
147a) Lemieux, R. U.; Rudloff, E. V. Can. J. Chem. 1955, 33, 1701–1709; b) Rudloff, E. V. Can. J. Chem. 1955, 33,
1714–1719; c) Wee, A. G.; Liu, B. In e-EROS Encycl. Reagents Org. Synth. JohnWiley & Sons, Ltd: Chichester, UK,
2001; d) Nicolaou, K. C.; Duggan,M. E.; Hwang, C.-K.; Somers, P. K. J. Chem. Soc. Chem. Commun. 1985,
1359–1362; e) Majetich, G.; Hull, K. Tetrahedron 1987, 43, 5621–5635
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alent of oxidantwas somehowcomplexedwith the substrate. Potassiumpermanganate being
cheaper and safer than osmium tetroxide, we focused our effort on the Lemieux Von-Rudloff
oxidation (KMnO4/NaIO4).
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Scheme 5.9 – Lemieux Von-Rudloff Oxidation
As shown in Scheme 5.9, the hydroxyketone 348 was first formed, and then oxidized
by NaIO4 or KMnO4 into the carboxylic acid 340. Use of TMS-diazomethane gave themethyl
ester 349. The optimization of the permanganate oxidation was somehow tedious. The first
oxidation of the terminal olefin into the hydroxyketone happened in few second. The subse-
quent oxidation into the carboxylic acid wasmuch slower. If harsher conditions were applied,
the trisubstituted olefin started to get oxidized.
On small scale, the standard one-pot Lemieux Von-Rudloff worked well, giving car-
boxylic acid in 71% yield and 91% BRSM. But when the reaction was run on 0.5-1.5mmol,
the yield droped to 40-50%. A more robust version of this oxidation could be done stepwise
on 3mmol scale, using only KMnO4 to reach cleanly the hydroxyketone, and after work-up
oxidysing it into the carboxylic acid using only NaIO4.
As an attempt to improve the overall yield, oxidation of homoallyl group was tried be-
fore the decarboxylative coupling (Scheme 5.10). A short screening of previously tried con-
ditions showed us that enolate moiety of intermediate 344 was highly sensitive to oxidation.
Fortunately, careful ozonolysis in the presence of NaOH could afford methyl ester 350 along
with minor quantity of ozonide 351. As the terminal olefin was slighly more reactive than
the vinyl triflate, if ozone was highly diluted and added slowly, the reaction could be stopped
when all the terminal olefin had reacted without formation of overoxidation products.
Decarboxylative coupling with potassium salt 345 afforded ester derivative 352. As the
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Scheme 5.10 – Oxidation pathway employing ozone
overall yield of both decarboxylative coupling and oxidation was lower than before, we kept
the pathway coupling-azidation-Lemieux-von-Rudloff.
Frommethyl ester 349, preliminary studies on our iORC showed that cyclizationwould
occur exclusively from C7, no trace of the attack from nucleophillic N1 was observed. Unfor-
tunately, the cis-selectivity was observed as predicted. Optimized conditions used zinc in
acidic medium to reduce the azide and nitro groups, and afforded 40% of intermediate 353.
We were wondering if lactamization of 353 into 354 could take place. However, only degrada-
tion were observed when bases where applied,148 tautomeric catalyst (hydroxypyridine)149
or coupling on the aminoacid derivative of 353.150
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Scheme 5.11 – iORC on precursor 349
As the regioselectivity was not an issue, we pursue our plan to form lactam 339. Even if
eight-membered ring are not easy tomake, the Thorpe-Ingold effect of the spirocyclopentene
should help the cyclization.151 From acid 340, direct anhydrous Staudinger lactamization152
or Staudinger reduction followed by coupling reaction153 did not provided the desired lactam.
148Bashore, C. G.; Samardjiev, I. J.; Bordner, J.; Coe, J. W. J. Am. Chem. Soc. 2003, 125, 3268–3272
149Rony, P. R. J. Am. Chem. Soc. 1969, 91, 6090–6096
150Bergmeier, S. C.; Cobas, A. A.; Rapoport, H. J. Org. Chem. 1993, 58, 2369–2376
151Beesley, R. M.; Ingold, C. K.; Thorpe, J. F. J. Chem. Soc. Trans. 1915, 107, 1080–1106
152Kosal, A. D.; Wilson, E. E.; Ashfeld, B. L. Angew. Chem. Int. Ed. 2012, 51, 12036–12040
153a) Yamamoto, Y.; Furuta, T. Chem. Lett. 1989, 18, 797–800; b) Szemes, F; Rybár, A; Uhrín, D; Solcˇániová, E Chem.
Pap. 1991, 45, 667–675; c) Falcone, B. V.; Creighton, C. J.; Parker, M. H.; Reitz, A. B. Synth. Commun. 2008, 38,
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Pentafluorophenyl ester 355wasmadewith EDCI as coupling agent, and Staudinger reaction
afforded lactam 339. 154 However, the combined yield of both step was low.
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Scheme 5.12 – Different lactamization pathways
Using Maarseveen’s Staudinger ligation methodology,155 the coupling between thio-
phosphine ligand 356 and acid 340 afforded thioether 357 with good yield if HATU and
DIPEA were used. Releasing the phosphine with DABCO156 allowed the intramolecular
Staudinger lactamization of 357 to take place, affording lactam 339 quantitatively.
Having lactam 339 in hand, optimization of our iORC could be done. During the ox-
idation step, the presence of base (NaHCO3) gave dirty mixtures. When Me2S was used as
reducing agent, careful analysis of the crude mixture revealed the presence of the two inter-
mediate 358 and 359. The ratio between them was dependant on the conditions. Similar
cyclizations were already observed by Schultz and co-workers in 1999.157 A surprising ob-
servation was the formation of 358 as major product if Me2S was used, and 359 if PPh3 was
411–418
154Formacrolactamization of Pentafluorophenyl ester and azide into eight-membered ring lactams, see a)
Koizumi, Y.; Kobayashi, H.; Wakimoto, T.; Furuta, T.; Fukuyama, T.; Kan, T. J. Am. Chem. Soc. 2008, 130,
16854–16855; b) Chida, N.; Tobe, T.; Murai, K.; Yamazaki, K.; Ogawa, S.Heterocycles 1994, 38, 2383–2388
155a) David, O.; Meester, W. J. N.; Bieräugel, H.; Schoemaker, H. E.; Hiemstra, H.; vanMaarseveen, J. H. Angew.
Chem. Int. Ed. 2003, 42, 4373–4375; Other examples of the use of this thiophosphane ligand, see b)
Soellner, M. B.; Nilsson, B. L.; Raines, R. T. J. Org. Chem. 2002, 67, 4993–4996; c) Parkhouse, S. M.; Garnett, M. C.;
Chan, W. C. Bioorg. Med. Chem. 2008, 16, 6641–6650; d) Carroll, L.; Boldon, S.; Bejot, R.; Moore, J. E.; Declerck, J.;
Gouverneur, V.Org. Biomol. Chem. 2011, 9, 136–140
156Dang, H.-S.; Diart, V.; Roberts, B. P. J. Chem. Soc. Perkin Trans. 1 1994, 1033–1041
157Schultz, A. G.; Dai, M. Tetrahedron Lett. 1999, 40, 645–648
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used. The cleanest reaction happened when the ozonide was quenched with PPh3, giving
exclusively 359. During the optimization of the reduction of nitro group, we observed that
most reduction conditions afforded unstable side-product 361, with only traces of desired
product 336. Reduction with zinc or TiCl3 in acidic media afforded 361 as only product. This
side-product would be due to the reactive iminium intermediate 360. The strongly activated
olefin was easily reduced and the difficulty was to find reducing conditions strong enough
to reduce the nitro group, but mild enough to allow intermediate 360 to cyclize into 336 be-
fore being reduced to 361. Raney Nickel Hydrogenation in acidic conditions seemed to give
desired product 336 without the side-product, but in low yield. If Raney Nickel was used
in neutral or basic anhydrous conditions (wash of the raney nickel with dry THF), an un-
stable polar intermediate that couldn’t be analysed was formed. If acid was added on this
unknown intermediate after full conversion, this intermediate would cyclized into desired
product 336. Using this method, the yield could be pushed to 58%, but the yields were not
reproducible, due to the difficulties to control the stoichiometry of theNickel (slurry solution
in H2O). Adams’ catalyst showed similar activity as Raney nickel, but could be weighted. As
a results, the yield could be improved to 63% as a single diastereoisomer with no traces of
side-product 361.
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Scheme 5.13 – iORC on precursor 339 and endgame
For the end game (Scheme 5.14), we first considered to protect the indole moiety of
336 in situ with TMS158 or COO–,159 followed by the oxidation conditions used by She (LDA,
O2, Na2S2O3), and removal of the protecting group in the work-up. Unfortunately, the ox-
idation was not successful. We decided to first optimise the oxidation with a more stable
158a) Fishwick, C. W. G.; Jones, A. D.; Mitchell, M. B.Heterocycles 1991, 32, 685–692; b) Smith, C. J.; Tsang, M. W. S.;
Holmes, A. B.; Danheiser, R. L.; Tester, J. W.Org. Biomol. Chem. 2005, 3, 3767–3781
159Katritzky, A. R.; Akutagawa, K. Tetrahedron Lett. 1985, 26, 5935–5938
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protecting group, like TBS (362). Surprizingly, every oxidations resulted in deprotection of
the indole. When the protected indole 362 was treated with strong base at -50 °C, deprotec-
tion occured. Similar results were observed with Boc or TIPS-protected indole. However, we
noticed that even if the deprotected indole was present, the oxidation still occured with low
yield. We decided to directly optimize the oxidation on the free indole. α-Hydroxylation of
amide are well described in litterature, and many conditions exists.160 Deep screening of
this last oxidation step were performed, and optimum conditions happened to be lithium
dimethylamine (LDMA), HMPA and bis(trimethylsilyl)peroxide. Under these conditions, the
desired alkaloid was obtained with 91% yield as single diastereoisomer. Using LDMA as the
base was essential for the success of the above transformation, as other bulkier bases led es-
sentially to no reaction or degradation depending on the nature of the oxidant. The result is
in line with She’s observation that the amide enolate is difficult to form because of the steric
hindrance around the α-pseudoaxial proton of the amide.
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Scheme 5.14 – Final oxidation toward (±)-kopsihainanine A 6
5.4 Conclusion
In summary, the total synthesis of (±)-kopsihainanine A 6 was accomplished
(Scheme 5.15).100 Once again, our palladium-catalyzed decarboxylative coupling af-
forded an intermediate bearing all the carbons needed for the natural product (346). An
azidation, followed by regioselective Lemieux von-Rudloff oxidation of the terminal double
bond and a Staudinger lactamization developped by Maarseveen and co-workers allowed
us to reach eight-memberd lactam 339 efficiently. Finally, our iORC could cyclize on C7
with a trans-selectivity (through intermediate 360) to afford 18-dehydroxykopsihainanine
A 336. Oxidation of 336 was performed with LDMA and bistrimethylsilylperoxide to afford
(±)-kopsihainanine A 6 in 91% as a single diastereoisomer. We demonstrated that selectivity
160For a review, see Chen, B.-C.; Zhou, P.; Davis, F. A.; Ciganek, E. InOrg. React. 2004; Vol. 62, p 1, , and references
cited within
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of the cyclization could be achieved by design of our iORC precursor. Macrolactamization of
precursor reversed the selectivity of our iORC process from cis to trans.
Oxidation with a non hindered base as LDMA afforded the final alkaloid in good yield
without any need for protection of the indol nitrogen. This work showed us the importance
to design the iORC precursor in order to select the cis/trans diastereoselectivity of the cycliza-
tion.
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Scheme 5.15 – iORC on precursor 339 and endgame
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CHAPTER6
Approach Towards the Total Synthesis of
Kopsinitarine E
In 1994 and 1996, Kamand co-workers discovered in the leafs ofMalayan treeKopsia teoi four
unprecedented cage-like structures they called kopsinitarine A-D 363-366 (Figure 6.1).161 A
decade later, they reported kopsinitarine E 7, found in the same plant specie.162
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Figure 6.1 – Kopsinitarine A-E and some related alkaloids
These alkaloids possess theKopsia pentacyclic skeleton, with the C18 connected to the
C2 position. C17 is oxidized to create an additional bridged hemiaminal ether moiety with
oxidized C5. C16 is also oxidized and formed a bridged α-hydroxy-ketone with the C22 car-
bonyl, which itself is connected to C6. As a result, these structures form congested cage-like
skeletons. The complexity of such highly oxidised structuresmakes their synthesis a fascinat-
161a) Kam, T.-S.; Yoganathan, K.; Chuah, C.-H. Tetrahedron Lett. 1994, 35, 4457–4460; b) Kam, T.-S.; Yoganathan, K.;
Wei, C. J. Nat. Prod. 1996, 59, 1109–1112
162Lim, S.-H.; Sim, K.-M.; Abdullah, Z.; Hiraku, O.; Hayashi, M.; Komiyama, K.; Kam, T.-S. J. Nat. Prod. 2007, 70,
1380–1383
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ing challenge. To this day and to the best of our knowledge, no total synthesis of kopsinitarine
A-E has been reported.
However, some related alkaloids were synthetized. For example aspidofractinine
367163 and kopsinine 31765,163b,164 possess a similar C2-C16 connection, but not the bridged
hemiaminal or bridged ketone of the kopsinitarine structure. Kopsanone 31865,163b,165 and
kopsine 319138 are to our knowledge the closest structures to the kopsinitarine skeleton that
have been synthesized.
No reports on the potential biosynthetic pathway of kopsinitarines skeletons are re-
ported. Nevertheless, there is one report from Kam and co-workers in 2001,166 in which
they isolated kopsiloscine C 368 (an oxidized version of kopsinine 317) from Kopsia sin-
gapurensis,167 and used electrochemical oxidation to reach the cage-like structure of the
kopsinitarine skeleton (Scheme 6.1). By submitting natural product 368 to an anodic oxi-
dation with 0.95V in an attempt to form dimeric indole alkaloid structures, they obtained
12-demethoxykopsinitarine D 371 as a side-product with 17% yield.
From a mechanistic point of view, they suggested first the oxidation of the tertiary
amine to form iminium intermediate 369, from this intermediate, equilibration of this
iminium moiety to its enamine form, followed by intramolecular enamine-ester reaction,
creates the C6-C22 bond. However from this point, in order to have cyclisation of the C17
alcohol on the iminium, epimerization of the C17 center is required. Via which mechanism
this epimerization occurs is not known. Once iminium 370 is reached, the alcohol on the
C17 position and the iminium moiety have the proper conformation for cyclisation to reach
12-demethoxykopsinitarine D 371. Such a transformation sequence could be similar to the
biosynthetic pathway.
6.1 Synthetic Studies of Kopsinitarine E
The skeleton of kopsinitarine alkaloids, with its congested cage-like structure and the high
number of C-O bonds it possesses represents an appealing challenge. Hence we chose
163See a) Kinoshita, H.; Ohnuma, T.; Oishi, T.; Ban, Y. Chem. Lett. 1986, 15, 927–930; b) Gagnon, D.; Spino, C. J. Org.
Chem. 2009, 74, 6035–6041; c) Kuehne, M. E.; Seaton, P. J. J. Org. Chem. 1985, 50, 4790–4796
164See a) Magnus, P.; Brown, P. J. Chem. Soc. Chem. Commun. 1985, 184–186; b) Harada, S.; Sakai, T.; Takasu, K.;
Yamada, K.-i.; Yamamoto, Y.; Tomioka, K. Chem. Asian J. 2012, 7, 2196–2198; c) Harada, S.; Sakai, T.; Takasu, K.;
Yamada, K.-i.; Yamamoto, Y.; Tomioka, K. Tetrahedron 2013, 69, 3264–3273; d) Xie, J.; Wolfe, A. L.; Boger, D. L.
Org. Lett. 2013, 15, 868–870
165Gallagher, T.; Magnus, P. J. Am. Chem. Soc. 1983, 105, 2086–2087
166Kam, T.-S.; Lim, T.-M.; Tan, G.-H. J. Chem. Soc. Perkin Trans. 1 2001, 1594–1604
167Subramaniam, G.; Kam, T. S.Helv. Chim. Acta 2008, 91, 930–937
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Scheme 6.1 – Electrochemical cyclization of kopsinitarine skeleton
kopsinitarine E 7 as our next target. Its structure is highly related to aspidospermidine. We
were therefore convinced that the iORC method would allow us to readily form the core
structure of this alkaloid. The difficulty lies in the high number of reactive sites this alkaloid
shows (α-hydroxyketone, indole, hemiaminal ether). Targeting such complex alkaloid would
require to have a highly functionalized iORC precursor. Therefore, we planned to use this
synthesis to investigate the sensitivity of our key step towards the presence of a large number
of functional groups.
6.1.1 Retrosynthetic Approach
From a retrosynthetic perspective (Scheme 6.2), kopsinitarine E 7 could arise from precur-
sor 372 through indole protection and cyclization of the C17 alcohol on the C5 hemiami-
nal.168 This cyclization would require the correct stereochemistry on C17. Intermediate 372
would come from 373 through reduction of the amide moiety,169 decarboxylation of quater-
nary ester and deprotection of the diol moiety. The indoline of 373 could be the result of an
intramolecular Mannich reaction on indolenine 374. This step would mean that the stere-
168For the formation of hemiaminal and hemiaminal ether in C5 position, see a) Kam, T.-S.; Lim, T.-M.; Choo, Y.-M.
Tetrahedron 1999, 55, 1457–1468; b) Hájícˇek, J. Collect. Czechoslov. Chem. Commun. 2007, 72, 821–898; c)
Lim, K.-H.; Low, Y.-Y.; Tan, G.-H.; Kam, T.-S.; Lim, T.-M.Helv. Chim. Acta 2008, 91, 1559–1566
169For selective reduction of amide in the presence of ketone, see Preparation of Taxol and Docetaxel Through
Primary Amines. Patent, WO9623780 (A1), 1996
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ochemistry of the C16 carbon before this step is not relevant for our synthesis. From the
previous iORC processes described in Chapter 5, we knew that controlling the diastereose-
lectivity of our key domino process would be challenging. To force the cyclization of the fused
[6,6] ring system in a trans fashion, we needed to already have the connection between C6
and C22. If we disconnect this bond (Dieckmann cyclization), any iORC to form precursor
375would give the undesired cis selectivity. To circumvent this, we have to perform the iORC
before this disconnection. Following our iORC, indolenine 374 could result from the cycliza-
tion of iminium 376. This structure would come from aldehyde intermediate 377, which in
turn would arise from the ozonolysis and reduction of nitroaryl intermediate 378.
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Scheme 6.2 – Retrosynthetic analysis of kopsinitarine E 7
This key intermediate could be reached from a Dieckmann condensation and
Staudinger lactamization of azide precursor 379. For the lactamization, saponification of
one of the methyl esters of the malonate moiety is needed. Theoretically, it should be easier
to saponify a malonate ester than the C20 methyl ester.170 We planned to reach intermediate
379 from potassium salt 380 and vinyl triflate 381 via our palladium-catalyzed decarboxyla-
tive coupling as used in our previous syntheses. This vinyl triflate could result from enone
382, using conjugated 1,4-addition and enol trapping with Comins’ reagent. A Stetter reac-
170Germain, J.; Deslongchamps, P. J. Org. Chem. 2002, 67, 5269–5278
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tion171 followed by aldol condensation could form enone 382 from aldehyde 383. We are
hoping that the diol moiety on enantiopure enone 382 would help direct the nucleophile
during the conjugate addition and allow us to form the quaternary center of vinyl triflate 381
in a diastereoselective fashion.
The choice of protecting group on the diol moiety would depend on the stereochem-
istry used. Dieckmann condensation to afford 378 would be favoured if the ester is close to
the 1,3-dicarbonyl position. This conformation will require a different protecting group de-
pending on the diol configuration. If we use a syn-diol, as in mesotartaric acid derivatives,
a cyclic ketal protecting group would be a good choice. Nonetheless, if the two alcohols are
anti as in D-tartaric acid, such cyclic protection would push away the ester and the cycliza-
tion might become difficult. Two silyl or benzyl groups would therefore be a better choice.
6.1.2 Synthetic Route Towards Cyclopentenone 382
Our first synthetic attempts towards cyclopentenone derivative 382 started with known 3-
iodocyclopentenone172 (Scheme 6.3). A Heck coupling withmethyl acrylate afforded 384.173
We anticipated that the trans-disubstituted olefin would be more accessible than the cyclic
trisubstituted one and could therefore be oxidized selectively. Unfortunately, all our dihy-
droxylation attempts with oxidants such as AD-mix, mCPBA or DMDO resulted in messy
mixtures and no diol 385was observed.
O
I
Pd(OAc)2,(Ph2PCH2)2CH2,
Et3N,
Methyl acrylate
DMF, 85 °C
42%
O
CO2Me
O
MeO2C
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OH
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Scheme 6.3 – First pathway to enone derivatives
We decided to develop a synthesis to reach derivatives of aldehyde 383. This strategy
was chosen due to the relation between aldehyde 383 and chiral pool reagents such as tartaric
acids (meso- or D-), isoascorbic acid, or monosaccharids (L-erythrose or L-threose).
We first planned to reach this aldehyde from dimethyl meso-tartrate 386, synthesized
171Stetter, H.; Schreckenberg, M. Angew. Chem. Int. Ed. 1973, 12, 81–81
172Lemière, G.; Gandon, V.; Cariou, K.; Hours, A.; Fukuyama, T.; Dhimane, A. L.; Fensterbank, L.; Malacria, M. J. Am.
Chem. Soc. 2009, 131, 2993–3006
173Duvvuru, D.; Betzer, J.-F.; Retailleau, P.; Frison, G.; Marinetti, A. Adv. Synth. Catal. 2011, 353, 483–493
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by dihydroxylation of maleic acid174 (Scheme 6.4). Protection of the diol moiety afforded
387. A desymmetrisation of 387 was planned using enzymes, as good ee’s and yields were
reported onmanymeso-1,2-diester substrates.175 Even if some examples on five-membered
ring meso-1,2-diesters showed inferior results,176 we were confident in this strategy since
the D-tartrate derivative of our substrate seemed to be working well.177 However, the selec-
tive saponification of the desired ester function proved unsuccessful after using a range of
esterases (porcine liver esterase, hog liver esterase, or liver acetone powder), yielding only
traces of the desired acid.
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Scheme 6.4 – First pathway to aldehyde derivatives
We then turned our attention to our study on enantiopure derivatives from the chi-
ral pool. As such, we targeted derivatives of unnatural dimethyl D-(-)-tartrate (Scheme 6.5).
Double TBS protection proceeded smoothly to afford 389178 but selective reduction of one
of the methyl ester did not afforded alcohol 390 or aldehyde 391. When a reducing agent
like DIBAL-H (with or without MgBr2),
179 BH3·Me2S/NaBH4,180 or NaBH4/LiCl181 was used,
a messy reaction or reduction of both esters was observed. A second attempt via the saponi-
fication of one ester182 followed by BH3 reduction of the acid to alcohol,
183 acid chloride for-
174Crout, D. H. G.; Gaudet, V. S. B.; Hallinan, K. O. J. Chem. Soc. Perkin Trans. 1 1993, 805–812
175See a) Boland, W.; Niedermeyer, U.; Jaenicke, L.Helv. Chim. Acta 1985, 68, 2062–2073; b) Häbich, D.; Hartwig, W.
Tetrahedron Lett. 1987, 28, 781–784; c) Van der Eycken, J.; Vandewalle, M.; Heinemann, G.; Laumen, K.;
Schneider, M. P.; Kredel, J.; Sauer, J. J. Chem. Soc. Chem. Commun. 1989, 306–308; d) Kocienski, P.; Stocks, M.;
Donald, D.; Perry, M. Synlett 1990, 1, 38–39; e) Brion, F.; Marie, C.; Mackiewicz, P.; Roul, J.; Buendia, J.
Tetrahedron Lett. 1992, 33, 4889–4892
176See a) Gais, H. J.; Buelow, G.; Zatorski, A.; Jentsch,M.; Maidonis, P.; Hemmerle, H. J. Org. Chem. 1989, 54,
5115–5122; b) Rosenquist, A. s.; Kvarnström, I.; Svensson, S. C. T.; Classon, B.; Samuelsson, B.; Kady, M. M.;
Christensen, S. B. g. Acta Chem. Scand. 1992, 46, 1127–1129; c) Renold, P.; Tamm, C. Tetrahedron Asymmetry
1993, 4, 1047–1050
177Piel, J.; Boland, W. Tetrahedron Lett. 1997, 38, 6387–6390
178Hiyama, T.; Minami, T.; Takahashi, K. Bull. Chem. Soc. Jpn. 1995, 68, 364–372
179a) Keck, G. E.; Andrus, M. B.; Romer, D. R. J. Org. Chem. 1991, 56, 417–420; b) Maeda, H.; Kraus, G. a. J. Org.
Chem. 1996, 61, 2986–2987
180Saito, S.; Hasegawa, T.; Inaba, M.; Nishida, R.; Fujii, T.; Nomizu, S.; Moriwake, T. Chem. Lett. 1984, 13, 1389–1392
181Mahadevegowda, S. H.; Khan, F. A. Tetrahedron 2013, 69, 8494–8504
182Trost, B. M.; Miege, F. J. Am. Chem. Soc. 2014, 136, 3016–3019
183a) Gutman, A. L.; Boltanski, A. J. Chem. Soc. Perkin Trans. 1 1989, 47–49; b) Homer, J. H.; Musa, O. M.;
Bouvier, A.; Newcomb, M. J. Am. Chem. Soc. 1998, 120, 7738–7748; c) Candy, M.; Tomas, L.; Parat, S.; Heran, V.;
Bienaymé, H.; Pons, J. M.; Bressy, C. Chem. Eur. J. 2012, 18, 14267–14271
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mation/reduction,184 or thioesterification/reduction182,185 was attempted. These attempts
only resulted in messy reactions with no traces of the desired product observed.
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96%
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Scheme 6.5 – Aldehyde derivatives from dimethyl D-(-)-tartrate
Another precursor from the chiral pool studiedwasD-isoascorbic acid, an epimer of vi-
taminC. A described procedure allowed us to convert this product into 2,3-O-isopropylidene-
D-erythronolactone 392 (Scheme 6.6).186 We were planning to open the lactone with
methanol to reach 393 and oxidize the alcohol moiety into an aldehyde. Unfortunately, the
basic conditions needed for the opening of the lactone epimerized the product and only trans
394 was observed. As the use of Et3N
187 did not resulted in good yields, we used sodium
methoxyde as nucleophile188 to obtain 394 in 63% yield. Other lactone opening conditions
were attempted to avoid this epimerization, such as MeMgCl or Ti(OiPr)4 in MeOH. Saponifi-
cation with LiOH in water was also tried. These reactions only resulted in degradation of the
starting lactone. The major problem of this strategy lied in the polarity of these compounds.
All these derivatives are highly water-soluble and could not be extracted. In addition, the
products were too sensitive to be distilled. The oxidation of alcohol 394 proved to be not triv-
ial. Among all the conditions attempted (IBX, DMP, PCC, PDC, TPAP, Swern, Parikh-Doering,
Corey-Kim, Oppenauer), the Swern oxidation using DIPEA seemed to be the cleanest. As no
aqueous work-up was possible, this aldehyde was used in the following reaction after filtra-
tion. Unfortunately, Stetter reaction on aldehyde 395 with NHC catalyst189 gave 396 with
unreproducible results since the stoichiometry and purity of aldehyde 395 could not be con-
trolled.
In an attempt to diminish the polarity and volatility of intermediates 392-396, we de-
cided to change the acetonide for a more hydrophobic group and chose 4-heptylidene ketal
397 (Scheme 6.7). This bulkier protecting group allowed these intermediates to be extracted
184a) Bartlett, P. a.; Johnson, C. R. J. Am. Chem. Soc. 1985, 107, 7792–7793; b) Ku, T. W.; McCarthy, M. E.;
Weichman, B. M.; Gleason, J. G. J. Med. Chem. 1985, 28, 1847–1853; c) DeMeijere, A.; Bagutski, V.; Zeuner, F.;
Fischer, U. K.; Rheinberger, V.; Moszner, N. Eur. J. Org. Chem. 2004, 3669–3678
185D’Aniello, F.; Mann, A.; Taddei, M. J. Org. Chem. 1996, 61, 4870–4871
186Cohen, N.; Banner, B. L.; Laurenzano, A. J.; Carozza, L. Org. Synth. 1985, 63, 127
187Allegretti, P. A.; Ferreira, E. M. Org. Lett. 2011, 13, 5924–5927
188Guo, H.; Kim, C. U.; Lee, I. Y.; Mitchell, M. L.; Rhodes, G.; Son, J. C.; Xu, L. Novel HIV reverse transcriptase
inhibitors. Patent, WO2009005674 (A2), 2009
189Galopin, C. C. Tetrahedron Lett. 2001, 42, 5589–5591
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Scheme 6.6 – Aldehyde derivatives fromD-isoascorbic acid
and purified more easily. Unfortunately, it also seemed to change the equilibrium of the lac-
tone opening reaction and conversion of 397 into ester 398 could not be driven to comple-
tion. An optimum yield of 46% of ester 398was obtained with 90% yield based on recovered
starting materials. Optimization of the alcohol oxidation and the Stetter reaction190 was still
ongoing at the end of this thesis. Currently, optimal conditions give 16% yield of desired 1,4-
diketone 399.
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Scheme 6.7 – New strategy fromD-isoascorbic acid
6.1.3 Synthetic attempts towards potassium salt 380
In order to reach potassium salt 380 we planned to start from ester 400 obtained by esterifi-
cation of 2-(2-nitrophenyl)acetic acid with tert-butyl alcohol (Scheme 6.8).191 Alkylation of
400 with dimethyl bromomalonate to afford 401 were attempted without success. The simi-
190Novák, L.; Rohály, J.; Gálik, G.; Fekete, J.; Varjas, L.; Szántay, C. Liebigs Ann. der Chemie 1986, 509–524
191Riss, P. J.; Kroll, C.; Nagel, V.; Rösch, F. Bioorg. Med. Chem. Lett. 2008, 18, 5364–5367; See also Flitsch, W.;
Ruß kamp, P. Liebigs Ann. der Chemie 1985, 1398–1412
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lar pKa of both electrophile and nucleophile, caused proton transfer and subsequent degra-
dation of the electrophile. Reversing the reactivity by using dimethyl malonate and bromide
derivative 402192 proved unsuccessful as well, intermediate 401was never observed.
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Scheme 6.8 – First Pathway to potassium salt 380
In an attempt to have amore suitable electrophile, we tried using iodide 403 (obtained
in two steps from glycerol) to alkylate 400. To our surprise, instead of adduct 404, a mixture
of quinoline 1-oxide derivatives 405 and 406 were obtained in 41% yield, with 405 being the
major product.
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Scheme 6.9 – Second Pathway to potassium salt 380
A possible mechanism is shown in Scheme 6.10. After the desired nucleophilic substi-
tution, deprotonation of the substrate could occur, leading to 407. This intermediate could
undergo a 1,8-O,O-silyl migration to reach 408. To the best of our knowledge, 1,8-silyl migra-
tions have not been reported yet,193 but it is conceivable that the rigidity of the structure 407
allowed the required promiscuity between the silylated alcohol and the nitro group. Silylated
192Grewer, C.; Madani Mobarekeh, S. A.; Watzke, N.; Rauen, T.; Schaper, K. Biochemistry 2001, 40, 232–240
193For a review, see Kira, M.; Iwamoto, T. In Chem. Org. Silicon Compd. Rappoport, Z., Apeloig, Y., Eds.; JohnWiley
& Sons, Ltd: 2001; Vol. 3; Chapter 16, pp 0–471, and references cited within
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nitro groups have been previously reported.194 In these studies they underline the weakness
of the resulting N−OSi bond, this could explain howwe lost both silyl groups during the reac-
tion. We postulated that formaldehyde could be eliminated from 408 to afford anionic inter-
mediate 409. It would then be conceivable to have elimination of TBSOH from intermediate
410. This intermediate would again have the correct conformation for a 1,8-silyl migration
towards enolate 411. This structure would be in equilibrium with aldehyde 412, that could
condense into 413. Hydrolysis of the silyl group would give observed side-product 405.
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Scheme 6.10 –Mechanism hypothesis for the formation of quinoline 1-oxide 405
Considering the trouble encountered with these derivatives, we decided to modify our
strategy. We hoped to reach potassium salt 380 fromolefin 414 (Scheme6.11). However, Kno-
evenagel reaction195 with ester 400 has proven unsuccessful. Attempts to transformbromide
derivative 402 into a phosphine derivative196 to performaWittig-type reaction with dimethyl
ketomalonate resulted only in a messy reaction mixture.
Oxidation of ester 400 to keto ester 415 (unpublished procedure from our labora-
194a) Tishkov, A. A.; Dilman, A. D.; Faustov, V. I.; Birukov, A. A.; Lysenko, K. S.; Belyakov, P. A.; Ioffe, S. L.;
Strelenko, Y. A.; Antipin, M. Y. J. Am. Chem. Soc. 2002, 124, 11358–11367; b) Lyapkalo, I. M.; Ioffe, S. L.;
Strelenko, Y. A.; Tartakovsky, V. A. Russ. Chem. Bull. 1996, 45, 856–862; c) Dilman, A. D.; Lyapkalo, I. M.;
Belyakov, P. A.; Ioffe, S. L.; Strelenko, Y. A.; Tartakovsky, V. A. Russ. Chem. Bull. 2000, 49, 1649–1650
195Craig, R. Synthesis of Electron-Poor tetrasubstituted olefins and their reactions with electron-rich comonomers.,
Ph.D. Thesis, University of Arizona, 1982
196a) Nader, F. W.; Brecht, A.; Kreisz, S. Chem. Ber. 1986, 119, 1208–1216; b) Ianni, A.; Waldvogel, S. R. Synthesis
2006, 38, 2103–2112
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tory),197 followed by Knoevenagel condensation198 with dimethyl malonate afforded olefin
414. However, the yield was low due to the four electron-withdrawing groups making this
product highly unstable. When using TiCl4 ·THF and pyridine, our best reaction conditions,
only 10% yield of olefin 414was obtained. Horner–Wadsworth–Emmons reaction with phos-
phorylated derivatives of malonic ester199 were attempted but did not afford any product
414.
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Scheme 6.11 – Third Pathway to potassium salt 380
Since potassium salt 380 seemed troublesome to synthesise, we planned to change
strategy from our decarboxylative coupling to a Heck, or reductive Heck, reaction
(Scheme 6.12). Knoevenagel condensation of dimethyl malonate or Meldrum’s acid with 2-
nitrobenzaldehyde afforded compounds 417200 and 418201 respectively. Heck,202 or reduc-
tive Heck,203 reactions with vinyl triflate 419 as model substrate should allow us to reach the
scaffold we needed for our synthesis. During this screening, Palladium catalysts (Pd(OAc)2,
Pd(PPh3)2Cl2 or Pd(PPh3)4), were tested with or without ligands (PPh3, P(nBu)3, dppp, dppe,
197The reported procedures for similar oxidation were unsuccessful in our case. See a) Nagano, T.; Kobayashi, S.
Chem. Lett. 2008, 37, 1042–1043; b) Moriyama, K.; Takemura, M.; Togo, H.Org. Lett. 2012, 14, 2414–2417
198a) Rakufs, K.; Verevkin, S. P.; Keller, M.; Beckhaus, H.-D.; Rüchardt, C. Liebigs Ann. 1995, 1483–1493; b) Sylla, M.;
Joseph, D.; Chevallier, E.; Camara, C.; Dumas, F. Synthesis 2006, 38, 1045–1049; c) Wilsily, A.; Fillion, E.Org. Lett.
2008, 10, 2801–2804; d) Mukherjee, H.; Martinez, C. A. ACS Catal. 2011, 1, 1010–1013; e) Yu, J.; Li, N.; Chen, D.-F.;
Luo, S.-W. Tetrahedron Lett. 2014, 55, 2859–2864
199a) Cai, X.; Liu, Z.; Yang, Z.Huaxue Yanjiu 2006, 17, 41–43; b) Sal’keeva, L. K.; Taishibekova, E. K.; Minaeva, E. V.;
Shibaeva, a. K.; Kasenov, R. Z.; Sal’keeva, a. K.; Muratbekova, a. a. Russ. J. Gen. Chem. 2013, 83, 659–662
200Mase, N.; Horibe, T. Org. Lett. 2013, 15, 1854–1857
201Thirupathi, G.; Venkatanarayana,M.; Dubey, P. K.; Kumari, Y. B. Org. Chem. Int. 2012, 191584
202See, TheMizoroki‚ÄìHeck Reaction; Oestreich, M., Ed.; JohnWiley & Sons, Ltd: 2009
203See Yang, X.; Ma, S.; Du, Y.; Tao, Y. Chinese J. Org. Chem. 2013, 33, 2325
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X-Phos, BINAP, NHC or AsPh3), base (Et3N, piperidine, or K2CO3), additives (TBAC) and
hydride sources (HCO2H or HCO2Na) in various solvents such as DMF, MeCN or water in
oxygen-free conditions. In most attempts, the starting materials were unreactive at less then
60 °C. When heated more, one could observe the disappearance of vinyl triflate, suggesting
the palladium oxidative addition was working, but the coupling with the olefin never oc-
curred. All vinyl triflate was consumed, while olefin 417was recovered. In all attempts using
olefin 418, degradation of the olefin occurred at higher temperature (>80 °C).
Direct cobalt-catalyzed conjugate addition of triflate reagents into similar activated
double bond were attempted,204 as well as alkenylchromium reagents prepared from 419.205
Both reactions showed only degradations, apparently due to sensitivity of the nitrophenyl
moiety to metals.
MeO2C CO2Me
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NO2
MeO2C CO2Me
NO2
O
O
O
O
O
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O
NO2
NO2
TfO
dimethyl malonate
(cat.)
neat, 85%
Meldrum's acid
L-tyrosine
PhMe, 
68%
N H2N
CO2
Cross coupling
TfO
Cross coupling
NO2
MeO2C CO2Me
Bpin
(Bpin)2
[Cu] cat.
Suzuki Coupling
416
416
417
418
419
419
420
421
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Scheme 6.12 – Heck, reductive Heck and Suzuki attempts towards 420 or 421
Finally, synthesis of boronic ester 422 was planned in prevision of a Suzuki coupling
with triflate 419. Unfortunately, copper-catalyzed 1,4-Addition of pinacol diborane to reach
422 has proven unsuccessful.206 The boranewas not stable enough and total protodeborona-
tion was observed. We are currently exploring similar couplings with model triflate 419.
204a) Amatore, M.; Gosmini, C.; Périchon, J. J. Org. Chem. 2006, 71, 6130–6134; b) Amatore, M.; Gosmini, C. Synlett
2009, 20, 1073–1076
205Takai, K.; Tagashira, M.; Kuroda, T.; Oshima, K.; Utimoto, K.; Nozaki, H J. Am. Chem. Soc. 1986, 108, 6048–6050
206a) Ito, H.; Yamanaka, H.; Tateiwa, J.-i.; Hosomi, A. Tetrahedron Lett. 2000, 41, 6821–6825; b) Mun, S.; Lee, J. E.;
Yun, J. Org. Lett. 2006, 8, 4887–4889; c) Chea, H.; Sim, H. S.; Yun, J. Adv. Synth. Catal. 2009, 351, 855–858; d)
Thorpe, S. B.; Calderone, J. A.; Santos, W. L. Org. Lett. 2012, 14, 1918–1921; e) Stavber, G.; Cˇasar, Z. Appl.
Organomet. Chem. 2013, 27, 159–165
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6.2 Conclusion
In summary, we studied the total synthesis of kopsinitarine E 7 via a palladium-catalyzed
coupling/iORC pathway. Several attempts were made for the synthesis of the starting ma-
terials needed for the decarboxylative or Heck coupling (Scheme 6.13). The formation of
enone 382 was attempted from various pathways, such as dihydroxylation of 384, desym-
metrisation ofmeso-tartrate derivative 389, or from isopropylidene ketal 394. Unfortunately
no success were obtained with these strategies. On the last one, the high solubility of such
ketal intermediates caused many difficulties. By changing the protecting group of 394 for
the 4-heptylidene ketal 398, the solubility issue could be solved and preliminary results to-
wards enone 382 seemed promising. The optimisation of the route towards enone 382 is still
ongoing. The plan was to convert this enone in vinyl triflate 381 using a conjugate addition
and trapping of the enolate with Comins’ reagent. Using 417 or 380 as coupling parter with
381, we planned to reach 379. This intermediate could be cyclized into 378, which would be
the iORC precursor to reach indole intermediate 374. Fewmore reactions should allow us to
reach kopsinitarine E 7. Many attempts were done towards the potassium carboxylate 380,
without success. Alkylation, Wittig-type reaction or Knoevenagel reaction did not succeed to
afford desired product. For this reason, the Heck coupling was chosen due to the easy access
to olefin 417. Preliminary results on Heck and reductive Heck using 417 with a known vinyl
triflate as model substrate did not presented promising results so far. Nevertheless, as many
other coupling reactions are conceivable, this total synthesis is still pursued.
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Scheme 6.13 – Current State of the Synthetic Study of Kopsinitarine E
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General Conclusion
In summary, we developed a domino sequence called an integrated
oxidation/reduction/cyclization (iORC) process allowing us to reach easily the poly-
cyclic core of Aspidosperma alkaloids. This reaction uses latent functionalities hidden
within molecules, like double bonds, and nitro or azide to generate in situ carbonyls and
amines which in turn spontaneously condense to form three or more cycles during a skeletal
rearrangement process that affords the indole polycyclic skeleton of our target products with
a high degree of chemo-, regio-, and diastereoselectivity.
Our first target was minfiensine 1 (Scheme 7.1). The goal of this strategy was to reach
intermediate 95, and to performa domino reduction/cyclization sequence. This represented
an unpolished version of our iORC which lacked the oxidation step. Such a reaction should
have allowed us to reach aminal 94, which could supposedly be transformed into minfien-
sine 1 in a short and straightforward manner. In our synthetic study towards minfiensine
1, five main strategies were attempted in order to reach key intermediate 95. Instalment of
the quaternary C7 center by allylation or alkylation failed due to the steric hindrance around
this center. Cross metathesis of an allyl ketone to install the olefin moiety did not succeed
due to the incompatibility of our substrate with metathesis catalysts. Furthermore, the vari-
ous cycloadditions to afford the cyclohexenone moiety proved unsuccessful. Cyclohexenone
structure 95 proved difficult to reach and our synthetic route became too long to remain at-
tractive. It was therefore decided to stop this synthesis and focus on our newly developed
iORC.
The next studies focused on the use of our domino iORC sequence. We first chose to
target aspidospermidine 3 and dehydroaspidospermidine 2 (Scheme 7.2). The key macrocy-
cle 212was reached in only 6 steps and 17.4% overall yield featuring our palladium-catalyzed
decarboxylative coupling to build in one step a compound having all the carbons needed for
the synthesis of the natural product. Two consecutiveMitsunobu reactions closed themacro-
cycle needed in our key intermediate 212. Our key domino process allowed us to reach se-
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Scheme 7.1 – Summary of the synthetic study towardsminfiensine 1 and the different strategies attempted
to reach 94
lectively dehydroaspidospermidine 2 or aspidospermidine 3 with an optimised yield of 50%
from 212. Full diastereocontrol was observed as we formed a cis-fused [6,6] ring system.
From dehydroaspidospermidine 2, vincadifformine 4 could be synthetized in one step and
50% yield.
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Scheme 7.2 – Summary of the total synthesis of dehydroaspidospermidine 2, aspidospermidine 3 and vin-
cadifformine 4
Following a similar synthetic route as for aspidospermidine, we attempted to reach as-
pidoalbidine 5 with our iORC (Scheme 7.3) from macrocycle 293, obtained in 9 steps and
11.4% overall yield. This macrocycle was obtained using a palladium-catalyzed decarboxyla-
tive coupling to link the two main fragments of the molecule and two Mitsunobu reactions
to close the ten-membered ring. Anti-Markovnikov hydroxylation of the terminal olefin af-
forded the primary alcohol moiety of key intermediate 293. Our key-step is still under devel-
opment at this time and aspidoalbidine 5 has not yet been reached though we believe this is
just a matter of time until we obtain our target structure.
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Scheme 7.3 – Summary of the synthetic study towards aspidoalbidine 5
As all these previous examples of iORC domino process gave cis-fused [6,6] ring sys-
tem, we decided to change the diastereoselectivity of this reaction and force the reaction
into giving a trans-fused [6,6] ring system. This would allow us to reach kopsihainanine A
6 (Scheme 7.4). In order to change the selectivity, we introduced a constrain in the key in-
termediate to push the reaction towards our desired conformation. We formed 8-membered
ring 339 in 8 steps and 36% overall yield, featuring our palladium-catalyzed decarboxylative
coupling, and a Staudinger lactamization. To our delight, performing our key domino pro-
cess on this lactam allowed us to reach intermediate 336with a trans-fused C/D ring system
in 63% yield with full stereocontrol. An α-keto hydroxylation concluded our total synthesis
of racemic kopsihainanine A 6 in 91% yield.
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Scheme 7.4 – Summary of the total synthesis of kopsihainanine A 6
Our final synthetic studywas designed to see how far couldwe go for generatingmolec-
ular complexity by the iORC process (Scheme 7.5). We targeted kopsinitarine E 7 via indole-
nine 423. This intermediate was supposed to be reached by performing our iORC domino
process on highly substituted precursor 424. Unfortunately, the presence of these functional
groups made the synthesis of precursor 424 challenging. This project was still at an early
stage.
To conclude, we were able to demonstrate the power of our iORC and our ability to
control the cyclization step from a regioselective perspective (goniomitine versus aspidosper-
midine), as well as a diastereoselective perspective (aspidospermidine versus kopsinainanine
A). The quaternary center in C20 of these aspidosperma alkaloids is the one controlling the
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Scheme 7.5 – Summary of the synthetic study towards kopsinitarine E 7
relative stereoselectivity, and if the formation of this center could be done in an enantios-
elective manner, the total syntheses of these alkaloids would become enantioselective. We
are currently considering this synthetic challenge. Nonetheless, such domino processes have
some drawbacks. The sensitivity of the key step towards the reductive conditions usedmakes
this transformation challenging, as a slightly different substrate requires totally different re-
ductive conditions to achieve good yields. In addition, we sometimes experienced troubles
to reach iORC precursors as for the synthesis of kopsinitarine E or minfiensine. However, the
ability to trigger such skeleton rearrangement and form complex polycyclic indole skeletons
from simple precursors is certainly a great asset and a significant addition to the strategies
available for the total synthesis of indole alkaloids, and could allow easy synthetic entry into
many other families of indole alkaloids.
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Experimental Section
8.1 General Remarks
Reagents and solvents were purchased from commercial sources (Aldrich, Acros, Merck,
Fluka, TCI and VWR international) and preserved under argon. More sensitive compounds
were stored in a desiccator or glove-box if required. Reagents were used without further pu-
rification unless otherwise noted.
All reactions were performed under argon (or nitrogen) unless otherwise noted. When
needed, glassware was dried overnight in an oven ( T > 100 °C) or under vacuum with a heat
gun (T > 200 °C).
When solvents are indicated asdry theywere either purchased as such, distilled prior to use or
were dried by a passage through a column of anhydrous alumina or copper using a Puresolv
MD 5 from Innovative Technology Inc., based on the Grubb’s design.207
Reactions heated bymicrowave irradiation were performed in a CEMDiscover SPmicrowave
instrument.
Flash column chromatographies208 were performed using Silicycle P60 silica: 230-400 mesh
(40-63μm) silica.
Reactions were monitored using Merck Kieselgel 60F254 aluminium or glass backed plates.
TLC’s were visualized by UV fluorescence (254nm) then one of the following: KMnO4, PMA,
ninhydrin, pancaldi, p-anisaldehyde, vanillin.
NMR spectra were recorded on a Bruker AvanceIII-400, Bruker Avance-400, Bruker DRX-400,
or Bruker AvanceII-800 spectrometer at room temperature, 1H frequency is at 400.13MHz,
207Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J.Organometallics 1996, 15, 1518–1520
208Still, W.; Kahn, M. J. Org. Chem. 1978, 43, 2923–2925
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13C frequency is at 100.62MHz. Chemical shifts (δ) were reported in parts per million (ppm)
relative to residual solvent peaks rounded to the nearest 0.01ppm for proton and 0.1ppm
for carbon (ref : CHCl3
[
1H: 7.26ppm, 13C: 77.2ppm
]
, MeOH
[
1H: 3.31ppm, 13C 49.0ppm
]
,
DMSO
[
1H: 2.50ppm, 13C 39.5ppm
]
). Coupling constants (J) were reported inHz to the near-
est 0.1Hz. Peak multiplicity was indicated as follows s (singlet), d (doublet), t (triplet), q
(quartet), m (multiplet) and br (broad). Attribution of peaks was done using the multiplici-
ties and integrals of the peaks. COSY, HSQC, and HMBC experiments were used to confirm
the attribution.
IR spectra were recorded in a Jasco FT/IR-4100 spectrometer outfitted with a PIKE technol-
ogy MIRacleTM ATR accessory as neat films compressed onto a Zinc Selenide window. The
spectra are reported in cm−1. Abbreviations used are: w (weak),m (medium), s (strong) and
br (broad).
Mass spectra were obtained by using aWaters ACQUITY H-class UPLC/MS ACQ-SQD by elec-
tron ionisation (EI positive and negative) or a Finnigan TSQ7000 by electrospray ionization
(ESI+). The accurate masses were measured by themass spectrometry service of the EPFL by
ESI-TOF using a QTOF Ultima fromWaters.
Specific optical rotations [α]D were obtained with a Jasco P-2000 polarimeter (589nm).
Enantiomeric excesses were determined with a Thar SFC Investigator system using chiral
stationary phase columns by comparing the samples with the appropriate racemic samples,
column and elution details specified in each entry.
Melting points are uncorrected and were recorded on a Stuart SMP30 melting point appara-
tus.
When a rigorously inert and dry atmosphere was needed reactions were carried out in a Pure-
Lab HE 4GB 2500 Glove-box System from Innovative Technologies inc.
For all general procedures the order of addition of reagents has to be respected.
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Ethyl 2-(hydroxymethyl)acrylate 425
O
O
P
O
O
O
HCHO
K2CO3
H2O, 40 °C
77%
1
2
3
4
HO5 O
O 6
7
425
Following a reported procedure,209 a solution of paraformaldehyde (4.8 g, 0.16mol, 4.0 equiv)
in H2O (11mL) and phosphoric acid (1.0M solution, 0.40mL) was heated to 90 °C for 5h.
The reactionmixture was allowed to cool down to RT, and triethyl phosphonoacetate (8.0mL,
40mmol) was added. A solution of K2CO3 (6.1 g, 40mmol, 1.0 equiv) in H2O (6.0mL) was
added dropwise carefully, by avoiding the reaction mixture to go higher than 40 °C. The reac-
tion was then stirred at 40 °C for 5minutes. The reaction mixture was then cooled down to
0 °C. Brine and Et2O were added to the mixture. The solution was then extracted with Et2O.
The combined organic phases were washed with brine, dried over Na2SO4 and concentrated
in vacuo. Purification by vacuum distillation (Bp = 55 °C/0.1mbar) afforded compound 425
as a colorless oil (4.0 g, 77% yield). The spectroscopic data of this compound were in accord
with those reported in the literature.210
1H NMR (400 MHz, CDCl3): δ 6.25 (s, 1H, C
4−H), 5.82 (s, 1H, C4−H), 4.32 (d, J = 6.6 Hz, 2H,
C3−H), 4.24 (q, J = 7.1 Hz, 2H, C6−H), 2.36 (t, J = 6.6 Hz, 1H, O5−H), 1.31 (t, J = 7.1 Hz, 3H,
C7−H).
13C NMR (101MHz, CDCl3): δ 166.5 (C
2), 139.6 (C1), 125.8 (C4), 62.8 (C6), 61.0 (C3), 14.3 (C7).
Rf (PE/EtOAc 8:2)= 0.2.
2-azidoethyl 4-methylbenzenesulfonate 426
ClHO
1. NaN3, DMF
    80 °C
2. TsCl, Et3N
THF, RT
70%
1
2
N3
O3
4
5
6
7
8
9
S
O
O
426
209Villieras, J; Rambaud, MOrg. Synth. 1988, 66, 220
210Patil, S.; Chen, L.; Tanko, J. M. Tetrahedron Lett. 2014, 55, 7029–7033
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Following a reported procedure,211 to a solution of 2-chloroethanol (4.3mL, 63mmol) in
DMF (20mL) was added sodium azide (5.7 g, 88mmol, 1.4 equiv). The solution was stirred
at 80 °C for 24h. The reaction mixture was allowed to cool down to RT, and then filtered
through Celite. The Celite was washed with THF and the solution was directly used for the
next reaction.
To the crude 2-azidoethanol in solution (THF/DMF 2:1) was added triethylamine (26mL,
0.19mol, 3.0 equiv) and tosyl chloride (14g, 72mmol, 1.2 equiv). The mixture was stirred
overnight. The solution was then concentrated in vacuo, diluted in DCM and washed with
H2O, 1M HCl, 10% NaOH, brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/EtOAc 5:1) afforded compound 426 as a yellow oil (11 g, 70% yield). The spectro-
scopic data of this compound were in accord with those reported in the literature.211
1HNMR (400MHz, CDCl3): δ 7.82 (d, J = 8.3Hz, 2H, C4,8−H), 7.37 (d, J = 8.3 Hz, 2H, C5,7−H),
4.16 (t, J = 5.2 Hz, 2H, C2−H), 3.48 (t, J = 5.2 Hz, 2H, C1−H), 2.46 (s, 3H, C9−H).
13C NMR (101MHz, CDCl3): δ 145.3 (C
3), 132.6 (C6), 130.0 (C5,7), 128.0 (C4,8), 68.1 (C1), 49.6
(C2), 21.7 (C9).
Rf (PE/EtOAc 8:2) = 0.28.
methyl 2-(2-nitrophenyl)acetate 96
NO2
H2SO4 cat.
MeOH, 
quant.
1
2
3
4
5
6
NO2
7
8
O
OH
O
O 9
96
To a solution of 2-(2-nitrophenyl)-acetic acid (10.0 g, 55.0mmol) in methanol (300mL) was
added 3.0mL of conc. H2SO4. The solution was heated at reflux for 2h. The solutionwas then
concentrated under reduced pressure, diluted with EtOAc, washed with saturated NaHCO3,
brine, dried over Na2SO4 and concentrated in vacuo. The crude compound 96 thus obtained
was used for the next stepwithout further purification (yellow wax, 10.7 g). The spectroscopic
data of this compoundwere in accordwith those reported in the literature.212 The compound
was used without further purification.
1HNMR (400MHz, CDCl3): δ 8.12 (dd, J = 7.9,1.2 Hz, 1H, C2−H), 7.60 (td, J = 7.9,1.2 Hz, 1H,
C4−H), 7.48 (td, J = 7.9,1.2 Hz, 1H, C3−H), 7.36 (dd, J = 7.9,1.2 Hz, 1H, C5−H), 4.03 (s, 2H,
C7−H), 3.71 (s, 3H, C9−H).
211Macleod, F.; Lang, S.; Murphy, J. A. Synlett 2010, 21, 529–534
212Lee, S.; Lim, H.-J.; Cha, K. L.; Sulikowski, G. A. Tetrahedron 1997, 53, 16521–16532
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13C NMR (101MHz, CDCl3): δ 170.5 (C
8), 148.9 (C1), 133.7 (C4), 133.5 (C5), 129.9 (C3), 128.8
(C6), 125.5 (C2), 52.4 (C9), 39.7 (C7).
Rf (EtOAc) = 0.71.
Ethyl 2-(bromomethyl)acrylate 99
HO O
O
1
2
3
4
Br O
O 8
9
PBr3
Et2O,
-10 °C to RT
91%425 99
Following a reported procedure,210 to a solution of acrylate 425 (8.0 g, 61mmol) in Et2O
(65mL) at -10 °C was added dropwise PBr3 (2.3mL, 25mmol, 0.40 equiv). The solution was
stirred and allowed to warm up slowly to RT over a period of 4h. The solution was then
cooled down to -10 °C, water was added slowly, and themixture was extractedwith Et2O. The
combined organic phases were washed with brine, dried over Na2SO4, and concentrated in
vacuo. Purification by vacuum distillation (Bp = 55 °C/8.0mbar) afforded compound 99 as a
colorless oil (11 g, 91% yield). The spectroscopic data of this compound were in accord with
those reported in the literature.210
1H NMR (400MHz, CDCl3): δ 6.33 (d, J = 0.7 Hz, 1H, C4−H), 5.94 (d, J = 0.7 Hz, 1H, C4−H),
4.27 (q, J = 7.1 Hz, 2H, C8−H), 4.18 (d, J = 0.8 Hz, 2H, C3−H), 1.33 (t, J = 7.1 Hz, 3H, C9−H).
13C NMR (101MHz, CDCl3): δ 165.0 (C
2), 137.7 (C1), 129.1 (C4), 61.5 (C8), 29.5 (C3), 14.3 (C9).
Rf (PE/EtOAc 8:2) = 0.68.
2-azidoiodoethane 97
1
2
N3
I
NaI
Acetone, 
75%
N3
TsO
426 97
Sodium iodide (4.7 g, 31mmol, 1.5 equiv) was added to a solution of 426 (5.0mL, 21mmol)
in acetone (100mL). The solution was stirred at reflux for 18h. The reaction mixture was
allowed to cool down to RT, and concentrated under reduced pressure. Water was added
and the mixture was extracted with Et2O. The combined organic phases were washed with
brine, dried over Na2SO4 and concentrated in vacuo. Purification by vacuum distillation (Bp
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= 70 °C/20mbar) afforded compound 97 as a colorless oil (3.1 g, 75% yield). The spectro-
scopic data of this compound were in accord with those reported in the literature.211
1H NMR (400MHz, CDCl3): δ 3.66 (t, J = 7.1 Hz, 2H, C2−H), 3.25 (t, J = 7.1 Hz, 2H, C1−H).
13C NMR (101MHz, CDCl3): δ 53.1 (C
2), 1.0 (C1).
Rf (PE/EtOAc 5:1) = 0.78.
1-ethyl 5-methyl 2-methylene-4-(2-nitrophenyl)-pentanedioate 427
Cs2CO3
DMF, 40 °C,
61%
CO2EtBr
NO2
CO2Me 1
2
3
4
5
6
NO2
7
8
9
10
+
11
O O
12 O
O
13
14
15
96 99 427
The ester 96 (0.20 g, 1.0mmol) was dissolved in DMF (1.0mL). The acrylate 99 was added
(0.12g, 1.2mmol, 1.2 equiv), followed by cesium carbonate (0.33 g, 2.0mmol, 2.0 equiv). The
reaction mixture was then stirred at 45 °C for 9h. The solution was then cooled down to
RT, acidified with 0.5M HCl and extracted with EtOAc. The combined organic phases were
washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/DCM 1:1) afforded compound 427 as a yellow oil (0.19 g, 61% yield).
1H NMR (400 MHz, CDCl3): δ 7.89 (dd, J = 7.8,1.1 Hz, 1H, C3−H), 7.57 (td, J = 7.8,1.1 Hz,
1H, C1−H), 7.49 (dd, J = 7.8,1.3 Hz, 1H, C6−H), 7.42 (td, J = 7.8,1.3 Hz, 1H, C2−H), 6.11 (d,
J = 1.0 Hz, 1H, C10−H), 5.42 (d, J = 1.0 Hz, 1H, C10−H), 4.55 (t, J = 8.1 Hz, 1H, C7−H), 4.20
(q, J = 7.2 Hz, 2H, C14−H), 3.66 (s, 3H, C13−H), 3.24 (dd, J = 14.1,8.1 Hz, 1H, C8−H), 2.82 (dd,
J = 14.1,8.1 Hz, 1H, C8−H), 1.29 (t, J = 7.2 Hz, 3H, C15−H).
13C NMR (101 MHz, CDCl3): δ 172.4 (C
12), 166.5 (C11), 149.5 (C4), 137.2 (C9), 133.1 (C1),
132.98 (C5), 130.7 (C6), 128.4 (C2), 127.9 (C10), 124.9 (C3), 61.1 (C14), 52.4 (C13), 45.7 (C7), 35.3
(C8), 14.3 (C15).
IR: 1736 (s), 1714 (s), 1527 (s), 1352 (m), 1194 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C15H18NO6+: 308.1134; Found: 308.1126.
Rf (PE/DCM 1:1) = 0.23.
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methyl 4-azido-2-(2-nitrophenyl)butanoate 98
Cs2CO3
DMF, 60 °C
73%
N3I
NO2
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The ester 96 (0.20 g, 1.0mmol) was dissolved in DMF (2.0mL). Compound 97 was added
(0.43g, 2.1mmol, 2.0 equiv), followed by cesium carbonate (0.33 g, 2.1mmol, 2.0 equiv). The
reaction mixture was then stirred at 60 °C for 18h. The solution was then cooled down
to RT, acidified with 0.5M HCl and extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(toluene) afforded compound 98 as a yellow oil (0.19 g, 73% yield).
1H NMR (400 MHz, CDCl3): δ 7.95 (dd, J = 7.9,1.2 Hz, 1H, C3−H), 7.61 (td, J = 7.9,1.2 Hz,
1H, C1−H), 7.50-7.42 (m, 2H, C2,6−H), 4.29 (t, J = 7.2 Hz, 1H, C7−H), 3.67 (s, 3H, C13−H),
3.46-3.29 (m, 2H, C9−H), 2.50 (dq, J = 14.2,7.0 Hz, 1H, C8−H), 2.09 (dq, J = 14.2,7.0 Hz, 1H,
C8−H).
13C NMR (101MHz, CDCl3): δ 172.3 (C
12), 149.1 (C4), 133.4 (C1), 132.8 (C5), 130.3 (C6), 128.6
(C2), 125.2 (C3), 52.5 (C13), 49.3 (C9), 44.1 (C7), 31.9 (C8).
IR: 2098 (w), 1734 (w), 1528 (s), 1352 (w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C11H12N4NaO4+: 287.0751; Found: 287.0754.
Rf (Toluene) = 0.45.
5-ethyl 1-methyl 2-(2-azidoethyl)-4-methylene-2-(2-nitrophenyl)pentanedioate
100
NO2
N3
O
O
Cs2CO3
DMF, 40 °C
17%
CO2EtBr+ 1
2
3
4
5
6
NO2
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8
9
N3
16 O
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The ester 98 (30mg, 0.12mmol) was dissolved in DMF (0.30mL). Compound 99 was added
(27mg, 0.14mmol, 1.2 equiv), followed by cesium carbonate (75mg, 0.18mmol, 1.5 equiv).
The reaction mixture was then stirred at 40 °C for 24h. The solution was then cooled down
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to RT, acidified with 0.5M HCl and extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 9:1) afforded compound 100 as a yellow oil (7.7mg, 17% yield).
1H NMR (400 MHz, CDCl3): δ 7.96 (dd, J = 7.9,1.4 Hz, 1H, C3−H), 7.58 (td, J = 7.9,1.4 Hz,
1H, C1−H), 7.47 (td, J = 7.9,1.1 Hz, 1H, C2−H), 7.33 (dd, J = 7.9,1.1 Hz, 1H, C6−H), 6.26 (d,
J = 1.1 Hz, 1H, C12−H), 5.41 (d, J = 1.1 Hz, 1H, C12−H), 4.01-3.84 (m, 2H, C14−H), 3.68 (s, 3H,
C17−H), 3.63 (d, J = 13.8 Hz, 1H, C10−H), 3.35-3.16 (m, 2H, C9−H), 3.12 (d, J = 13.8 Hz, 1H,
C10−H), 2.44-2.28 (m, 2H, C8−H), 1.16 (t, J = 7.1 Hz, 3H, C15−H).
13C NMR (101 MHz, CDCl3): δ 172.5 (C
16), 166.9 (C13), 149.9 (C4), 136.2 (C11), 134.0 (C5),
132.4 (C2), 130.3 (C12), 129.1 (C6), 128.3 (C1), 126.0 (C3), 61.0 (C14), 52.1 (C17), 52.0 (C7), 47.5
(C9), 38.1 (C10), 35.0 (C8), 14.0 (C15).
IR: 2924 (s), 2851 (w), 2099 (m), 1718 (m), 1530 (s), 1357 (w).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C17H21N4O6+: 377.1456; Found: 377.1464.
Rf (DCM) = 0.5.
ethyl 2-(acetoxymethyl)acrylate 116
HO O
O
1
2
3
4
O O
O 8
9
AcCl
Et3N
DCM, 0 °C
68%
1011
O
425 116
Following a reported procedure,213 to a solution of acrylate 425 (50mg, 0.38mmol) in DCM
(1.5mL) at 0 °Cwas added dropwise Et3N (80μL, 0.58mmol, 1.5 equiv). Acetyl chloride (40μL,
0.58mmol, 1.5 equiv) was then added dropwise. The solution was stirred for 20min. The
mixture was quenched with brine. The phases were separated and the aqueous one was
washed with DCM. The combined organic phases were dried over Na2SO4 and concentrated
in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded compound 116 as a yellow oil (45mg,
68% yield). The spectroscopic data of this compound were in accord with those reported in
the literature.213
1H NMR (400MHz, CDCl3): δ 6.36 (d, J = 1.1 Hz, 1H, C4−H), 5.83 (d, J = 1.1 Hz, 1H, C4−H),
4.81 (s, 2H, C3−H), 4.24 (q, J = 7.1 Hz, 2H, C8−H), 2.10 (s, 3H, C11−H), 1.31 (t, J = 7.1 Hz, 3H,
C9−H).
213Kang, S.; Shi, Q.; Ha, M. W.; Ku, J.-M.; Cheng, M.; Jeong, B.-S.; Park, H.-g.; Jew, S.-s. Tetrahedron 2010, 66,
4326–4329
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13C NMR (101 MHz, CDCl3): δ 170.6 (C
10), 165.3 (C2), 135.6 (C1), 127.4 (C4), 62.6 (C3), 61.1
(C8), 21.0 (C11), 14.3 (C9).
Rf (DCM) = 0.54.
4-azido-2-(2-nitrophenyl)butanoic acid 109
LiOH
THF/H2O, RT
85%NO2
CO2Me 1
2
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6
NO2
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To a solution of ester 98 (0.50 g, 1.9mmol) in a mixture of THF/H2O (1:1, 20mL) was added
LiOH (91mg, 3.8mmol, 2.0 equiv). The solutionwas stirred at RT for 3h. HCl (1.0M)was then
added and the solution was extractedwith DCM. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2)
afforded acid 109 as a yellow oil (0.40 g, 85% yield).
1HNMR (400MHz, CDCl3): δ 8.00 (dd, J = 8.1,1.3 Hz, 1H, C3−H), 7.64 (td, J = 8.1,1.3 Hz, 1H,
C1−H), 7.52-7.45 (m, 2H, C2,6−H), 4.32 (t, J = 7.1 Hz, 1H, C7−H), 3.42 (dt, J = 13.6,7.1 Hz, 1H,
C9−H), 3.30 (dt, J = 13.6,7.1 Hz, 1H, C9−H), 2.52 (dq, J = 14.1,7.1 Hz, 1H, C8−H), 2.10 (dq,
J = 14.1,7.1 Hz, 1H, C8−H).
13C NMR (101MHz, CDCl3): δ 176.9 (C
12), 149.0 (C4), 133.7 (C5), 132.4 (C6), 130.9 (C1), 129.0
(C2), 125.5 (C3), 49.3 (C9), 44.5 (C7), 31.5 (C8).
IR: 2926 (w), 2856 (w), 2750 (w), 2635 (w), 2571 (w), 2102 (w), 1701 (s), 1612 (w), 1578 (w), 1518
(s), 1431 (m), 1410 (m), 1342 (s), 1241 (s), 938 (m), 706 (s).
HRMS: (ESI+−) m/z: [M−H]− Calcd for C10H9N4O4–: 249.0624; Found: 249.0631.
Rf (EtOAc) = 0.61.
N-methoxy-N-methyl-2-(2-nitrophenyl)acetamide 113
MeNHOMe
DCC
DCM, RT
quant.
NO2
CO2H 1
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To a solution of 2-(2-nitrophenyl)acetic acid (50mg, 0.27mmol) in DCM (0.60mL) at 0 °C was
added freshly distilled N,O-dimethylhydroxylamine (25mg, 0.41mmol, 1.5 equiv) and DCC
(62mg, 0.30mmol, 1.1 equiv). The solution was stirred at RT for 24h. HCl (1.0M) was then
added and themixturewas extractedwith EtOAc. The combined organic phaseswerewashed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (EtOAc) af-
forded pureWeinreb amide 113 as a yellow oil (60mg, quantitative yield).
1HNMR (400MHz, CDCl3): δ 8.09 (dd, J = 7.7,1.4 Hz, 1H, C3−H), 7.58 (td, J = 7.7,1.4 Hz, 1H,
C1−H), 7.45 (td, J = 7.7,1.3 Hz, 1H, C2−H), 7.36 (dd, J = 7.7,1.3 Hz, 1H, C6−H), 4.17 (s, 2H,
C7−H), 3.81 (s, 3H, C10−H), 3.22 (s, 3H, C9−H).
13C NMR (101MHz, CDCl3): δ 170.5 (C
6), 149.2 (C4), 133.5 (C6), 133.4 (C1), 130.7 (C5), 128.3
(C2), 125.2 (C3), 61.3 (C10), 37.9 (C7), 32.4 (C9).
IR: 2936 (w), 2856 (w), 2359 (w), 2342 (w), 1665 (s), 1525 (s), 1350 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C10H13N2O4+: 225.0870; Found: 225.0869.
Rf (PE/EtOAc 8:2) = 0.07.
4-azido-2-(2-nitrophenyl)butan-1-ol 428
LiBH4
Et2O, RT
81%NO2
CO2Me 1
2
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NO2
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To a solution of ester 98 (6.7 g, 25mmol) in Et2O (25mL) was added LiBH4 (1.1 g, 51mmol,
2.0 equiv). The solution was stirred at RT for 2h. SaturatedNH4Cl was then added and the so-
lution was extracted with Et2O. The combined organic phases were washed with brine, dried
over Na2SO4 and concentrated in vacuo. Purification by FCC (DCM) afforded compound 428
as an orange oil (4.8 g, 81% yield).
1H NMR (400 MHz, CDCl3): δ 7.77 (dd, J = 7.8,1.3 Hz, 1H, C3−H), 7.61 (td, J = 7.8,1.3 Hz,
1H, C1−H), 7.50 (dd, J = 7.8,1.3 Hz, 1H, C6−H), 7.41 (td, J = 7.8,1.3 Hz, 1H, C1−H), 3.86
(dd, J = 9.3,5.3 Hz, 2H, C12−H), 3.49 (tt, J = 9.3,5.9 Hz, 1H, C7−H), 3.37-3.15 (m, 2H, C9−H),
2.15 (dtd, J = 14.0,7.6,5.6 Hz, 1H, C8−H), 1.97 (dtd, J = 14.0,7.6,5.6 Hz, 1H, C8−H), 1.70 (t,
J = 5.3 Hz, 1H, O13−H).
13C NMR (101MHz, CDCl3): δ 151.2 (C
4), 135.5 (C5), 132.7 (C1), 128.4 (C6), 127.73 (C2), 124.3
(C3), 66.5 (C12), 49.4 (C9), 39.5 (C7), 31.1 (C8).
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IR: 2920 (w), 2878 (w), 2360 (w), 2094 (s), 1520 (s), 1353 (s), 1038 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C10H13N4O3+: 237.0982; Found: 237.0992.
Rf (DCM) = 0.19.
4-azido-2-(2-nitrophenyl)butan-1-al 111
IBX
DMSO, RT
80%NO2
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To a solution of alcohol 428 (4.5 g, 19mmol) in DMSO (20mL) was added IBX (6.0 g, 25mmol,
1.3 equiv). The solution was stirred at RT for 3h. Saturated NaHCO3 was then added and the
solution was filtered and extracted with EtOAc. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2)
afforded compound 111 as an orange oil (3.5 g, 80% yield).
1H NMR (400 MHz, CDCl3): δ 9.75 (s, 1H, C
12−H), 8.02 (dd, J = 7.9,1.0 Hz, 1H, C3−H),
7.67 (td, J = 7.9,1.0 Hz, 1H, C1−H), 7.52 (td, J = 7.9,1.0 Hz, 1H, C2−H), 7.31 (dd, J =
7.9,1.0 Hz, 1H, C6−H), 4.28 (t, J = 7.6 Hz, 1H, C7−H), 3.40 (dt, J = 13.1,6.7 Hz, 1H, C9−H),
3.31 (dt, J = 13.1,6.7 Hz, 1H, C9−H), 2.52 (ddt, J = 14.2,7.6,6.7 Hz, 1H, C8−H), 2.02 (ddt,
J = 14.2,7.6,6.7 Hz, 1H, C8−H).
13C NMR (101MHz, CDCl3): δ 197.9 (C
12), 149.8 (C4), 133.7 (C5), 131.2 (C2), 130.7 (C6), 129.1
(C1), 125.5 (C3), 51.4 (C7), 49.1 (C9), 29.0 (C8).
IR: 2934 (w), 2838 (w), 2725 (w), 2097 (s), 1724 (s), 1523 (s), 1348 (s).
HRMS: (ESI+) m/z: [M−N+H]+ Calcd for C10H11N3O3+: 221.0795; Found: 221.0805.
Rf (DCM) = 0.73.
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methyl 2-(2-azidophenyl)acetate 102
NO2
CO2Me
1. H2, Pd/C, 
    MeOH, RT
2. NaNO2, NaN3
    aq. HCl, RT
61%
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A solution of 96 (1.0 g, 5.1mmol) in methanol (10mL) under nitrogen was treated with 10%
palladium on activated charcoal (0.25 g, 5.0mol%). The nitrogen atmosphere was then re-
placed by hydrogen. The solution was stirred for 4h. It was then filtered through Celite,
washed with saturated NaHCO3 and extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo to give the crude
amine that was used without further purification.
The crude amine was dissolved in aqueous HCl (2.0M, 30mL). A solution of NaNO2 (0.50g,
7.2mmol, 1.4 equiv) in 6.0mL H2O was added dropwise. After 15min, a solution of NaN3
(0.40g, 6.1mmol, 1.2 equiv) in 6.0mL H2O was added carefully. The reaction mixture was
stirred for 3h. The solution was then extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 9:1) afforded compound 102 as a yellow oil (0.59 g, 61% yield).
1HNMR (400MHz, CDCl3): δ 7.36 (td, J = 7.9,1.3 Hz, 1H, C2−H), 7.25 (dd, J = 7.9,1.3 Hz, 1H,
C6−H), 7.19 (dd, J = 7.9,1.1 Hz, 1H, C3−H), 7.14 (td, J = 7.9,1.1 Hz, 1H, C1−H), 3.73 (s, 3H,
C10−H), 3.64 (s, 2H, C8−H).
13C NMR (101MHz, CDCl3): δ 171.6 (C
9), 138.7 (C4), 131.5 (C6), 128.8 (C2), 125.6 (C5), 124.8
(C1), 118.2 (C3), 52.2 (C10), 36.5 (C8).
IR: 2953 (w), 2120 (s), 1737 (s), 1491 (m), 1286 (s), 1161 (s), 750 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C9H9N3NaO2+: 214.0587; Found: 214.0592.
Rf (DCM) = 0.7.
dimethyl 2-(2-nitrophenyl)malonate 104
NO2
F Dimethyl malonate
NaH
DMF, 70 °C
89%
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To a suspension of NaH (60% in oil, 0.60 g, 1.4mmol, 2.2 equiv) in DMF (9.0mL) at 0 °C was
added dimethyl malonate (1.7 g, 1.3mmol, 2.0 equiv) dropwise. A solution of o-fluoronitro-
benzene (0.70mL, 0.6mmol) in DMF (2.0mL) was then added dropwise. The solution was
then heated at 70 °C for 2h. The reaction mixture was then cooled down, quenched with
saturated NH4Cl, then extracted with EtOAc. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc
9:1) afforded compound 104 as a yellow oil (0.14 g, 89% yield). The spectroscopic data of this
compound were in accord with those reported in the literature.214
1HNMR (400MHz, CDCl3): δ 8.09 (dd, J = 7.8,1.1 Hz, 1H, C3−H), 7.67 (td, J = 7.8,1.1 Hz, 1H,
C1−H), 7.54 (td, J = 7.8,1.4 Hz, 1H, C2−H), 7.52 (dd, J = 7.8,1.4 Hz, 1H, C6−H), 5.35 (s, 1H,
C7−H), 3.82 (s, 6H, C10,11−H).
13C NMR (101MHz, CDCl3): δ 167.7 (C
8,9), 148.7 (C4), 133.6 (C1), 131.4 (C6), 129.4 (C2), 127.9
(C5), 125.3 (C3), 54.1 (C7), 53.2 (C10,11).
Rf (DCM) = 0.17.
dimethyl 2-(2-azidoethyl)malonate 106
CO2MeMeO2C I N3+
1
2
3 N3
NaH
THF, RT
89%
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O O
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To a suspension of NaH (60% in oil, 23mg, 1.0mmol, 1.3 equiv) in THF (1.0mL) at 0 °C
was added dimethyl malonate (0.10 g, 0.76mmol) dropwise. After 15 minutes, 1-azido-2-
iodoethane 97 (0.20 g, 1.0mmol, 1.3 equiv) was added dropwise. The solution was then
stirred at RTovernight. The reactionmixturewas then cooleddown, quenchedwith saturated
NH4Cl, then extracted with EtOAc. Purification by FCC (PE/EtOAc 8:2) afforded compound
106 as a yellow oil (0.14 g, 89% yield).
1H NMR (400 MHz, CDCl3): δ 3.79 (s, 6H, C
5,7−H), 3.56 (t, J = 7.2 Hz, 1H, C1−H), 3.42 (t,
J = 6.6 Hz, 2H, C3−H), 2.20 (dt, J = 7.2,6.5 Hz, 2H, C2−H).
13C NMR (101MHz, CDCl3): δ 169.2 (C
4,6), 52.8 (C5,7), 49.1 (C1), 48.7 (C3), 28.2 (C2).
IR: 2955 (w), 2924 (w), 2853 (w), 2099 (s), 1732 (s), 1437 (m), 1343 (w), 1250 (m), 1155 (s).
214Goetz, F. J.; Hirsch, J. A.; Augustine, R. L. J. Org. Chem. 1983, 48, 2468–2472
117
Chapter 8: Experimental Section
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C7H11N3NaO4+: 224.0642; Found: 224.0635.
Rf (PE/EtOAc 7:3) = 0.67.
allyl 4-azido-2-(2-nitrophenyl)butanoate 107
Allyl-Br
NaHCO3
DMF, RT
65%NO2
CO2H 1
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To a solution of acid 109 (0.60 g, 2.4mmol) in DMF (4.8mL) was added NaHCO3 (0.20g,
2.6mmol, 1.1 equiv) and allyl bromide (1.4 g, 12mmol, 5.0 equiv). The solution was stirred at
RT for 48h. The mixture was then concentrated under reduced pressure, diluted with DCM,
washed with H2O, saturated NaHCO3, brine, dried over Na2SO4 and concentrated in vacuo.
Purification by FCC (DCM) afforded compound 107 as a yellow oil (0.45 g, 65% yield).
1H NMR (400 MHz, CDCl3): δ 7.95 (dd, J = 8.0,1.2 Hz, 1H, C3−H), 7.61 (td, J = 8.0,1.2 Hz,
1H, C1−H), 7.51-7.42 (m, 2H, C2,6−H), 5.82 (ddt, J = 17.2,10.6,5.7 Hz, 1H, C12−H), 5.27-5.18
(m, 2H, C13−H), 4.65-4.56 (m, 2H, C11−H), 4.31 (t, J = 7.1 Hz, 1H, C7−H), 3.48-3.30 (m, 2H,
C9−H), 2.51 (m, 1H, C8−H), 2.11 (m, 1H, C8−H).
13CNMR (101MHz, CDCl3): δ 171.5 (C
10), 149.2 (C4), 133.4 (C1), 132.8 (C5), 131.5 (C12), 130.3
(C6), 128.6 (C2), 125.2 (C3), 118.7 (C13), 66.0 (C11), 49.4 (C9), 44.2 (C7), 31.9 (C8).
IR: 2926 (w), 2865 (w), 2361 (w), 2337 (w), 2097 (s), 1734 (s), 1526 (s), 1351 (s), 1170 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C13H14N4NaO4+: 313.0907; Found: 313.09165.
Rf (DCM) = 0.49.
7-azido-5-(2-nitrophenyl)hept-1-en-4-ol 112
THF, 
0 °C to RT
88%, dr= 1:1NO2
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To a solution of allylboronic acid pinacol ester (1.6mL, 8.5mmol, 1.7 equiv) in THF (20mL)
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at 0 °C was added the aldehyde 111 (1.2 g, 4.9mmol). The solution was stirred at 0 °C for
3h, and then at RT overnight. Saturated aqueous NaHCO3 was added, and the mixture was
stirred for 30min at RT. Themixturewas extractedwith EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 8:1) afforded compound 112 as a yellow oil (1.2 g, 88% yield as an inseparable
mixture of two diastereoisomers).
1H NMR (400 MHz, CDCl3): δ 7.72 (m, 1H, C
3−H), 7.59 (m, 1H, C1−H), 7.51 (m, 1H, C2−H),
7.40 (m, 1H, C6−H), 5.76 (m, 1H, C12−H), 5.23-5.10 (m, 2H, C13−H), 3.88 (m, 1H, C10−H), 3.36
(m, 1H, O14−H), 3.25-3.10 (m, 2H, C9−H), 2.36 (m, 1H, C7−H), 2.21-1.83 (m, 4H, C8,11−H).
13C NMR (101MHz, CDCl3): δ 151.9 (C
4), 151.3 (C4), 135.4 (C5), 134.5 (C5), 133.9 (C12), 133.9
(C12), 132.5 (C1), 132.3 (C1), 129.9 (C6), 128.9 (C6), 127.7 (C2), 127.6 (C2), 124.1 (C3), 123.8 (C3),
119.3 (C13), 119.1 (C13), 73.5 (C10), 72.9 (C10), 49.5 (C9), 49.4 (C9), 42.2 (C11), 41.5 (C11), 39.9
(C7), 39.8 (C7), 32.0 (C8), 30.3 (C8).
IR: 3436 (w), 3079 (w), 2936 (w), 2878 (w), 2096 (s), 1730 (w), 1524 (s), 1355 (s), 1251 (m), 998
(m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C13H16N4NaO3+: 299.1115; Found: 299.1124.
Rf (DCM) = 0.48.
7-azido-5-(2-nitrophenyl)hept-1-en-4-one 110
DMP
DCM, RT
80%
1
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O
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To a solution of alcohol 112 (3.0mg, 0.010mmol) in DCM (1.0mL) was added DMP (8.0mg,
0.020mmol, 1.8 equiv). The solution was stirred at RT for 1h. Aqueous 2% NaOH was then
added and the solution was extractedwith DCM. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2)
afforded compound 110 as a yellow oil (2.2mg, 80% yield).
1H NMR (400 MHz, CDCl3): δ 7.90 (dd, J = 7.9,1.2 Hz, 1H, C3−H), 7.59 (td, J = 7.9,1.2 Hz,
1H, C1−H), 7.46 (td, J = 7.9,1.1 Hz, 1H, C2−H), 7.33 (dd, J = 7.9,1.1 Hz, 1H, C6−H), 5.81
(ddt, J = 17.1,10.1,6.9 Hz, 1H, C12−H), 5.14 (dd, J = 10.1,1.2 Hz, 1H, C13−H), 5.04 (dd, J =
17.1,1.2 Hz, 1H, C13−H), 4.48 (t, J = 7.1 Hz, 1H, C7−H), 3.35-3.13 (m, 4H, C9,11−H), 2.38 (ddt,
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J = 16.9,7.1,6.9Hz, 1H, C8−H), 1.94 (ddt, J = 16.9,7.1,6.9 Hz, 1H, C8−H).
13C NMR (101MHz, CDCl3): δ 205.7 (C
10), 150.0 (C4), 133.4 (C1), 131.9 (C5), 129.9 (C6), 129.7
(C12), 128.7 (C2), 125.0 (C3), 119.5 (C13), 49.2 (C9), 49.0 (C7), 47.0 (C11), 31.4 (C8).
IR: 2958 (w), 2929 (w), 2854 (w), 2096 (s), 1716 (m), 1526 (s), 1350 (s), 1259 (s), 788 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C13H14N4NaO3+: 297.0958; Found: 297.0969.
Rf (DCM) = 0.71.
ethyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-acrylate 117
HO O
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Following a reported procedure,215 the acrylate 425 (1.2 g, 9.2mmol) was dissolved in DCM
(30mL). Imidazole (1.6 g, 24mmol, 2.5 equiv) was added slowly, followed by TBSCl (1.5 g,
10mmol, 1.1 equiv). The mixture was stirred for 2h and then quenched with saturated
NaHCO3. The mixture was extracted with DCM. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 9:1)
afforded compound 117 as a colorless oil (2.3 g, quantitative yield). The spectroscopic data
of this compound were in accord with those reported in the literature.215
1H NMR (400 MHz, CDCl3): δ 6.25 (q, J = 2.0 Hz, 1H, C4−H), 5.90 (q, J = 2.0 Hz, 1H, C4−H),
4.37 (t, J = 2.0 Hz, 2H, C3−H), 4.22 (q, J = 7.1 Hz, 2H, C5−H), 1.30 (t, J = 7.1 Hz, 3H, C6−H),
0.92 (s, 9H, C10,11,12−H), 0.09 (s, 6H, C7,8−H).
13C NMR (101MHz, CDCl3): δ 166.0 (C
2), 139.9 (C1), 123.6 (C4), 61.5 (C3), 60.5 (C5), 25.9 (C9),
18.4 (C10,11,12), 14.2 (C6), -5.4 (C7,8).
Rf (DCM) = 0.17.
215Crimmins, M. T.; Jacobs, D. L. Org. Lett. 2009, 11, 2695–2698
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((7-azido-5-(2-nitrophenyl)hept-1-en-4-yl)oxy)-triethylsilane 114
TESCl
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0 °C to RT
69%
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The compound 112 (0.10 g, 0.36mmol) was dissolved in DCM (1.0mL) at 0 °C. Imidazole
(0.12mL, 0.72mmol, 2.0 equiv) and TESCl (0.10 g, 1.5mmol, 4.0 equiv) were added. The re-
actionmixture was stirred for 1h at 0 °C, then 1h at RT. The solution was then quenched with
saturated NaHCO3 and extracted with EtOAc. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc
9:1) afforded compound 114 as a yellow oil (97mg, 69% yield as an inseparable mixture of
two diastereoisomers).
1H NMR (400 MHz, CDCl3): δ 7.72 (m, 1H, C
3−H), 7.54 (m, 1H, C1−H), 7.47 (m, 1H, C2−H),
7.37 (m, 1H, C6−H), 5.72 (m, 1H, C12−H), 5.03-4.90 (m, 2H, C13−H), 3.96 (m, 1H, C10−H),
3.41-3.22 (m, 2H, C9−H), 3.11 (m, 1H, C7−H), 2.34-1.94 (m, 4H, C8,11−H), 1.02-0.85 (m, 9H,
C15−H), 0.64-0.48 (m, 6H, C14−H).
13C NMR (101MHz, CDCl3): δ 151.2 (C
4), 135.8 (C5), 135.1 (C5), 133.5 (C12), 133.4 (C12), 132.0
(C1), 132.0 (C1), 130.2 (C6), 129.8 (C6), 127.4 (C2), 127.4 (C2), 124.2 (C3), 123.9 (C3), 117.9 (C13),
75.0 (C10), 74.8 (C10), 49.6 (C7), 49.6 (C7), 40.7 (C9), 40.4 (C11), 40.0 (C11), 32.0 (C8), 28.3 (C8),
6.9 (C15), 5.0 (C14).
IR: 2957 (w), 2877 (w), 2099 (w), 1528 (w), 1355 (w), 905 (s), 726 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H31N4O3Si+: 391.2160; Found: 391.2179.
Rf (PE/EtOAc 9:1) = 0.59.
2-((tert-butyldimethylsilyloxy)methyl)acrylic acid 118
O O
O
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3
4
O OH 5
O
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9
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Following a reported procedure,216 to a solution of acrylate 117 (20mg, 0.080mmol) in amix-
ture of THF/H2O (1:1, 0.50mL) was added LiOH (4.0mg, 0.16mmol, 2.0 equiv). The reaction
mixture was stirred overnight at RT. It was then quenched with saturatedNH4Cl. Themixture
was extracted with EtOAc. The combined organic phases were washed with brine, dried over
Na2SO4 and concentrated in vacuo. The crude product 118 thus obtained was used for the
next step without further purification as a colorless oil (11mg, 65% yield). The spectroscopic
data of this compound were in accord with those reported in the literature.217
1H NMR (400 MHz, CDCl3): δ 6.40 (q, J = 2.0 Hz, 1H, C4−H), 6.03 (q, J = 2.0 Hz, 1H, C4−H),
4.38 (t, J = 2.0 Hz, 2H, C3−H), 0.93 (s, 9H, C9,10,11−H), 0.10 (s, 6H, C6,7−H).
13C NMR (101 MHz, CDCl3): δ 170.5 (C
2), 138.9 (C1), 126.4 (C4), 61.3 (C3), 25.9 (C8), 18.4
(C9,10,11), -5.4 (C6,7).
Rf (PE/EtOAc 5:5) = 0.50.
6-azido-4-(2-nitrophenyl)-3-((triethylsilyl)oxy)-hexanal 128
O3, NaHCO3
then Me2S
DCM/MeOH
-78 °C to RT
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To a solution of compound 114 (0.10 g, 0.25mmol) in a mixture DCM/MeOH (1:1, 1.0mL) at
-78 °C was added NaHCO3 (60mg, 0.63mmol, 2.5 equiv). O3 was then bubbled through the
solution for 20 s. Argon was bubbled through the solution to remove the ozone and Me2S
(excess) was added to the solution. It was then allowed to warm up to RT. The mixture was
stirred for 4h. The mixture was then filtered through Celite and concentrated in vacuo. Pu-
rification by FCC (PE/EtOAc 9:1) afforded compound 128 as a slightly yellow oil (79mg, 80%
yield as an inseparable mixture of two diastereoisomers).
1H NMR (400MHz, CDCl3): δ 9.69 (m, 1H, C
12−H), 7.76 (m, 1H, C3−H), 7.59 (m, 1H, C1−H),
7.49-7.31 (m, 2H, C2,6−H), 4.53 (m, 1H, C10−H), 3.42 (m, 1H, C7−H), 3.23-3.05 (m, 2H, C9−H),
2.64-2.42 (m, 2H, C11−H), 2.39-1.83 (m, 2H, C8−H), 1.03-0.85 (m, 9H, C14−H), 0.70-0.55 (m,
6H, C13−H).
216Jaegli, S.; Vors, J. P.; Neuville, L.; Zhu, J. Synlett 2009, 20, 2997–2999
217Adams, R. S.; Calderwood, E. F.; Gould, A. E.; Greenspan, P. D.; Lamarche, M. J.; Tian, Y.; Vos, T. J. Cinnamide and
hydrocinnamide derivatives with kinase inhibitory activity. US Patent Application Publication, US2006160803
(A1) (US), 2006
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13CNMR (101MHz, CDCl3): δ 200.2 (C
12), 200.2 (C12), 151.4 (C4), 134.4 (C5), 133.4 (C5), 132.4
(C1), 132.1 (C1), 130.1 (C6), 129.1 (C6), 128.1 (C2), 128.0 (C2), 124.3 (C3), 123.8 (C3), 70.9 (C10),
70.1 (C10), 50.1 (C7), 49.4 (C7), 43.1 (C9), 41.8 (C11), 41.4 (C11), 31.6 (C8), 30.1 (C8), 6.9 (C14),
5.0 (C13).
IR: 2957 (w), 2877 (w), 2099 (s), 1725 (w), 1529 (s), 1356 (m), 1244 (w), 1114 (w), 1007 (w), 746
(m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C18H28N4NaO4Si+: 415.1772; Found: 415.1781.
Rf (PE/EtOAc 8:2) = 0.48.
7-azido-5-(2-nitrophenyl)hept-1-en-4-yl 2-((tert-butyldimethylsilyloxy)methyl)-
acrylate 119
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To a solution of the alcohol 112 (40mg, 0.15mmol) and the acid 118 (40mg, 0.18mmol,
1.2 equiv) in DCM (1.0mL) at 0 °C was added DCC (0.16g, 0.75mmol, 5.0 equiv), followed
by DMAP (9.4mg, 0.080mmol, 0.50 equiv). The reaction mixture was stirred for 30min at
0 °C, and then overnight at RT. The reaction was then quenched with saturated NaHCO3. The
mixture was extracted with DCM. The combined organic phases were washed with brine,
dried over Na2SO4 and concentrated in vacuo. The crude product 119 was then used with-
out further purification as a yellow oil (16mg, 22% yield as an inseparable mixture of two
diastereoisomers).
1H NMR (400 MHz, CDCl3): δ 7.76 (m, 1H, C
3−H), 7.61 (m, 1H, C1−H), 7.54-7.41 (m, 2H,
C2,6−H), 6.24 (m, 1H, C16−H), 5.93 (m, 1H, C16−H), 5.66 (m, 1H, C12−H), 5.34 (m, 1H, C10−H),
5.12-5.00 (m, 2H, C13−H), 4.48-4.30 (m, 2H, C17−H), 3.66 (m, 1H, C7−H), 3.27-3.05 (m, 2H,
C9−H), 2.35-2.16 (m, 2H, C11−H), 2.13 (m, 1H, C8−H), 1.94 (m, 1H, C8−H), 1.02-0.88 (m, 9H,
C20,21,22−H), 0.21-0.05 (m, 6H, C18,19−H).
13C NMR (101 MHz, CDCl3): δ 165.3 (C
14), 164.9 (C14), 151.3 (C4), 139.5 (C15), 134.3 (C12),
132.8 (C5), 132.5 (C5), 132.4 (C1), 132.3 (C1), 128.7 (C6), 128.2 (C6), 128.0 (C16), 124.5 (C2),
124.3 (C2), 124.0 (C3), 118.8 (C13), 118.6 (C13), 75.4 (C10), 74.8 (C10), 61.5 (C17), 61.3 (C17), 49.1
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(C7), 49.0 (C7), 39.9 (C9), 39.6 (C9), 37.3 (C11), 37.2 (C11), 31.8 (C8), 30.6 (C8), 25.9 (C23), 18.4
(C20,21,22), -5.4 (C18,19).
IR: 2954 (w), 2930 (w), 2885 (w), 2857 (w), 2098 (m), 1715 (m), 1529 (s), 1356 (m), 1260 (s),
1091 (s), 839 (s), 780 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C23H34N4NaO5Si+: 497.2191; Found: 497.2200.
Rf (PE/EtOAc 9.5:0.5) = 0.19.
ethyl 2-(diethoxyphosphoryl)acrylate 125
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Following a reportedprocedure,44e a solution of paraformaldehyde (2.5 g, 82mmol, 2.0 equiv)
in MeOH (100mL) and piperidine (0.40mL, 4.1mmol, 0.1 equiv) was stirred at RT. Triethyl
phosphonoacetate (9.2 g, 41mmol) was added over 30 minutes. The solution was then re-
fluxed for 24h. The solvent was evaporated under reduced pressure. The crude compound
was dissolved in toluene (100mL). p-Toluenesulfonic acid monohydrate (0.80 g, 4.1mmol,
0.10 equiv) was added and the solution was refluxed with a Dean-Stark apparatus for 8h. Pu-
rification by vacuum distillation (Bp = 90 °C/1.0mbar) afforded compound 125 as a colorless
oil (7.6 g, 78% yield). The spectroscopic data of this compound were in accord with those
reported in the literature.218
1H NMR (400MHz, CDCl3): δ 7.00 (dd, J = 42.0,1.6 Hz, 1H, C2−H), 6.76 (dd, J = 20.4,1.6 Hz,
1H, C2−H), 4.30 (q, J = 7.2 Hz, 2H, C4−H), 4.29-4.11 (m, 4H, C6,8−H), 1.41-1.30 (m, 9H,
C5,7,9−H).
13C NMR (101 MHz, CDCl3): δ 163.8 (d, J = 16 Hz, C3), 143.3 (d, J = 5 Hz, C2), 133.2 (d,
J = 186 Hz, C1), 62.8 (d, J = 6 Hz, C6,8), 61.6 (s, C4), 16.4 (d, J = 7 Hz, C7,9), 14.1 (s, C5).
Rf (EtOAc)= 0.44.
218a) Biju, A. T.; Padmanaban, M.; Wurz, N. E.; Glorius, F. Angew. Chem. Int. Ed. 2011, 50, 8412–8415; b)
Cherkasov, A. R.; Galkin, V. I.; Sibgatullin, I. M.; Khusainova, N. G.; Zyablikova, T. A.; Buzykin, B. I.;
Cherkasov, R. A. Russ. J. Gen. Chem. 2001, 71, 343–347; c) Galvez-Ruano, E.; Bellanato, J.; Fernandez-Ibañez,M.;
Sainz-Diaz, C.; Arias-Perez, M. J. Mol. Struct. 1986, 142, 397–402
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1-(2-nitrophenyl)propan-2-one 429
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Following a reported procedure,51 to a solution of 2-(2-nitropheny)lacetic acid (9.5 g,
52mmol) in Ac2O (25mL) at RT was added 1-methylimidazole (2.1mL, 51mmol, 0.5 equiv).
The solution was stirred for 12h. It was then poured into water. The crude product was ex-
tracted with Et2O. The combined organic layers were washed with brine, dried over Na2SO4,
and concentrated in vacuo. The crude compound 429 thus obtained was used for the next
step without further purification as a yellow oil. The spectroscopic data of this compound
were in accord with those reported in the literature.219
1HNMR (400MHz, CDCl3): δ 8.12 (dd, J = 7.9,1.1 Hz, 1H, C3−H), 7.60 (td, J = 7.9,1.1 Hz, 1H,
C1−H), 7.47 (td, J = 7.9,1.2 Hz, 1H, C2−H), 7.28 (dd, J = 7.9,1.2 Hz, 1H, C6−H), 4.13 (s, 2H,
C7−H), 2.33 (s, 3H, C9−H).
13C NMR (101MHz, CDCl3): δ 203.7 (C
8), 148.7 (C4), 133.7 (C1), 133.6 (C6), 130.5 (C5), 128.5
(C2), 125.4 (C3), 48.7 (C7), 30.1 (C9).
Rf (PE/EtOAc 6.5:3.5)= 0.5.
3-(2-nitrophenyl)but-3-en-2-one 135
NO2
1
2
3
4
5
6
7
8
O
9
NO2
HCHO
morpholine
AcOH, 100 °C
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Following a reported procedure,51 a solution of crude 1-(2-nitrophenyl)propan-2-one 429
(From 52mmol of 2-(2-nitrophenyl)acetic acid), morpholine (1.1 g, 13mmol, 0.25 equiv), and
37% HCHO in H2O (13mL) in AcOH (55mL) was heated at 100 °C for 24h. The solution was
concentrated under reduced pressure, and Et2O and H2O were added. The organic layer was
separated, washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by
FCC (PE/EtOAc 8:2) afforded compound 135 as a slightly yellow wax (2.3 g, 23% yield in two
219Coffman, K. C.; Palazzo, T. A.; Hartley, T. P.; Fettinger, J. C.; Tantillo, D. J.; Kurth, M. J. Org. Lett. 2013, 15,
2062–2065
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steps). The spectroscopic data of this compound were in accord with those reported in the
literature.51
1HNMR (400MHz, CDCl3): δ 8.10 (dd, J = 7.8,1.2 Hz, 1H, C3−H), 7.64 (td, J = 7.8,1.2 Hz, 1H,
C1−H), 7.52 (td, J = 7.8,1.3 Hz, 1H, C2−H), 7.32 (dd, J = 7.8,1.3 Hz, 1H, C6−H), 6.29 (s, 1H,
C10−H), 6.02 (s, 1H, C10−H), 2.49 (s, 3H, C9−H).
13C NMR (101MHz, CDCl3): δ 197.3 (C
8), 148.4 (C4), 133.7 (C1), 133.4 (C5), 132.1 (C6), 129.3
(C7), 129.3 (C2), 125.6 (C10), 124.6 (C3), 26.3 (C9).
Rf (PE/Et2O 8:2)= 0.07.
ethyl 2,5-dihydrothiophene-3-carboxylate 430
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Following a reported procedure,44b a solution of 1,4-dithiane-2,5-diol (0.46 g, 3.0mmol,
0.60 equiv) and Et3N (0.90mL, 6.5mmol, 1.3 equiv) inDCM (37mL)was heated at reflux. A so-
lution of the acrylate 125 (1.2 g, 5.0mmol) inDCM (5.0mL)was added dropwise. The reaction
mixture was stirred at reflux for 4h. When the reaction was finished, the mixture was cooled
down, diluted with DCM, washed with HCl (5%), brine, dried over Na2SO4, and concentrated
in vacuo. Purification by vacuum distillation (Bp = 190 °C/1.5mbar) afforded compound 430
as a colorless oil (0.59 g, 75% yield). The spectroscopic data of this compound were in accord
with those reported in the literature.220
1H NMR (400 MHz, CDCl3): δ 6.91 (m, 1H, C
1−H), 4.24 (q, J = 7.1 Hz, 2H, C6−H), 4.01-3.85
(m, 4H, C3,4−H), 1.32 (t, J = 7.1 Hz, 3H, C7−H).
Rf (PE/Et2O 8:2)= 0.42.
220Martyres, D. H.; Baldwin, J. E.; Adlington, R. M.; Lee, V.; Probert, M. R.; Watkin, D. J. Tetrahedron 2001, 57,
4999–5007
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ethyl 2,5-dihydrothiophene-3-carboxylate 1,1-dioxide 131
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DCM, RT
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Following a reported procedure,44b a solution of 430 (0.30 g, 1.9mmol) in DCM (3.0mL)
was stirred at 0 °C when a solution of mCPBA (0.85g, 3.8mmol, 2.0 equiv) in DCM (10mL)
was added dropwise. The mixture was allowed to warm up slowly (3h) and then stirred
overnight at RT. The solution was then filtered, washed with saturated Na2CO3, brine, dried
over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded com-
pound 131 as a colorless oil (0.31 g, 86% yield).
1H NMR (400 MHz, CDCl3): δ 7.03 (m, 1H, C
1−H), 4.28 (q, J = 7.1 Hz, 2H, C6−H), 4.03-3.98
(m, 4H, C3,4−H), 1.32 (t, J = 7.1 Hz, 3H, C7−H).
13C NMR (101MHz, CDCl3): δ 162.0 (C
5), 133.1 (C1), 130.3 (C2), 61.8 (C3), 57.8 (C6), 55.1 (C4),
14.2 (C7).
IR: 2983 (w), 2939 (w), 1716 (s), 1632 (w), 1316 (s), 1266 (s), 1213 (s), 1135 (m), 1072 (s), 1018
(w), 731 (w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C7H10NaO4S+: 213.0197; Found: 213.0203.
Rf (PE/Et2O 8:2)= 0.07.
((4-azido-2-(2-nitrophenyl)but-1-en-1-yl)oxy)(tert-butyl)dimethylsilane 431
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A solution of the aldehyde 111 (0.10 g, 0.43mmol) in DCM (1.0mL) was stirred at 0 °C. Et3N
(0.30mL, 2.1mmol, 5.0 equiv)was added, followed by TBSOTf (0.20mL, 0.86mmol, 2.0 equiv).
The reaction mixture was stirred for 5h at 0 °C. DCM was added, followed by aqueous 5%
NaHCO3. The mixture was extracted with DCM. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 9:1)
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afforded compound 431 as a yellow oil (75mg, 50% yield as amixture of inseparable isomers.
Ratio: 1:1.5).
1H NMR (400 MHz, CDCl3): δ 7.87 (dd, J = 7.9,1.4 Hz, 1H, C3−H, minor), 7.81 (dd, J =
8.0,1.5 Hz, 1H, C3−H, major), 7.58-7.49 (m, 2H, C1−H, minor+major), 7.42-7.30 (m, 4H,
C2,6−H, minor+major), 6.35 (s, 1H, C10−H, minor), 6.33 (s, 1H, C10−H, major), 3.35 (t,
J = 7.3 Hz, 2H, C9−H, minor), 3.30 (t, J = 7.5 Hz, 2H, C9−H, major), 2.71 (t, J = 7.5 Hz, 2H,
C8−H, major), 2.61 (t, J = 7.3 Hz, 2H, C8−H, minor), 0.96 (s, 9H, C14,15,16−H, major), 0.71 (s,
9H, C14,15,16−H, minor), 0.18 (s, 6H, C11,12−H, major), 0.03 (s, 6H, C11,12−H, minor).
13C NMR (101 MHz, CDCl3): δ 150.0 (C
4, minor+major), 140.7 (C10, major), 138.8 (C10,
minor), 134.4 (C1, major + minor), 132.4 (C5, minor + major), 131.2 (C6, major + minor),
127.9 (C2, major), 127.7 (C2, minor), 124.4 (C3, major), 124.3 (C3, minor), 115.9 (C7, major),
113.6 (C7, minor), 50.5 (C9, minor), 49.6 (C9, major), 32.5 (C8, minor), 28.6 (C8, major), 25.7
(C14,15,16, major), 25.4 (C14,15,16, minor), 18.3 (C18, major), 18.1 (C18, minor), -5.2 (C11,12, ma-
jor), -5.5 (C11,12, minor)
IR: 2954 (w), 2931 (w), 2858 (w), 2095 (m), 1650 (w), 1527 (s), 1353 (w), 1256 (m), 1179 (s), 838
(s), 784 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C16H24N4NaO3Si+: 371.1510; Found: 371.1505.
Rf (PE/Et2O 9:1)= 0.58.
tert-butyldimethyl((3-(2-nitrophenyl)but-3-en-2-yl)oxy)silane 432
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Diisopropylamine (0.040mL, 0.29mmol, 1.4 equiv) was stirred at -78 °C when n-BuLi was
added dropwise (1.6M solution in Et2O, 0.18mL, 0.29mmol, 1.4 equiv)). The solution was
stirred for 30 minutes. THF (1.0mL) was then added and the solution was stirred for 5 min-
utes. A solution of ketone 135 (40mg, 0.21mmol) in THF (0.50mL) was added dropwise. The
reaction mixture was stirred for 30 minutes. TBSCl (44mg, 0.29mmol, 1.4 equiv) was then
added. The solution was stirred for 30 minutes, then 15 minutes at RT. It was then quenched
with saturated NaHCO3. The mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/EtOAc 9.5:0.5) afforded compound 432 as a yellow oil (9.6mg, 15% yield).
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1H NMR (400MHz, CDCl3): δ 7.85 (dd, J = 7.8,0.9 Hz, 1H, C3−H), 7.65-7.56 (m, 2H, C1,6−H),
7.39 (td, J = 7.8,1.1 Hz, 1H, C2−H), 5.66 (s, 1H, C10−H), 5.44 (s, 1H, C10−H), 4.48 (m, 1H,
C9−H), 3.45 (m, 1H, C9−H), 1.02 (s, 9H, C14,15,16−H), 0.37 (s, 3H, C11−H), 0.10 (s, 3H, C12−H).
13C NMR (101MHz, CDCl3): δ 155.1 (C
8), 149.0 (C4), 143.7 (C7), 135.6 (C5), 132.8 (C1), 132.5
(C6), 128.7 (C2), 124.2 (C3), 115.8 (C10), 95.6 (C9), 25.9 (C14,15,16), 18.4 (C13), -4.5 (C11,12),
IR: 2956 (w), 2930 (w), 2857 (w), 1586 (w), 1529 (s), 1472 (w), 1350 (s), 1257 (m), 1218 (m), 1017
(m), 826 (s), 784 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C16H24NO3Si+: 306.1520; Found: 306.1526.
Rf (PE/Et2O 9:1)= 0.33.
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Following a reported procedure,221 to a solution of the acrylate 99 (2.5 g, 11mmol) in a mix-
ture of THF/H2O (1:1, 33mL) was added indium (1.3 g, 11mmol, 1.0 equiv) followed by aque-
ous 37% formaldehyde (0.75mL, 11mmol, 1.0 equiv). Themixturewas stirred at RT overnight.
The reaction was quenched with HCl (2.0M) and extracted with EtOAc. The combined or-
ganic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Pu-
rification by FCC (PE/EtOAc 5:1) afforded compound 140 as a yellow oil (1.6 g, quantitative
yield). The spectroscopic data of this compound were in accord with those reported in the
literature.221
1H NMR (400MHz, CDCl3): δ 6.25 (s, 1H, C
4−H), 5.69 (s, 1H, C4−H), 4.24 (q, J = 7.1 Hz, 2H,
C7−H), 3.83 (t, J = 5.7 Hz, 2H, C5−H), 2.61 (t, J = 5.7 Hz, 2H, C3−H), 1.32 (t, J = 7.1 Hz, 3H,
C8−H), OH peak not observed.
13C NMR (101 MHz, CDCl3): 168.3 (C
2), 137.7 (C1), 127.8 (C4), 62.4 (C5), 61.5 (C7), 35.4 (C3),
14.2 (C8).
Rf (PE/EtOAc 9:1)= 0.07.
221Nagano, H.; Kuwahara, R.; Yokoyama, F. Tetrahedron 2007, 63, 8810–8814
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ethyl 2-methylene-4-((methylsulfonyl)oxy)-butanoate 433
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To a solution of the acrylate 140 (3.0 g, 20mmol) in DCM (70mL) at 0 °C was added Et3N
(5.7mL, 40mmol, 2.0 equiv) followed by MsCl (3.2mL, 40mmol, 2.0 equiv). The mixture was
stirred at RT overnight. The reaction was quenched with saturated NH4Cl and extracted with
EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and con-
centrated in vacuo. Purification by FCC (PE/EtOAc 9:1) afforded compound 433 as a yellow
oil (4.4 g, quantitative yield). The spectroscopic data of this compound were in accord with
those reported in the literature.222
1H NMR (400 MHz, CDCl3): δ 6.31 (s, 1H, C
4−H), 5.73 (d, J = 1.0 Hz, 1H, C4−H), 4.37 (t,
J = 6.6 Hz, 2H, C5−H), 4.22 (q, J = 7.1 Hz, 2H, C7−H), 2.99 (s, 3H, C9−H), 2.76 (t, J = 6.6 Hz,
2H, C3−H), 1.31 (t, J = 7.1 Hz, 3H, C8−H).
13C NMR (101 MHz, CDCl3): 166.3 (C
2), 135.2 (C1), 128.4 (C4), 68.0 (C5), 61.0 (C7), 37.4 (C9),
32.3 (C3), 14.2 (C8).
Rf (PE/EtOAc 8:2)= 0.16.
ethyl 4a-morpholino-1,4,4a,5,6,7,8,8a-octahydro-naphthalene-2-carboxylate 132
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To a solution of 1-(N-morpholino)cyclohex-1-ene (22mg, 0.13mmol) in dioxane (0.50mL)
was added 131 (30mg, 0.16mmol, 1.2 equiv). The solution was then heated by microwave
irradiation (150W) at 120 °C for 2h. HCl (1.0M) was added and the reaction mixture was
extracted with EtOAc. The combined organic phases were washed with brine, dried over
222Jaegli, S. Approche vers la synthèse d’analogues de la Rustmicine et nouvelles voies d’accès à des spiro-oxindoles
par réactions domino palladocatalysées., Ph.D. Thesis, Paris Sud XI, 2008
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Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded compounds
132, 133 and 134. The spectroscopic data of compound 134 were in accord with those re-
ported in the literature.223
Compound 132:
Red oil, 12mg, 30% yield.
1H NMR (400 MHz, CDCl3): δ 6.83 (m, 1H, C
8−H), 4.19 (q, J = 7.1 Hz, 2H, C17−H), 3.76-
3.57 (m, 4H, C12,13−H), 2.60-2.41 (m, 4H, C11,14−H), 2.45 (m, 1H, C7−H), 2.30-2.20 (m, 2H,
C7,10−H), 2.09 (d, J = 19.2 Hz, 1H, C10−H), 1.99 (m, 1H, C5−H), 1.68-1.21 (m, 11 H).
13C NMR (101MHz, CDCl3): δ 167.5, 136.8, 128.3, 68.0, 60.3, 44.8, 33.6, 32.0, 29.7, 28.1, 27.5,
27.4, 22.7, 21.8, 14.3.
IR: 2925 (m), 2852 (w), 2811 (w), 1708 (s), 1658 (w), 1451 (w), 1247 (s), 1155 (m), 1118 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C17H28NO3+: 294.2069; Found: 294.2070.
Rf (PE/EtOAc 8:2)= 0.38.
Compound 133:
yellow oil, 7.0mg, 24% yield as an inseparable mixture of two diastereoisomers.
1H NMR (400 MHz, CDCl3): δ 5.87-5.67 (m, 1H, C
9−H), 5.24-5.03 (m, 2H, C10−H), 4.24-4.05
(m, 2H, C13−H), 3.24-3.06 (m, 1H, C8−H), 2.44-2.22 (m, 4H, C5,3−H), 2.15-2.00 (m, 2 H), 1.91-
1.79 (m, 1 H), 1.72-1.60 (m, 2 H), 1.44-1.30 (m, 1 H), 1.29-1.21 (m, 4H, C12−H).
13C NMR (101 MHz, CDCl3): δ 174.0, 173.9, 136.0, 135.9, 117.7, 117.3, 60.7, 48.1, 47.9, 47.8,
42.3, 34.6, 34.2, 31.7, 31.6, 28.2, 28.1, 25.2, 14.2.
HRMS: (ESI+) m/z: [M+H]+ Calcd for C13H21O3+: 225.1491; Found: 225.1495.
Rf (PE/EtOAc 8:2)= 0.67.
Compound 134:
slightly yellow oil, 8.0mg, 20% yield (calculated based on sulfonene 131).
223Xu, S.; Chen, R.; He, Z. J. Org. Chem. 2011, 76, 7528–7538
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1H NMR (400 MHz, CDCl3): δ 6.96 (m, 1H, C
4−H), 5.88 (dd, J = 17.5,10.7 Hz, 1H, C7−H),
5.15 (dd, J = 10.7,0.5 Hz, 1H, C8−H), 5.11 (dd, J = 17.5,0.5 Hz, 1H, C8−H), 4.24-4.10 (m, 4H,
C11,14−H), 2.80 (m, 1H, C3−H), 2.40-2.28 (m, 3H, C3,6−H), 2.07 (m, 1H, C1−H), 1.78 (m, 1H,
C1−H), 1.31-1.21 (m, 6H, C10,13−H).
13C NMR (101MHz, CDCl3): δ 174.4 (C
12), 167.0 (C9), 139.6 (C7), 136.8 (C4), 129.6 (C5), 115.1
(C8), 61.0 (C11), 60.4 (C14), 47.2 (C2), 32.2 (C3), 29.7 (C6), 21.7 (C1), 14.3 (C13), 14.1 (C10).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C14H21O4+: 253.1440; Found: 253.1438.
Rf (PE/EtOAc 8:2)= 0.67.
ethyl 4-azido-2-methylenebutanoate 434
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Following a known procedure,222 mesylate 433 (0.50 g, 2.3mmol) was dissolved in DMF
(25mL). NaN3 (0.22g, 3.4mmol, 1.5 equiv) was added and the solution was heated to 60 °C
overnight. The reaction was allowed to cool down to room temperature, and saturated aque-
ous NaHCO3 was added. The mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/EtOAc 9:1) afforded azide 434 as a colorless oil (0.27 g, 71%). The spectroscopic
data of this compound were in accord with those reported in the literature.222
1H NMR (400 MHz, CDCl3): δ 6.29 (s, 1H, C
5−H), 5.69 (s, 1H, C5−H), 4.23 (q, J = 7.1 Hz, 2H,
C6−H), 3.44 (t, J = 6.9 Hz, 2H, C1−H), 2.61 (t, J = 6.9 Hz, 2H, C2−H), 1.31 (t, J = 7.2 Hz, 3H,
C7−H).
13C NMR (101MHz, CDCl3): δ 166.5 (C
4), 137.0 (C3), 127.6 (C5), 61.0 (C6), 50.1 (C1), 31.9 (C2),
14.3. (C7).
IR: 2983 (w), 2935 (w), 2095 (s), 1713 (s), 1447 (w), 1299 (m), 1199 (s), 1150 (s), 1024 (m), 953
(m).
Rf (PE/EtOAc 8:2) = 0.82.
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4-azido-2-methylenebutan-1-ol 435
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To a solution of ester 434 (50mg, 0.32mmol) in THF (5.0mL) was added dropwise DIBALH
(1M solution in toluene, 0.96mL, 0.96mmol, 3.0 equiv). The reaction mixture was stirred
at room temperature for 16h. Saturated Rochelle’s salts was added, and the mixture was
extracted with EtOAc. The combined organic phases were washed with brine, dried over
Na2SO4 and concentrated in vacuo. The crude alcohol 435was used directly in the next step
without further purification.
1H NMR (400MHz, CDCl3): δ 5.16 (s, 1H, C
1−H), 4.99 (s, 1H, C1−H), 4.11 (s, 2H, C4−H), 3.44
(t, J = 7.0 Hz, 2H, C5−H), 2.39 (t, J = 7.0 Hz, 2H, C3−H).
13C NMR (101MHz, CDCl3): δ 145.3 (C
2), 112.7 (C1), 66.0 (C4), 50.0 (C5), 32.4 (C3).
IR: 3338 (br w), 2928 (w), 2875 (w), 2090 (s), 1263 (m), 1023 (m), 904 (m).
No HRMS could be obtained from this structure due to its instability.
Rf (PE/EtOAc 7:3) = 0.33.
4-azido-2-methylenebutan-1-al 139
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To a solution of alcohol 435 (40mg, 0.31mmol) in DMSO (2.0mL) was added IBX (0.18g,
0.62mmol, 2.0 equiv) and the reaction mixture was stirred for 1h. The mixture was filtered,
saturated NaHCO3 was added and the mixture was extracted with Et2O. The combined or-
ganic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purifi-
cation by FCC (PE/EtOAc 7:3) afforded aldehyde 139 as a colorless oil (35mg, 90%).
1H NMR (400MHz, CDCl3): δ 9.55 (s, 1H, C
4−H), 6.40 (s, 1H, C1−H), 6.15 (s, 1H, C1−H), 3.41
(t, J = 6.8 Hz, 2H, C5−H), 2.55 (t, J = 6.8 Hz, 2H, C3−H).
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13C NMR (101MHz, CDCl3): δ 194.0 (C
4), 146.3 (C2), 136.4 (C1), 49.3 (C5), 27.9 (C3).
IR: 2932 (w), 2823 (w), 2090 (s), 1686 (s), 1260 (m), 954 (m).
No HRMS could be obtained from this structure due to its instability.
Rf (PE/EtOAc 7:3) = 0.59.
4-(tert-butyldimethylsilyloxy)-2-(2-nitrophenyl)butan-1-ol 146
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To a solution of ester 145 (50mg, 0.14mmol) in THF (5.0mL) was added dropwise DIBALH
(1M solution in toluene, 0.42mL, 0.42mmol, 3.0 equiv). The reaction mixture was stirred
at room temperature for 0.5h. Saturated Rochelle’s salts was added, and the mixture was
extracted with EtOAc. The combined organic phases were washed with brine, dried over
Na2SO4 and concentrated in vacuo. Purification by FCC (9:1 PE/EtOAc) afforded the desired
alcohol 146 as a yellow oil (32mg, 71% yield).
1H NMR (400 MHz, CDCl3): δ 7.74 (m, 1H, C
2−H), 7.56-7.54 (m, 2H, C3,5−H), 7.35 (m, 1H,
C4−H), 3.85 (dd, J = 4.4 Hz, 2H, C10−H), 3.70 (m, 1H, C9−H), 3.60 (m, 1H, C9−H), 3.47 (m,
1H, C7−H), 2.03 (m, 1H, C8−H), 1.93 (m, 1H, C8−H), 0.88 (s, 9H, C14−H), 0.03 (s, 3H, C12−H),
0.03 (s, 3H, C12−H), OH peak not observed.
13C NMR (101MHz, CDCl3): δ 150.6 (C
1), 137.8 (C6), 132.7 (C3), 129.0 (C5), 127.3 (C4), 124.2
(C2), 66.7 (C10), 61.7 (C9), 40.2 (C7), 35.9 (C8), 26.0 (C14), 18.3 (C13), -5.4. (C12).
IR: 3366 (br w), 2930 (m), 2857 (m), 1527 (s), 1358 (m), 1256 (w), 837 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C16H28NO4Si+: 326.1782; Found: 326.1792.
Rf (PE/EtOAc 8:2) = 0.32.
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To a solution of the alochol 146 (63mg, 0.19mmol) in Et2O (2.0mL) was added triethylamine
(60μL, 0.43mmol, 2.2 equiv) followed by MsCl (16μL, 0.21mmol, 1.1 equiv). After 1h, the
reaction was quenched with saturated NaHCO3 and extracted with EtOAc. The combined
organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. The
crudemesyl alcohol was dissolved in toluene (2.0mL), andDBU (40μL, 0.29mmol, 1.5 equiv)
was added. The reaction was stirred for 0.5h at room temperature. Water was added, and the
mixture was extracted with EtOAc. The combined organic phases were washed with brine,
dried over Na2SO4 and concentrated in vacuo. Purification by FCC (9:1 PE/EtOAc) afforded
the side-product 147 as a yellow oil (33mg, 90% yield). The desired elimination product 142
was not observed.
1H NMR (400 MHz, CDCl3): δ 7.77 (m, 1H, C
2−H), 7.61-7.52 (m, 2H, C3,5−H), 7.35 (m, 1H,
C4−H), 4.08-3.99 (m, 2H, C9,10−H), 3.96-3.81 (m, 3H, C7,9,10−H), 2.49 (m, 1H, C8−H), 2.04 (m,
1H, C8−H).
13C NMR (101MHz, CDCl3): δ 150.3 (C
1), 138.4 (C6), 133.1 (C3), 128.2 (C5), 127.2 (C4), 124.0
(C2), 74.4 (C10), 68.3 (C9), 39.5 (C7), 34.8 (C8).
IR: 2930 (w), 2866 (w), 1525 (s), 1355 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C10H12NO3+: 194.0812; Found: 194.0811.
Rf (PE/EtOAc 8:2) = 0.26.
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4-((tert-butyldimethylsilyl)oxy)-2-(2-nitrophenyl)butyl 4-methylbenzene-
sulfonate 149
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To a solution of the alcohol 146 (50mg, 0.15mmol) in pyridine (1.0mL) at 0 °C was added to-
syl chloride (44mg, 0.23mmol, 1.5 equiv). The solution was stirred at room tempreature for
2h. Aqueous 1MHCL was added, and themixture was extracted with EtOAc. The combined
organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Pu-
rification by FCC (9:1 PE/EtOAc) afforded the tosylate 149 as a yellow oil (58mg, 80% yield).
1H NMR (400 MHz, CDCl3): δ 7.74 (dd, J = 8.1,1.3 Hz, 1H, C2−H), 7.65 (d, J = 8.3 Hz, 2H,
C16−H), 7.52 (td, J = 7.5,1.4 Hz, 1H, C4−H), 7.42 (dd, J = 7.9,1.3 Hz, 1H, C5−H), 7.36 (m, 1H,
C3−H), 7.35-7.18 (m, 2H, C17−H), 4.28 (d, J = 5.3 Hz, 2H, C10−H), 3.73 (m, 1H, C7−H), 3.52
(m, 1H, C9−H), 3.41 (m, 1H, C9−H), 2.43 (s, 3H, C19−H), 2.00-1.91 (m, 2H, C8−H), 0.80 (s, 9H,
C14−H), -0.09 (s, 3H, C12−H), -0.09 (s, 3H, C12−H).
13CNMR (101MHz, CDCl3): δ 150.5 (C
1), 144.8 (C15), 134.6 (C6), 132.6 (C4), 132.6 (C18), 129.8
(C17), 129.5 (C5), 127.8 (C16), 127.3 (C3), 124.5 (C2), 72.6 (C10), 60.0 (C9), 35.8 (C7), 34.2 (C8),
25.8 (C14), 21.7 (C19), 18.2 (C13), -5.6 (C12).
IR: 2953 (w), 2930 (w), 2857 (w), 1527 (s), 1358 (s), 1177 (s), 1098 (m), 966 (m), 837 (s), 780 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C23H33NNaO6SSi+: 502.1690; Found: 502.1699.
Rf (PE/EtOAc 8:2) = 0.5.
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tert-butyldimethyl((3-(2-nitrophenyl)but-3-en-1-yl)oxy)silane 142
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To a solution of the tosylate 149 (20mg, 0.042mmol) in glyme (0.50mL) was added NaI
(13mg, 0.065mmol, 2.0 equiv) and DBU (12μL, 0.065mmol, 2.0 equiv). The mixture was
heated at 80 °C overnight. Saturated NaHCO3 was added, and themixture was extracted with
EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and con-
centrated in vacuo. Purification by FCC (95:5 PE/EtOAc) afforded the olefin 142 as a yellow
oil (10mg, 78% yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.8,1.1 Hz, 1H, C2−H), 7.54 (td, J = 7.8,1.3 Hz,
1H, C3−H), 7.40 (m, 1H, C4−H), 7.34 (dd, J = 7.8,1.3 Hz, 1H, C5−H), 5.22 (q, J = 1.2 Hz, 1H,
C10−H), 5.03 (m, 1H, C10−H), 3.69 (t, J = 6.8 Hz, 2H, C9−H), 2.59 (td, J = 6.8,0.8 Hz, 2H,
C8−H), 0.85 (s, 9H, C14−H), -0.01 (s, 6H, C12−H).
13C NMR (101MHz, CDCl3): δ 148.2 (C
1), 144.5 (C6), 138.3, (C9), 132.6 (C5), 131.4 (C3), 128.0
(C4), 124.1 (C2), 116.1 (C10), 61.8 (C9), 40.0 (C8), 25.9 (C14), 18.2 (C13), -5.4 (C12).
IR: 2953 (w), 2929 (w), 2885 (w), 2856 (w), 1527 (s), 1471 (w), 1349 (m), 1255 (m), 1096 (s), 933
(w), 906 (w), 834 (s), 776 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C16H26NO3Si+: 308.1676; Found: 308.1700.
Rf (PE/EtOAc 8:2) = 0.8.
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8.3 Experimental Procedures of Chapter 3
3-ethoxycyclopent-2-en-1-one 217
O
p-TsOH,
EtOH
PhMe, 
80%O 4 3
2
1
5
O
O
6
7
217
Following a reported procedure,224 to a solution of 1,3-cyclopentadione (20g, 0.20mol) and
EtOH (46mL, 0.83mol, 4.0 equiv) in toluene (200mL) was added p-TsOH (0.3 g, 2.0mmol,
1.0mol%). The reaction mixture was heated at refluxing temperature for 16h. Water was
added, and the mixture was extracted with EtOAc. The organic phases were combined,
washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification by FCC
(PE/EtOAc 9:1) afforded pure enone 217 as a yellow oil (21 g, 80% yield). The spectroscopic
data of this compound were in accord with those reported in the literature.225
1HNMR (400MHz, CDCl3): δ 5.28 (s, 1H, C
2−H), 4.04 (q, J = 7.1 Hz, 2H, C6−H), 2.62-2.58 (m,
2H, C5−H), 2.46-2.41 (m, 2H, C4−H), 1.41 (t, J = 7.1 Hz, 3H, C7−H).
13C NMR (101MHz, CDCl3): δ 206.1 (C
1), 190.2 (C3), 104.7 (C2), 67.7 (C6), 34.0 (C5), 28.6 (C4),
14.2 (C7).
Rf (EtOAc) = 0.46.
3-(3-hydroxypropyl)cyclopent-2-en-1-one 218
1 2
3
4
5
O
6
7
8
OH
ClMg OMgCl
THF, reflux
then HCl 2 N, RT
EtO
O +
217 218
Following a reported procedure,22 to a solution of 3-chloropropanol (2.4mL, 29mmol,
2.0 equiv) in THF (45mL) at -78 °C was added dropwise a solution of MeMgCl (3M in THF,
9.5mL, 29mmol, 2.0 equiv). The solution was allowed to warm to RT. When nomore gas was
produced, magnesium turning (0.76g, 31mmol, 2.2 equiv) was added and the mixture was
224Kikani, B. B.; Mckee, J. R.; Zanger, M. Synthesis 1991, 23, 176–176
225Reimann, E; Poeschl, K Pharmazie 1995, 50, 589–592
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heated at reflux for 3h. To the above freshly prepared Grignard reagent solution at reflux-
ing temperature was added dropwise a solution of 3-ethoxycyclopent-2-en-1-one 217 (1.8 g,
14mmol) in THF (45mL) over 20min. The reaction mixture was stirred at refluxing temper-
ature for 2h before being allowed to cool down to RT. The reaction was quenched by slow
addition of saturated aqueous NH4Cl. DCM and 2M HCl was added to the reaction mixture
and the biphasic reaction mixture was stirred vigorously for 3h. The layers were separated
and the aqueous phase was extractedwith DCM. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo to give crude enone 218 as a yellow
oil (1.4 g), which was used for the next reaction without further purification. An analytical
sample was obtained by FCC (EtOAc) to give 218 as a colorless oil. The spectroscopic data of
this compound were in accord with those reported in the literature.22
1H NMR (400 MHz, CDCl3): δ 5.96 (t, J = 1.4 Hz, 1H, C2−H), 3.70 (t, J = 7.1 Hz, 2H, C8−H),
2.62-2.57 (m, 2H, C5−H), 2.52 (t, J = 7.1 Hz, 2H, C6−H), 2.43-2.38 (m, 2H, C4−H), 1.92 (br s,
1H, C8−OH), 1.85 (quintet, J = 7.1 Hz, 2H, C7−H).
13C NMR (101MHz, CDCl3): δ 210.3 (C
1), 182.7 (C3), 129.6 (C2), 62.1 (C8), 35.4 (C5), 31.8 (C6),
30.1 (C7 or C4), 30.0 (C7 or C4).
IR: 3402 (br w), 2936 (w), 2867 (w), 1703 (s), 1673 (s), 1611 (s), 1437 (w), 1190 (w), 1056 (m),
HRMS: (ESI+) m/z: [M+H]+ Calcd for C8H13O2+: 141.0910; Found: 141.0909.
Rf (EtOAc) = 0.23.
3-(3-((tert-butyldimethylsilyl)oxy)propyl)cyclopent-2-en-1-one 220
O
OH TBSCl
Imidazole
DMF, RT
1 2
3
45
O
6
7
8
O Si
9
10 11
218 220
Following a reported procedure,22 to a solution of crude 218 (obtained from 14mmol of 3-
ethoxycyclopent-2-en-1-one) in DMF (100mL) at 0 °C were added imidazole (1.5 g, 22mmol,
1.5 equiv) and TBSCl (2.4 g, 16mmol, 1.1 equiv). The solution was stirred at RT for 3h. Satu-
rated aqueousNaHCO3 was added, and themixturewas extractedwith EtOAc. The combined
organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Pu-
rification by FCC (PE/EtOAc 4:1) afforded compound 220 as a slighly yellow oil (2.2 g, 60%
yield over two steps). The spectroscopic data of this compound were in accord with those
reported in the literature.22
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1HNMR (400MHz, CDCl3): δ 5.95 (s, 1H, C
2−H), 3.66 (t, J = 6.1 Hz, 2H, C8−H), 2.62-2.57 (m,
2H, C5−H), 2.48 (t, J = 7.5 Hz, 2H, C6−H), 2.43-2.38 (m, 2H, C4−H), 1.80 (tt, J = 7.5,6.1 Hz,
2H, C7−H), 0.89 (s, 9H, C11−H), 0.05 (s, 6H, C9−H).
13C NMR (101MHz, CDCl3): δ 210.2 (C
1), 183.0 (C3), 129.6 (C2), 62.4 (C8), 35.5 (C5), 31.8 (C6),
30.3 (C7 or C4), 30.2 (C7 or C4), 26.1 (C11), 18.5 (C10), -5.2 (C9).
Rf (EtOAc) = 0.87.
3-(3-((triethylsilyl)oxy)propyl)cyclopent-2-en-1-one 219
O
OH TESCl
Imidazole
DMF, RT
1 2
3
45
O
6
7
8
O Si 9
10
218 219
To a solution of crude 218 (obtained from14mmol of 3-ethoxycyclopent-2-en-1-one) inDMF
(100mL) at 0 °C were added imidazole (1.5 g, 22mmol, 1.5 equiv) and TESCl (2.6mL, 16mmol,
1.1 equiv) were added. The solution was stirred at RT for 3h. Saturated aqueous NaHCO3
was added, and the mixture was extracted with EtOAc. The combined organic phases were
washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 8:2) afforded compound 219 as a yellow oil (2.2 g, 61% yield over two steps).
1H NMR (400 MHz, CDCl3): δ 5.94 (t, J = 1.4 Hz, 1H, C2−H), 3.65 (t, J = 6.4 Hz, 2H, C8−H),
2.62-2.56 (m, 2H, C5−H), 2.48 (t, J = 8.0 Hz, 2H, C6−H), 2.42-2.37 (m, 2H, C4−H), 1.80 (tt,
J = 8.0,6.4 Hz, 2H, C7−H), 0.95 (t, J = 7.9 Hz, 9H, C10−H), 0.59 (q, J = 7.9 Hz, 6H, C9−H).
13C NMR (101MHz, CDCl3): δ 210.2 (C
1), 183.0 (C3), 129.6 (C2), 62.0 (C8), 35.5 (C5), 31.8 (C6),
30.3 (C7 or C4), 30.2 (C7 or C4), 6.9 (C10), 4.5 (C9).
IR: 2953 (w), 2912 (w), 2876 (w), 1708 (s), 1676 (w), 1617 (w), 1097 (s), 1009 (w), 732 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C14H27O2Si+: 255.1775; Found: 255.1781.
Rf (PE/EtOAc 1:1) = 0.5.
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3-(1-ethyl-3-oxocyclopentyl)propyl benzoate 223
O
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O Cu(OTf)2, L*
EtMgBr
Et2O, -30 °C
N N
OH
PF6
L*
TBSO
OTBS
220 222 223
Following a reported procedure,93,226 to a solution of Cu(OTf)2 (1.6mg, 0.0045mmol,
0.75mol%) and the ligand (2.4mg, 0.0060mmol, 1.0mol%) in Et2O (2.0mL) at -30 °C was
added dropwise a solution of EtMgBr (3.0M in Et2O, 0.24mL, 1.2 equiv). The mixture was
stirred for 40min at -30 °C. Then, a solution of 220 (0.15 g, 0.60mmol) in Et2O (6.0mL) was
added dropwise to the mixture via an automatic syringe pump over 30min, and the mixture
was stirred for 2h. The reaction mixture was quenched by dropwise addition of a saturated
NH4Cl solution at -30 °C, and the reaction mixture was allowed to warm up to RT. The mix-
ture was extracted with Et2O. The combined organic phases were washed with brine, dried
over Na2SO4, and concentrated in vacuo. The crude compound 222 thus obtained was used
for the next step without further purification.
To a solution of the crude ketone 222 (obtained from 0.60mmol of enone 220) in MeOH
(7.0mL) was added acetyl chloride (8.0μL, 20mol%) at 0 °C. The reaction mixture was stirred
at RT for 2h. The solution was concentrated in vacuo. The crude alcohol thus obtained was
used for the next step without further purification.
The crude alcoholwasdissolved inDCM(10mL) and stirred at 0 °C. Pyridine (95μL, 1.4mmol,
2.0 equiv) and benzoyl chloride (0.11mL, 0.90mmol, 1.5 equiv)were added. The reactionmix-
ture was stirred for 2h. Aqueous 1M HCl was added. The mixture was extracted with DCM.
The combined organic phases were washed with brine, dried over Na2SO4, and concentrated
in vacuo. Purification by FCC (9:1 PE/EtOAc) afforded benzoyl ester 223 as a colorless oil
(0.12 g, 75%, ee=5%).
1H NMR (400 MHz, CDCl3): δ 8.03 (dd, J = 8.2,1.4 Hz, 2H, C13,17−H), 7.56 (m, 1H, C15−H),
7.45 (dd, J = 8.2,1.4 Hz, 2H, C14,16−H), 4.32 (t, J = 6.5 Hz, 2H, C10−H), 2.28 (t, J = 8.0 Hz,
2H, C5−H), 2.13 (d, J = 18.0 Hz, 1H, C2−H), 2.08 (d, J = 18.0 Hz, 1H, C2−H), 1.90-1.78 (m, 2H,
C4−H), 1.78-1.74 (m, 2H, C9−H), 1.57-1.49 (m, 2H, C8−H), 1.46 (q, J = 7.3 Hz, 2H, C6−H), 0.88
(t, J = 7.3 Hz, 3H, C7−H).
13C NMR (101 MHz, CDCl3): δ 220.0 (C
11), 167.1 (C1), 133.4 (C15), 130.7 (C12), 130.0 (C13),
226The chiral ligand used for enantioselective 1,4 additions on cyclopentenonewas kindly provided by Professor
Alexakis (Geneva Univeristy).
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128.9 (C14), 65.7 (C10), 51.1 (C2), 42.8 (C3), 36.9 (C5), 33.9 (C8), 33.2 (C4), 30.1 (C6), 24.3 (C9),
9.0 (C7).
IR: 2957 (w), 1737 (s), 1718 (s), 1281 (s), 1069 (m), 1028 (m), 714 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C17H23O3+: 275.1647; Found: 275.1644.
Rf (PE/Et2O/Et3N 8:2) = 0.6.
Peak # Ret. Time Area Area %
1 10.24 min 2941.6099 50.5215
2 11.07 min 2880.884 49.4785
Co-Solvent % Total Flow Column Co-Solvent Back Pressure
5 4 IC MeOH 150
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Peak # Ret. Time Area Area %
1 10.26 min 652.8797 47.9373
2 11.07 min 709.0667 52.0627
Co-Solvent % Total Flow Column Co-Solvent Back Pressure
5 4 IC MeOH 150
3-allylcyclopent-2-en-1-one 224
O
1
234
5
1
2
3
4
5
HO 6
7
8
6 7
8
O
AllylMgBr
THF, RT
60%
PDC
DCM, RT
83%
436 224
Following a known procedure,94 a solution of cyclopent-2-en-1-one (1.2mL, 15mmol) in
THF (2.4mL) was added dropwise to a stirred solution of allylmagnesium bromide (1M in
Et2O, 18mL, 18mmol, 1.2 equiv) at 0 °C. The mixture was allowed to warm to RT and stirred
for 2h. The reaction mixture was cooled to 0 °C, 15mL of a saturated solution of NH4Cl were
added and the mixture was stirred at RT for 15min. The aqueous layer was extracted with
Et2O and the combined organic phases were washed with brine, dried over Na2SO4, and
concentrated in vacuo. Purification by Kugelrohr distillation (Bp = 120-130 °C/1.2mmHg)
afforded product 436 as a colorless oil (1.1 g, 60% yield). The spectroscopic data of this com-
pound were in accord with those reported in the literature.94
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Pyridium dichromate (5.5 g, 15mmol, 2.0 equiv) was added in one portion to a stirred so-
lution of 436 (0.90 g, 7.2mmol, 1.0 equiv) in DCM (9.0mL) at RT. The resulting brown sus-
pension was stirred for 6h. Et2O was added and the solid residue was removed by filtration
through a plug of silica gel, and washed with Et2O. The filtrate was concentrated in vacuo.
Purification by Kugelrohr distillation (Bp= 118-128 °C/1.2mmHg) afforded product 224 as a
colorless oil (0.73 g, 83% yield). The spectroscopic data of this compoundwere in accord with
those reported in the literature.94
Compound 436
1H NMR (400 MHz, CDCl3): δ 5.91-5.80 (m, 2H, C
7,2−H), 5.70 (dt, J = 5.6,2.2 Hz, 1H,
C1−H), 5.22-5.01 (m, 2H, C8−H), 2.50 (dddt, J = 17.0,8.7,4.6,2.3 Hz, 1H, C5−H), 2.41 (dt,
J = 7.4,1.2 Hz, 2H, C6−H), 2.29 (dddt, J = 17.0,8.7,4.6,2.3 Hz, 1H, C5−H), 2.04 (ddd, J =
13.4,8.7,4.6 Hz, 1H, C4−H), 1.83 (ddd, J = 13.4,8.7,4.6 Hz, 1H, C4−H), OH peak not observed.
Rf (PE/EtOAc 1:1) = 0.67.
Compound 224
1H NMR (400 MHz, CDCl3): δ 5.94 (s, 1H, C
2−H), 5.91-5.77 (m, 1H, C7−H), 5.19 (m, 1H,
C8−H), 5.13 (m, 1H, C8−H), 3.13 (d, J = 6.9 Hz, 2H, C6−H), 2.62-2.55 (m, 2H, C4−H), 2.42-
2.38 (m, 2H, C5−H).
13C NMR (101 MHz, CDCl3): δ 210.0 (C
1), 180.6 (C3), 132.9 (C7), 130.2 (C2), 118.4 (C8), 38.0
(C6), 35.5 (C5), 31.4 (C4).
Rf (PE/EtOAc 1:1) = 0.44.
Enantioselective synthesis of 3-allyl-3-ethylcyclopentan-1-one 226
O
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60% yield
Styrene
Grubbs II
DCM, 74%
N N
OH
PF6
L*224 225 226
Following a reported procedure,93 to a solution of Cu(OTf)2 (1.6mg, 0.0045mmol, 0.75mol%)
and the ligand (2.4mg, 0.0060mmol, 1.0mol%) in Et2O (2.0mL) at -30 °C was added dropwise
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a solution of EtMgBr (3M in Et2O, 0.24mL, 1.2 equiv). The mixture was stirred for 40min at
-30 °C. Then, a solution of 224 (73mg, 0.60mmol) in Et2O (6.0mL) was added dropwise to the
mixture via an automatic syringe pump over 30min, and the mixture was stirred for 2h. The
reactionmixture was quenched by dropwise addition of a saturatedNH4Cl solution at -30 °C,
and the reactionmixture was allowed to warmup to RT. Themixture was extractedwith Et2O.
The combined organic phases were washed with brine, dried over Na2SO4, and concentrated
in vacuo. Purification by FCC (9:1 PE/Et2O) afforded product 225 as a colorless oil (55mg,
60% yield).
To a solution of compound 225 (27mg, 0.18mmol) and styrene (84μL, 0.36mmol, 2.0 equiv)
in DCM (18mL) was added Grubbs II catalyst (30mg, 0.036mmol, 0.20 equiv). The reaction
mixture was stirred at RT overnight. It was then heated at 30 °C for 4h. Aqueous 1MHCl was
added, and themixture was extractedwith DCM. The combined organic phases were washed
with brine, dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/Et2O 10:0
to 9:1) afforded 226 as a colorless oil (16mg, 40%, ee =10%).
Compound 225
1H NMR (400 MHz, CDCl3): δ 5.77 (ddt, J = 16.7,10.5,7.4 Hz, 1H, C7−H), 5.13-5.01 (m, 2H,
C8−H), 2.26 (t, J = 8.0 Hz, 2H, C5−H), 2.14 (d, J = 7.4 Hz, 2H, C6−H), 2.12 (d, J = 7.8 Hz, 1H,
C2−H), 2.03 (d, J = 7.8Hz, 1H, C2−H), 1.89-1.72 (m, 2H, C4−H), 1.44 (q, J = 7.4 Hz, 2H, C9−H),
0.89 (t, J = 7.4 Hz, 3H, C10−H).
13C NMR (101MHz, CDCl3): δ 219.5 (C
1), 134.3 (C7), 118.0 (C8), 49.9 (C2), 42.7 (C6), 41.4 (C3),
36.6 (C5), 32.2 (C4), 30.6 (C9), 8.5 (C10).
IR: 2963 (w), 2921 (w), 1741 (s), 1462 (w), 1405 (w), 1166 (w), 915 (w).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C10H17O+: 153.1279; Found: 153.1361.
Rf (PE/Et2O 3:2) = 0.50.
Compound 226
1H NMR (400 MHz, CDCl3): δ 7.38-7.28 (4H, m, C
12,13−H), 7.23 (m, 1H, C14−H), 6.43 (dt,
J = 15.8,1.3 Hz, 1H, C8−H), 6.17 (dt, J = 15.4,7.5 Hz, 1H, C7−H), 2.30 (t, J = 5.2 Hz, 2H, C5−H),
2.28 (dd, J = 2.6,4.1 Hz, 2H, C6−H), 2.19 (d, J = 18.1 Hz, 1H, C2−H), 2.09 (d, J = 18.1 Hz,
1H, C2−H), 1.89-1.71 (m, 2H, C4−H), 1.49 (q, J = 7.4 Hz, 2H, C9−H), 0.93 (t, J = 7.4 Hz, 3H,
C10−H).
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13C NMR (101 MHz, CDCl3): δ 219.9 (C
1), 137.1 (C11), 132.9 (C8), 128.4 (C13), 127.1 (C14),
125.9 (C12), 125.8 (C7), 49.8 (C2), 43.2 (C3), 40.3 (C5), 36.5 (C6), 32.1 (C4), 30.7 (C9), 8.5 (C10).
IR: 2961 (w), 2923 (w), 1739 (s), 1450 (w), 1160 (w), 967 (m), 737 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C16H21O+: 229.1592; Found: 229.1585.
Rf (PE/Et2O 9:1) = 0.16.
Peak # Ret. Time Area Area %
1 5.12 min 1553.6693 48.8672
2 6.27 min 1625.703 51.1328
Co-Solvent % Total Flow Column Co-Solvent Back Pressure
5 4 AD-H MeOH 150
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Peak # Ret. Time Area Area %
1 5.14 min 6598.3104 44.492
2 6.19 min 8232.0092 55.508
Co-Solvent % Total Flow Column Co-Solvent Back Pressure
5 4 AD-H MeOH 150
3-(but-3-en-1-yl)cyclopent-2-en-1-one 228
Mg
I2
THF, 
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Following a reported procedure,94 to a suspention of magnesium turning (0.92g, 38mmol,
2.0 equiv) in THF (50mL) at RT was added I2 (one crystal), and the solution was heated to
60 °C. 4-bromo-1-butene (2.2mL, 22mmol, 1.2 equiv) was added dropwise, keeping a gentle
reflux. After addition, the mixture was heated to refluxing temperature for 1h. Then, a solu-
tion of 3-ethoxycyclopent-2-en-1-one 217 (2.4 g, 18mmol) in THF (10mL) was added drop-
wise, and the mixture was stirred for 30min at reflux. The reaction mixture was cooled down
to RT. The reactionwas quenched with aqueous NH4Cl. 2MHCl was then added, followed by
DCM. The biphasicmixture was stirred for 30min. Themixture was extractedwith DCM. The
combined organic phases were washed with brine, dried over Na2SO4 and concentrated in
vacuo. Purification by FCC (PE/Et2O 1:1) afforded the pure product 228 as colorless oil (2.2 g,
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91% yield). The spectroscopic data of this compound were in accord with those reported in
the literature.94
1H NMR (400 MHz, CDCl3): δ 5.96 (quint, J = 1.4 Hz, 1H, C2−H), 5.80 (ddt, J =
17.0,10.3,6.5 Hz, 1H, C8−H), 5.06 (dq, J = 17.0,1.5 Hz, 1H, C9−H), 5.02 (dq, J = 10.3,1.5 Hz,
1H, C9−H), 2.60-2.56 (m, 2H, C4−H), 2.51 (t, J = 7.4 Hz, 2H, C6−H), 2.41-2.38 (m, 2H, C5−H),
2.38-2.31 (m, 2H, C7−H).
13C NMR (101 MHz, CDCl3): δ 210.1 (C
1), 182.1 (C3), 136.9 (C8), 129.9 (C2), 115.9 (C9), 35.4
(C5), 32.8 (C6), 31.7 (C4), 31.1 (C7).
Rf (PE/Ether 1:1) = 0.30
methyl 3-(3-oxocyclopent-1-en-1-yl)propanoate 227
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To a solution of the enone 228 (1.0 g, 7.3mmol) in DCM/MeOH (2:1, 15mL) was added
NaHCO3 (0.12g, 15mmol, 2.0 equiv). The reaction mixture was cooled down to -78 °C, and
ozone was bubbled through the solution. When the blue color persisted, argon was bub-
bled through the solution for 10min. Triethylamine (2.0mL, 14mmol, 2.0 equiv), and Ac2O
(1.3mL, 14mmol, 1.9 equiv) were added, and the mixture was stirred at RT for 2h. Water was
added. The mixture was extracted with Et2O. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/Et2O 1:9)
afforded product 227 as a colorless oil (0.77 g, 63% yield).
1H NMR (400 MHz, CDCl3): δ 5.94 (m, 1H, C
2−H), 3.70 (s, 3H, C9−H), 2.73 (m, 2H, C7−H),
2.66-2.59 (m, 4H, C5,6−H), 2.42 (m, 2H, C4−H).
13C NMR (101 MHz, CDCl3): δ 209.7 (C
1), 180.4 (C3), 172.7 (C8), 129.6 (C2), 52.1 (C9), 35.4
(C5), 31.8 (C6or7), 31.5 (C6or7), 28.6 (C4).
IR: 2955 (w), 2924 (w), 2852 (w), 1737 (s), 1703 (s), 1616 (m), 1437 (m), 1175 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C9H13O3+: 169.0859; Found: 169.0858.
Rf (Ether) = 0.4
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3-ethyl-3-(3-((triethylsilyl)oxy)propyl)cyclopent-1-en-1-yl trifluoromethane-
sulfonate 214
O
O Si
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THF, -40 °C
then Comins' reagent, RT
82%
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SO O
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219 214
To a suspention of CuBr·Me2S (5.7 g, 28mmol, 2.0 equiv) in THF (85mL) at -78 °C was added
dropwise EtMgBr (3M in THF, 18mL, 55mmol, 4.0 equiv). The reactionmixturewas stirred at
-78 °C for 1h and then warmed to -40 °C. To the above prepared cuprate solution was added
dropwise a solution of the ketone 219 (3.5 g, 14mmol) in THF (30mL) while keeping the so-
lution below -40 °C. The reaction mixture was stirred at -40 °C for 3h. A solution of Comins’
reagent (10.8 g, 28mmol, 2.0 equiv) in THF (30mL) was added to the reaction mixture. The
reactionmixture was allowed to warm to RT, and stirred for 24h. The reaction was quenched
with NH4Cl. The reaction mixture was diluted with water and extracted with EtOAc. The
combined organic phases were washed with brine, dried over Na2SO4 and concentrated in
vacuo. Purification by FCC (PE/EtOAc 20:1) afforded compound 214 as a colorless oil (4.7 g,
82% yield).
1H NMR (400 MHz, CDCl3): δ 5.42 (t, J = 1.6 Hz, 1H, C2−H), 3.58 (t, J = 5.9 Hz, 2H, C11−H),
2.57 (td, J = 7.9,1.6, 2H, C5−H), 1.81-1.76 (m, 2H, C4−H), 1.49-1.40 (m, 6H, C7,9,10−H), 0.95 (t,
J = 7.9 Hz, 9H, C13−H), 0.84 (t, J = 7.4 Hz, 3H, C8−H), 0.59 (t, J = 7.9 Hz, 6H, C12−H).
13C NMR (101 MHz, CDCl3): δ 148.0 (C
1), 124.7 (C2), 118.7 (q, J = 320.3 Hz, C6), 63.6 (C11),
48.9 (C3), 35.6 (C9), 32.4 (C7), 31.5 (C4), 31.1 (C5), 28.0 (C10), 8.8 (C8), 6.9 (C13), 4.6 (C12).
IR: 2957 (w), 2878 (w), 1421 (w), 1214 (w), 1141 (w), 1089 (w), 906 (s), 729 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C17H32F3O4SSi+: 417.1737; Found: 417.1728.
Rf (PE/EtOAc 95:5) = 0.48.
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3-ethyl-3-(3-((dimethyltertbutylsilyl)oxy)propyl)cyclopent-1-en-1-yl trifluoro-
methanesulfonate 58
O
O Si
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O SiEtMgBrCuBr·Me2S
THF, -40 °C
then Comins' reagent, RT
82%
11
7
SO O
CF3
8
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To a suspention of CuBr·Me2S (5.7 g, 28mmol, 2.0 equiv) in THF (85mL) at -78 °C was added
dropwise EtMgBr (3M in THF, 18mL, 55mmol, 4.0 equiv). The reactionmixture was stirred at
-78 °C for 1h and then warmed to -40 °C. To the above prepared cuprate solution was added
dropwise a solution of the ketone 220 (3.5 g, 14mmol) in THF (30mL) while keeping the so-
lution below -40 °C. The reaction mixture was stirred at -40 °C for 3h. A solution of Comins’
reagent (11g, 28mmol, 2.0 equiv) in THF (30mL) was added. The reaction mixture was al-
lowed to warm to RT, and stirred for 24h. The reaction was quenched with NH4Cl. The reac-
tionmixture was diluted with water and extractedwith EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 40:1) afforded compound 58 as a colorless oil (4.7 g, 82% yield). The spectroscopic
data of this compound were in accord with those reported in the literature.22
1H NMR (400 MHz, CDCl3): δ 5.42 (t, J = 1.4 Hz, 1H, C2−H), 3.58 (t, J = 5.4 Hz, 2H, C11−H),
2.57 (td, J = 7.9,1.4 Hz, 2H, C5−H), 1.83-1.77 (m, 2H, C4−H), 1.49-1.39 (m, 6H, C7,9,10−H),
0.89 (s, 9H, C14−H), 0.84 (t, J = 7.4 Hz, 3H, C8−H), 0.04 (s, 6H, C12−H).
13C NMR (101 MHz, CDCl3): δ 148.0 (C
1), 124.8 (C2), 118.7 (q, J = 322.2 Hz, C6), 63.6 (C11),
48.9 (C3), 35.6 (C9), 32.4 (C7), 31.5 (C4), 31.1 (C5), 28.0 (C10), 26.1 (C14), 18.5 (C13), 8.8 (C8),
-5.2 (C12).
Rf (PE/EtOAc 10:1) = 0.8.
3-ethyl-3-(3-hydroxypropyl)cyclopent-1-en-1-yl trifluoromethanesulfonate 221
O
O SiSO O
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MeOH, 0 °C to RT
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58 221
To a solution of 58 (14 g, 33mmol) in MeOH (100mL) at 0 °C was added acetyl chloride
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(0.23mL, 3.3mmol, 0.10 equiv). After stirring at RT for 1h, the reaction mixture was concen-
trated in vacuo to afford 221 as a yellowish oil (10 g, quantitative yield). The spectroscopic
data of this compound were in accord with those reported in the literature.22 The product
thus obtained was used for the next step without further purification.
1H NMR (400 MHz, CDCl3): δ 5.41 (s, 1H, C
2−H), 3.62 (t, J = 6.0 Hz, 2H, C11−H), 2.57 (td,
J = 7.3,1.1 Hz, 2H, C5−H), 1.82-1.75 (m, 2H, C4−H), 1.54 (s, 1H, C11−OH), 1.55-1.40 (m, 6H,
C7,9,10−H), 0.84 (t, J = 7.5 Hz, 3H, C8−H).
13C NMR (101 MHz, CDCl3): δ 148.1 (C
1), 124.6 (C2), 118.7 (q, J = 319.4 Hz, C6), 63.4 (C11),
48.9 (C3), 35.6 (C9), 32.4 (C7), 31.4 (C4), 31.1 (C5), 27.9 (C10), 8.8 (C8).
Rf (PE/EtOAc 1:1) = 0.56.
tert-butyl(2-iodoethoxy)dimethylsilane 144
1
2
I O
1. NaH, TBSCl
2. I2, PPh3, Imidazole
85%
HO OH Si
3
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Following a reported procedure,227 ethylene glycol (3.0mL, 54mmol) was added dropwise to
a suspension of NaH (60% in mineral oil, 2.2 g, 54mmol, 1.0 equiv) in THF (100mL) at 0 °C.
The reaction mixture was stirred at RT for 1h. TBSCl (7.2 g, 54mmol, 1.0 equiv) was added
at 0 °C and the mixture was stirred for 1h at RT. The reaction was quenched with saturated
NH4Cl and the reactioin mixture was extracted with EtOAc. The combined organic phases
were washed with saturatedNaHCO3, brine, dried over Na2SO4 and concentrated in vacuo to
afford the crudemonoprotected diol as a colorless oil.
To a solution of the crude monoprotected diol in THF (300mL) were added imidazole (5.5 g,
81mmol, 1.5 equiv) and PPh3 (18g, 70mmol, 1.3 equiv). The solution was cooled down to
0 °C and iodine (16g, 65mmol, 1.2 equiv) was added slowly. The resultingmixture was stirred
at RT for 1h, quenched with saturated Na2S2O3, diluted with saturated NH4Cl and extracted
with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and
concentrated in vacuo. Purification by FCC (PE) afforded compound 144 as a colorless oil
(13 g, 85% yield). The spectroscopic data of this compound were in accord with those re-
ported in the literature.226
1H NMR (400 MHz, CDCl3): δ 3.83 (t, J = 7.0 Hz, 2H, C2−H), 3.20 (t, J = 7.0 Hz, 2H, C1−H),
227Yamashita, S.; Iso, K.; Hirama, M. Org. Lett. 2008, 10, 3413–3415
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0.90 (s, 9H, C5−H), 0.08 (s, 6H, C3−H).
13C NMR (101MHz, CDCl3): δ 64.4 (C
2), 26.0 (C5), 16.4 (C4), 7.2 (C1), -5.1 (C3).
Rf (PE) = 0.26.
methyl 4-((tert-butyldimethylsilyl)oxy)-2-(2-nitrophenyl)butanoate 145
NO2
O
O I OTBS
Cs2CO3
DMF, 60 °C
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To a solution of the ester 96 (10 g, 51mmol) and the iodide 144 (16 g, 56mmol, 1.1 equiv) in
DMF (300mL) was added Cs2CO3 (25g, 77mmol, 1.5 equiv). The reactionmixturewas stirred
at 60 °C for 18h. The reaction mixture was allowed to cool down to RT. Water was added and
themixturewas extractedwith EtOAc. The combined organic phaseswerewashedwith brine,
dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5) afforded
compound 145 as a yellow wax (17g, 95% yield). The spectroscopic data of this compound
were in accord with those reported in the literature.22
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.7,1.3 Hz, 1H, C2−H), 7.57 (td, J = 7.7,1.3 Hz,
1H, C4−H), 7.51 (dd, J = 7.7,1.5 Hz, 1H, C5−H), 7.41 (td, J = 7.7,1.5 Hz, 1H, C3−H),
4.40 (t, J = 7.2 Hz, 1H, C7−H), 3.70-3.63 (m, 1H, C11−H), 3.66 (s, 3H, C9−H), 3.52 (ddd,
J = 10.3,7.4,5.3 Hz, 1H, C11−H), 2.45 (dtd, J = 13.9,7.2,5.5 Hz, 1H, C10−H), 2.00 (dtd, J =
13.9,7.2,5.7 Hz, 1H, C10−H), 0.87 (s, 9H, C14−H), 0.01 (s, 3H, C12−H), 0.00 (s, 3H, C12−H).
13C NMR (101MHz, CDCl3): δ 173.2 (C
8), 149.4 (C1), 133.8 (C6), 133.1 (C4), 130.9 (C5), 128.2
(C3), 125.0 (C2), 60.5 (C11), 52.4 (C9), 43.3 (C7), 35.6 (C10), 26.0 (C14), 18.4 (C13), -5.4 (C12).
Rf (PE/EtOAc 9:1) = 0.43.
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4-((tert-butyldimethylsilyl)oxy)-2-(2-nitrophenyl)butanoic acid 216
KOH
THF/H2O, RT
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To a solution of the ester 145 (2.0 g, 5.7mmol) in THF (50mL) was added a solution of aque-
ous 10% KOH (10mL). The reaction mixture was stirred until complete consumption of the
ester. Water was added and the reaction mixture was acidified to pH 5-6 with 1M HCl. The
mixture was extracted with EtOAc. The combined organic phases were washed with brine,
dried over Na2SO4 and concentrated in vacuo to afford carboxylic acid 216 as a yellow oil
(1.9 g, quantitative yield). The spectroscopic data of this compoundwere in accordwith those
reported in the literature.22 The compound was used for the next step without further purifi-
cation.
1HNMR (400MHz,CDCl3): δ 10.78 (br s, 1H, O
9−H), 7.95 (dd, J = 7.8,1.4 Hz, 1H, C2−H), 7.58
(td, J = 7.8,1.4 Hz, 1H, C4−H), 7.50 (dd, J = 7.8,1.5 Hz, 1H, C5−H), 7.43 (td, J = 7.8,1.5 Hz,
1H, C3−H), 4.41 (t, J = 7.0 Hz, 1H, C7−H), 3.69 (dt, J = 10.4,5.3 Hz, 1H, C11−H), 3.51 (ddd,
J = 10.4,8.0,5.3 Hz, 1H, C11−H), 2.47 (dddd, J = 14.0,8.1,7.0,5.3 Hz, 1H, C10−H), 2.01 (ddt,
J = 14.0,7.0,5.3 Hz, 1H, C10−H), 0.86 (s, 9H, C14−H), 0.00 (two s, 6H, C12−H).
13C NMR (101 MHz, CDCl3): δ 178.7 (C
8), 149.1 (C1), 133.3 (C6), 133.2 (C4), 131.2 (C5), 128.4
(C3), 125.1 (C2), 60.5 (C11), 43.9 (C7), 35.1 (C10), 25.9 (C14), 18.3 (C13), -5.4 (C12).
Rf (PE/EtOAc 8:2) = 0.24.
potassium 4-((tert-butyldimethylsilyl)oxy)-2-(2-nitrophenyl)butanoate 215
t-BuOK
EtOH/H2O
RT
quant.
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Following a reported procedure,22 to a solution of crude acid 216 (1.9 g, 5.7mmol) in EtOH
(50mL) was added dropwise a solution of t-BuOK (0.64g, 5.7mmol, 1.0 equiv) in EtOH
(5.0mL). The reaction mixture was stirred for 1h, then concentrated in vacuo and coevap-
orated with toluene to afford the crude carboxylate 215 as a white amorphous solid (2.2 g,
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quantitative yield). The spectroscopic data of this compound were in accord with those re-
ported in the literature.22 This compoundwas used for the next step without further purifica-
tion.
1H NMR (400 MHz, CD3OD): δ 7.79 (dd, J = 8.2,1.4 Hz, 1H, C2−H), 7.68 (dd, J = 7.7,1.6 Hz,
1H, C4−H), 7.58 (td, J = 7.7,1.4 Hz, 1H, C5−H), 7.38 (ddd, J = 8.1,7.3,1.5 Hz, 1H, C3−H),
4.41 (t, J = 7.2 Hz, 1H, C7−H), 3.65 (ddd, J = 10.0,6.4,6.1 Hz, 1H, C11−H), 3.60 (ddd, J =
10.0,7.0,6.8 Hz, 1H, C11−H), 2.38 (dq, J = 13.5,7.2 Hz, 1H, C10−H), 2.01 (dq, J = 13.5,7.2 Hz,
1H, C10−H), 0.87 (s, 9H, C14−H), 0.00 (two s, 6H, C12−H).
13C NMR (101MHz, CD3OD): δ 179.8 (C
8), 151.7 (C1), 138.1 (C6), 133.6 (C4), 131.6 (C5), 128.2
(C3), 125.2 (C2), 62.9 (C11), 47.5 (C7), 38.2 (C10), 26.6 (C14), 19.2 (C13), -5.1 (C12).
3-(3-(3-((tert-butyldimethylsilyl)oxy)-1-(2-nitrophenyl)propyl)-1-ethylcyclopent-
2-en-1-yl)propan-1-ol 213
From free alcohol 221
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An oven-dried flask was charged with salt 215 (2.0 g, 5.3mmol, 1.2 equiv), X-Phos (0.32g,
0.66mmol, 15mol%) and allylpalladium chloride dimer (40mg, 0.11mmol, 5.0mol%) and
flushed with nitrogen. Degassed and dry diglyme (30mL) was added, and the reaction mix-
ture was stirred for 5 minutes. A solution of the vinyl triflate 221 (1.3 g, 4.4mmol) in diglyme
(30mL) was added, and the reaction mixture was heated at 100 °C for 2h. The reaction mix-
ture was allowed to cool down to RT, and saturated aqueous NaHCO3 was added. The mix-
ture was extracted with EtOAc. The combined organic phases were washed with brine, dried
over Na2SO4 and concentrated in vacuo. The two diastereoisomers were separated by FCC
(PE/EtOAc 8:2), giving 213a and 213b as yellow oils (0.89 g, 45% yield, dr 1:1).
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From TES-protected alcohol 214
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An oven-dried flask was charged with salt 215 (2.0 g, 5.3mmol, 1.2 equiv), X-Phos (0.32g,
0.66mmol, 15mol%) and allylpalladium chloride dimer (40mg, 0.11mmol, 5.0mol%) and
flushed with nitrogen. Degassed and dry diglyme (30mL) was added, and the reaction mix-
ture was stirred for 5 minutes. A solution of the vinyl triflate 214 (1.8 g, 4.4mmol) in diglyme
(30mL) was added, and the reaction mixture was heated at 100 °C for 2h. The reaction mix-
ture was cooled down to 0 °C, and TBAF (1M solution in THF, 5mL, 5mmol, 1.1 equiv) was
added dropwise. The reaction was monitored by TLC until total conversion. Saturated aque-
ous NaHCO3 was added. The mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. The two di-
astereoisomers were separated by FCC (PE/EtOAc 8:2), giving 213a and 213b as yellow oils
(1.1 g, 57% yield, dr 1:1).
Compound 213a
1H NMR (400 MHz, CDCl3): δ 7.68 (dd, J = 7.8,1.5 Hz, 1H, C12−H), 7.49 (td, J = 7.8,1.5 Hz,
1H, C10−H), 7.38 (dd, J = 7.8,1.5 Hz, 1H, C9−H), 7.30 (td, J = 7.8,1.5 Hz, 1H, C11−H), 5.25 (d,
J = 1.7 Hz, 1H, C21−H), 4.07 (t, J = 7.4 Hz, 1H, C7−H), 3.59 (t, J = 6.4 Hz, 2H, C3−H), 3.53 (t,
J = 6.8 Hz, 2H, C5−H), 2.18-1.89 (m, 4H, C6,15−H), 1.70 (br s, 1H, O4−H), 1.66-1.53 (m, 2H,
C17−H), 1.49-1.41 (m, 2H, C14−H), 1.40-1.31 (m, 4H, C16,19−H), 0.85 (s, 9H, C24−H), 0.78 (t,
J = 7.5 Hz, 3H, C18−H), -0.02 (s, 6H, C22−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 144.1 (C2), 137.8 (C8), 133.0 (C21), 132.3 (C10),
129.2 (C9), 127.0 (C11), 124.0 (C12), 63.8 (C3), 61.2 (C5), 51.8 (C20), 37.4 (C7), 37.1 (C6), 35.3
(C15), 33.6 (C16), 33.5 (C17), 32.1 (C19), 28.3 (C14), 26.0 (C24), 18.4 (C23), 9.1 (C18), -5.3 (C22).
IR: 3378 (br w), 2930 (w), 2856 (w), 1527 (s), 1462 (w), 1356 (m), 1254 (m), 1099 (s), 1061 (m),
834 (s), 777 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H42NO4Si+: 448.2878; Found: 448.2885.
Rf (PE/EtOAc 6:4) = 0.43.
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Compound 213b
1H NMR (400 MHz, CDCl3): δ 7.67 (dd, J = 7.7,1.5 Hz, 1H, C12−H), 7.48 (td, J = 7.7,1.5 Hz,
1H, C10−H), 7.38 (dd, J = 7.7,1.6 Hz, 1H, C9−H), 7.29 (td, J = 7.7,1.6 Hz, 1H, C11−H), 5.26 (d,
J = 1.9 Hz, 1H, C21−H), 4.11 (t, J = 7.3 Hz, 1H, C7−H), 3.58 (t, J = 6.5 Hz, 2H, C3−H), 3.52 (t,
J = 6.8 Hz, 2H, C5−H), 2.16-2.00 (m, 3H, C6,15−H), 1.95 (dq, J = 13.6,6.8 Hz, 1H, C6−H), 1.73
(br s, 1H, O4−H), 1.57 (t, J = 7.4 Hz, 2H, C17−H), 1.50-1.40 (m, 2H, C14−H), 1.40-1.30 (m, 4H,
C16,19−H), 0.84 (s, 9H, C24−H), 0.77 (t, J = 7.3 Hz, 3H, C18−H), -0.03 (s, 6H, C22−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 143.9 (C2), 137.7 (C8), 133.2 (C21), 132.2 (C10),
129.1 (C9), 127.0 (C11), 124.0 (C12), 63.7 (C3), 61.1 (C5), 51.8 (C20), 37.3 (C7), 36.9 (C6), 35.3
(C15), 33.4 (C16), 33.3 (C17), 32.1 (C19), 28.3 (C14), 26.0 (C24), 18.4 (C23), 9.1 (C18), -5.3 (C22).
IR: 3362 (br w), 2934 (w), 2856 (w), 1527 (s), 1463 (w), 1356 (m), 1254 (m), 1099 (s), 1062 (m),
834 (s), 778 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H42NO4Si+: 448.2878; Found: 448.2876.
Rf (PE/EtOAc 6:4) = 0.57.
3-(3-(3-(hydroxy)-1-(2-nitrophenyl)propyl)-1-ethylcyclopent-2-en-1-yl)propan-
1-ol 229
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To a solution of compounds 213a/213b (dr 1:1, 2.7 g, 6.0mmol) in MeOH (50mL) at 0 °C was
added dropwise acetyl chloride (40μL, 0.60mmol, 10mol%). The reaction was stirred at RT
for 1h, then concentrated in vacuo. The crude alcohols 229a/229b (2.0 g, quantitative yield,
no change in dr) thus obtained was used for the next step without further purification.
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From TBS-protected alcohol 58
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An oven-dried flask was charged with salt 215 (dr 1:1, 2.0 g, 5.3mmol, 1.2 equiv), X-Phos
(0.32g, 0.66mmol, 15mol%) and allylpalladium chloride dimer (40mg, 0.11mmol, 5.0mol%)
and flushed with nitrogen. Degassed and dry diglyme (30mL) was added, and the reac-
tion mixture was stirred for 5 minutes. A solution of the vinyl triflate 58 (1.8 g, 4.4mmol)
in diglyme (30mL) was added, and the reaction mixture was heated at 100 °C for 2h. The
reaction mixture was cooled down to RT, and TBAF (1M solution in THF, 13mL, 13mmol,
3.0 equiv) was added dropwise. The reaction was monitored by TLC until total conversion.
Saturated aqueous NaHCO3 was added. The mixture was extracted with EtOAc. The com-
bined organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo.
Purification by FCC (PE/EtOAc 8:2) afforded the two diastereoisomers 229a and 229b as yel-
low oils (0.81 g, 55% yield, dr 1:1).
Compound 229a
1H NMR (400 MHz, CDCl3): δ 7.67 (dd, J = 7.7,1.4 Hz, 1H, C12−H), 7.51 (td, J = 7.7,1.4 Hz,
1H, C10−H), 7.38 (dd, J = 7.7,1.6 Hz, 1H, C9−H), 7.31 (td, J = 7.7,1.6 Hz, 1H, C11−H), 5.29
(d, J = 1.7 Hz, 1H, C21−H), 4.06 (t, J = 7.4 Hz, 1H, C7−H), 3.61-3.48 (m, 4H, C3,5−H), 2.46
(br s, 2H, O4,22−H), 2.20 (ddt, J = 13.2,6.6,6.6 Hz, 1H, C6−H), 2.14-2.04 (m, 1H, C15−H), 2.04-
1.92 (m, 2H, C6,15−H), 1.65-1.50 (m, 2H, C17−H), 1.49-1.39 (m, 2H, C14−H), 1.40-1.30 (m, 4H,
C16,19−H), 0.76 (t, J = 7.4 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.8 (C
13), 143.9 (C2), 137.3 (C8), 133.3 (C21), 132.5 (C10),
129.2 (C9), 127.2 (C11), 124.0 (C12), 63.7 (C3), 60.8 (C5), 51.9 (C20), 37.5 (C7), 36.9 (C6), 35.2
(C15), 33.5 (C16), 33.5 (C17), 32.1 (C19), 28.2 (C14), 9.1 (C18).
IR: 3343 (br w), 2937 (w), 2875 (w), 1525 (s), 1451 (w), 1355 (m), 1052 (m), 909 (m), 731 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H28NO4+: 334.2013; Found: 334.2001.
Rf (PE/EtOAc 4:6) = 0.22.
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Compound 229b
1H NMR (400 MHz, CDCl3): δ 7.67 (dd, J = 7.7,1.7 Hz, 1H, C12−H), 7.50 (td, J = 7.7,1.7 Hz,
1H, C10−H), 7.38 (dd, J = 7.7,1.6 Hz, 1H, C9−H), 7.31 (td, J = 7.7,1.6 Hz, 1H, C11−H), 5.31
(d, J = 1.8 Hz, 1H, C21−H), 4.03 (t, J = 7.5 Hz, 1H, C7−H), 3.61-3.48 (m, 4H, C3,5−H), 2.50 (br
s, 2H, O4,22−H), 2.19 (ddt, J = 13.5,13.0,6.7 Hz, 1H, C6−H), 2.14-2.04 (m, 1H, C15−H), 2.02-
1.91 (m, 2H, C6,15−H), 1.59-1.53 (m, 2H, C17−H), 1.50-1.41 (m, 2H, C14−H), 1.40-1.30 (m, 4H,
C16,19−H), 0.77 (t, J = 7.4 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 143.9 (C2), 137.4 (C8), 133.2 (C21), 132.5 (C10),
129.2 (C9), 127.2 (C11), 123.9 (C12), 63.7 (C3), 60.7 (C5), 51.9 (C20), 37.5 (C7), 37.0 (C6), 35.3
(C15), 33.7 (C16), 33.3 (C17), 32.2 (C19), 28.2 (C14), 9.2 (C18).
IR: 3330 (br w), 2937 (w), 2875 (w), 1525 (s), 1461 (w), 1355 (m), 1052 (m), 910 (w), 855 (w),
784 (m), 732 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H28NO4+: 334.2013; Found: 334.2012.
Rf (PE/EtOAc 4:6) = 0.22.
3-(-1-ethyl-3-(-3-((methylsulfonyl)oxy)-1-(2-nitrophenyl)propyl)cyclopent-2-en-
1-yl)propyl methanesulfonate 233
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To a solution of diols 229a/229b (dr 1:1, 50mg, 0.15mmol) in DCM (15mL) at 0 °C was added
Et3N (63μL, 0.50mmol, 3.0 equiv) and MsCl (29μL, 0.37mmol, 2.5 equiv). The reaction mix-
ture was stirred at RT until complete consumption of the starting material. The reaction
mixture was poured into water and extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 8:2) afforded the pure compounds 233a/233b as a mixture of two diastereoiso-
mers (yellow oils, 54mg, 74% yield, no change in dr).
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Compound 233a
1H NMR (400 MHz, CDCl3): δ 7.75 (dd, J = 7.9,1.3 Hz, 1H, C12−H), 7.58 (td, J = 7.9,1.3 Hz,
1H, C10−H), 7.41-7.35 (m, 2H, C9,11−H), 5.31 (d, J = 1.4 Hz, 1H, C21−H), 4.25-4.05 (m, 5H,
C5,7,14−H), 3.00 (s, 3H, C23−H), 2.97 (s, 3H, C22−H), 2.41 (dq, J = 14.3,6.9 Hz, 1H, C6−H), 2.23
(dq, J = 14.3,7.3 Hz, 1H, C6−H), 2.15 (m, 1H, C15−H), 2.02 (m, 1H, C15−H), 1.72-1.62 (m, 3H,
C17,14−H), 1.55 (m, 1H, C14−H), 1.45-1.34 (m, 4H, C16,19−H), 0.80 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.6 (C
13), 143.7 (C2), 136.0 (C8), 133.2 (C21), 133.0 (C10),
129.0 (C9), 127.9 (C11), 124.4 (C12), 71.0 (C3), 67.5 (C5), 51.9 (C20), 37.6 (C7), 37.5 (C22), 37.5
(C23), 34.8 (C15), 33.7 (C6or16), 33.6 (C6or16), 33.4 (C17), 32.1 (C19), 25.0 (C14), 9.1 (C18).
IR: 2959 (w), 2941 (w), 2851 (w), 1526 (m), 1350 (s), 1172 (s), 958 (m), 918 (m), 815 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C21H32NO8S2+: 490.1564; Found: 490.1508.
Rf (PE/EtOAc 4:6) = 0.58.
Compound 233b
1HNMR(400MHz, CDCl3): δ 7.74 (dd, J = 7.6,1.4 Hz, 1H, C12−H), 7.56 (td, J = 7.6,1.4 Hz, 1H,
C10−H), 7.31 (td, J = 7.6,1.5 Hz, 2H, C9,11−H), 5.33 (d, J = 1.3 Hz, 1H, C21−H), 4.28-4.05 (m,
5H, C5,7,14−H), 3.01 (s, 3H, C23−H), 2.97 (s, 3H, C22−H), 2.39 (dq, J = 14.1,7.0 Hz, 1H, C6−H),
2.23 (dq, J = 14.1,7.0 Hz, 1H, C6−H), 2.13 (ddd, J = 16.1,7.8,7.2 Hz, 1H, C15−H), 2.02 (ddd,
J = 16.1,7.8,7.2 Hz, 1H, C15−H), 1.70-1.55 (m, 4H, C14,17−H), 1.46-1.35 (m, 4H, C16,19−H), 0.8
(t, J = 7.0 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.6 (C
13), 143.5 (C2), 136.1 (C8), 133.3 (C21), 132.8 (C10),
129.0 (C9), 127.8 (C11), 124.4 (C12), 70.9 (C3), 67.5 (C5), 51.9 (C20), 37.6 (C7), 37.5 (C22or23), 37.4
(C22or23), 35.0 (C15), 33.6 (C6or16), 33.6 (C6or16), 33.2 (C17), 33.1 (C19), 24.9 (C14), 9.2 (C18).
IR: 2960 (w), 2942 (w), 2850 (w), 1527 (m), 1351 (s), 1173 (s), 967 (m), 919 (m), 815 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C21H32NO8S2+: 490.1564; Found: 490.1563.
Rf (PE/EtOAc 4:6) = 0.58.
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1-(1-(3-ethyl-3-(3-iodopropyl)cyclopent-1-en-1-yl)-3-iodopropyl)-2-nitro-
benzene 232
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To a solution of diols 229a/229b (dr 1:1, 50mg, 0.15mmol) in THF (15mL) at 0 °C was added
imidazole (34mg, 0.50mmol, 3.0 equiv) and PPh3 (97mg, 0.37mmol, 2.5 equiv), followed
by portionwise addition of iodine (84mg, 0.33mmol, 2.2 equiv). The reaction mixture was
stirred at RT until complete consumption of the starting material. The reaction mixture was
pourred into saturated aqueous NH4Cl, and extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purifica-
tion by FCC (PE/EtOAc 8:2) afforded the pure compounds 232a/232b as a mixture of two
diastereoisomers (yellow oils, 80mg, 96% yield, no change in dr).
Compound 232a
1H NMR (400 MHz, CDCl3): δ 7.74 (dd, J = 8.0,1.5 Hz, 1H, C12−H), 7.56 (td, J = 8.0,1.5 Hz,
1H, C10−H), 7.40-7.34 (m, 2H, C9,11−H), 5.30 (d, J = 1.9 Hz, 1H, C21−H), 4.04 (t, J = 7.4 Hz,
1H, C7−H), 3.19-3.12 (m, 2H, C3−H), 3.11 (ddd, J = 9.7,9.6,6.1 Hz, 1H, C5−H), 3.04 (ddd, J =
9.7,9.6,6.1 Hz, 1H, C5−H), 2.47 (dq, J = 14.1,6.9 Hz, 1H, C6−H), 2.33 (ddt, J = 13.9,9.3,6.6 Hz,
1H, C6−H), 2.15 (ddd, J = 15.8,7.7,7.7 Hz, 1H, C16−H), 2.02 (ddd, J = 15.8,7.7,7.7 Hz, 1H,
C16−H), 1.73 (quint, J = 7.16 Hz, 2H, C14−H), 1.69-1.50 (m, 2H, C17−H), 1.42 (q, J = 7.8 Hz,
2H, C19−H), 1.41-1.34 (m, 2H, C15−H), 0.80 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 143.3 (C2), 136.2 (C8), 133.3 (C21), 132.8 (C10),
129.0 (C9), 127.6 (C11), 124.4 (C12), 52.0 (C20), 42.5 (C7), 40.3 (C15), 38.4 (C6), 33.7 (C16or17),
33.5 (C16or17), 32.3 (C19), 29.6 (C14), 9.1 (C18), 8.1 (C3), 2.8 (C5).
IR: 2933 (w), 2918 (w), 2848 (w), 1526 (s), 1458 (w), 1353 (m), 1230 (w), 1172 (w), 786 (w), 746
(w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H25I2NNaO2+: 575.9867; Found: 575.9861.
Rf (PE/EtOAc 8:2) = 0.42.
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Compound 232b
1H NMR (400 MHz, CDCl3): δ 7.74 (dd, J = 8.4,1.4 Hz, 1H, C12−H), 7.54 (td, J = 7.5,1.4 Hz,
1H, C10−H), 7.39-7.34 (m, 2H, C9,11−H), 5.30 (d, J = 1.7 Hz, 1H, C21−H), 4.06 (t, J = 7.4 Hz,
1H, C7−H), 3.16 (t, J = 6.6 Hz, 2H, C3−H), 3.10 (ddd, J = 9.5,9.4,6.1 Hz, 1H, C5−H), 3.03
(ddd, J = 9.5,9.4,6.1 Hz, 1H, C5−H), 2.46 (m, 1H, C6−H), 2.32 (m, 1H, C6−H), 2.14 (ddd, J =
15.8,7.7,7.4 Hz, 1H, C16−H), 2.02 (ddd, J = 15.8,7.7,7.4 Hz, 1H, C16−H), 1.79-1.65 (m, 2H,
C14−H), 1.60 (t, J = 7.4 Hz, 2H, C17−H), 1.46-1.33 (m, 2H, C15−H), 1.36 (q, J = 7.5 Hz, 2H,
C19−H), 0.80 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.8 (C
13), 143.2 (C2), 136.2 (C8), 133.6 (C21), 132.7 (C10),
128.9 (C9), 127.6 (C11), 124.4 (C12), 51.9 (C20), 42.5 (C7), 40.3 (C15), 38.3 (C6), 33.5 (C16or17),
33.4 (C16or17), 32.1 (C19), 29.4 (C14), 9.2 (C18), 8.1 (C3), 2.8 (C5).
IR: 2956 (w), 2932 (w), 2847 (w), 1525 (s), 1447 (w), 1353 (m), 1230 (w), 1170 (w), 909 (w), 855
(w), 783 (w), 733 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H25I2NNaO2+: 575.9867; Found: 575.9870.
Rf (PE/EtOAc 8:2) = 0.42.
N-(3-(-3-(-3-((tert-butyldimethylsilyl)oxy)-1-(2-nitrophenyl)propyl)-1-ethyl-
cyclopent-2-en-1-yl)propyl)-2-nitrobenzenesulfonamide 437
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To a solution of alcohols 213a/213b (dr 1:1, 60mg, 0.13mmol), neopentyl alcohol (5.8mg,
0.060mmol, 0.40 equiv), o-nitrophenylsulfonamide (53mg, 0.27mmol, 2.0 equiv) and PPh3
(35mg, 0.13mmol, 1.0 equiv) in toluene (4.0mL) at RT was added DEAD (40 wt.% in toluene,
60μL, 0.13mmol, 1.0 equiv). After stirring for 1h at RT, additional PPh3 (35mg, 0.13mmol,
1.0 equiv) and DEAD (40 wt.% in toluene, 60μL, 0.13mmol, 1.0 equiv) were added. The re-
action mixture was stirred for one more hour. Saturated aqueous NaHCO3 was added. The
mixture was extracted with EtOAc. The combined organic phases were washed with brine,
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dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded
the two diastereoisomers 437a and 437b as yellow oils (67mg, 81% yield, no change in dr).
Compound 437a
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
30−H), 7.84 (m, 1H, C27−H), 7.76-7.71 (m, 2H,
C28,29−H), 7.70 (d, J = 7.8 Hz, 1H, C12−H), 7.54 (t, J = 7.8 Hz, 1H, C10−H), 7.36 (d, J = 7.8 Hz,
1H, C9−H), 7.33 (t, J = 7.8 Hz, 1H, C11−H), 5.24 (t, J = 5.8 Hz, 1H, C4−H), 5.14 (d, J = 1.4 Hz,
1H, C21−H), 4.05 (t, J = 7.2 Hz, 1H, C7−H), 3.56-3.46 (m, 2H, C5−H), 3.07 (q, J = 6.6 Hz, 2H,
C3−H), 2.20-2.06 (m, 2H, C6,16−H), 2.02-1.88 (m, 2H, C6,16−H), 1.58 (m, 1H, C17−H), 1.46-
1.35 (m, 3H, C14,17−H), 1.32-1.23 (m, 4H, C15,19−H), 0.85 (s, 9H, C24−H), 0.73 (t, J = 7.4 Hz,
3H, C18−H), -0.02 (s, 6H, C22−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 148.3 (C26), 144.8 (C2), 137.6 (C8), 134.1 (C25),
133.6 (C28), 132.9 (C29), 132.5 (C10), 132.3 (C21), 131.2 (C30), 129.2 (C9), 127.2 (C11), 125.5 (C27),
124.1 (C12), 61.1 (C5), 51.8 (C20), 44.8 (C3), 37.5 (C7), 37.1 (C6), 36.2 (C15), 33.8 (C16), 33.4 (C17),
32.2 (C19), 26.1 (C24), 25.3 (C14), 18.4 (C23), 9.1 (C18), -5.3 (C22).
IR: 3353 (br w), 2950 (m), 2932 (m), 2856 (m), 1721 (w), 1529 (s), 1358 (s), 1256 (m), 1169 (s),
1100 (s), 836 (s), 781 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C31H46N3O7SSi+: 632.2820; Found: 632.2820.
Rf (PE/EtOAc 6:4) = 0.57.
Compound 437b
1H NMR (400 MHz, CDCl3): δ 8.14 (m, 1H, C
30−H), 7.86 (m, 1H, C27−H), 7.77-7.72 (m, 2H,
C28,29−H), 7.69 (dd, J = 7.9,1.1 Hz, 1H, C12−H), 7.51 (t, J = 7.9 Hz, 1H, C10−H), 7.36 (d, J =
7.9 Hz, 1H, C9−H), 7.32 (t, J = 7.9 Hz, 1H, C11−H), 5.26 (t, J = 6.0 Hz, 1H, C4−H), 5.16 (s, 1H,
C21−H), 4.13 (t, J = 7.3 Hz, 1H, C7−H), 3.54-3.46 (m, 2H, C5−H), 3.11-3.03 (m, 2H, C3−H),
2.08 (dq, J = 13.9,7.0 Hz, 1H, C6−H), 2.01 (t, J = 7.2 Hz, 2H, C16−H), 1.95 (dq, J = 14.0,7.0 Hz,
1H, C6−H), 1.53 (dd, J = 14.3,8.2 Hz, 1H, C17−H), 1.44 (dd, J = 14.3,7.6 Hz, 1H, C17−H), 1.42-
1.35 (m, 2H, C14−H), 1.31-1.22 (m, 4H, C15,19−H), 0.86 (s, 9H, C24−H), 0.73 (t, J = 7.4 Hz, 3H,
C18−H), 0.02 (s, 6H, C22−H).
13C NMR (101 MHz, CDCl3): δ 150.8 (C
13), 148.2 (C26), 144.4 (C2), 137.4 (C8), 134.1 (C25),
133.6 (C28), 132.9 (C21), 132.8 (C29), 132.3 (C10), 131.2 (C30), 129.0 (C9), 127.1 (C11), 125.5 (C27),
124.2 (C12), 61.1 (C5), 51.8 (C20), 44.8 (C3), 37.3 (C6), 36.6 (C15), 36.3 (C7), 33.3 (C16), 32.9 (C17),
32.2 (C19), 26.1 (C24), 25.2 (C14), 18.4 (C23), 9.2 (C18), -5.3 (C22).
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IR: 3329 (br w), 2953 (w), 2934 (w), 2856 (w), 1723 (s), 1528 (s), 1353 (s), 1249 (s), 1168 (s), 1097
(s), 1063 (s), 836 (s), 779 (s), 740 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C31H46N3O7SSi+: 632.2820; Found: 632.2806,.
Rf (PE/EtOAc 6:4) = 0.57.
N-(3-(-1-ethyl-3-(-3-hydroxy-1-(2-nitrophenyl)propyl)cyclopent-2-en-1-yl)-
propyl)-2-nitrobenzenesulfonamide 239
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To a solution of compounds 437a/437b (dr 1:1, 3.2 g, 5.0mmol) in MeOH (50mL) at 0 °C was
added dropwise acetyl chloride (30μL, 0.50mmol, 10mol%). After stirring for 1h at RT, the re-
action mixture was concentrated in vacuo. The crude compounds 239a/239b thus obtained
was used for the next step without further purification (2.6 g, quantitative yield, no change in
dr).
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To a solution of alcohols 213a/213b (dr 1:1, 60mg, 0.13mmol), neopentyl alcohol (5.8mg,
0.060mmol, 0.40 equiv), o-nitrophenylsulfonamide (53mg, 0.27mmol, 2.0 equiv) and PPh3
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(35mg, 0.13mmol, 1.0 equiv) in toluene (4.0mL) at RT was added DEAD (40 wt.% in toluene,
60μL, 0.13mmol, 1.0 equiv). After stirring for 1h at RT, additional PPh3 (35mg, 0.13mmol,
1.0 equiv) and DEAD (40 wt.% in toluene, 60μL, 0.13mmol, 1.0 equiv) were added. The reac-
tion mixture was stirred for one more hour. TBAF (1M solution in THF, 0.39mL, 0.39mmol,
3.0 equiv) was added and the reaction mixture was stirred at RT for 3h. Saturated aque-
ous NaHCO3 was added, and the mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/EtOAc 8:2) afforded the two diastereoisomers 239a and 239b as amixture (yellow
oil, 50mg, 75% yield, no change in dr).
Compound 239a
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
28−H), 7.85 (m, 1H, C25−H), 7.77-7.71 (m, 2H,
C26,27−H), 7.69 (d, J = 7.5 Hz, 1H, C12−H), 7.56 (t, J = 7.0 Hz, 1H, C10−H), 7.40-7.31 (m, 2H,
C9,11−H), 5.27 (br s, 1H, N4−H), 5.21 (s, 1H, C21−H), 4.05 (t, J = 6.9 Hz, 1H, C7−H), 3.61 (m,
1H, C5−H), 3.52 (m, 1H, C5−H), 3.07 (q, J = 6.4 Hz, 2H, C3−H), 2.21 (m, 1H, C6−H), 2.10 (m,
1H, C16−H), 2.04-1.88 (m, 2H, C6,16−H), 1.58 (m, 1H, C17−H), 1.47-1.36 (m, 3H, C14,17−H),
1.35-1.22 (m, 4H, C15,19−H), 0.73 (t, J = 7.4 Hz, 3H, C18−H), OH peak not observed.
13CNMR(101MHz,CDCl3): δ 150.9 (C
13), 148.2 (C24), 144.7 (C2), 137.1 (C8), 134.0 (C23), 133.7
(C26), 132.9 (C21), 132.7 (C27), 132.5 (C10), 131.2 (C28), 129.2 (C9), 127.4 (C11), 125.5 (C25), 124.0
(C12), 60.8 (C5), 51.8 (C20), 44.8 (C3), 37.5 (C7), 37.0 (C6), 36.2 (C15), 33.7 (C16), 33.4 (C17), 32.2
(C19), 25.4 (C14), 9.1 (C18).
IR: 3565 (br w), 3354 (br w), 2937 (w), 2852 (w), 1525 (m), 1352 (m), 1165 (m), 1051 (w), 909
(m), 730 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H31N3NaO7S+: 540.1775; Found: 540.1771.
Rf (PE/EtOAc 4:6) = 0.48.
Compound 239b
1H NMR (400 MHz, CDCl3): δ 8.14 (m, 1H, C
28−H), 7.87 (m, 1H, C25−H), 7.78-7.72 (m, 2H,
C26,27−H), 7.69 (dd, J = 8.0,1.6 Hz, 1H, C12−H), 7.52 (td, J = 7.6,1.6 Hz, 1H, C10−H), 7.38-
7.31 (m, 2H, C9,11−H), 5.28 (t, J = 6.2 Hz, 1H, N4−H), 5.22 (d, J = 1.8 Hz, 1H, C21−H), 4.07 (t,
J = 7.1 Hz, 1H, C7−H), 3.61 (m, 1H, C5−H), 3.52 (m, 1H, C5−H), 3.07 (q, J = 6.7 Hz, 2H, C3−H),
2.19 (m, 1H, C6−H), 2.02-1.91 (m, 3H, C6,16−H), 2.55-1.35 (m, 4H, C14,17−H), 1.35-1.23 (m, 4H,
C15,19−H), 0.74 (t, J = 7.5 Hz, 3H, C18−H), OH peak not observed.
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13CNMR(101MHz,CDCl3): δ 150.9 (C
13), 148.2 (C24), 144.5 (C2), 137.0 (C8), 134.1 (C23), 133.7
(C26), 132.9 (C21), 132.7 (C27), 132.6 (C10), 131.2 (C28), 129.2 (C9), 127.4 (C11), 125.5 (C25), 124.1
(C12), 60.8 (C5), 51.8 (C20), 44.7 (C3), 37.4 (C6), 36.8 (C15), 36.2 (C7), 33.4 (C16), 33.2 (C17), 32.2
(C19), 25.2 (C14), 9.1 (C18).
IR: 3566 (br w), 3341 (br w), 2935 (w), 2853 (w), 1526 (s), 1358 (s), 1166 (s), 1061 (w), 741 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H31N3NaO7S+: 540.1775; Found: 540.1786.
Rf (PE/EtOAc 4:6) = 0.48.
3-(3-ethyl-3-(3-((2-nitrophenyl)sulfonamido)propyl)cyclopent-1-en-1-yl)-3-(2-
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To a solution of alcohols 239a/239b (dr 1:1, 20mg, 0.040mmol) in DCM (1.0mL) at RT was
added triethylamine (8.0μL, 0.060mmol, 1.5 equiv) andMsCl (3.7μL, 0.050mmol, 1.2 equiv)
dropwise. The reaction mixture was stirred for 0.5h. Saturated aqueous NaHCO3 was added.
The mixture was extracted with EtOAc. The combined organic phases were washed with
brine, dried over Na2SO4 and concentrated in vacuo. The crude product thus obtained was
used for the next step without further purification (24mg, quantitative yield, no change in
dr). An analytical sample was obtained by FCC (PE/EtOAc 4:6) to afford 438a and 438b (yel-
low oils).
Compound 438a
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
28−H), 7.85 (m, 1H, C25−H), 7.77-7.71 (m, 3H,
C12,26,27−H), 7.59 (t, J = 7.8 Hz, 1H, C10−H), 7.39 (t, J = 7.8 Hz, 1H, C11−H), 7.36 (d, J = 7.8 Hz,
1H, C9−H), 5.32 (t, J = 6.4 Hz, 1H, N4−H), 5.26 (m, 1H, C21−H), 4.21 (dt, J = 9.9,6.5 Hz, 1H,
C5−H), 4.13 (dt, J = 9.9,6.5 Hz, 1H, C5−H), 4.09 (t, J = 7.4 Hz, 1H, C7−H), 3.07 (q, J = 6.4 Hz,
2H, C3−H), 2.99 (s, 3H, C22−H), 2.38 (dddd, J = 14.2,7.1,7.1,7.0 Hz, 1H, C6−H), 2.22 (dddd,
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J = 14.2,7.1,7.1,7.0 Hz, 1H, C6−H), 2.10 (m, 1H, C16−H), 1.96 (m, 1H, C16−H), 1.64-1.54 (m,
2H, C17−H), 1.49-1.40 (m, 2H, C14−H), 1.35-1.27 (m, 4H, C15,19−H), 0.74 (t, J = 7.3 Hz, 3H,
C18−H).
13C NMR (101 MHz, CDCl3): δ 150.6 (C
13), 148.2 (C24), 143.3 (C2), 136.0 (C8), 134.0 (C23),
133.7 (C26), 133.6 (C21), 133.0 (C10or27), 132.9 (C10or27), 131.2 (C28), 129.0 (C9), 127.9 (C11),
125.5 (C25), 124.4 (C12), 67.5 (C5), 51.9 (C20), 44.7 (C3), 37.6 (C22), 37.5 (C7), 36.0 (C15), 33.4
(C6), 33.4 (C16), 33.4 (C17), 32.1 (C19), 25.4 (C14), 9.1 (C18).
IR: 3343 (br w), 2930 (w), 2853 (w), 1529 (s), 1355 (s), 1172 (s), 976 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C26H34N3O9S2+: 596.1731; Found: 596.1722.
Rf (PE/EtOAc 6:4) = 0.48.
Compound 438b
1H NMR (400 MHz, CDCl3): δ 8.14 (m, 1H, C
28−H), 7.86 (m, 1H, C25−H), 7.78-7.71 (m, 3H,
C12,26,27−H), 7.55 (t, J = 7.7 Hz, 1H, C10−H), 7.41-7.34 (m, 2H, C9,11−H), 5.35 (t, J = 5.7 Hz,
1H, N4−H), 5.28 (s, 1H, C21−H), 4.23 (dt, J = 10.0,7.0 Hz, 1H, C5−H), 4.15 (dt, J = 10.0,7.0 Hz,
1H, C5−H), 4.06 (t, J = 7.4 Hz, 1H, C7−H), 3.11-3.04 (m, 2H, C3−H), 3.00 (s, 3H, C22−H), 2.35
(m, 1H, C6−H), 2.22 (m, 1H, C6−H), 2.09-1.94 (m, 2H, C16−H), 1.55-1.48 (m, 2H, C17−H), 1.47-
1.39 (m, 2H, C14−H), 1.36-1.28 (m, 4H, C15,19−H), 0.76 (t, J = 7.4 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 150.5 (C
13), 148.2 (C24), 143.2 (C2), 136.2 (C8), 134.0 (C23),
133.6 (C26), 133.5 (C21), 132.9 (C27), 132.9 (C10), 131.2 (C28), 128.9 (C9), 127.8 (C11), 125.5 (C25),
124.5 (C12), 67.6 (C5), 52.0 (C20), 44.7 (C3), 37.6 (C22), 37.4 (C7), 36.2 (C15), 33.6 (C6), 33.6 (C16),
33.2 (C17), 32.2 (C19), 25.3 (C14), 9.2 (C18),
IR: 3329 (br w), 2938 (w), 2852 (w), 1528 (s), 1353 (s), 1171 (s), 970 (w), 921 (w), 786 (w), 743
(w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C26H33N3NaO9S2+: 618.1550; Found: 618.1541.
Rf (PE/EtOAc 6:4) = 0.48.
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1-ethyl-8-(2-nitrophenyl)-5-((2-nitrophenyl)sulfonyl)-5-azabicyclo[7.2.1]dodec-
9(12)-ene 212
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To a solution of alcohols 239a/239b (dr 1:1, 68mg, 0.13mmol), neopentyl alcohol (5.8mg,
0.060mmol, 0.40 equiv) and PPh3 (35mg, 0.13mmol, 1.0 equiv) in toluene (4.5mL) at RT was
added DEAD (40 wt.% in toluene, 60μL, 0.13mmol, 1.0 equiv). After stirring for 1h at RT, ad-
ditional PPh3 (35mg, 0.13mmol, 1.0 equiv) and DEAD (40 wt.% in toluene, 60μL, 0.13mmol,
1.0 equiv) were added. The reaction mixture was stirred for one more hour. Saturated aque-
ous NaHCO3 was added. The mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/EtOAc 8:2) afforded the two diastereoisomers 212a and 212b as yellow prism and
yellow oil, respectively (53mg, 81% yield, no change in dr).
Compound 212a
mp= 188.6-189 °C (CHCl3 / C7H16).
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.4,2.0 Hz, 1H, C27−H), 7.74-7.65 (m, 3H,
C12,25,26−H), 7.59 (dd, J = 7.3,1.9 Hz, 1H, C24−H), 7.55 (td, J = 7.7,1.3 Hz, 1H, C10−H),
7.47 (dd, J = 7.7,1.4 Hz, 1H, C9−H), 7.35 (td, J = 7.7,1.4 Hz, 1H, C11−H), 5.47 (s, 1H,
C21−H), 4.33 (dd, J = 12.3,3.2 Hz, 1H, C7−H), 4.03 (dd, J = 15.6,7.2 Hz, 1H, C5−H), 3.73
(ddd, J = 15.3,10.3,4.9 Hz, 1H, C3−H), 2.80 (dd, J = 15.6,8.6 Hz, 1H, C5−H), 2.72 (ddd,
J = 15.0,6.7,2.4 Hz, 1H, C3−H), 2.68-2.54 (m, 2H, C6,16−H), 2.13 (ddd, J = 14.5,7.2,3.2 Hz,
1H, C6−H), 2.03 (m, 1H, C14−H), 1.82-1.63 (m, 3H, C16,17−H), 1.53 (dd, J = 14.6,6.7 Hz, 1H,
C15−H), 1.42-1.20 (m, 4H, C14,15,19−H), 0.75 (t, J = 7.5 Hz, 3H, C18−H).
13CNMR(101MHz,CDCl3): δ 150.3 (C
13), 149.1 (C23), 141.9 (C2), 136.2 (C21), 136.1 (C8), 133.7
(C25), 132.3 (C10), 131.4 (C26), 131.2 (C22), 130.6 (C27), 128.6 (C9), 127.2 (C11), 124.4 (C12), 124.1
(C24), 56.6 (C3), 54.8 (C5), 53.5 (C20), 43.0 (C7), 40.3 (C15), 35.7 (C6), 33.9 (C19), 32.6 (C17), 31.4
(C16), 28.2 (C14), 9.4 (C18).
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IR: 2960 (w), 2934 (w), 2849 (w), 1544 (s), 1529 (s), 1465 (w), 1355 (s), 1164 (m), 784 (m), 755
(m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H30N3O6S+: 500.1850; Found: 500.1860.
Rf (PE/EtOAc 4:6) = 0.59.
Compound 212b
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.5,1.9 Hz, 1H, C27−H), 7.78 (dd, J = 7.8,1.4 Hz,
1H, C12−H), 7.70 (td, J = 7.5,1.9 Hz, 1H, C25−H), 7.66 (td, J = 7.5,1.8 Hz, 1H, C26−H), 7.60 (dd,
J = 7.8,1.5 Hz, 1H, C9−H), 7.57 (dd, J = 7.5,1.8 Hz, 1H, C24−H), 7.54 (td, J = 7.8,1.4 Hz, 1H,
C10−H), 7.35 (td, J = 7.8,1.5 Hz, 1H, C11−H), 5.63 (s, 1H, C21−H), 3.85 (dd, J = 11.5,3.4 Hz,
1H, C7−H), 3.54 (ddd, J = 15.4,7.5,2.1 Hz, 1H, C5−H), 3.27 (m, 1H, C3−H), 3.07 (m, 1H,
C3−H), 2.94 (ddd, J = 15.4,7.2,2.6 Hz, 1H, C5−H), 2.54 (dddd, J = 15.2,11.4,7.2,2.1 Hz, 1H,
C6−H), 2.44-2.36 (m, 2H, C16−H), 2.17 (ddt, J = 15.3,7.9,3.3 Hz, 1H, C6−H), 1.80-1.63 (m, 3H,
C14,15,17−H), 1.58 (ddd, J = 13.6,8.4,3.7 Hz, 1H, C17−H), 1.53-1.43 (m, 2H, C19−H), 1.42-1.38
(m, 2H, C14,15−H), 0.85 (t, J = 7.5 Hz, 3H, C18−H).
13CNMR(101MHz,CDCl3): δ 149.7 (C
13), 149.0 (C23), 140.7 (C2), 137.6 (C21), 137.4 (C8), 133.7
(C25), 132.9 (C10), 131.4 (C26), 131.2 (C22), 131.0 (C27), 129.6 (C9), 127.4 (C11), 124.5 (C12), 124.0
(C24), 54.5 (C20), 52.5 (C3), 48.7 (C5), 42.1 (C7), 39.2 (C16), 38.3 (C15), 35.6 (C6), 33.3 (C19), 32.1
(C17), 22.3 (C14), 9.8 (C18).
IR: 2958 (w), 2932 (w), 2850 (w), 1545 (s), 1526 (s), 1462 (w), 1354 (s), 1165 (m), 782 (m), 734
(m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H30N3O6S+: 500.1850; Found: 500.1843.
Rf (PE/EtOAc 4:6) = 0.59.
168
8.3. Experimental Procedures of Chapter 3
5-ethyl-9-(2-nitrophenyl)-1-((2-nitrophenyl)sulfonyl)-8-oxoazacycloundecane-5-
carbaldehyde 211
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A solution of the macrocycle 212 (dr 1:1, 10mg, 0.020mmol) in DCM (0.50mL) was stirred
at -78 °C. Ozone was bubbled through the solution until a blue color appears (approximately
15 s). Argon was then bubbled through the solution for 10min. Me2S (0.10mL) was added
and the reaction mixture was stirred overnight at RT. The reaction mixture was concentrated
in vacuo. Purification by FCC (PE/EtOAc 4:6) afforded the compound 211 as a yellow oil
(8.6mg, 81% yield, no change in dr).
Compound 211a
1H NMR (400MHz, CDCl3): δ 9.45 (s, 1H, C
21−H), 7.89 (dd, J = 7.7,1.4 Hz, 1H, C12−H), 7.83
(dd, J = 8.1,0.9 Hz, 1H, C27−H), 7.71 (td, J = 7.5,1.5 Hz, 1H, C25−H), 7.67 (td, J = 7.5,1.6 Hz,
1H, C26−H), 7.55 (dd, J = 7.6,1.5 Hz, 1H, C24−H), 7.50 (td, J = 7.7,1.4 Hz, 1H, C10−H), 7.41 (td,
J = 7.7,1.0 Hz, 1H, C11−H), 7.22 (dd, J = 7.7,1.0 Hz, 1H, C9−H), 5.25 (dd, J = 11.4,2.1 Hz, 1H,
C7−H), 3.70-3.54 (m, 1H, C3−H), 3.27 (dd, J = 15.1,5.5 Hz, 1H, C5−H), 3.12 (m, 1H, C5−H),
2.82 (dt, J = 13.1,2.6 Hz, 1H, C3−H), 2.69 (m, 1H, C16−H), 2.29 (m, 1H, C6−H), 2.14 (m,
1H, C6−H), 2.04-1.92 (m, 3H, C15,17−H), 1.88 (m, 1H, C16−H), 1.71 (td, J = 13.7,5.9 Hz, 1H,
C17−H), 1.63-1.43 (m, 2H, C19−H), 0.95-0.70 (m, 2H, C14−H), 0.79 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 211.6 (C
2), 206.0 (C21), 150.5 (C13), 149.2 (C23), 134.0 (C10),
132.9 (C25), 131.8 (C8), 131.5 (C26or27), 131.4 (C26or27), 130.1 (C22), 130.0 (C9), 128.7 (C11), 125.3
(C12), 124.0 (C24), 53.0 (C20), 51.5 (C3), 49.3 (C7), 46.0 (C5), 36.9 (C16), 32.1 (C6), 27.9 (C15), 27.4
(C19), 25.4 (C17), 20.5 (C14), 8.6 (C18).
IR: 2961 (w), 2878 (w), 1711 (m), 1545 (s), 1529 (s), 1465 (w), 1373 (s), 1354 (s), 1171 (m), 785
(m), 745 (m), 731 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H30N3O8S+: 532.1748; Found: 532.1754.
Rf (PE/EtOAc 4:6) = 0.47.
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Compound 211b
1H NMR (400MHz, CDCl3): δ 9.41 (s, 1H, C
21−H), 7.86 (dd, J = 7.8,1.4 Hz, 1H, C12−H), 7.85
(dd, J = 7.7,1.3 Hz, 1H, C27−H), 7.69 (td, J = 7.7,1.3 Hz, 1H, C25−H), 7.65 (td, J = 7.7,1.4 Hz,
1H, C26−H), 7.54 (dd, J = 7.7,1.4 Hz, 1H, C24−H), 7.53 (td, J = 7.8,1.3 Hz, 1H, C10−H), 7.43
(td, J = 7.8,1.0 Hz, 1H, C11−H), 7.22 (dd, J = 7.8,1.0 Hz, 1H, C9−H), 5.31 (dd, J = 11.5,1.9 Hz,
1H, C7−H), 3.61 (td, J = 13.1,3.1 Hz, 1H, C3−H), 3.26 (dd, J = 15.0,5.3 Hz, 1H, C5−H), 3.06
(ddd, J = 15.2,12.5,4.8 Hz, 1H, C5−H), 2.87 (dd, J = 14.7,10.9 Hz, 1H, C16−H), 2.71 (dt, J =
13.3,2.7 Hz, 1H, C3−H), 2.26 (m, 2H, C6,17−H), 2.12 (m, 1H, C6−H), 2.00 (dd, J = 14.7,10.3 Hz,
1H, C16−H), 1.92-1.70 (m, 3H, C15,17−H), 1.77 (q, J = 7.7 Hz, 2H, C19−H), 1.31-1.12 (m, 2H,
C14−H), 0.76 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 212.7 (C
2), 205.9 (C21), 150.5 (C13), 149.1 (C23), 134.0 (C10),
133.0 (C25), 131.8 (C8), 131.3 (C26or27), 131.3 (C26or27), 130.0 (C22), 129.8 (C9), 128.7 (C11), 125.3
(C12), 124.0 (C24), 53.0 (C20), 51.4 (C3), 48.9 (C7), 46.0 (C5), 34.4 (C16), 32.3 (C6), 30.5 (C15), 27.3
(C19), 23.3 (C17), 21.7 (C14), 8.7 (C18).
IR: 2963 (w), 2932 (w), 2878 (w), 1713 (m), 1544 (s), 1528 (s), 1465 (w), 1352 (s), 1168 (m), 912
(w), 852 (w), 782 (m), 733 (m), 674 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H30N3O8S+: 532.1748; Found: 532.1754.
Rf (PE/EtOAc 4:6) = 0.47.
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A solution of the macrocycles 212a/212b (dr 1:1, 10mg, 0.020mmol) in DCM (0.50mL) was
stirred at -78 °C. Ozone was bubbled through the solution until a blue color appeared (ap-
proximately 15 s). Argon was then bubbled through the solution for 10min. Me2S (50μL)
was added and the reaction mixture was stirred overnight at RT. Cesium carbonate (20mg,
0.060mmol, 3.0 equiv) and thiophenol (6.0μL, 0.060mmol, 3.0 equiv) were added. The re-
action mixture was stirred at RT for 24h. Methanol (0.20mL) was then added, followed by
aqueous NH4OAc (2.5M solution in H2O, 0.30mL). A mixture of TiCl3 (20% in aqueous 3%
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HCl, 60μL, 0.10mmol, 5.0 equiv) and aqueous NH4OAc (2.5M solution in H2O, 0.3.0mL)
was then added dropwise. The dark purple solution was stirred at RT for 30min. The re-
action mixture was then poured into saturated aqueous NaHCO3. The mixture turned black.
EtOAc was added and, after vigorous shaking, the mixture turned to white. The layers were
separated and the aqueous phase was extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by
FCC (PE/EtOAc/Et3N 90:10:2) afforded (±)-1,2-dehydroaspidospermidine 2 as a colorless oil
(2.8mg, 50% yield, single diastereoisomer). The spectroscopic data of this compound were
in accord with those reported in the literature.66
1H NMR (400MHz, CDCl3): δ 7.51 (d, J = 7.3 Hz, 1H, C12−H), 7.33 (d, J = 7.3 Hz, 1H, C9−H),
7.29 (td, J = 7.3,1.3 Hz, 1H, C11−H), 7.16 (td, J = 7.3,1.0 Hz, 1H, C10−H), 3.18 (t, J = 7.5 Hz,
2H, C3,5−H), 3.11 (ddd, J = 14.4,11.8,5.3 Hz, 1H, C16−H), 2.76 (ddd, J = 14.4,10.5,3.6 Hz,
1H, C16−H), 2.59 (ddd, J = 11.5,8.4,5.7 Hz, 1H, C5−H), 2.46 (td, J = 12.8,3.3 Hz, 1H, C17−H),
2.40 (s, 1H, C21−H), 2.14-2.06 (m, 2H, C3,6−H), 1.85 (qt, J = 13.4,4.7 Hz, 1H, C14−H), 1.65
(dd, J = 12.2,5.4 Hz, 1H, C6−H), 1.61-1.52 (m, 2H, C14,17−H), 1.47 (dd, J = 13.7,2.7 Hz, 1H,
C15−H), 1.00 (td, J = 13.6,5.0 Hz, 1H, C15−H), 0.70 (dq, J = 14.5,7.4 Hz, 1H, C19−H), 0.64 (dq,
J = 14.5,7.4 Hz, 1H, C19−H), 0.49 (t, J = 7.4 Hz, 3H, C18−H).
13CNMR(101MHz,CDCl3): δ 192.5 (C
2), 154.7 (C13), 147.3 (C8), 127.6 (C11), 125.3 (C10), 121.1
(C9), 120.3 (C12), 79.2 (C21), 61.5 (C7), 54.7 (C5), 52.2 (C3), 36.7 (C20), 35.3 (C6), 33.4 (C15), 29.9
(C19), 27.4 (C17), 23.9 (C16), 22.2 (C14), 7.4 (C18).
IR: 2933 (m), 2773 (m), 1575 (m), 1456 (m), 1324 (w), 1251 (w), 1194 (w), 1123 (w), 1014 (w),
751 (w), 615 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H25N2+: 281.2012; Found: 281.2008.
Rf (PE/EtOAc/Et3N 4:4:0.5) = 0.54 (red to blue with molybdenate stain).
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A solution of the macrocycles 212a/212b (dr 1:1, 10mg, 0.020mmol) in DCM (0.50mL) was
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stirred at -78 °C. Ozone was bubbled through the solution until a blue color appeared (ap-
proximately 15 s). Argon was then bubbled through the solution for 10min. Me2S (0.050mL)
was added and the reaction mixture was stirred overnight at RT. Cesium carbonate (20mg,
0.060mmol, 3.0 equiv) and thiophenol (6.0μL, 0.060mmol, 3.0 equiv) were added. The re-
action mixture was stirred at RT for 24h. Methanol (0.20mL) was then added, followed by
aqueous NH4OAc (2.5M solution in H2O, 0.30mL). A mixture of TiCl3 (20% in aqueous 3%
HCl, 60μL, 0.10mmol, 5.0 equiv) and aqueous NH4OAc (2.5M solution in H2O, 0.30mL) was
then added dropwise. The dark purple solution was stirred at RT for 30min. Saturated aque-
ous NaHCO3 (1.0mL) was then added. The mixture turned black, and after vigorous stirring
for 15min, themixture turned towhite. NaBH4 (7.6mg, 0.20mmol, 10 equiv) was then added,
and themixturewas stirred for 2h. EtOAcwas added. The layerswere separated and the aque-
ous phase was extracted with EtOAc. The combined organic phases were washed with brine,
dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc/Et3N 90:10:2)
afforded (±)-aspidospermidine 3 as a colorless oil (2.9mg, 51% yield, single diastereoiso-
mer). The spectroscopic data of this compound were in accord with those reported in the
literature.70
1H NMR (800 MHz, CDCl3): δ 7.08 (d, J = 7.5 Hz, 1H, C9−H), 7.02 (td, J = 7.6,1.0 Hz, 1H,
C11−H), 6.73 (td, J = 7.2,0.7 Hz, 1H, C10−H), 6.64 (d, J = 7.8 Hz, 1H, C12−H), 3.51 (dd, J =
11.1,6.2 Hz, 1H, C2−H), 3.12 (td, J = 8.9,2.7 Hz, 1H, C5−H), 3.06 (m, 1H, C3−H), 2.29 (dt,
J = 13.0,8.6 Hz, 1H, C6−H), 2.24 (dt, J = 10.1,8.6 Hz, 1H, C5−H), 2.21 (s, 1H, C21−H), 2.01-
1.90 (m, 2H, C3,16−H), 1.74 (qt, J = 13.1,3.9 Hz, 1H, C14−H), 1.66-1.61 (m, 2H, C15,17−H), 1.51
(m, 1H, C14−H), 1.50-1.45 (m, 2H, C6,19−H), 1.39 (dt, J = 13.9,2.7 Hz, 1H, C17−H), 1.11 (td,
J = 13.4,4.8 Hz, 1H, C15−H), 1.05 (dt, J = 13.7,2.9 Hz, 1H, C16−H), 0.87 (dq, J = 14.4,7.9 Hz,
1H, C19−H), 0.63 (t, J = 7.5 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 149.5 (C
13), 135.9 (C8), 127.2 (C11), 123.0 (C9), 119.1 (C10),
110.5 (C12), 71.4 (C21), 65.8 (C2), 54.0 (C3), 53.5 (C7), 53.2 (C5), 39.0 (C6), 35.8 (C20), 34.6 (C15),
30.1 (C19), 28.2 (C17), 23.2 (C16), 21.9 (C14), 7.0 (C18).
IR: 3361 (w), 2930 (m), 2778 (w), 2772 (w), 1729 (w), 1607 (w), 1481 (m), 1462 (m), 1332 (w),
1259 (m), 1179 (w), 1024 (m), 905 (w), 737 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H27N2+: 283.2169; Found: 283.2107.
Rf (PE/EtOAc/Et3N 4:4:0.5) = 0.25 (red to blue with molybdenate stain).
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To a solution of (±)-1,2-dehydroaspidospermidine 2 (10mg, 0.036mmol) in THF (0.50mL)
at -78 °C was added dropwise n-BuLi (1.1M in THF, 36μL, 0.036mmol, 1.0 equiv). The
solution was stirred for 30min. Methyl cyanoformate (4.5μL, 0.058mmol, 1.6 equiv) was
added dropwise. The reaction mixture was stirred at -78 °C for 30min, and allowed to
warm to 0 °C. The reaction was monitored by TLC. After complete consumption of the start-
ing material, saturated aqueous NaHCO3 was added slowly, and the reaction mixture was
warmed up to RT. The mixture was extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/Et2O/Et3N 80:10:2) afforded (±)-vincadifformine 4 as a colorless oil (6.0mg, 50% yield,
single diastereoisomer). The spectroscopic data of this compound were in accord with those
reported in the literature.70
1H NMR (400 MHz, CDCl3): δ 8.89 (s, 1H, N
1−H), 7.18 (d, J = 7.6 Hz, 1H, C9−H), 7.12 (t,
J = 7.1 Hz, 1H, C11−H), 6.85 (t, J = 7.4 Hz, 1H, C10−H), 6.79 (d, J = 7.6 Hz, 1H, C12−H), 3.76
(s, 3H, C23−H), 3.12 (m, 1H, C3−H), 2.92 (t, J = 7.4 Hz, 1H, C5−H), 2.72 (d, J = 15.1 Hz,
1H, C17−H), 2.55 (ddd, J = 11.4,8.2,4.6 Hz, 1H, C5−H), 2.45 (d, J = 0.9 Hz, 1H, C21−H),
2.40 (td, J = 10.7,3.0 Hz, 1H, C3−H), 2.27 (dd, J = 15.2,1.6 Hz, 1H, C17−H), 2.05 (ddd,
J = 11.3,11.3,6.5 Hz, 1H, C6−H), 1.88-1.76 (m, 2H, C14−H), 1.70 (dd, J = 11.5,4.8 Hz, 1H,
C6−H), 1.21 (m, 1H, C15−H), 0.96 (m, 1H, C19−H), 0.88 (m, 1H, C15−H), 0.62 (m, 1H, C19−H),
0.57 (t, J = 7.0 Hz, 3H, C18−H).
13C NMR (101 MHz, CDCl3): δ 169.4 (C
22), 168.0 (C2), 143.5 (C13), 138.1 (C8), 127.6 (C11),
121.1 (C9), 120.6 (C10), 109.5 (C12), 92.8 (C16), 72.9 (C21), 55.16 (C7), 51.9 (C3), 51.1 (C5), 50.9
(C23), 45.4 (C6), 38.4 (C20), 33.0 (C15), 29.4 (C19), 25.6 (C17), 22.3 (C14), 7.3 (C18).
IR: 3378 (br m), 2927 (s), 2854 (m), 2776 (w), 1736 (w), 1676 (s), 1609 (s), 1464 (w), 1437 (w),
1252 (m), 1159 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C21H27N2O2+: 339.2067; Found: 339.2063.
Rf (PE/Et2O/Et3N 8:2:0.5) = 0.4 (red to blue with molybdenate stain).
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8.4 Experimental Procedures of Chapter 4
3-vinyl-3-(3-((triethylsilyl)oxy)propyl)cyclopent-1-en-1-yl trifluoromethane-
sulfonate 295
O
O Si
2 3
4
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O Si
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vinylmagnesium bromide
CuBr·Me2S
THF, -40 °C
then Comins' reagent, RT
76%
11 12
SO O
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219 295
To a suspention of CuBr·Me2S (5.7 g, 28mmol, 2.0 equiv) in THF (85mL) at -78 °C was added
dropwise vinylmagnesium bromide (0.8M in THF, 69mL, 55mmol, 4.0 equiv). The reaction
mixturewas stirred at -78 °C for 1h and thenwarmed to -40 °C. To the above prepared cuprate
solution was added dropwise a solution of the ketone 219 (3.5 g, 14mmol) in THF (30mL)
while keeping the solution below -40 °C. The reaction mixture was stirred at -40 °C for 3h. A
solution of Comins’ reagent (11g, 28mmol, 2.0 equiv) in THF (30mL) was added to the reac-
tion mixture. The reaction mixture was allowed to warm to RT, and stirred for 24h. The reac-
tion was quenched with NH4Cl. The reaction mixture was diluted with water and extracted
with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and
concentrated in vacuo. Purification by FCC (PE/EtOAc 20:1) afforded compound 295 as a
colorless oil (4.2 g, 73% yield).
1H NMR (400 MHz, CDCl3): δ 5.73 (dd, J = 17.5,10.8 Hz, 1H, C7−H), 5.55 (t, J = 1.6 Hz, 1H,
C3−H), 5.01 (dd, J = 10.8,1.9 Hz, 1H, C8a−H), 4.96 (dd, J = 17.5,1.9 Hz, 1H, C8b−H), 3.58 (t,
J = 5.8 Hz, 2H, C11−H), 2.68-2.50 (m, 2H, C6−H), 1.99-1.85 (m, 2H, C5−H), 1.59-1.42 (m, 4H,
C9,10−H), 0.95 (t, J = 7.8 Hz, 9H, C13−H), 0.59 (q, J = 7.8 Hz, 6H, C12−H).
13C NMR (101 MHz, CDCl3): δ 149.1 (C
2), 143.8 (C7), 122.7 (C3), 118.4 (q, J = 338.0 Hz, C1),
112.7 (C8), 63.1 (C11), 51.4 (C4), 36.6 (C9), 34.0 (C5), 30.3 (C6), 28.4 (C10), 6.9 (C13), 4.5 (C12).
IR: 2954 (m), 2910 (w), 2878 (w), 1661 (w), 1425 (m), 1221 (s), 11.42 (m), 1097 (m), 1006 (w),
914 (m), 839 (w), 741 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C17H29F3NaO4SSi+: 437.1400; Found: 437.1400.
Rf (PE/EtOAc 10:1) = 0.88
174
8.4. Experimental Procedures of Chapter 4
3-(-3-(-3-((tert-butyldimethylsilyl)oxy)-1-(2-nitrophenyl)propyl)-1-
vinylcyclopent-2-en-1-yl)propan-1-ol 294
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An oven-dried flask was charged with salt 215 (10 g, 27mmol, 1.2 equiv), X-Phos (1.6 g,
3.3mmol, 15mol%), allylpalladium chloride dimer (0.20g, 0.55mmol, 5.0mol%) and flushed
with nitrogen. Degassed and dry diglyme (150mL) was added, and the reaction mixture was
stirred for 5 minutes. A solution of the vinyl triflate 295 (9.0 g, 22mmol) in diglyme (150mL)
was added, and the reaction mixture was heated at 100 °C for 2h. The reaction mixture was
cooled down to 0 °C, and TBAF (1M solution in THF, 24mL, 24mmol, 1.1 equiv) was added
dropwise. The reaction was monitored by TLC until total conversion. Saturated aqueous
NaHCO3 was added. The mixture was extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. The two diastereoiso-
mers were separated by FCC (PE/EtOAc 8:2), giving 294a and 294b as yellow oils (5.7 g, 58%
yield, dr 1:1).
Compound 294a
1H NMR (400 MHz, CDCl3): δ 7.70 (dd, J = 7.8,1.2 Hz, 1H, C12−H), 7.51 (td, J = 7.8,1.2 Hz,
1H, C10−H), 7.38 (dd, J = 7.8,1.2 Hz, 1H, C9−H), 7.32 (td, J = 7.8,1.2 Hz, 1H, C11−H), 5.83
(dd, J = 17.5,10.1 Hz, 1H, C19−H), 5.40 (m, 1H, C21−H), 4.92 (dd, J = 10.1,1.6 Hz, 1H, C18−H),
4.91 (dd, J = 17.5,1.6 Hz, 1H, C18−H), 4.17 (t, J = 7.4 Hz, 1H, C7−H), 3.65-3.59 (m, 2H, C3−H),
3.51-3.50 (m, 2H, C5−H), 2.19-2.03 (m, 3H, C6,15−H), 1.97 (m, 1H, C6−H), 1.80-1.67 (m, 2H,
C17−H), 1.54-1.46 (m, 4H, C14,16−H), 0.86 (s, 9H, C3’−H), -0.09 (s, 6H, C1’−H), OH peak not
observed.
13C NMR (101 MHz, CDCl3): δ 150.8 (C
13), 145.5 (C19), 145.2 (C2), 137.4 (C8), 132.4 (C10),
131.2 (C21), 129.1 (C9), 127.1 (C11), 124.2 (C12), 111.2 (C18), 63.7 (C3), 61.1 (C5), 54.5 (C20), 37.4
(C7), 36.9 (C6), 36.2 (C15), 35.8 (C17), 32.6 (C16), 28.7 (C14), 26.1 (C3’), 18.4 (C2’), -5.3 (C1’).
IR: 3354 (br w), 2931 (m), 2856 (w), 1528 (s), 1357 (m), 1255 (m), 1101 (s), 1061 (m), 836 (s),
777 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H39NNaO4Si+: 468.2541; Found: 468.2549.
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Rf (PE/EtOAc 6:4) = 0.60
Compound 294b
1H NMR (400 MHz, CDCl3): δ 7.71 (dd, J = 7.8,1.5 Hz, 1H, C12−H), 7.51 (td, J = 7.8,1.5 Hz,
1H, C10−H), 7.39 (dd, J = 7.8,1.5 Hz, 1H, C9−H), 7.33 (td, J = 7.8,1.5 Hz, 1H, C11−H), 5.83
(dd, J = 14.0,10.7 Hz, 1H, C19−H), 5.40 (m, 1H, C21−H), 4.93 (dd, J = 14.0,1.3 Hz, 1H, C18−H),
4.89 (dd, J = 10.7,1.3 Hz, 1H, C18−H), 4.12 (t, J = 7.4 Hz, 1H, C7−H), 3.64-3.59 (m, 2H, C3−H),
3.57-3.50 (m, 2H,C5−H), 2.25-2.12 (m, 2H,C6,15−H), 2.06 (m, 1H,C15−H), 1.97 (m, 1H,C6−H),
1.84-1.78 (m, 2H, C17−H and C3−OH), 1.68 (m, 1H, C17−H), 1.55-1.45 (m, 4H, C14,16−H), 0.85
(s, 9H, C3’−H), -0.02 (s, 6H, C1’−H).
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 145.6 (C2), 145.3 (C19), 137.6 (C8), 132.4 (C10),
131.0 (C21), 129.2 (C9), 127.1 (C11), 124.2 (C12), 111.4 (C18), 64.0 (C3), 61.1 (C5), 54.6 (C20), 37.6
(C7), 37.2 (C6), 36.2 (C15), 35.9 (C17), 33.0 (C16), 28.7 (C14), 26.1 (C3’), 18.4 (C2’), -5.3 (C1’).
IR: 3352 (br w), 2929 (m), 2857 (w), 1528 (s), 1358 (m), 1255 (m), 1102 (s), 1062 (m), 835 (s),
778 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H39NNaO4Si+: 468.2541; Found: 468.2544.
Rf (PE/EtOAc 6:4) = 0.48
N-(3-(3-(3-((tert-butyldimethylsilyl)oxy)-1-(2-nitrophenyl)propyl)-1-
vinylcyclopent-2-en-1-yl)propyl)-2-nitrobenzenesulfonamide 439
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To a solution of alcohols 294a/294b (dr 1:1, 6.0 g, 13mmol), neopentyl alcohol (0.58 g,
6.0mmol, 0.40 equiv), o-nitrophenylsulfonamide (5.3 g, 27mmol, 2.0 equiv) and PPh3 (3.5 g,
13mmol, 1.0 equiv) in toluene (400mL) at RT was added DEAD (40 wt.% in toluene, 6.0mL,
13mmol, 1.0 equiv). After stirring for 1h at RT, additional PPh3 (3.5 g, 13mmol, 1.0 equiv) and
DEAD (40 wt.% in toluene, 6.0mL, 13mmol, 1.0 equiv) were added. The reactionmixture was
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stirred for onemore hour. Saturated aqueousNaHCO3 was added. Themixturewas extracted
with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and
concentrated in vacuo. Purification by FCC (DCM) afforded the two diastereoisomers 439a
and 439b as yellow oils (6.3 g, 77% yield, no change in dr).
Compound 439a
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
30−H), 7.85 (m, 1H, C27−H), 7.76-7.69 (m, 3H,
C12,28,29−H), 7.54 (td, J = 7.5,1.6 Hz, 1H, C10−H), 7.37 (d, J = 7.5 Hz, 1H, C9−H), 7.34 (t, J =
7.5 Hz, 1H, C11−H), 5.72 (dd, J = 17.2,10.5 Hz, 1H, C19−H), 5.28-5.22 (m, 2H, C4,21−H), 4.88
(dd, J = 10.5,1.4 Hz, 1H, C18−H), 4.84 (dd, J = 17.2,1.4 Hz, 1H, C18−H), 4.09 (t, J = 7.3 Hz, 1H,
C7−H), 3.75-3.45 (m, 2H, C5−H), 3.10-3.04 (m, 2H, C3−H), 2.23-2.09 (m, 2H, C6,17−H), 2.05-
1.91 (m, 2H, C6,17−H), 1.75 (ddd, J = 13.1,9.2,5.0 Hz, 1H, C16−H), 1.60-1.50 (m, 1H, C16−H),
1.49-1.35 (m, 4H, C14,15−H), 0.85 (s, 9H, C24−H), -0.02 (s, 6H, C22−H),
13C NMR (101 MHz, CDCl3): δ 150.7 (C
13), 148.3 (C26), 146.2 (C2), 144.8 (C19), 137.3 (C8),
134.0 (C25), 133.6 (C28), 132.9 (C21), 132.5 (C29), 131.2 (C10), 130.3 (C30), 129.2 (C9), 127.3 (C11),
125.5 (C27), 124.2 (C12), 111.7 (C18), 61.0 (C5), 54.4 (C20), 44.6 (C3), 37.6 (C7), 37.1 (C6or15), 37.0
(C6or15), 35.8 (C16), 33.1 (C17), 26.1 (C24), 25.6 (C14), 18.4 (C23), -5.3 (C22).
IR: 3352 (w), 2950 (w), 2930 (w), 2856 (w), 1540 (s), 1527 (s), 1413 (m), 1356 (s), 1255 (m), 1167
(s), 1100 (s), 853 (s), 836 (s), 779 (s), 742 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C31H43N3NaO7SSi+: 652.2483; Found: 652.2482.
Rf (DCM) = 0.39
Compound 439b
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
30−H), 7.86 (m, 1H, C27−H), 7.76-7.72 (m, 2H,
C28,29−H), 7.70 (dd, J = 8.0,1.2 Hz, 1H, C12−H), 7.51 (m, 1H, C10−H), 7.40-7.30 (m, 2H,
C9,11−H), 5.71 (dd, J = 12.0,18.4 Hz, 1H, C19−H), 5.29 (m, 1H, C21−H), 5.25 (t, J = 5.5 Hz,
1H, N4−H), 4.91-4.80 (m, 2H, C18−H), 4.18 (t, J = 7.4 Hz, 1H, C7−H), 3.56-3.47 (m, 2H, C5−H),
3.11-3.05 (m, 2H, C3−H), 2.10 (m, 1H, C6−H), 2.07-2.01 (m, 2H, C17−H), 1.96 (m, 1H, C6−H),
1.71 (m, 1H, C16−H), 1.63-1.53 (m, 1H, C16−H), 1.48-1.35 (m, 4H, C14,15−H), 0.86 (s, 9H,
C24−H), -0.1 (s, 6H, C22−H),
13CNMR(101MHz,CDCl3): δ 150.8 (C
13), 148.2 (C26), 145.6 (C2), 144.9 (C19), 137.1 (C8), 134.1
(C25), 133.6 (C28), 132.9 (C21), 132.4 (C29), 131.3 (C10), 130.8 (C30), 129.0 (C9), 127.2 (C11), 125.5
(C27), 124.2 (C12), 111.5 (C18), 61.0 (C5), 54.3 (C20), 44.6 (C3), 37.3 (C7), 36.9 (C15), 36.6 (C6),
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35.8 (C16), 32.2 (C17), 26.1 (C24), 25.5 (C14), 18.4 (C23), -5.3 (C22).
IR: 3346 (w), 2951 (w), 2929 (w), 2855 (w), 1542 (s), 1527 (s), 1414 (w), 1357 (s), 1255 (m), 1169
(s), 1100 (s), 853 (m), 835 (s), 780 (s), 741 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C31H43N3NaO7SSi+: 652.2483; Found: 652.2486.
Rf (DCM) = 0.39
N-(3-(3-(3-hydroxy-1-(2-nitrophenyl)propyl)-1-vinylcyclopent-2-en-1-yl)propyl)-
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To a solution of compounds 439a/439b (dr 1:1, 6.3 g, 10mmol) in MeOH (100mL) at 0 °C
was added dropwise acetyl chloride (60 uL, 1.0mmol, 10mol%). After stirring for 1h, the
reaction mixture was concentrated in vacuo. The crude compound 440 thus obtained (5.2 g,
quantitative yield, no change in dr) was used for the next step without further purification.
Compound 297a
1H NMR (400 MHz, CDCl3): δ 8.12 (m, 1H, C
28−H), 7.84 (m, 1H, C25−H), 7.76-7.72 (m, 2H,
C26,27−H), 7.69 (dd, J = 8.0,1.3 Hz, 1H, C12−H), 7.56 (td, J = 8.0,1.3 Hz, 1H, C10−H), 7.37 (dd,
J = 8.0,1.3 Hz, 1H, C9−H), 7.35 (td, J = 8.0,1.3 Hz, 1H, C11−H), 5.71 (dd, J = 17.2,10.7 Hz, 1H,
C19−H), 5.33 (m, 1H, C21−H), 5.30 (m, 1H, N4−H), 4.87 (dd, J = 10.7,1.3 Hz, 1H, C18−H), 4.83
(dd, J = 17.2,1.3 Hz, 1H, C18−H), 4.08 (t, J = 7.8 Hz, 1H, C7−H), 3.60 (m, 1H, C5−H), 3.51 (m,
1H, C5−H), 3.11-3.03 (m, 2H, C3−H), 2.22 (m, 1H, C6−H), 2.12 (m, 1H, C17−H), 2.03-1.90 (m,
2H, C6,17−H), 1.74 (ddd, J = 12.8,8.8,5.0 Hz, 1H, C16−H), 1.54 (ddd, J = 12.8,8.8,6.1 Hz, 1H,
C16−H), 1.49-1.35 (m, 4H, C14,15−H), OH peak not observed.
13C NMR (101 MHz, CDCl3): δ 150.9 (C
13), 148.2 (C24), 146.1 (C2), 144.7 (C19), 136.9 (C8),
134.0 (C23), 133.7 (C26), 132.9 (C21), 132.7 (C27), 131.2 (C10), 130.5 (C28), 129.2 (C9), 127.5 (C11),
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125.5 (C25), 124.1 (C12), 111.8 (C18), 60.7 (C5), 54.4 (C20), 44.5 (C3), 37.7 (C7), 37.0 (C6or15), 37.0
(C6or15), 35.8 (C16), 33.0 (C17), 25.6 (C14).
IR: 3323 (w), 3081 (w), 2935 (w), 2847 (w), 2357 (w), 2323 (w), 1541 (s), 1525 (s), 1342 (s), 1165
(m), 915 (m), 854 (m), 786 (m), 733 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H29N3NaO7S+: 538.1618; Found: 538.1619.
Rf (PE/EtOAc 4:6) = 0.50
Compound 297b
1H NMR (400 MHz, CDCl3): δ 8.13 (m, 1H, C
28−H), 7.86 (m, 1H, C25−H), 7.77-7.73 (m, 2H,
C26,27−H), 7.69 (dd, J = 7.7,1.7 Hz, 1H, C12−H), 7.53 (td, J = 7.7,1.7 Hz, 1H, C10−H), 7.35 (d,
J = 7.7 Hz, 1H, C9−H), 7.34 (m, 1H, C11−H), 5.72 (dd, J = 17.6,10.5 Hz, 1H, C19−H), 5.35 (m,
1H, C21−H), 5.29 (t, J = 5.9 Hz, 1H, N4−H), 4.88 (dd, J = 10.5,1.4 Hz, 1H, C18−H), 4.84 (dd,
J = 17.6,1.4 Hz, 1H, C18−H), 4.12 (m, 1H, C7−H), 3.61 (m, 1H, C5−H), 3.53 (m, 1H, C5−H),
3.13-3.02 (m, 2H,C3−H), 2.20 (m, 1H,C6−H), 2.06-1.93 (m, 3H,C6,17−H), 1.70 (m, 1H,C16−H),
1.64-1.56 (m, 1H, C16−H), 1.49-1.37 (m, 4H, C14,15−H), OH peak not observed.
13C NMR (101 MHz, CDCl3): δ 150.9 (C
13), 148.2 (C24), 145.6 (C2), 144.9 (C19), 136.7 (C8),
134.0 (C23), 133.7 (C26), 132.9 (C21), 132.6 (C27), 131.2 (C10), 130.8 (C28), 129.1 (C9), 127.5 (C11),
125.5 (C25), 124.1 (C12), 111.6 (C18), 60.8 (C5), 54.4 (C20), 44.6 (C3), 37.6 (C7), 36.9 (C6or15), 36.7
(C6or15), 35.7 (C16), 32.6 (C17), 25.5 (C14).
IR: 3349 (w), 3075 (w), 2945 (w), 2877 (w), 1540 (s), 1525 (s), 1415 (w), 1358 (s), 1165 (m), 1031
(w), 913 (w), 854 (w), 783 (m), 731 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H29N3NaO7S+: 538.1618; Found: 538.1620.
Rf (PE/EtOAc 4:6) = 0.50
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(E)-8-(2-nitrophenyl)-5-((2-nitrophenyl)sulfonyl)-1-vinyl-5-
azabicyclo[7.2.1]dodec-9(12)-ene 298
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To a solution of alcohols 297a/297b (dr 1:1, 0.10 g, 0.19mmol), neopentyl alcohol (7.5mg,
0.078mmol, 0.40 equiv), and PPh3 (50mg, 0.19mmol, 1.0 equiv) in toluene (40mL) at RT was
added DEAD (40 wt.% in toluene, 85μL, 0.19mmol, 1.0 equiv). After stirring for 1h at RT, ad-
ditional PPh3 (50mg, 0.19mmol, 1.0 equiv) and DEAD (40 wt.% in toluene, 85μL, 0.19mmol,
1.0 equiv) were added. The reaction mixture was stirred for one more hour. Saturated aque-
ous NaHCO3 was added. The mixture was extracted with EtOAc. The combined organic
phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification
by FCC (PE/DCM 1:9) afforded the two diastereoisomers 298a and 298b as yellow oils (78mg,
83% yield, no change in dr).
Compound 298a
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.4,1.8 Hz, 1H, C27−H), 7.75-7.65 (m, 3H,
C12,25,26−H), 7.61-7.53 (m, 2H, C10,24−H), 7.48 (dd, J = 7.5,1.8 Hz, 1H, C9−H), 7.36 (td, J =
7.5,1.8 Hz, 1H, C11−H), 5.87 (dd, J = 17.1,11.0 Hz, 1H, C19−H), 5.58 (m, 1H, C21−H), 4.96 (dd,
J = 17.1,1.7 Hz, 1H, C18−H), 4.88 (dd, J = 11.0,1.7 Hz, 1H, C18−H), 4.36 (dd, J = 12.7,2.8 Hz,
1H, C7−H), 4.04 (dd, J = 15.5,7.2 Hz, 1H, C5−H), 3.77 (ddd, J = 14.9,9.9,5.0 Hz, 1H, C3−H),
2.84-2.61 (m, 4H, C3,5,6,17−H), 2.17-2-03 (m, 2H, C14,16−H), 1.94-1.83 (m, 2H, C6,17−H), 1.83-
1.69 (m, 2H, C14,16−H), 1.69-1.61 (m, 1H, C15−H), 1.42 (m, 1H, C15−H).
13CNMR(101MHz,CDCl3): δ 150.3 (C
13), 149.1 (C23), 147.2 (C19), 143.2 (C2), 135.9 (C8), 134.4
(C21), 133.8 (C25), 132.4 (C10), 131.4 (C26), 131.0 (C27), 130.6 (C22), 128.6 (C9), 127.4 (C11), 124.4
(C12), 124.1 (C24), 110.8 (C18), 56.7 (C3), 55.4 (C5), 55.1 (C20), 43.1 (C7), 39.4 (C15), 35.9 (C6),
35.4 (C16), 31.4 (C17), 28.0 (C14).
IR: 2938 (w), 2913 (w), 2852 (w), 1544 (s), 1527 (s), 1465 (w), 1353 (s), 1164 (m), 1126 (w), 913
(w), 852 (w), 784 (m), 755 (m), 732 (m),
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HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H27N3NaO6S+: 520.1513; Found: 520.1512.
Rf (DCM) = 0.5
Compound 298b
1HNMR (400MHz, CDCl3): δ 7.91 (m, 1H, C
27−H), 7.79 (dd, J = 8.0,1.1 Hz, 1H, C12−H), 7.73-
7.65 ( (m, 2H, C25,26−H), 7.63-7.52 (m, 3H, C9,10,24−H), 7.35 (td, J = 8.0,1.1 Hz, 1H, C11−H),
5.99 (dd, J = 17.6,10.3 Hz, 1H, C19−H), 5.73 (m, 1H, C21−H), 4.98 (dd, J = 17.6,1.7 Hz, 1H,
C18−H), 4.93 (dd, J = 10.3,1.7 Hz, 1H, C18−H), 3.88 (dd, J = 11.4,3.4 Hz, 1H, C7−H), 3.53
(ddd, J = 15.4,6.8,1.7 Hz, 1H, C5−H), 3.27 (m, 1H, C3−H), 3.10 (m, 1H, C3−H), 2.98 (ddd,
J = 15.4,6.8,1.7 Hz, 1H, C5−H), 2.58 (m, 1H, C6−H), 2.51-2.38 (m, 2H, C17−H), 2.19 (m, 1H,
C6−H), 1.89 (m, 1H, C16−H), 1.83-1.69 (m, 3H, C14,15,16−H), 1.61-1.40 (m, 2H, C14,15−H).
13C NMR (101 MHz, CDCl3): δ 149.7 (C
13), 149.0 (C23), 146.6 (C19), 141.9 (C2), 137.2 (C8),
135.8 (C21), 133.8 (C25), 133.0 (C10), 131.4 (C26), 131.0 (C27or22), 131.0 (C27or22), 129.6 (C9),
127.5 (C11), 124.6 (C12), 124.0 (C24), 111.9 (C18), 56.3 (C20), 52.5 (C3), 48.9 (C5), 41.9 (C7), 39.0
(C17), 37.9 (C15), 35.5 (C6), 34.3 (C16), 22.3 (C14).
IR: 2929 (w), 2849 (w), 1544 (s), 1525 (s), 1373 (m), 1354 (s), 1165 (w), 1126 (w), 912 (w), 853
(w), 782 (w), 732 (w),
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H28N3O6S+: 498.1693; Found: 498.1690.
Rf (DCM) = 0.5
(E)-2-(8-(2-nitrophenyl)-5-((2-nitrophenyl)sulfonyl)-5-azabicyclo[7.2.1]dodec-
9(12)-en-1-yl)ethan-1-ol 299
10
11
12
13
8
9
NO21
7
6
2
16 17
2021 15
19
143
18
9-BBN, THF, RT
then EtOH, H2O2,
NaOH, 0 °C to RT
THF, 78%
+
5 N
S
22
O O
23
24
25
26
27 NO2
10
11
12
13
8
9
NO21
7
6
2
16 17
2021 15
19
143
18
5 N
S
22
O O
23
24
25
26
27 NO2
NO2
+
N
SO O
NO2
NO2
N
SO O
NO2
OH
28
OH
28
298a 298b 299a 299b
To a solution of olefins 298a/298b (dr 1:1, 78mg, 0.16mmol) in THF (10mL) at RT was
added 9-BBN (0.5M in THF, 0.32mL, 0.32mmol, 2.0 equiv). After stirring for 2h at RT, EtOH
(0.50mL), NaOH (6M in H2O, 0.50mL) and H2O2 (30% in H2O, 0.40mL) were added at 0 °C.
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The reactionmixturewas stirred at 0 °C for 15minutes, and then at RT for 2h. Saturated aque-
ous Na2S2O3 was added, followed by saturated aqueous NH4Cl. The mixture was extracted
with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and
concentrated in vacuo. Purification by FCC (PE/EtOAc 5:5) afforded the twodiastereoisomers
299a and 299b as yellow oils (65mg, 78% yield, no change in dr).
Compound 299a
1H NMR (400MHz, CDCl3): δ 7.91 (m, 1H, C
27−H), 7.75-7.65 (m, 3H, C12,25,26−H), 7.62-7.54
(m, 2H,C10,24−H), 7.48 (m, 1H,C9−H), 7.37 (m, 1H,C11−H), 5.60 (m, 1H,C21−H), 4.28 (dd, J =
13.0,3.0 Hz, 1H, C7−H), 4.04 (dd, J = 16.5,7.5 Hz, 1H, C5−H), 3.76 (ddd, J = 15.0,10.0,5.0 Hz,
1H, C3−H), 3.70-3.59 (m, 2H, C18−H), 2.79 (dd, J = 16.5,7.5 Hz, 1H, C5−H), 2.74-2.53 (m, 3H,
C3,6,17−H), 2.15 (m, 1H, C6−H), 2.05 (m, 1H, C14−H), 1.83-1.63 (m, 5H, C14,16,17,19−H), 1.62-
1.50 (m, 2H, C15,19−H), 1.34 (m, 1H, C15−H), 1.25 (br m, 1H, O28−H).
13C NMR (101 MHz, CDCl3): δ 150.3 (C
13), 149.1 (C23), 142.4 (C2), 135.8 (C8), 135.7 (C21),
133.8 (C25), 132.5 (C10), 131.4 (C26), 131.0 (C27), 130.6 (C22), 128.5 (C9), 127.4 (C11), 124.4 (C12),
124.1 (C24), 60.1 (C18), 56.6 (C3), 54.8 (C5), 52.0 (C20), 44.0 (C19), 43.0 (C7), 41.6 (C15), 35.6 (C6),
33.2 (C16), 31.2 (C17), 28.1 (C14).
IR: 3342 (w), 2928 (m), 2852 (w), 1544 (s), 1527 (s), 1465 (w), 1351 (s), 1164 (m), 1006 (w), 852
(w), 784 (m), 756 (m), 731 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H29N3NaO7S+: 538.1618; Found: 538.1620.
Rf (PE/EtOAc 4:6) = 0.2
Compound 299b
1H NMR (400 MHz, CDCl3): δ 7.90 (m, 1H, C
27−H), 7.78 (m, 1H, C12−H), 7.73-7.64 (m,
2H, C25,26−H), 7.60-7.51 (m, 3H, C9,10,24−H), 7.35 (m, 1H, C11−H), 5.71 (s, 1H, C21−H), 3.87
(dd, J = 11.7,2.9 Hz, 1H, C7−H), 3.77-3.65 (m, 2H, C18−H), 3.54 (ddd, J = 16.6,7.8,2.0 Hz,
1H, C5−H), 3.26 (m, 1H, C3−H), 3.07 (m, 1H, C3−H), 2.96 (ddd, J = 16.6,7.8,2.0 Hz, 1H,
C5−H), 2.57 (m, 1H, C6−H), 2.47-2.34 (m, 2H, C16−H), 2.18 (m, 1H, C6−H), 1.88-1.62 (m, 6H,
C14,15,17,19−H), 1.52-1.36 (m, 2H, , C14,15−H), 1.25 (br s, 1H, O28−H).
13C NMR (101 MHz, CDCl3): δ 149.7 (C
13), 149.0 (C23), 141.3 (C2), 137.3 (C8), 137.0 (C21),
133.8 (C25), 133.0 (C10), 131.5 (C26), 131.1 (C22), 131.0 (C27), 129.5 (C11), 127.5 (C9), 124.6 (C12),
124.1 (C24), 60.6 (C18), 52.6 (C20), 52.4 (C3), 48.9 (C5), 43.7 (C19), 42.0 (C7), 39.0 (C15or16), 39.0
(C15or16), 35.4 (C6), 33.1 (C17), 22.2 (C14).
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IR: 3362 (w), 2929 (w), 2849 (w), 1546 (s), 1525 (s), 1373 (m), 1353 (s), 1165 (m), 1043 (w), 1004
(w), 910 (w), 853 (w), 788 (w), 732 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H29N3NaO7S+: 538.1618; Found: 538.1623.
Rf (PE/EtOAc 4:6) = 0.2
12-(2-nitrophenyl)-9-((2-nitrophenyl)sulfonyl)-2-oxa-9-
azaspiro[4.10]pentadecane-1,13-dione 303
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A suspension of macrocycles 299a/299b (dr 1:1, 50mg, 0.10mmol) and NaHCO3 (17mg,
0.20mmol, 2.0 equiv) in DCM (0.50mL) was stirred at -78 °C. Ozone was bubbled through the
solution until full conversion was observed by TLC. Argon was then bubbled through themix-
ture for 10min. The mixture was then stirred at 0 °C for 15min. Ca(OCl)2 (29mg, 0.20mmol,
2.0 equiv) was added and the reaction mixture was stirred for 24h at RT. The reaction mix-
ture was filtered through Celite and concentrated in vacuo. Purification by FCC (PE/EtOAc
4:6) afforded the two diastereoisomers 303a and 303b as yellow foams (38mg, 70% yield, no
change in dr).
Compound 303a
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.1,1.6 Hz, 1H, C27−H), 7.86 (dd, J = 7.6,1.1 Hz,
1H, C12−H), 7.71 (td, J = 7.1,1.6 Hz, 1H, C25−H), 7.68 (td, J = 7.1,1.6 Hz, 1H, C26−H),
7.57-7.51 (m, 2H, C10,24−H), 7.42 (td, J = 7.6,1.1 Hz, 1H, C11−H), 7.31 (dd, J = 7.6,1.1 Hz,
1H, C9−H), 5.25 (dd, J = 11.7,2.3 Hz, 1H, C7−H), 4.31-4.20 (m, 2H, C18−H), 3.55 (m, 1H,
C3−H), 3.41-3.15 (m, 3H, C5,16−H), 2.86 (m, 1H, C3−H), 2.40 (m, 1H, C6−H), 2.31-2.11 (m,
4H, C6,15,17,19−H), 2.05-1.88 (m, 3H, C15,16,19−H), 1.55-1.20 (m, 3H, C14,17−H).
13C NMR (101 MHz, CDCl3): δ 211.3 (C
2), 180.0 (C21), 150.3 (C13), 149.2 (C23), 134.1 (C10),
133.1 (C25), 131.8 (C8), 131.5 (C26), 131.4 (C27), 130.5 (C22), 130.0 (C9), 128.7 (C11), 125.3 (C12),
124.0 (C24), 64.9 (C18), 51.1 (C3), 50.3 (C7), 46.4 (C5), 44.3 (C20), 35.8 (C19), 35.3 (C16), 32.1 (C6),
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29.5 (C15or17), 29.3 (C15or17), 22.0 (C14).
IR: 2930 (w), 2863 (w), 1764 (m), 1711 (w), 1545 (s), 1529 (s), 1456 (w), 1360 (s), 1356 (s), 1169
(m), 1028 (w), 849 (w), 780 (w), 742 (m), 733 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H27N3NaO9S+: 568.1360; Found: 568.1366.
Rf (PE/EtOAc 1:9) = 0.44
Compound 303b
1H NMR (400 MHz, CDCl3): δ 7.86 (dd, J = 7.6,1.6 Hz, 1H, C12−H), 7.83 (dd, J = 7.5,1.7 Hz,
1H, C27−H), 7.71 (td, J = 7.5,1.7 Hz, 1H, C25−H), 7.65 (td, J = 7.5,1.7 Hz, 1H, C26−H), 7.54 (dd,
J = 7.5,1.7 Hz, 1H, C24−H), 7.53 (td, J = 7.6,1.6 Hz, 1H, C10−H), 7.44 (td, J = 7.6,1.6 Hz, 1H,
C11−H), 7.22 (dd, J = 7.6,1.6 Hz, 1H, C9−H), 5.36 (dd, J = 11.4,2.6 Hz, 1H, C7−H), 4.38-4.30
(m, 2H, C18−H), 3.59 (td, J = 13.0,2.9 Hz, 1H, C3−H), 3.30 (dd, J = 15.0,5.0 Hz, 1H, C5−H),
3.10 (m, 1H, C5−H), 2.88 (dd, J = 15.0,10.0 Hz, 1H, C16−H), 2.78-2.64 (m, 2H, C3,17−H), 2.42
(ddd, J = 12.9,5.9,3.2 Hz, 1H, C19−H), 2.30 (td, J = 12.9,3.7 Hz, 1H, C6−H), 2.22-1.99 (m, 4H,
C6,15,16,19−H), 1.77 (td, J = 12.9,3.7 Hz, 1H, C15−H), 1.67 (dd, J = 11.2,15.4 Hz, 1H, C17−H),
1.62-1.52 (m, 1H, C14−H), 1.45 (m, 1H, C14−H).
13C NMR (101 MHz, CDCl3): δ 210.9 (C
2), 179.9 (C21), 150.6 (C13), 149.1 (C23), 134.0 (C10),
133.1 (C25), 131.7 (C8), 131.4 (C26), 131.1 (C27), 129.8 (C9 and C22 superimposed), 128.8 (C11),
125.3 (C12), 124.0 (C24), 65.3 (C18), 51.3 (C3), 48.5 (C7), 46.0 (C5), 45.9 (C20), 36.7 (C19), 36.2
(C16), 32.1 (C6), 30.8 (C17), 30.3 (C15), 21.5 (C14).
IR: 2923 (w), 2852 (w), 1761 (m), 1715 (w), 1543 (s), 1530 (s), 1456 (w), 1374 (s), 1359 (s), 1164
(w), 1027 (w), 915 (w), 748 (w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C25H27N3NaO9S+: 568.1360; Found: 568.1373.
Rf (PE/EtOAc 1:9) = 0.65
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(E)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-8-(2-nitrophenyl)-5-((2-
nitrophenyl)sulfonyl)-5-azabicyclo[7.2.1]dodec-9(12)-ene 293
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To a solution of macrocycles 299a/299b (dr 1:1, 50mg, 0.10mmol) and Imidazole (14mg,
0.20mmol, 2.0 equiv) in THF (0.50mL) at RT was added TBSCl (23mg, 0.15mmol, 1.5 equiv).
The reaction mixture was stirred for 2h. Water was added, and the mixture was extracted
with EtOAc. The organic phases were combined, washed with brine, dried over Na2SO4, and
concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded the twodiastereoisomers
293a and 293b as colorless oils (57mg, 90% yield, no change in dr).
Compound 293a
1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 7.8,1.7 Hz, 1H, C27−H), 7.74-7.65 (m, 3H,
C12,25,26−H), 7.59 (dd, J = 7.8,1.7 Hz, 1H, C24−H), 7.55 (td, J = 7.8,1.2 Hz, 1H, C10−H), 7.46
(dd, J = 7.8,1.2 Hz, 1H, C9−H), 7.35 (td, J = 7.8,1.2 Hz, 1H, C11−H), 5.51 (s, 1H, C21−H),
4.30 (dd, J = 12.4,3.4 Hz, 1H, C7−H), 4.03 (dd, J = 15.1,6.6 Hz, 1H, C5−H), 3.74 (ddd,
J = 15.0,10.0,5.0 Hz, 1H, C3−H), 3.59 (t, J = 7.0 Hz, 2H, C18−H), 2.78 (dd, J = 15.1,8.5 Hz,
1H, C5−H), 2.70 (m, 1H, C3−H), 2.65-2.52 (m, 2H, C6,17−H), 2.12 (ddd, J = 15.3,7.6,3.4 Hz,
1H, C6−H), 2.02 (m, 1H, C14−H), 1.83-1.73 (m, 3H, C16,17−H), 1.71-1.53 (m, 4H, C14,15,19−H),
1.30 (m, 1H, C15−H), 0.87 (s, 9H (C30), 0.04 (s, 3H, C28−H), 0.02 (s, 3H, C28−H).
13C NMR (101 MHz, CDCl3): δ 150.3 (C
13), 149.1 (C23), 142.1 (C2), 136.0 (C8), 135.8 (C21),
133.8 (C25), 132.3 (C10), 131.4 (C26), 131.1 (C27), 130.6 (C22), 128.6 (C9), 127.3 (C11), 124.4 (C12),
124.1 (C24), 60.6 (C18), 56.6 (C3), 54.8 (C5), 51.7 (C20), 44.2 (C19), 43.0 (C7), 40.8 (C15), 35.8 (C6),
33.6 (C16), 31.3 (C17), 28.0 (C14), 26.1 (C30), 18.4 (C29), -5.2 (C28), -5.2 (C28).
IR: 2929 (w), 2851 (w), 1545 (s), 1529 (s), 1465 (w), 1357 (s), 1251 (w), 1164 (m), 1090 (m), 852
(m), 837 (s), 779 (s), 754 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C31H43N3NaO7SSi+: 652.2483; Found: 652.2491.
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Rf (PE/EtOAc 6:4) = 0.55
Compound 293b
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.3,2.0 Hz, 1H, C27−H), 7.74 (dd, J = 7.3,2.0 Hz,
1H, C12−H), 7.66 (td, J = 7.3,2.0 Hz, 1H, C25−H), 7.63 (td, J = 7.3,2.0 Hz, 1H, C26−H), 7.55 (dd,
J = 7.3,2.0 Hz, 1H, C24−H), 7.53 (dd, J = 7.3,2.0 Hz, 1H, C9−H), 7.49 (td, J = 7.3,2.0 Hz, 1H,
C10−H), 7.31 (td, J = 7.3,2.0 Hz, 1H, C11−H), 5.65 (s, 1H, C21−H), 3.81 (dd, J = 10.1,4.3 Hz, 1H,
C7−H), 3.70-3.57 (m, 2H, C18−H), 3.50 (dd, J = 15.8,7.2 Hz, 1H, C5−H), 3.21 (m, 1H, C3−H),
3.05 (m, 1H, C3−H), 2.90 (dd, J = 15.8,7.2 Hz, 1H, C5−H), 2.48 (m, 1H, C6−H), 2.41-2.29 (m,
2H, C16−H), 2.14 (m, 1H, C6−H), 1.81 (m, 1H, C17−H), 1.75-1.57 (m, 5H, C14,15,17,19−H), 1.44-
1.33 (m, 2H, C14,15−H), 0.84 (s, 9H, C30−H), 0.00 (s, 6H, C28−H).
13C NMR (101 MHz, CDCl3): δ 149.6 (C
13), 148.9 (C23), 140.7 (C2), 137.3 (C21), 137.2 (C8),
133.6 (C25), 132.8 (C10), 131.3 (C26), 131.1 (C22), 130.9 (C27), 129.4 (C11), 127.3 (C9), 124.4 (C12),
123.9 (C24), 60.8 (C18), 52.4 (C3), 52.1 (C20), 48.4 (C5), 43.6 (C19), 41.7 (C7), 39.1 (C16), 38.6 (C15),
35.4 (C6), 33.1 (C17), 26.0 (C30), 22.0 (C14), 18.3 (C29), -5.2 (C28).
IR: 2929 (w), 2855 (w), 1545 (s), 1526 (s), 1460 (w), 1373 (m), 1356 (m), 1254 (w), 1167 (m),
1125 (w), 1090 (m), 852 (m), 837 (s), 777 (s), 744 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C31H43N3NaO7SSi+: 652.2483; Found: 652.2500.
Rf (PE/EtOAc 6:4) = 0.55
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potassium 2-(2-nitrophenyl)acetate 345
NO2
CO2H 4
3
2
1
6
5
NO2
7
CO2K
8
t-BuOK
EtOH, RT
quant.
345
To a solution of 2-(2-nitrophenyl)acetic acid (10g, 55mmol) in EtOH (100mL) was added
dropwise a solution of t-BuOK (6.2 g, 55mmol, 1.0 equiv) in EtOH (20mL). The reaction mix-
turewas stirred for 1h, and then concentrated in vacuo. The crude salt 345 thus obtainedwas
used for the next step without further purification (white solid, 12 g, quantitative yield). The
spectroscopic data of this compound were in accord with those reported in the literature.22
1HNMR (400MHz, MeOD): δ 7.98 (dd, J = 8.6,1.5 Hz, 1H, C2−H), 7.57 (td, J = 7.5,1.5 Hz, 1H,
C4−H), 7.44-7.38 (m, 2H, C3,5−H), 3.88 (s, 2H, C7−H).
13C NMR (101MHz, MeOD): δ 177.6 (C8), 155.1 (C1), 135.0 (C6), 134.5 (C4), 134.2 (C5), 128.5
(C3), 125.7 (C2), 43.9 (C7).
3-(but-3-en-1-yl)-3-(3-((tert-butyldimethylsilyl)oxy)propyl)cyclopent-1-en-1-yl
trifluoromethanesulfonate 344
O
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4-bromobut-1-ene
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CuBr·Me2S
THF, reflux to -40 °C
then Comins' reagent, RT 
91%
220 344
To a solution of 4-bromobut-1-ene (2.4mL, 24mmol, 4.0 equiv) in THF (100mL) was added
magnesium turning (0.57g, 24mmol, 4.0 equiv) and the mixture was heated to reflux for
3h. The mixture was then cooled down to -78 °C, CuBr·Me2S (2.4 g, 12mmol, 2.0 equiv) was
added and the mixture was stirred for 1h. The reaction mixture was then warmed up to -
40 °C, and a solution of the enone 220 (1.5 g, 5.9mmol) in THF (20mL) was added dropwise.
The reaction mixture was then stirred for 3h. A solution of Comins’ reagent (4.6 g, 12mmol,
2.0 equiv) in THF (20mL) was added, and the reactionmixture was stirred at RT for 24h. Satu-
rated NaHCO3 was added, and themixture was extracted with EtOAc. The combined organic
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phases were dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc
95:5) afforded the vinyl triflate 344 as a colorless oil (2.4 g, 91% yield).
1H NMR (400MHz, CDCl3): δ 5.80 (ddt, J = 17.2,10.1,6.6 Hz, 1H, C9−H), 5.44 (s, 1H, C3−H),
5.01 (dd, J = 17.2,1.9 Hz, 1H, C10−H), 4.94 (dd, J = 10.1,1.9 Hz, 1H, C10−H), 3.61-3.53 (m,
2H, C13−H), 2.61-2.55 (m, 2H, C6−H), 2.05-1.95 (m, 2H, C8−H), 1.82 (t, J = 7.6 Hz, 2H, C5−H),
1.53-1.47 (m, 2H, C7−H), 1.47-1.43 (m, 4H, C11,12−H), 0.89 (s, 9H, C16−H), 0.04 (s, 6H, C14−H).
13C NMR (101 MHz, CDCl3): δ 148.1 (C
2), 138.8 (C9), 124.7 (C3), 118.7 (q, J = 319.9 Hz, C1),
114.6 (C10), 63.5 (C13), 48.5 (C4), 39.1 (C7), 36.0 (C11), 32.0 (C5), 31.0 (C6), 29.0 (C8), 28.0 (C12),
26.1 (C16), 18.5 (C15), -5.2 (C14).
IR: 2941 (w), 2931 (w), 2858 (w), 1660 (w), 1643 (w), 1424 (m), 1251 (m), 1210 (s), 1141 (s), 1096
(s), 912 (s), 835 (s), 776 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H34F3O4SSi+: 443.1894; Found: 443.1893.
Rf (PE/EtOAc 95:5) = 0.72.
methyl 3-(1-(3-((tert-butyldimethylsilyl)oxy)propyl)-3-(((trifluoromethyl)-
sulfonyl)oxy)cyclopent-2-en-1-yl)propanoate 350 and 3-(2-(1,2,4-trioxolan-3-
yl)ethyl)-3-(3-((tert-butyldimethylsilyl)oxy)propyl)cyclopent-1-en-1-yl trifluoro-
methanesulfonate 351
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To a solution of the olefin 344 (50mg, 0.11mmol) in DCM (1.0mL) was added a solution of
NaOH (23mg, 0.56mmol, 5.0 equiv) in MeOH (0.25mL). The mixture was cooled to -78 °C,
and ozone was bubbled through the reaction mixture. The reaction mixture turned yellow,
followed by decoloration and subsequent blue coloration. When the blue color appeared, ar-
gon was bubbled through the solution, and the mixture was warmed up to 0 °C. Water and
ether were added, and the biphasic mixture was stirred for 1h. The two layers were separated
and the aqueous layer was extracted with ether. The combined organic phases were dried
over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5) afforded prod-
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uct 350 (colorless oil, 31mg, 60% yield) alongwith the side product 351 (colorless oil, mixture
of 2 diastereoisomers, dr 1:1, 19mg, 35% yield).
Compound 350
1H NMR (400 MHz, CDCl3): δ 5.39 (t, J = 1.6 Hz, 1H, C3−H), 3.66 (s, 3H, C10−H), 3.60-3.55
(m, 2H, C13−H), 2.58 (td, J = 7.6,1.5 Hz, 2H, C6−H), 2.26 (t, J = 8.3 Hz, 2H, C8−H), 1.89-1.69
(m, 4H, C5,7−H), 1.49-1.42 (m, 4H, C11,12−H), 0.87 (s, 9H, C16−H), 0.03 (s, 6H, C14−H).
13C NMR (101 MHz, CDCl3): δ 174.1 (C
9), 148.5 (C2), 123.9 (C3), 118.7 (d, J = 321.0 Hz, C1),
63.3 (C13), 51.8 (C10), 48.2 (C4), 36.2 (C11), 34.7 (C7), 31.5 (C5), 31.0 (C6), 29.6 (C8), 27.9 (C12),
26.0 (C16), 18.4 (C15), -5.2 (C14).
IR: 2952 (w), 2932 (w), 2858 (w), 1740 (m), 1423 (m), 1209 (s), 1141 (s), 1098 (m), 914 (m), 835
(s), 776 (m).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H34F3O6SSi+: 475.1792; Found: 475.1792.
Rf (PE/EtOAc 95:5) = 0.36.
Compound 351 (mixture of diastereoisomers, dr 1:1)
1H NMR (400 MHz, CDCl3): δ 5.42 (m, 1H, C
3−H), 5.17 (s, 1H, C10−H), 5.13 (td, J =
4.07,0.8 Hz, 1H, C9−H), 5.04 (s, 1H, C10−H), 3.61-3.55 (m, 2H, C13−H), 2.59 (td, J = 7.7,2.0 Hz,
2H, C6−H), 1.87-1.77 (m, 2H, C5−H), 1.72-1.64 (m, 2H, C8−H), 1.58-1.51 (m, 2H, C7−H), 1.48-
1.42 (m, 4H, C11,12−H), 0.88 (s, 9H, C16−H), 0.04 (s, 6H, C14−H).
13C NMR (101 MHz, CDCl3): δ 148.4 (C
2), 124.1 (C3), 118.7 (d, J = 320.5 Hz, C1), 103.7 (C9),
94.2 (C10), 63.3 (C13), 48.1 (C4), 36.1 (C11), 36.0 (C11), 33.4 (C7), 31.7 (C5), 31.7 (C5), 31.0 (C6),
27.9 (C12), 26.8 (C8), 26.1 (C16), 18.5 (C15), -5.2 (C14).
IR: 2958 (w), 2933 (w), 2890 (w), 2859 (w), 1663 (w), 1422 (m), 1251 (w), 1210 (s), 1141 (s), 1099
(m), 1055 (m), 914 (m), 835 (s), 777 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H33F3NaO7SSi+: 513.1561; Found: 513.1553.
Rf (PE/EtOAc 95:5) = 0.30.
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methyl 3-(1-(3-((tert-butyldimethylsilyl)oxy)propyl)-3-(2-nitrobenzyl)cyclopent-
2-en-1-yl)propanoate 352
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An oven-dried flask was charged with salt 345 (0.12 g, 0.53mmol, 1.2 equiv), X-Phos (32mg,
0.066mmol, 15mol%), allylpalladium chloride dimer (4.0mg, 0.011mmol, 5.0mol%) and
flushed with nitrogen. Degassed and dry diglyme (3.0mL) was added, and the reaction
mixture was stirred for 5 minutes. A solution of the vinyl triflate 350 (0.21 g, 0.44mmol) in
diglyme (3.0mL) was added, and the reaction mixture was heated at 100 °C for 2h. The re-
action mixture was allowed to cool down to RT, and TBAF (1M in THF, 1.3mL, 1.3mmol,
3.0 equiv) was added. The reaction mixture was stirred for 2h. Saturated aqueous NaHCO3
was added, and the mixture was extracted with EtOAc. The combined organic phases were
washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 95:5) afforded the pure product 352 as a yellow oil (0.13 g, 62% yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 1.0,7.8 Hz, 1H, C12−H), 7.53 (td, J = 1.1,7.8 Hz,
1H, C10−H), 7.37 (td, J = 1.3,7.8 Hz, 1H, C11−H), 7.32 (dd, J = 7.6,1.8 Hz, 1H, C9−H), 4.84 (s,
1H, C21−H), 3.67 (s, 2H, C7−H), 3.63 (s, 3H, C22−H), 3.58 (t, J = 6.1 Hz, 2H, C3−H), 2.25 (t,
J = 7.2 Hz, 2H, C16−H), 2.22-2.16 (m, 2H, C18−H), 1.76-1.64 (m, 4H, C17,19−H), 1.49-1.22 (m,
4H, C14,15−H), OH peak not observed.
13CNMR (101MHz, CDCl3): δ 174.8 (C
6), 149.6 (C13), 141.8 (C2), 134.7 (C8), 133.0 (C10), 132.6
(C9), 132.4 (C21), 127.5 (C11), 124.9 (C12), 63.7 (C3), 51.7 (C20), 51.5 (C22), 36.0 (C15), 35.1 (C18),
35.0 (C7), 34.7 (C17), 33.9 (C19), 30.0 (C16), 28.1 (C14).
IR: 3397 (br w), 2940 (w), 2847 (w), 1735 (m), 1526 (s), 1436 (w), 1353 (m), 1199 (w), 1172 (w),
1055 (w).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H26NO5+: 348.1806; Found: 348.1807.
Rf (PE/EtOAc 6:4) = 0.11.
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(3-(1-oxaspiro[4.4]non-6-en-7-yl)propoxy)(tert-butyl)dimethylsilane 342
O
OTBS
4
5
6
7
8
9
10
11
OO
3
2
1
Si
12
13
14CuBr·Me2S
THF
-78 °C to -40 °C
43%
ClMg OMgCl+
220 342
To a solution of 3-chloropropan-1-ol (2.0mL, 24mmol, 4.0 equiv) in THF (100mL) at 0 °C was
added MeMgBr (1.2M in THF, 20mL, 24mmol, 4.0 equiv). The mixture was then warmed
up to RT, and magnesium turning (0.57g, 24mmol, 4.0 equiv) was added. The mixture was
heated to reflux for 3h. The solution was then cooled down to -78 °C, CuBr·Me2S (2.4 g,
12mmol, 2.0 equiv) was added and the solution was stirred for 1h. The reaction mixture was
then warmed up to -40 °C, and a solution of enone 220 (1.5 g, 5.9mmol) in THF (20mL) was
added dropwise. The reaction mixture was then stirred at -40 °C for 3h. Saturated NaHCO3
was added, and the mixture was extracted with EtOAc. The combined organic phases were
dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded
compound 342 as a colorless oil (0.75 g, 43% yield).
1H NMR (400 MHz, CDCl3): δ 5.33 (s, 1H, C
8−H), 3.81 (t, J = 6.8 Hz, 2H, C3−H), 3.61 (t,
J = 6.4 Hz, 2H, C11−H), 2.40 (m, 1H, C5−H), 2.19 (m, 1H, C5−H), 2.14-2.08 (m, 2H, C9−H),
2.01 (ddd, J = 13.5,8.9,4.6 Hz, 1H, C6−H), 1.94 (t, J = 6.8 Hz, 2H, C2−H), 1.91 (m, 1H, C6−H),
1.85-1.78 (m, 2H, C1−H), 1.73-1.64 (m, 2H, C10−H), 0.89 (s, 9H, C14−H), 0.04 (s, 6H, C12−H).
13C NMR (101MHz, CDCl3): δ 148.3 (C
7), 128.0 (C8), 94.5 (C4), 67.0 (C3), 63.0 (C11), 37.5 (C6),
36.8 (C1), 33.8 (C5), 30.8 (C10), 27.7 (C9), 26.5 (C2), 26.1 (C14), 18.5 (C13), -5.1 (C12).
IR: 2953 (m), 2930 (m), 2856 (m), 1471 (w), 1254 (w), 1096 (m), 1046 (w), 835 (s), 775 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C17H32NaO2Si+: 319.2069; Found: 319.2068.
Rf (PE/EtOAc 1:1) = 0.48.
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Following a known procedure,228 a suspension of sodium iodide (5.4 g, 36mmol, 1.3 equiv) in
acetone (20mL) was heated to reflux. Ethyl bromopropionate (3.0mL, 28mmol) was added
dropwise over 30min. The reaction mixture was heated for 4h. The mixture was allowed
to cool down to RT, diluted with diethyl ether (20mL), and filtered. The filtrate was washed
with 2% NaOH, water, brine, dried over Na2SO4 and concentrated in vacuo. The crude com-
pound 441 thus obtained was used for the next step without further purification (colourless
oil, 5.8 g, quantitative yield). The spectroscopic data of this compound were in accord with
those reported in the literature.228
1H NMR (400 MHz, CDCl3): δ 3.71 (s, 3H, C
4−H), 3.31 (t, J = 7.1 Hz, 2H, C1−H), 2.97 (t,
J = 7.1 Hz, 2H, C2−H).
13C NMR (101MHz, CDCl3): δ 171.6 (C
3), 52.1 (C4), 38.5 (C2), -3.8 (C1).
(3-(1-(but-3-en-1-yl)-3-(2-nitrobenzyl)cyclopent-2-en-1-yl)propoxy)(tert-butyl)-
dimethylsilane 442
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An oven-dried flask was charged with salt 345 (1.2 g, 5.3mmol, 1.2 equiv), X-Phos (0.32g,
0.66mmol, 15mol%), allylpalladium chloride dimer (40mg, 0.11mmol, 5.0mol%) and
flushed with nitrogen. Degassed and dry diglyme (30mL) was added. The reaction mixture
was stirred for 5 minutes. A solution of the vinyl triflate 344 (2.0 g, 4.4mmol) in diglyme
(30mL) was added, and the reaction mixture was heated at 100 °C for 2h. The reaction mix-
turewas allowed to cool down toRT, and saturated aqueousNaHCO3 was added. Themixture
was extracted with EtOAc. The combined organic phases were washed with brine, dried over
Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5) afforded the pure
product 442 as a yellow oil (1.6 g, 87% yield).
1H NMR (400 MHz, CDCl3): δ 7.87 (d, J = 7.8 Hz, 1H, C12−H), 7.51 (td, J = 7.8,1.4 Hz,
1H, C10−H), 7.36 (t, J = 7.8 Hz, 1H, C11−H), 7.33 (d, J = 7.8 Hz, 1H, C9−H), 5.79 (ddt,
J = 16.0,10.1,6.5 Hz, 1H, C6−H), 4.97 (dd, J = 16.0,1.6 Hz, 1H, C22−H), 4.96 (s, 1H, C21−H),
228Chow, C. P.; Shea, K. J. J. Am. Chem. Soc. 2005, 127, 3678–3679
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4.89 (d, J = 10.1 Hz, 1H, C22−H), 3.67 (s, 2H, C7−H), 3.55 (t, J = 6.4 Hz, 2H, C3−H), 2.22 (t,
J = 7.2 Hz, 2H, C18−H), 2.01-1.88 (m, 2H, C16−H), 1.68 (t, J = 7.2 Hz, 2H, C19−H), 1.47-1.24
(m, 6H, C14,15,17−H), 0.88 (s, 9H, C25−H), 0.04 (s, 6H, C23−H).
13C NMR (101MHz, CDCl3): δ 149.7 (C
13), 140.5 (C2), 139.8 (C6), 135.0 (C8), 134.2 (C21), 132.8
(C10), 132.3 (C9), 127.3 (C11), 124.8 (C12), 113.9 (C22), 64.1 (C3), 51.7 (C20), 39.1 (C17), 35.8 (C18),
34.9 (C19), 34.8 (C7), 34.5 (C15), 29.3 (C16), 28.4 (C14), 26.1 (C25), 18.5 (C24), -5.1 (C23).
IR: 2929 (m), 2854 (w), 1528 (s), 1462 (w), 1353 (m), 1255 (m), 1095 (s), 835 (s), 776 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C25H40NO3Si+: 430.2772; Found: 430.2771.
Rf (PE/EtOAc 9:1) = 0.61.
3-(1-(but-3-en-1-yl)-3-(2-nitrobenzyl)cyclopent-2-en-1-yl)propan-1-ol 346
CO2K
NO2 TfO
TBSO
+
[Pd(allyl)Cl]2
X-Phos
Diglyme, 100 °C
then TBAF, RT
88%
10
11
12
13
8
9 7
NO2
1
19
20
21
2
18
17
15
14
3
16
6
22
HO
345 344 346
An oven-dried flask was charged with salt 345 (1.2 g, 5.3mmol, 1.2 equiv), X-Phos (0.32g,
0.66mmol, 15mol%), allylpalladium chloride dimer (40mg, 0.11mmol, 5.0mol%) and
flushed with nitrogen. Degassed and dry diglyme (30mL) was added. The reaction mixture
was stirred for 5 minutes. A solution of the vinyl triflate 344 (2.0 g, 4.4mmol) in diglyme
(30mL) was added, and the reaction mixture was heated at 100 °C for 2h. The reaction mix-
ture was allowed to cool down to RT, and TBAF (1M in THF, 14mL, 14mmol, 3.0 equiv) was
added. The reaction mixture was then stirred until complete consumption of intermediate
442. Saturated aqueous NaHCO3 was added. The mixture was extracted with EtOAc. The
combined organic phases were washed with brine, dried over Na2SO4 and concentrated in
vacuo. Purification by FCC (PE/EtOAc 95:5) afforded the pure product 346 as a yellow oil
(1.2 g, 88% yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.8,1.5 Hz, 1H, C12−H), 7.52 (td, J = 7.8,1.5 Hz,
1H, C10−H), 7.37 (td, J = 7.8,1.5 Hz, 1H, C11−H), 7.33 (d, J = 7.8 Hz, 1H, C9−H), 5.78 (ddt,
J = 17.5,10.2,6.6 Hz, 1H, C6−H), 4.97 (dd, J = 17.5,2.1 Hz, 1H, C22−H), 4.92-4.86 (m, 2H,
C21,22−H), 3.68 (s, 2H, C7−H), 3.58 (t, J = 6.3 Hz, 2H, C3−H), 2.23 (t, J = 7.3 Hz, 2H, C18−H),
2.02-1.87 (m, 2H, C16−H), 1.74-1.63 (m, 2H, C19−H), 1.49-1.22 (m, 6H, C14,15,17−H), OH peak
not observed.
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13CNMR (101MHz, CDCl3): δ 149.7 (C
13), 140.8 (C2), 139.7 (C6), 134.9 (C8), 133.7 (C21), 132.9
(C10), 132.4 (C9), 127.4 (C11), 124.8 (C12), 113.9 (C22), 63.8 (C3), 51.7 (C20), 39.2 (C17), 35.8 (C18),
35.0 (C19), 34.9 (C7), 34.4 (C15), 29.3 (C16), 28.2 (C14).
IR: 3354 (br w), 2934 (w), 2848 (w), 1526 (s), 1450 (w), 1353 (w), 1054 (w), 908 (s), 730 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H25NNaO3+: 338.1727; Found: 338.1716.
Rf (PE/EtOAc 6:4) = 0.39.
1-((3-(3-azidopropyl)-3-(but-3-en-1-yl)cyclopent-1-en-1-yl)methyl)-2-nitro-
benzene 347
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One pot: MsCl, Et3N
              then NaN3
              DMF, 0 °C to RT to 40 °C
              89%
346 443 347
Stepwise preparation of 347
To a solution of the alcohol 346 (1.0 g, 3.2mmol) and Et3N (0.60mL, 4.8mmol, 1.5 equiv) in
DMF (60mL) at 0 °Cwas addedMsCl (0.27mL, 3.5mmol, 1.1 equiv). The reactionmixturewas
stirred at RT for 30min, and then water was added. The mixture was extracted with EtOAc.
The combined organic phases were washed with brine, dried over Na2SO4 and concentrated
in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded the pure product 443 as a yellow oil
(1.1 g, 88% yield).
To a refluxing solution of themesylate 443 (1.0 g, 2.5mmol) in DCM (50mL) was added NaN3
(0.50g, 7.6mmol, 3.0 equiv). The reaction mixture was stirred for 3h, and then water was
added. The mixture was extracted with EtOAc. The combined organic phases were washed
with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2)
afforded the azide 347 as a yellow oil (0.76 g, 89% yield).
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One-pot preparation of 347
To a solution of the alcohol 346 (1.0 g, 3.2mmol) and Et3N (0.60mL, 4.8mmol, 1.5 equiv) in
DMF (60mL) at 0 °C was added MsCl (0.27mL, 3.5mmol, 1.1 equiv). The reaction mixture
was then stirred at RT for 30min. NaN3 (0.62g, 9.5mmol, 3.0 equiv) was added and the re-
action mixture was stirred at 40 °C for 3h. Water was added, and the mixture was extracted
with EtOAc. The combined organic phases were washed with brine, dried over NaSO4 and
concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded the azide 347 as a yellow
oil (0.96 g, 89% yield).
Mesyl alcohol 443
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.8,1.3 Hz, 1H, C12−H), 7.53 (td, J = 7.8,1.3 Hz,
1H, C10−H), 7.38 (td, J = 7.8,1.4 Hz, 1H, C11−H), 7.33 (dd, J = 7.8,1.4 Hz, 1H, C9−H), 5.78
(ddt, J = 17.1,10.2,6.6 Hz, 1H, C6−H), 4.97 (dd, J = 17.1,1.9 Hz, 1H, C22−H), 4.93-4.85 (m,
2H, C21,22−H), 4.17 (td, J = 6.5,0.9 Hz, 2H, C3−H), 3.68 (s, 2H, C7−H), 3.00 (s, 3H, C23−H),
2.25 (t, J = 7.1 Hz, 2H, C18−H), 1.97-1.87 (m, 2H, C16−H), 1.72 (ddt, J = 13.6,8.5,6.6 Hz, 1H,
C19−H), 1.66 (ddt, J = 13.6,8.5,6.6 Hz, 1H, C19−H), 1.66-1.58 (m, 2H, C14−H), 1.47-1.30 (m,
4H, C15,17−H).
13C NMR (101MHz, CDCl3): δ 149.7 (C
13), 141.5 (C2), 139.4 (C6), 134.7 (C8), 133.0 (C21), 132.9
(C10), 132.4 (C9), 127.5 (C11), 124.9 (C12), 114.1 (C22), 71.0 (C3), 51.6 (C20), 39.2 (C17), 37.5 (C23),
35.6 (C18), 35.1 (C19), 35.0 (C7), 34.2 (C15), 29.2 (C16), 24.8 (C14).
IR: 2933 (w), 2848 (w), 1526 (s), 1353 (s), 1175 (s), 953 (m), 917 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C20H27NNaO5S+: 416.1502; Found: 416.1495.
Rf (PE/EtOAc 6:4) = 0.60.
Azide 347
1H NMR (400 MHz, CDCl3): δ 7.89 (dd, J = 7.8,1.4 Hz, 1H, C12−H), 7.53 (td, J = 7.8,1.4 Hz,
1H, C10−H), 7.37 (td, J = 7.8,1.5 Hz, 1H, C11−H), 7.33 (dd, J = 7.8,1.5 Hz, 1H, C9−H), 5.79
(ddt, J = 17.2,10.2,6.6 Hz, 1H, C6−H), 4.98 (dd, J = 17.2,1.9 Hz, 1H, C22−H), 4.93-4.88 (m,
2H, C21,22−H), 3.68 (s, 2H, C7−H), 3.22 (t, J = 6.8 Hz, 2H, C3−H), 2.25 (td, J = 7.4,2.0 Hz,
2H, C18−H), 1.96-1.88 (m, 2H, C16−H), 1.72 (ddt, J = 13.7,7.8,6.6 Hz, 1H, C19−H), 1.66 (ddt,
J = 13.7,7.8,6.6 Hz, 1H, C19−H), 1.50-1.30 (m, 6H, C14,15,17−H).
13C NMR (101MHz, CDCl3): δ 149.7 (C
13), 141.3 (C2), 139.5 (C6), 134.8 (C8), 133.3 (C21), 132.9
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(C10), 132.3 (C9), 127.5 (C11), 124.9 (C12), 114.1 (C22), 52.3 (C3), 51.8 (C20), 39.2 (C17), 37.0 (C18),
35.0 (C19), 34.9 (C7), 34.3 (C15), 29.2 (C16), 24.4 (C14).
IR: 2934 (w), 2847 (w), 2093 (s), 1526 (s), 1352 (m), 910 (m), 736 (m).
Anal. Calcd for C19H24N4O2: C, 67.04; H 7.11; N 16.46. Found: C 66.74; H 7.10; N 16.15.
Rf (PE/EtOAc 6:4) = 0.88.
4-(1-(3-azidopropyl)-3-(2-nitrobenzyl)cyclopent-2-en-1-yl)-1-hydroxybutan-
2-one 348 and 3-(1-(3-azidopropyl)-3-(2-nitrobenzyl)cyclopent-2-en-1-
yl)propanoic acid 340
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Stepwise preparation of 340
To a solution of the olefin 347 (20mg, 0.059mmol) in acetone/water/AcOH (5:1:0.1, 1.5mL)
at RT was added a solution of KMnO4 (14mg, 0.088mmol, 1.5 equiv) in a mixture of ace-
tone/water (5:1, 1.0mL). After 15 seconds of vigorous stirring, the reaction mixture was
poured into an ice-cooled saturated Na2SO3 solution, and extracted with EtOAc. The com-
bined organic phases were washedwith brine, dried over Na2SO4, and concentrated in vacuo.
The crude hydroxyketone 348 (13mg, 60%, 91% BRSM) thus obtained was used for the next
step without further purification. An analytical sample was obtained by FCC (PE/EtOAc 8:2)
to afford compound 348 as a yellow oil.
To a solution of hydroxyketone 348 (13mg, 0.035mmol) in t-BuOH (2.0mL) was added a solu-
tion of NaIO4 (26mg, 0.12mmol, 2.0 equiv) in aqueous K2CO3 (5%, 1.0mL), and the reaction
mixture was stirred at 50 °C. The reaction mixture was cooled down to 0 °C, and saturated
aqueous Na2SO3 was added until the color disappeared. The aqueous solution was acidified
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to pH 2-3, and extracted with EtOAc. The combined organic phases were washed with brine,
dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc/AcOH 8:2:0.1)
afforded the acid 340 as a yellow oil (13mg, quantitative yield).
One-pot preparation of 340
To a solution of the olefin 347 (20mg, 0.059mmol) in t-BuOH/water/ (3:1, 1.5mL) at 45 °C
was added a solution of KMnO4 (14mg, 0.088mmol, 1.5 equiv), NaIO4 (64mg, 0.30mmol,
5.0 equiv) in 5% aqueous K2CO3 (1.0mL). After 60 seconds of vigorous stirring, the reaction
mixture was poured into an ice-cooled saturated Na2SO3 solution, and extracted with EtOAc.
The combined organic phases were washed with brine, dried over Na2SO4, and concentrated
in vacuo. Purification by FCC (PE/EtOAc/AcOH 8:2:0.1) afforded the acid 340 as a yellow oil
(15mg, 72%, 83% BRSM).
Hydroxyketone 348
1H NMR (400 MHz, CDCl3): δ 7.89 (dd, J = 7.7,1.5 Hz, 1H, C12−H), 7.54 (td, J = 7.7,1.5 Hz,
1H, C10−H), 7.40 (td, J = 7.7,1.4 Hz, 1H, C11−H), 7.32 (dd, J = 7.7,1.4 Hz, 1H, C9−H), 4.76
(quint., J = 1.7 Hz, 1H, C21−H), 4.24 (s, 2H, C22−H), 3.68 (s, 2H, C7−H), 3.22 (t, J = 6.7 Hz, 2H,
C3−H), 2.31-2.22 (m, 4H, C16,18−H), 1.74-1.59 (m, 4H, C17,19−H), 1.52-1.42 (m, 2H, C14−H),
1.39-1.31 (m, 2H, C15−H). OH not observed.
13C NMR (101MHz, CDCl3): δ 210.3 (C
6), 149.6 (C13), 142.7 (C2), 134.4 (C8), 133.1 (C10), 132.5
(C9), 131.8 (C21), 127.7 (C11), 125.0 (C12), 68.2 (C22), 52.1 (C3), 51.5 (C20), 37.5 (C15), 35.3 (C7),
35.1 (C18), 34.1 (C17), 33.6 (C19), 33.1 (C16), 24.4 (C14).
IR: 3445 (br w), 2935 (w), 2852 (w), 2095 (s), 1718 (m), 1525 (s), 1353 (m), 1067 (w),
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H24N4NaO4+: 395.1690; Found: 395.1701.
Rf (PE/EtOAc/AcOH 6/3.5/0.5) = 0.4.
Carboxylic acid 340
1H NMR (400 MHz, CDCl3): δ 7.93 (dd, J = 7.8,1.4 Hz, 1H, C12−H), 7.53 (td, J = 7.8,1.4 Hz,
1H, C10−H), 7.38 (td, J = 7.8,1.4 Hz, 1H, C11−H), 7.32 (d, J = 7.8 Hz, 1H, C9−H), 4.84 (s,
1H, C21−H), 3.68 (s, 2H, C7−H), 3.22 (t, J = 6.7 Hz, 2H, C3−H), 2.32-2.20 (m, 4H, C16,18−H),
1.73-1.64 (m, 4H, C17,19−H), 1.53-1.44 (m, 2H, C14−H), 1.40-1.32 (m, 2H, C15−H). OH not
observed.
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13CNMR (101MHz, CDCl3): δ 178.0 (C
6), 149.6 (C13), 142.5 (C2), 134.5 (C8), 133.0 (C10), 132.4
(C9), 132.0 (C21), 127.6 (C11), 124.9 (C12), 52.2 (C3), 51.5 (C20), 37.2 (C15), 35.2 (C18), 34.9 (C7),
34.5 (C17), 33.7 (C19), 29.5 (C16), 24.4 (C14).
IR: 2923 (w), 2854 (w), 2095 (w), 1704 (s), 1526 (s), 1352 (m), 1298 (w),
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C18H22N4NaO4+: 381.1533; Found: 381.1547.
Rf (PE/EtOAc/AcOH 6/3.5/0.5) = 0.56.
pentafluorophenyl 3-(1-(3-azidopropyl)-3-(2-nitrobenzyl)cyclopent-2-en-1-yl)-
propanoate 355
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To a solution of the acid 340 (20mg, 0.056mmol) and pentafluorophenol (10mg, 0.056mmol,
1.0 equiv) in DCM (2.0mL) was added EDCI (11mg, 0.056mmol, 1.0 equiv) and DIPEA
(9.6mL, 0.067mmol, 1.2 equiv). The reaction mixture was stirred for 2h. Saturated NaHCO3
solution was added and themixture was extractedwith EtOAc. The combined organic phases
were washed with 1M HCl, water, brine, dried over Na2SO4, and concentrated in vacuo. Pu-
rification by FCC (PE/EtOAc 8:2) afforded the ester 355 as a yellow oil (16mg, 54%).
1H NMR (400 MHz, CDCl3): δ 7.90 (dd, J = 1.2,8.1 Hz, 1H, C12−H), 7.54 (td, J = 1.3,7.5 Hz,
1H, C10−H), 7.40 (td, J = 1.4,8.1 Hz, 1H, C11−H), 7.34 (dd, J = 1.2,7.6 Hz, 1H, C9−H), 4.88
(m, 1H, C21−H), 3.70 (s, 2H, C7−H), 3.27-3.22 (m, 2H, C3−H), 2.57-2.51 (m, 2H, C16−H), 2.35-
2.28 (m, 2H, C18−H), 1.82-1.72 (m, 4H, C17,19−H), 1.56-1.44 (m, 2H, C14−H), 1.43-1.33 (m, 2H,
C15−H).
13C NMR (101 MHz, CDCl3): δ 170.1 (C
6), 149.6 (C13), 143.1 (C2), 142.8-136.1 (m, C22–25),
134.4 (C8), 133.0 (C10), 132.4 (C9), 131.5 (C21), 127.7 (C11), 124.9 (C12), 52.1 (C3), 51.6 (C20),
37.3 (C15), 35.2 (C18), 35.0 (C7), 34.5 (C17), 33.6 (C19), 29.3 (C16), 24.4 (C14).
IR: 2926 (w), 2851 (w), 2095 (m), 1786 (w), 1518 (s), 1351 (m), 1088 (m), 993 (s), 733 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C24H21F5N4NaO4+: 547.1375; Found: 547.1375.
Rf (PE/EtOAc/AcOH 8:2) = 0.2.
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methyl 3-(1-(3-azidopropyl)-3-(2-nitrobenzyl)cyclopent-2-en-1-yl)propanoate
349
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340 349
To a solution of the acid 340 (12mg, 0.033mmol) in MeOH (1.0mL) was added TMS-
diazomethane (1M in THF) dropwise until the yellow color persisted and no more bubbling
was observed (approximately 0.050mL, 1.5 equiv). Excess of diazomethane was quenched by
addition of acetic acid (2drops). The reaction mixture was concentrated in vacuo, and the
crude mixture was filtered through a plug of silica gel (PE/EtOAc 8:2) to afford the methyl
ester 349 as a yellow oil (12mg, quantitative yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.6,1.5 Hz, 1H, C12−H), 7.53 (td, J = 7.6,1.5 Hz,
1H, C10−H), 7.37 (td, J = 7.6,1.4 Hz, 1H, C11−H), 7.31 (dd, J = 7.6,1.4 Hz, 1H, C9−H), 4.83 (m,
1H, C21−H), 3.66 (s, 2H, C7−H), 3.63 (s, 3H, C22−H), 3.21 (t, J = 6.8 Hz, 2H, C3−H), 2.25 (t,
J = 7.3 Hz, 2H, C18−H), 2.21-2.15 (m, 2H, C16−H), 1.70-1.62 (m, 4H, C17,19−H), 1.51-1.42 (m,
2H, C14−H), 1.37-1.28 (m, 2H, C15−H).
13C NMR (101MHz, CDCl3): δ 174.6 (C
6), 149.5 (C13), 142.2 (C2), 134.4 (C8), 132.9 (C10), 132.3
(C9), 132.1 (C21), 127.5 (C11), 124.8 (C12), 52.1 (C3), 51.6 (C20), 51.4 (C22), 37.0 (C15), 35.0 (C18),
34.8 (C7), 34.6 (C17), 33.7 (C19), 29.9 (C16), 24.3 (C14).
IR: 2933 (w), 2846 (w), 2095 (s), 1736 (s), 1526 (s), 1436 (w), 1352 (m), 1260 (w).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C19H24N4NaO4+: 395.1690; Found: 395.1688.
Rf (PE/EtOAc/ 8:2) = 0.50.
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(±)-methyl 3-(2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazol-4a-yl)-
propanoate 353
21
NO2
N3
O
O
O3, NaHCO3
DCM, -78 °C
then Me2S, RT
then Zn, HCl
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To a solution of methyl ester 349 (20mg, 0.054mmol) at -78 °C in DCM (0.50mL) was added
NaHCO3 (9.0mg, 0.11mmol, 2.0 equiv). Ozone was bubbled through the solution until the
blue color persisted. Argon was then bubbled through the solution for 15 minutes. Me2S
(excess) was added and the reaction mixture was stirred at RT overnight. Methanol (0.20mL)
was added, followed by HCl (0.5M aqueous solution, 0.11mL, 1.0 equiv) and zinc powder
(0.18 g, 2.7mmol, 50 equiv). The reaction was stirred for 30min. Aqueous NaHCO3 was
added, and the reaction mixture was extracted with EtOAc. The combined organic phases
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc/Et3N 3:5:0.2) afforded the pure product (±)-353 as colourless oils (6.7mg, 40%
yield).
1H NMR (400 MHz, CDCl3): δ 7.84 (br s, 1H, N
1−H), 7.56 (d, J = 7.1 Hz, 1H, C9−H), 7.26
(d, J = 7.1 Hz, 1H, C12−H), 7.10 (td, J = 7.1,1.5 Hz, 1H, C11−H), 7.07 (td, J = 7.1,1.2 Hz, 1H,
C10−H), 3.73 (s, 1H, C21−H), 3.60 (s, 3H, C22−H), 3.03 (br d, J = 12.9 Hz, 1H, C3−H), 2.82-2.69
(m, 3H, C3,18−H), 2.47-2.23 (m, 3H, N4−H, C16−H), 1.87-1.72 (m, 2H, C17,14−H), 1.67-1.36 (m,
6H, C14,15,17,19−H).
13CNMR (101MHz, CDCl3): δ 174.8 (C
6), 136.3 (C13), 133.8 (C2), 127.5 (C8), 121.3 (C11), 119.6
(C10), 117.8 (C9), 112.3 (C7), 110.6 (C12), 56.7 (C21), 51.8 (C22), 46.2 (C3), 34.5 (C20), 34.4 (C15),
32.4 (C17), 28.9 (C16), 24.6 (C19), 22.9 (C14), 20.2 (C18).
IR: 3342 (w), 2929 (m), 2850 (w), 1731 (s), 1436 (m), 1315 (w), 1254 (w), 741 (w),
HRMS: (ESI+) m/z: [M+H]+ Calcd for C19H25N2O2+: 313.1911; Found: 313.1899.
Rf (PE/EtOAc/Et3N 3:5:0.5) = 0.17.
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Diphenylphosphine borane complex 444
BH3·THF
THF, RT
quant.
P
PhPh
H
P
H
1
BH3
6
2
3 4
5
444
Following a reported procedure,229 diphenylphosphine (10g, 54mmol) in THF (0.10mL) was
added dropwise to a solution of BH3·THF in THF (1M, 54mL, 54mmol, 1.0 equiv) at 0 °C. The
mixture was stirred for 30minutes at RT, and then concentrated in vacuo. The oily residue
was dissolved in DCM, filtered and concentrated in vacuo. The crude complex 444 thus ob-
tained was used for the next step without further purification (colorless wax, 11g, quantita-
tive yield). The spectroscopic data of this compound were in accord with those reported in
the literature.229
1H NMR (400 MHz, CDCl3): δ 7.72-7.65 (m, 4H, C
3−H), 7.55-7.50 (m, 2H, C5−H), 7.50-7.43
(m, 4H, C4−H), 6.31 (dq, J = 379.0,7.0 Hz, 1H, P1−H), 1.07 (br q, J = 91.7 Hz, 3H, B6−H).
13C NMR (101 MHz, CDCl3): δ 133.0 (d, J = 9.2 Hz, C3), 131.7 (d, J = 1.7 Hz, C5), 129.11 (d,
J = 10.4 Hz, C4), 126.3 (d, J = 56.3 Hz, C2).
Bromomethyl thioacetate 445
Paraformaldehyde
then PBr3
neat, 80%SH
O
1 2 S
3
Br
O
445
Following a reported procedure,155c a mixture of thioacetic acid (8.0 g, 0.12mol) and
paraformaldehyde (3.6 g) was stirred at 80 °C for 18h. The reaction mixture was cooled down
to 0 °C. Then, PBr3 (21g, 80mmol, 0.70 equiv) was added at 0 °C, and the reaction mixture
was stirred at RT for 15 minutes. The reaction mixture was quenched with ice, and extracted
with Et2O. The combined organic phases were washed with water, brine, dried over Na2SO4
and concentrated in vacuo. Purification by FCC (PE/Et2O/Et3N 3:7) afforded product 445 as
a yellow oil (16 g, 80% yield). The spectroscopic data of this compound were in accord with
those reported in the literature.155c
1H NMR (400MHz, CDCl3): δ 4.69 (s, 2H, C
3−H), 2.38 (s, 3H, C1−H).
229Busacca, C. A.; Farber, E.; Deyoung, J.; Campbell, S.; Gonnella, N. C.; Grinberg, N.; Haddad, N.; Lee, H.; Ma, S.;
Reeves, D.; Shen, S.; Senanayake, C. H.Org. Lett. 2009, 11, 5594–5597
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13C NMR (101MHz, CDCl3): δ 191.9 (C
2), 30.5 (C3), 26.4 (C1).
Rf (Ether) = 0.8.
S-((diphenylphosphino)methyl) ethanethioate borane complex 446
NaH
DMF, RT
56%
S
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444 445 446
Following a reported procedure,155b to a solution of the phosphine borane complex 444
(11 g, 54mmol) in DMF (100mL) at 0 °C was added NaH (60% in mineral oil, 2.2 g, 54mmol,
1.0 equiv). When the gas evolution stopped, the thioesther 445 (9.1 g, 54mmol, 1.0 equiv) was
added. The reactionwas stirred at RT overnight. Saturated aqueous NaHCO3 was added. The
mixture was extracted with EtOAc. The combined organic phases were washed with brine,
dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded
the pure product 446 as a colorless oils (8.7 g, 56% yield). The spectroscopic data of this com-
pound were in accord with those reported in the literature.155b
1H NMR (400 MHz, CDCl3): δ 7.74-7.66 (m, 4H, C
5−H), 7.55-7.42 (m, 6H, C6,7−H), 3.71 (d,
J = 6.8 Hz, 2H, C3−H), 2.25 (s, 3H, C1−H), 1.40-0.40 (m, 3H, B8−H),
13C NMR (101 MHz, CDCl3): δ 193.4 (C
2), 132.6 (d, J = 8.3 Hz, C5), 131.9 (C7), 129.0 (d, J =
9.8 Hz, C6), 127.7 (d, J = 55.6 Hz, C4), 30.2 (C1), 23.9 (d, J = 35.5 Hz, C3),
Rf (PE/EtOAc 8:2) = 0.36.
(diphenylphosphino)methanethiol borane complex 356
NaOH
MeOH, RT
quant.
S
O
HS1
2
P
PPh2·BH3
BH3
7
3
6
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446 356
Following a reported procedure,155a compound 446 (8.7 g, 30mmol) was dissolved in MeOH
(60mL). NaOH (2.4 g, 60mmol, 2.0 equiv) in MeOH (10mL) was added dropwise. The reac-
tion mixture was stirred for 2h, and then concentrated in vacuo. Saturated aqueous NH4Cl
was added. The mixture was extracted with EtOAc. The combined organic phases were
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washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC
(PE/EtOAc 8:2) afforded product 356 as a colorless oil (7.4 g, quantitative yield). The spec-
troscopic data of this compound were in accord with those reported in the literature.155a
1H NMR (400 MHz, CDCl3): δ 7.75-7.67 (m, 4H, C
4−H), 7.57-7.44 (m, 6H, C5,6−H), 3.19 (dd,
J = 8.2,6.1 Hz, 2H, C2−H), 1.88 (ddd, J = 15.5,8.2,6.6 Hz, 1H, S1−H), 1.03 (q, J = 95.6 Hz, 3H,
B7−H),
13C NMR (101MHz, CDCl3): δ 132.7 (d, J = 7.5 Hz, C4), 131.8 (C6), 129.1 (d, J = 10.5 Hz, C5),
127.9 (d, J = 55.9 Hz, C3), 19.8 (d, J = 32.5 Hz, C2),
Rf (PE/EtOAc 8:2) = 0.43.
S-((diphenylphosphino)methyl) 3-(1-(3-azidopropyl)-3-(2-nitrobenzyl)-
cyclopent-2-en-1-yl)propanethioate borane complex 357
NO2
N3
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340 356 357
To a solution of the acid 340 (0.20 g, 0.56mmol) in DCM (10mL) was added compound 356
(0.14 g, 0.56mmol, 1.0 equiv). The solutionwas cooled down to 0 °C. HATU (0.26g, 0.67mmol,
1.2 equiv) andDIPEA (0.12mL, 0.67mmol, 1.2 equiv)were added, and the solutionwas stirred
at RT for 1h. Saturated aqueous NH4Cl was added. The mixture was extracted with EtOAc.
The combined organic phases were washed with NaHCO3, brine, dried over Na2SO4 and con-
centrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded product 357 as a yellow oil
(0.31 g, 91% yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (d, J = 7.8 Hz, 1H, C12−H), 7.73-7.65 (m, 4H, C24−H),
7.53-7.48 (m, 3H, C10,26−H), 7.48-7.41 (m, 4H, C25−H), 7.38 (t, J = 7.8 Hz, 1H, C11−H), 7.30
(d, J = 7.8 Hz, 1H, C9−H), 4.76 (s, 1H, C21−H), 3.69 (d, J = 6.8 Hz, 2H, C22−H), 3.64 (s, 2H,
C7−H), 3.20 (t, J = 6.4 Hz, 2H, C3−H), 2.36-2.29 (m, 2H, C16−H), 2.26-2.17 (m, 2H, C18−H),
1.68-1.54 (m, 2H, C19−H), 1.51-1.45 (m, 2H, C17−H), 1.45-1.37 (m, 2H, C14−H), 1.32-1.23 (m,
2H, C15−H), Broad signals of the BH3 between 0.7 and 1.7 ppmwere lost in the background
13C NMR (101MHz, CDCl3): δ 197.3 (C
6), 149.6 (C13), 142.7 (C2), 132.7 (C8), 133.1 (C10), 132.7
(d, J = 9.4 Hz, C24), 132.4 (C9), 131.9 (d, J = 1.6 Hz, C26), 131.8 (C21), 129.0 (d, J = 10.2 Hz, C25),
127.8 (d, J = 53.5 Hz, C23), 127.6 (C11), 124.9 (C12), 52.1 (C3), 51.3 (C20), 39.7 (C16), 37.2 (C15),
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35.2 (C17), 35.1 (C18), 34.9 (C7), 33.6 (C19), 24.3 (C14), 23.6 (d, J = 35.6 Hz, C22).
IR: 2924 (w), 2852 (w), 2385 (m), 2093 (s), 1697 (m), 1525 (s), 1436 (m), 1351 (m), 1261 (w),
1108 (w), 1058 (m), 741 (s), 703 (s),
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C31H36BN4NaO3PS+: 609.2231; Found: 609.2231.
Rf (PE/EtOAc 6:3) = 0.60.
2-(2-nitrobenzyl)-9-azaspiro[4.7]dodec-1-en-8-one 339
NO2
N3
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THF/H2O, 90 °C
quant.PPh2·BH3
357 339
To a refluxing solution of thioester 357 (0.80 g, 1.4mmol) in THF/H2O (99:1, 150mL) was
added DABCO (0.30g, 2.7mmol, 2.0 equiv). The reaction mixture was stirred at reflux for
24h. The reaction mixture was cooled down to RT, and water was added. The mixture was
extractedwith EtOAc. The combined organic phases were washedwith NaHCO3, brine, dried
over Na2SO4 and concentrated in vacuo. Purification by FCC (EtOAc/MeOH 98:2) afforded
the product 339 as a yellow wax (0.43g, quantitative yield).
1H NMR (400 MHz, CDCl3): δ 7.88 (dd, J = 7.8,1.4 Hz, 1H, C12−H), 7.53 (td, J = 7.8,1.4 Hz,
1H, C10−H), 7.38 (td, J = 7.8,1.2 Hz, 1H, C11−H), 7.32 (dd, J = 7.8,1.2 Hz, 1H, C9−H), 5.70
(m, 1H, C4−H), 5.21 (s, 1H, C21−H), 3.70 (s, 2H, C7−H), 3.29-3.21 (m, 2H, C3−H), 2.40 (t,
J = 6.7 Hz, 2H, C16−H), 2.25-2.17 (m, 2H, C18−H), 1.78-1.68 (m, 4H, C17,19−H), 1.65-1.55 (m,
4H, C14,15−H).
13CNMR (101MHz, CDCl3): δ 178.4 (C
6), 149.7 (C13), 140.9 (C2), 134.5 (C8), 133.8 (C10), 133.0
(C9), 132.3 (C21), 127.6 (C11), 124.9 (C12), 51.1 (C20), 41.9 (C3), 39.5 (C17), 38.3 (C19), 34.9 (C7),
33.5 (C15or18), 33.4 (C15or18), 30.8 (C16), 28.5 (C14).
IR: 3236 (br w), 2928 (m), 2852 (w), 1659 (s), 1525 (s), 1438 (w), 1355 (m), 1193 (w).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C18H23N2O3+: 315.1703; Found: 315.1695.
Rf (EtOAc/MeOH 98:2) = 0.21.
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(±)-16-dehydroxykopsihainanine A 336
O3, Sudan III
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then HCl, MeOH
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To a solution of the lactam 339 (10mg, 0.031mmol) in DCM (0.30mL) was added 0.10mg
of Sudan III. The solution was cooled down to -78 °C and ozone was bubbled through the
reaction mixture until the red color disappeared. Argon was then bubbled through the solu-
tion for 5 minutes, and PPh3 (16mg, 0.062mmol, 2.0 equiv) was added. After 5 minutes, the
reaction was allowed to warm to RT, and stirred for 30 minutes. PtO2 (7.0mg, 0.031mmol,
1.0 equiv) and MeOH (0.30mL) were added, and the flask was flushed with hydrogen. The
mixture was stirred vigorously under H2 atmosphere for 1.5h. The hydrogen was replaced by
argon, andHCl (1M aqueous solution, 60μL, 2.0 equiv) was added. The reactionmixture was
stirred for 1h at 50 °C. Aqueous NaHCO3 was added. The mixture was extracted with EtOAc.
The combined organic phases were washed with brine, dried over Na2SO4 and concentrated
in vacuo. Purification by FCC (PE/EtOAc 3:7) afforded product (±)-336 as a white amorphous
solid (5.5mg, 63% yield).
If Zinc/HCl or TiCl3/NH4OAc were used as reducing agents instead of H2/PtO2, the unstable
side product 361was observed as main product.
Compound 336
1H NMR (400 MHz, CDCl3): δ 7.79 (br s, 1H, C
1−H), 7.69 (d, J = 7.6 Hz, 1H, C9−H), 7.26 (m,
1H, C12−H), 7.12 (td, J = 7.6,0.9 Hz, 1H, C11−H), 7.03 (td, J = 7.6,0.9 Hz, 1H, C10−H), 4.41
(dd, J = 12.9,5.4 Hz, 1H, C3−H), 4.34 (s, 1H, C21−H), 3.15 (td, J = 12.9,3.2 Hz, 1H, C3−H), 3.03
(m, 1H, C18−H), 2.77 (m, 1H, C18−H), 2.10-2.04 (m, 2H, C17−H), 2.00-1.85 (m, 4H, C16,19−H),
1.73-1.67 (m, 2H, C15−H), 1.58-1.47 (m, 2H, C14−H).
13C NMR (101MHz, CDCl3): δ 186.0 (C
6), 136.3 (C13), 133.2 (C2), 125.1 (C8), 121.9 (C11), 120.4
(C9), 119.8 (C10), 111.3 (C7), 110.4 (C12), 64.4 (C21), 53.8 (C3), 40.0 (C15), 37.1 (C20), 35.0 (C17),
34.6 (C19), 27.8 (C16), 22.5 (C14), 19.8 (C18).
IR: 3274 (br w), 2923 (m), 2853 (w), 1655 (s), 1464 (m), 1331 (w), 1244 (w), 1168 (w), 741 (m).
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HRMS: (ESI+) m/z: [M+Na]+ Calcd for C18H20N2NaO+: 303.1468; Found: 303.1456.
Rf (EtOAc/MeOH 2:8) = 0.45.
Compound 361
1H NMR (400 MHz, CDCl3): δ 7.08 (br, s, 1H), 7.48 (d, J = 7.0 Hz, 1H), 7.31 (d, J = 7.0 Hz, 1H),
7.15 (td, J = 7.0,1.4 Hz, 1H), 7.11 (td, J = 7.0,1.4 Hz, 1H), 6.36 (br, s, 1H), 3.60-3.40 (m, 2H),
2.82-2.75 (m, 2H), 2.71 (d, J = 15.3 Hz, 1H), 2.58 (m, 1H), 2.59 (d, J = 15.3 Hz, 1H), 2.48 (m,
1H), 1.98 (m, 1H), 1.92-1.72 (m, 5H), 1.68-1.62 (m, 2H).
Compound 361 proved unstable at RT and fully degraded before 13C NMR analysis and 2D
spectra could be done.
IR: 3380 (br w), 2955 (s), 2924 (s), 2853 (w), 1733 (w), 1647 (m), 1463 (m), 1397 (w), 1016 (w),
749 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C18H22N2NaO+: 305.1624; Found: 305.1629.
Rf (EtOAc/MeOH/Et3N 95:5:0.2) = 0.28
(±)-1-tributyldimethylsilyl-16-dehydroxykopsihainanine A 362
TBSCl
NaH
THF, RT
quant.
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(±)- (±)-336 362
To a solution of (±)-336 (10mg, 0.036mmol) in THF (0.50mL) at 0 °C was added NaH (60% in
mineral oil, 2.9mg, 0.072mmol, 2.0 equiv), followed by TBSCl (11mg, 0.072mmol, 2.0 equiv).
The reaction mixture was stirred at RT for 2h. Aqueous NH4Cl was added. The mixture was
extracted with EtOAc. The combined organic phases were washed with saturated NaHCO3,
water, brine, dried over Na2SO4 and concentrated in vacuo. Purification by FCC (PE/EtOAc
1:1) afforded product (±)-362 as a white amorphous solid (14mg, quantitative yield).
1H NMR (400MHz, CDCl3): δ 7.72 (d, J = 7.8 Hz, 1H, C9−H), 7.48 (d, J = 7.8 Hz, 1H, C12−H),
7.07 (td, J = 7.8,1.4 Hz, 1H, C11−H), 7.02 (t, J = 7.8 Hz, 1H, C10−H), 4.41 (dd, J = 12.8,5.1 Hz,
1H, C3−H), 4.32 (s, 1H, C21−H), 3.15 (td, J = 12.8,3.3 Hz, 1H, C3−H), 2.99 (m, 1H, C18−H),
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2.86 (m, 1H, C18−H), 2.10-2.04 (m, 2H, C17−H), 2.00-1.88 (m, 3H, C16,19−H), 1.79 (ddd, J =
12.9,11.1,6.0 Hz, 1H, C15−H), 1.71-1.64 (m, 2H, C14,15−H), 1.60-1.45 (m, 2H, C14,16−H), 0.91
(s, 9H, C24−H), 0.68 (s, 6H, C22−H).
13C NMR (101MHz, CDCl3): δ 185.9 (C
6), 142.4 (C13), 139.4 (C2), 128.1 (C8), 121.4 (C11), 120.3
(C9), 119.8 (C10), 114.5 (C7), 114.0 (C12), 64.7 (C21), 53.7 (C3), 39.9 (C15), 36.2 (C20), 35.3 (C17),
35.0 (C19), 27.7 (C16), 26.9 (C24), 23.2 (C18), 22.5 (C14), 20.7 (C23), -0.3 (C22).
IR: 2929 (w), 2856 (w), 1677 (m), 1452 (m), 1256 (m), 1131 (w), 988 (w), 898 (w), 823 (s), 730
(s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C24H35N2OSi+: 395.2513; Found: 395.2519.
Rf (EtOAc/MeOH 3:7) = 0.57.
(±)-Kopsihainanine A 6
LDMA
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THF, -78 °C to RT
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(±)- (±)-336 6
To a solution of dimethylamine (2M in THF, 0.20mL, 0.40mmol, 14 equiv) and HMPA
(0.14mL, 0.84mmol, 30 equiv) in THF (1.2mL) at -78 °C was added n-BuLi (1.42M in hexane,
0.24mL, 0.34mmol, 12 equiv). The mixture was stirred at RT for 15min. This mixture was
added dropwise to a solution of (±)-336 (8.0mg, 0.028mmol) in THF (1.2mL) at 0 °C. The re-
action mixture was stirred at RT for 15min. The reaction mixture was cooled down to -78 °C,
and bis(trimethylsilyl) peroxide (0.18mL, 0.88mmol, 30 equiv) was added. The reaction mix-
ture was warmed to RT over 1h. Aqueous NaHCO3 was added. The mixture was extracted
with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4 and
concentrated in vacuo. Purification by preparative TLC (PE/EtOAc 3:7) afforded the pure (±)-
kopsihainanine A 6 as a white amorphous solid (7.5mg, 91% yield). The spectroscopic data
of this compound were in accord with those reported in the literature.144
1H NMR (400 MHz, CDCl3): δ 7.84 (br s, 1H, C
1−H), 7.62 (d, J = 7.8 Hz, 1H, C9−H), 7.27
(m, 1H, C12−H), 7.13 (t, J = 7.8 Hz, 1H, C11−H), 7.04 (t, J = 7.8 Hz, 1H, C10−H), 4.43 (dd,
J = 13.4,5.6 Hz, 1H, C3−H), 4.36 (s, 1H, C21−H), 4.02 (dd, J = 10.6,8.4 Hz, 1H, C16−H), 3.55
(br s, 1H, C16−OH), 3.26 (td, J = 12.9,3.1 Hz, 1H, C3−H), 3.09 (m, 1H, C18−H), 2.78 (dd, J =
17.5,6.5 Hz, 1H, C18−H), 2.38 (dd, J = 14.1,8.8 Hz, 1H, C17−H), 1.99-1.92 (m, 2H, C14,19−H),
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1.82 (ddd, J = 13.7,12.2,6.5 Hz, 1H, C19−H), 1.75-1.68 (m, 2H, C15−H), 1.60 (m, 1H, C14−H),
1.27 (m, 1H, C17−H),
13CNMR (101MHz, CDCl3): δ 186.0 (C
6), 136.4 (C13), 133.2 (C2), 124.8 (C8), 122.2 (C11), 120.0
(C9), 119.9 (C10), 110.6 (C12), 110.0 (C7), 68.9 (C16), 63.9 (C21), 54.0 (C3), 39.6 (C15), 37.8 (C20),
37.5 (C17), 34.7 (C19), 22.0 (C14), 19.8 (C18).
IR: 3394 (br w), 3314 (br w), 2925 (m), 2853 (w), 1660 (s), 1465 (m), 1329 (w), 1223 (w), 1134
(m), 1091 (m), 1037 (w), 736 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C18H20N2NaO2+: 319.1417; Found: 319.1418.
Rf (PE/EtOAc 3:7) = 0.30.
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methyl (E)-3-(3-oxocyclopent-1-en-1-yl)acrylate 384
O
I
Methyl acrylate
Pd(OAc)2 5 mol%
dppp 2.5 mol%
Et3N
DMF, 85 °C
31%
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Following a reported procedure,173 to a solution of 3-iodopentenone172 (1.0 g, 4.8mmol,
1.0 equiv) in DMF (20mL) was added methyl acrylate (1.1mL, 12mmol, 2.5 equiv), Pd(OAc)2
(54mg, 0.24mmol, 5.0mol%), dppp (50mg, 0.12mmol, 2.5mol%) and Et3N (1.3mL,
9.6mmol, 2.0 equiv). The mixture was heated at 85 °C for 16h. The reaction mixture was
allowed to cool down to RT, and quenched with 0.5M HCl. The mixture was extracted with
EtOAc. The combined organic phases were washed with NaHCO3, brine, dried over Na2SO4
and concentrated in vacuo. Purification by FCC (PE/EtOAc 1:1) afforded compound 384 as a
white solid (0.22 g, 31% yield). The spectroscopic data of this compound were in accord with
those reported in the literature.173
1HNMR (400MHz, CDCl3): δ 7.67 (d, J = 15.9 Hz, 1H, C6−H), 6.37-6.30 (m, 2H, C2,7−H), 3.82
(s, 3H, C9−H), 2.81-2.76 (m, 2H, C5−H), 2.56-2.50 (m, 2H, C4−H).
13C NMR (101MHz, CDCl3): δ 208.8 (C
1), 168.3 (C8), 166.2 (C3), 138.6 (C2), 136.1 (C6), 125.0
(C7), 52.3 (C9), 35.1 (C5), 27.0 (C4).
Rf (PE/EtOAc 1:1) = 0.44
dimethylmeso tartrate 386
OsO4
NaClO3
H2O, 50 °C
77%
MeO2C
MeO2C
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Following a reported procedure,230 to a solution of NaClO3 (1.2 g, 11mmol, 1.3 equiv) and
OsO4 (90mg, 0.21mmol, 2.5mol%) in H2O (14mL) was added dropwise dimethyl maleate
230Milas, N. A.; Terry, E. M. J. Am. Chem. Soc. 1925, 47, 1412–1418
209
Chapter 8: Experimental Section
(1.1mL, 8.6mmol). The reactionmixture was stirred at 50 °C overnight. The reactionmixture
was then allowed to cool down. Saturated aqueous Na2S2O3 was added, followed by magne-
sium silicate (1 g). The slurry mixture was filtered. The filtrate was brought to pH 2, and the
solution was extracted with EtOAc. The organic phases were combined, washed with brine,
dried over Na2SO4, and concentrated in vacuo. Purification by recrystallisation (Et2O/PE) af-
forded pure compound 386 as a white solid (1.2 g, 77% yield). The spectroscopic data of this
compound were in accord with those reported in the literature.231
mp = 113.5-114.8 °C (Et2O/PE)
1H NMR (400MHz, CDCl3): δ 4.58 (s, 2H, C
3−H), 3.82 (s, 6H, C1−H), 3.12 (br s, 2H, O3−H),
13C NMR (101MHz, CDCl3): δ 171.53 (C
2), 73.1 (C3), 53.1 (C1).
Rf (EtOAc) = 0.17
dimethyl dioxolanemeso tartrate 387
Me2C(OMe)2
p-TsOH
PhMe, 
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To a solution of dimethyl tartrate 386 (1.0 g, 5.6mmol) in toluene (20mL) was added 2,2-
dimethoxypropane (1.0mL, 8.4mmol, 1.5 equiv) and p-TsOH (96mg, 0.56mmol, 0.10 equiv).
The reaction mixture was then heated to reflux with a Dean-Stark apparatus for 16h. The
reactionmixture was then allowed to cool down, and saturated aqueous NaHCO3 was added.
The mixture was extracted with EtOAc. The organic phases were combined, washed with
brine, dried over Na2SO4, and concentrated in vacuo. The crude compound 387 thus ob-
tained (1.2 g, quantitative yield) was used for the next step without further purification. The
spectroscopic data of this compound were in accord with those reported in the literature.232
1H NMR (400 MHz, CDCl3): δ 4.82 (s, 2H, C
3−H), 3.72 (s, 6H, C1−H), 1.62 (s, 3H, C5or6−H),
1.39 (s, 3H, C5or6−H).
13C NMR (101 MHz, CDCl3): δ 168.7 (C
2), 113.1 (C3), 76.4 (C3), 52.6 (C1), 26.7 (C5or6), 25.8
(C5or6).
Rf (EtOAc) = 0.83
231Dinca, E.; Hartmann, P.; Smrcˇek, J.; Dix, I.; Jones, P. G.; Jahn, U. Eur. J. Org. Chem. 2012, 4461–4482
232de Napoli, L.; Messere, A.; Palomba, D.; Piccialli, V.; Evidente, A.; Piccialli, G. J. Org. Chem. 2000, 65, 3432–3442
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tert-butyl 2-(2-nitrophenyl)acetate 400
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To a solution of 2-(2-nitrophenyl)acetic acid (1.0 g, 5.5mmol) in DCM (20mL) was added
DCC (1.7 g, 8.3mmol, 1.5 equiv), DMAP (0.30g, 0.25mmol, 0.50 equiv) and dry t-BuOH (1.2 g,
17mmol, 3.0 equiv). The reaction mixture was stirred overnight. DCMwas added and the or-
ganic phase was washed with saturated aqueous NH4Cl, NaHCO3, brine, dried over Na2SO4,
and concentrated in vacuo. Purification by FCC (PE/EtOAc 3:1) afforded pure ester 400 as a
yellow oil (0.95 g, 73% yield). The spectroscopic data of this compound were in accord with
those reported in the literature.233
1HNMR (400MHz, CDCl3): δ 8.09 (dd, J = 7.5,1.3 Hz, 1H, C5−H), 7.58 (td, J = 7.5,1.3 Hz, 1H,
C3−H), 7.45 (td, J = 7.5,1.3 Hz, 1H, C4−H), 7.34 (dd, J = 7.5,1.3 Hz, 1H, C2−H), 3.94 (s, 2H,
C7−H), 1.44 (s, 9H, C10−H).
13C NMR (101MHz, CDCl3): δ 169.3 (C
8), 149.0 (C6), 133.5 (C1), 133.4 (C3), 130.5 (C2), 128.5
(C4), 125.3 (C5), 81.9 (C9), 41.1 (C7), 28.1 (C10).
Rf (PE/EtOAc 1:1) = 0.77
tert-butyl 2-bromo 2-(2-nitrophenyl)acetate 402
NBS, (BnO)2
CCl4, 
45%
4
3
2
1
6
5
NO2
7 8
O
O 9 10
NO2
O
O
Br
400 402
Following a reported procedure,192 dibenzoyl peroxide (97mg, 0.40mmol, 0.10 equiv) was
added to a solution of ester 400 (0.95 g, 4.0mmol) and NBS (0.78g, 4.4mmol, 1.1 equiv) in
CCl4 (20mL). The reaction mixture was heated to refluxing temperature for 72h. The reac-
tion mixture was filtered on a plug of Celite. Additional NBS (0.78g, 4.4mmol, 1.1 equiv) and
dibenzoyl peroxide (97mg, 0.40mmol, 0.10 equiv) were added, and the mixture was stirred
for an additional 48h. The mixture was filtered again, and poured into water. The mixture
was extractedwith EtOAc. The organic phases were combined, washed with brine, dried over
233Shi, D. D.; Trigo, F. F.; Semmelhack, M. F.; Wang, S. S.-H. J. Am. Chem. Soc. 2014, 136, 1976–1981
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Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5) afforded pure es-
ter 402 as a yellow oil (0.57 g, 45% yield). The spectroscopic data of this compound were in
accord with those reported in the literature.192
1H NMR (400MHz, CDCl3): δ 8.03-7.98 (m, 2H, C
2,5−H), 7.69 (td, J = 7.7,1.7 Hz, 1H, C4−H),
7.52 (td, J = 7.7,1.7 Hz, 1H, C3−H), 5.96 (s, 1H, C7−H), 1.48 (s, 9H, C10−H).
13C NMR (101MHz, CDCl3): δ 166.7 (C
8), 147.9 (C1), 133.8 (C4), 133.3 (C5), 131.7 (C6), 129.7
(C3), 124.9 (C2), 83.9 (C9), 44.5 (C7), 27.8 (C10).
Rf (PE/EtOAc 9:1) = 0.48
2,3-O-Isopropylidene-D-Erythrolactone 392
1. H2O2, K2CO3
    H2O, then HCl
2. Me2C(OMe)2
    p-TsOH, acetone
70% (2 steps)
1
O
4
O
OH
O
HO
HO
HO
O
2
3
O
O
5
7
6
392
Following a reported procedure,186 to a solution of erythorbic acid (35g, 0.20mol) in H2O
(500mL) at 0 °Cwas slowly addedK2CO3 (42g, 0.40mol, 2.0 equiv). H2O2 (30% inH2O, 45mL,
0.45mol, 2.3 equiv) was then added dropwise over 10min. The reaction mixture was stirred
for 5 minutes before removing the ice bath and heating the mixture to 42 °C. The reaction
mixture was stirred for 30min, and then activated charcoal (8.0 g) was added. The mixture
was stirred at 80 °C for 30min. The hot mixture was filtered through a plug of Celite and acid-
ified to pH 1 with 6M HCl. Concentration in vacuo afforded a pale yellow solid (84g). Ace-
tone (180mL) was added followed by MgSO4 (50g), 2,2-dimethoxypropane (350mL, 2.8mol,
14 equiv) and p-TsOH (0.42g, 2.0mmol, 1.0mol%). The suspension was stirred at RT for
16h. The reaction mixture was cooled down to 0 °C. Et2O (500mL) and triethylamine (62mL,
0.44mol, 2.2 equiv) were added, and the reaction mixture was filtered and concentrated in
vacuo. Purification by FCC (PE/EtOAc 1:1) afforded pure compound 392 as awhite solid (22g,
70% yield). The spectroscopic data of this compound were in accord with those reported in
the literature.186
mp = 66.0-66.5 °C (Et2O/PE)
[α]23D -113.5 (c = 1.11, H2O)
1H NMR (400 MHz, CDCl3): δ 4.88 (m, 1H, C
2−H), 4.74 (d, J = 5.2 Hz, 1H, C3−H), 4.48-4.38
(m, 2H, C1−H), 1.48 (s, 3H, C6or7−H), 1.39 (s, 3H, C6or7−H).
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13CNMR(101MHz,CDCl3): δ 174.3 (C
4), 114.1 (C5), 75.6 (C2), 74.7 (C3), 70.3 (C1), 26.9 (C6or7),
25.8 (C6or7).
Rf (DCM) = 0.39
1,5-bis(dimethyltertbutylsilyl)glycerol 447
OH
HO OH
TBSCl,
Imidazole
THF, RT,
93%
1
OH
2
OSi O Si 4
3
5
447
Following a reported procedure,234 to a solution of glycerol (5.0 g, 54mmol) in THF (100mL)
were added TBSCl (17g, 0.11mol, 2.1 equiv) and imidazole (8.0 g, 0.12mol, 2.2 equiv). The
reaction mixture was stirred overnight at RT. Saturated aqueous NH4Cl was added, and the
mixture was extracted with EtOAc. The organic phases were combined, washed with brine,
dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5) afforded
pure compound 447 as a colorless oil (16 g, 93% yield). The spectroscopic data of this com-
pound were in accord with those reported in the literature.234
1H NMR (400 MHz, CDCl3): δ 3.69-3.58 (m, 5H, C
1,2−H), 0.89 (s, 18H, C5−H), 0.06 (s, 12H,
C3−H).
13C NMR (101MHz, CDCl3): δ 72.0 (C
1), 63.6 (C2), 26.0 (C5), 18.4 (C4), -5.3 (C3).
Rf (PE/EtOAc 9:1) = 0.26
1,3-bis(dimethyltertbutylsilyloxy)-2-iodopropane 403
I2, PPh3
Imidazole
THF, RT,
76%
1
I
2
OSi O Si 4
3
5
OH
OSi O Si
447 403
To a solution of protected alcohol 447 (8.0 g, 25mmol), PPh3 (9.2 g, 35mmol, 1.4 equiv) and
imidazole (2.7 g, 40mmol, 1.6 equiv) in THF (400mL) at 0 °C was added slowly iodine (7.6 g,
30mmol, 1.2 equiv).The reaction mixture was stirred at RT for 3h, and saturated aqueous
Na2S2O3 was added. The reaction mixture was diluted with H2O, and extracted with EtOAc.
234Casida, J. E.; Gulevich, A. G.; Sarpong, R.; Bunnelle, E. M. Bioorg. Med. Chem. 2010, 18, 1942–1947
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The organic phases were combined, washedwith brine, dried overNa2SO4, and concentrated
in vacuo. PurificationbyFCC (PE/EtOAc95:5) affordedpure iodide 403 as a colorless oil (8.2 g,
76% yield).
1H NMR (400 MHz, CDCl3): δ 4.09 (quint, J = 5.7 Hz, 1H, C1−H), 3.85 (d, J = 5.7 Hz, 4H,
C2−H), 0.90 (s, 18H, C5−H), 0.08 (s, 6H, C3−H), 0.07 (s, 6H, C3−H).
13C NMR (101MHz, CDCl3): δ 64.7 (C
2), 36.7 (C1), 26.0 (C5), 18.5 (C4), -5.1 (C3), -5.2 (C3).
IR: 2955 (w), 2929 (w), 2864 (w), 2857 (w), 1472 (w), 1253 (m), 1136 (w), 1074 (m), 833 (s), 775
(s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C15H36IO2Si2+: 431.1293; Found: 431.1285.
Rf (PE/EtOAc 9:1) = 0.74
cyclopent-1-en-1-yl trifluoromethanesulfonate 419
LiHMDS,
PhNTf2
THF, -78 °C
70%
O
3
2
6 5
4O
SO
1O F
F F
419
Following a reported procedure,235 to a solution of cyclopentanone (2.0mL, 23mmol) in
THF (35mL) at -78 °C was added dropwise LiHMDS (0.8M solution in THF, 28mL, 23mmol,
1.0 equiv). The reaction mixture was stirred for 30min. A solution of phenyl triflimide (8.0 g,
23mmol, 1.0 equiv) in THF (35mL)was added and the reactionmixturewas stirred for 30min
before being allowed to warm up to RT. The reaction mixture was then stirred at RT for 18h.
Saturated aqueous NH4Cl was added, and the mixture was extracted with EtOAc. The or-
ganic phases were combined, washed with brine, dried over Na2SO4, and concentrated in
vacuo. Purification by FCC (PE) afforded pure vinyl triflate 419 as a colorless oil (3.4 g, 70%
yield). The spectroscopic data of this compound were in accord with those reported in the
literature.235
1HNMR (400MHz, CDCl3): δ 5.63 (m, 1H, C
3−H), 2.64-2.52 (m, 2H, C6−H), 2.46-2.35 (m, 2H,
C4−H), 2.09-1.97 (m, 2H, C5−H).
13C NMR (101 MHz, CDCl3): δ 149.7 (C
2), 118.7 (q, J = 320.7 Hz (C1), 117.9 (C3), 30.9 (C6),
28.1 (C4), 21.0 (C5).
235Stanislawski, P. C.; Willis, A. C.; Banwell, M. G. Org. Lett. 2006, 8, 2143–2146
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Rf (PE) = 0.45
2,3-bis(tertbutyldimethyl)-1,4-dimethyl-D-tartrate 389
TBSCl
Imidazole
DMF, 60 °C
96%
MeO2C
MeO2C
3
O
O
2
O
O
1
O
O Si
Si 5
4
6
OH
OH
389
Following a reported procedure,178 to a solution of dimetyl D-tartrate (5.0 g, 28mmol) inDMF
(26mL)were added TBSCl (13g, 84mmol, 3.0 equiv) and Imidazole (5.8 g, 84mmol, 3.0 equiv).
The reaction mixture was stirred overnight at 60 °C. Saturated aqueous NH4Cl was added,
and the mixture was extracted with EtOAc. The organic phases were combined, washed with
brine, dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 95:5)
afforded pure compound 389 as a colourless oil (11 g, 96% yield). The spectroscopic data of
this compound were in accord with those reported in the literature.178
[α]22D -48.99 (c = 2.03, CHCl3)
1HNMR (400MHz, CDCl3): δ 4.64 (s, 2H, C
3−H), 3.72 (s, 6H, C1−H), 0.87 (s, 18H, C6−H), 0.08
(s, 6H, C4−H), -0.01 (s, 6H, C4’−H).
13C NMR (101 MHz, CDCl3): δ 171.4 (C
2), 74.9 (C3), 52.0 (C1), 25.7 (C6), 18.4 (C5), -4.6 (C4),
-5.2 (C4’).
Rf (PE/EtOAc 9:1) = 0.60
methyl (4S,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 394
MeONa
MeOH, RT
63%
2
5
O
3
4
O
O
7
8
9
O
O
O
O
O6
HO
1
392 394
To a solution of lactone 392 (1.0 g, 6.3mmol) in MeOH (60mL) was added MeONa (5.4M in
MeOH, 1.2mL, 6.3mmol, 1.0 equiv). The reaction mixture was stirred at RT for 24h. 4M
HCl was added until pH 7, and the solution was concentrated in vacuo. Purification by FCC
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(PE/EtOAc 4:6) afforded pure compound 394 as a colorless oil (0.75 g, 63% yield). The spec-
troscopic data of this compound were in accord with those reported in the literature.236 The
expected (4R,5R) diastereoisomer was not observed.237
1H NMR (400 MHz, CDCl3): δ 4.48 (d, J = 7.8 Hz, 1H, C4−H), 4.25 (dt, J = 7.8,2.9 Hz, 1H,
C3−H), 3.96 (dd, J = 12.7,2.9 Hz, 1H, C2−H), 3.80 (s, 3H, C6−H), 3.76 (dd, J = 12.7,2.9 Hz, 1H,
C2−H), 1.90 (br s, 1H, O1−H), 1.49 (s, 3H, C8or9−H), 1.45 (s, 3H, C8or9−H).
13C NMR (101MHz, CDCl3): δ 171.4 (C
5), 111.5 (C7), 79.2 (C3), 75.0 (C4), 61.9 (C2), 52.7 (C6),
26.9 (C8or9), 25.8 (C8or9).
Rf (PE/EtOAc 2:8) = 0.60
4-(tert-butoxycarbonyl)quinoline 1-oxide 405 and 4-(tert-butoxycarbonyl)-2-
(2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)quinoline 1-oxide
406
Cs2CO3
DMF, 60 °CI
OSi O Si
NO2
CO2t-Bu 7
6
5
4
9
8
N+ 2
1
10
O-
+
7
6
5
4
9
8
N+
2
1
10
O-
+
11O O
12
13
11O O
14
15
O
O
Si
Si
16
17
1812
13
35% 6%
400 403
405 406
To a solution of ester 400 (50mg, 0.21mmol) and iodide 403 (0.10 g, 0.23mmol, 1.1 equiv)
in DMF (1.0mL) was added Cs2CO3 (0.21g, 0.63mmol, 3.0 equiv). The reaction mixture was
stirred at 60 °C overnight. H2O was added, and the mixture was extracted with EtOAc. The
organic phases were combined, washed with brine, dried over Na2SO4, and concentrated in
vacuo. Purification by FCC (PE/EtOAc 9:1) afforded pure compounds 405 as a colorless oil
(18mg, 35% yield) and pure compound 406 as a yellow oil (7.0mg, 6% yield). The spectro-
scopic data of compound 405were in accord with those reported in the literature.238
Compound 405
1H NMR (400MHz, CDCl3): δ 9.02 (d, J = 7.8 Hz, 1H, C5−H), 8.75 (d, J = 7.8 Hz, 1H, C8−H),
8.49 (d, J = 7.2 Hz, 1H, C2−H), 7.89 (d, J = 7.2 Hz, 1H, C1−H), 7.76 (t, J = 7.8 Hz, 1H, C7−H),
236Kothari, A.; Qureshi, M. K. N.; Beck, E. M.; Smith, M. D. Chem. Commun. 2007, 2814–2816
237Gypser, A.; Peterek, M.; Scharf, H.-D. J. Chem. Soc. Perkin Trans. 1 1997, 1013–1016
238Pagar, V. V.; Jadhav, A. M.; Liu, R. S. J. Am. Chem. Soc. 2011, 133, 20728–20731
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7.71 (t, J = 7.8 Hz, 1H, C6−H), 1.65 (s, 9H, C13−H).
13C NMR (101MHz, CDCl3): δ 164.1 (C
11), 142.2 (C4), 134.5 (C2), 130.4 (C7), 130.0 (C6), 128.5
(C10), 126.9 (C5), 125.4 (C9), 124.2 (C1), 119.9 (C8), 83.0 (C12), 28.3 (C13).
Rf (PE/EtOAc 9:1) = 0.10
Compound 406
1H NMR (400MHz, CDCl3): δ 8.98 (d, J = 7.8 Hz, 1H, C6−H), 8.80 (d, J = 7.8 Hz, 1H, C8−H),
7.97 (s, 1H, C1−H), 7.75 (t, J = 7.8 Hz, 1H, C7−H), 7.68 (t, J = 7.8 Hz, 1H, C6−H), 4.16-4.06
(m, 5H, C14,15−H), 1.65 (s, 9H, C13−H), 0.82 (s, 18H, C18−H), 0.01 (s, 6H, C16−H), -0.07 (s, 6H,
C16’−H).
13C NMR (101MHz, CDCl3): δ 164.7 (C
11), 147.1 (C2), 142.3 (C4), 130.1 (C6), 129.0 (C7), 127.0
(C10), 126.7 (C8), 125.4 (C1), 123.6 (C9), 120.0 (C5), 82.7 (C12), 60.1 (C15), 44.6 (C14), 28.4 (C13),
26.0 (C18), 18.3 (C17), -5.4 (C16).
IR: 2934 (w), 2857 (w), 1714 (w), 1251 (m), 1156 (s), 837 (s).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C29H50NO5Si2+: 548.3222; Found: 548.3224.
Rf (PE/EtOAc 9:1) = 0.41
tert-butyl 2-(2-nitrophenyl)-2-oxoacetate 415
1,2-Diiodoethane
Cs2CO3
DMF, RT,
66%
4
3
2
1
6
5
NO2
7
8
O
O 9 10
NO2
O
O
O
400 415
Following a procedure developed in our laboratory, to a solution of ester 400 (1.0 g, 4.2mmol)
in DMF (80mL) were added 1,2-diiodoethane (1.3 g, 4.6mmol, 1.1 equiv) and Cs2CO3 (3.0 g,
11mmol, 2.5 equiv). The reaction mixture was stirred at RT for 4h. H2O was added and the
mixture was extracted with EtOAc. The organic phases were combined, washed with brine,
dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2) afforded
pure compound 415 as a yellow wax (0.70g, 66% yield).
1H NMR (400 MHz, CDCl3): δ 8.17 (d, J = 7.4 Hz, 1H, C2−H), 7.80 (td, J = 7.4,1.4 Hz, 1H,
C4−H), 7.71 (td, J = 7.4,1.4 Hz, 1H, C3−H), 7.63 (dd, J = 7.4,1.4 Hz, 1H, C5−H), 1.50 (s, 9H,
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C10−H).
13C NMR (101MHz, CDCl3): δ 185.0 (C
7), 158.6 (C8), 147.9 (C1), 134.8 (C3), 133.5 (C6), 132.3
(C4), 130.4 (C5), 123.9 (C2), 85.3 (C9), 27.7 (C10).
IR: 2983 (w), 2933 (w), 1755 (m), 1717 (s), 1526 (s), 1372 (m), 1346 (s), 1254 (m), 1210 (s), 1153
(s), 984 (m), 845 (m), 830 (m), 789 (m), 740 (s), 705 (s).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C12H13NNaO5+: 274.0686; Found: 274.0688.
Rf (PE/EtOAc 8:2) = 0.43
2,2-dimethyl-5-(2-nitrobenzylidene)-1,3-dioxane-4,6-dione 418
NO2
O
Meldrum's acid
L-tyrosine
PhMe, 
68%
4
3
2
1
6
5
NO2
7
8 9
13
O
O
O
O10
11 12
418
To a solution of 2-nitrobenzaldehyde (6.0 g, 40mmol) and Meldrum’s acid (5.8 g, 40mmol,
1.0 equiv) in toluene (100mL) was added L-tyrosine (1.5 g, 8.0mmol, 0.20 equiv). The reac-
tion mixture was heated to reflux with a Dean-Stark apparatus for 16h. H2O was added, and
the mixture was extracted with EtOAc. The organic phases were combined, washed with
brine, dried over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 8:2)
afforded pure compound 418 as a yellow solid (7.5 g, 68% yield). The spectroscopic data of
this compound were in accord with those reported in the literature.239
mp= 117.0-118.5 °C (EtOH).
1H NMR (400 MHz, CDCl3): δ 8.78 (s, 1H, C
7−H), 8.29 (d, J = 8.4 Hz, 1H, C2−H), 7.74 (t,
J = 8.4 Hz, 1H, C4−H), 7.64 (t, J = 8.4 Hz, 1H, C3−H), 7.49 (d, J = 8.4 Hz, 1H, C5−H), 1.82 (s,
6H, C11,12−H).
13C NMR (101MHz, CDCl3): δ 161.7 (C
9or13), 159.1 (C9or13), 155.9 (C7), 146.4 (C1), 133.9 (C4),
131.0 (C3), 130.4 (C5), 130.0 (C6), 125.0 (C2), 117.9 (C8), 105.6 (C10), 27.9 (C11), 27.9 (C12).
IR: 2999 (w), 2365 (w), 2338 (w), 1766 (w), 1733 (s), 1522 (s), 1344 (s), 1283 (s), 1198 (s), 1033
(w), 933 (m), 799 (w), 727 (m).
239Le, W.-J.; Lu, H.-F.; Zhou, J.-T.; Cheng, H.-L.; Gao, Y.-H. Tetrahedron Lett. 2013, 54, 5370–5373
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HRMS: (ESI+) m/z: [M+Na]+ Calcd for C13H11NNaO6+: 300.0479; Found: 300.0475.
Rf (PE/EtOAc 7:3) = 0.50
dimethyl 2-(2-nitrobenzylidene)malonate 417
NO2
O
dimethylmalonate
catalyst
neat, 85%
4
3
2
1
6
5
NO2
7
8 911O
O
12
O
O
10
catalyst
NH2+
N
O-O
417
416
Following a reported procedure,200 to a solution of 2-nitrobenzaldehyde (4.0 g, 27mmol) in
dimethyl malonate (3.0mL, 27mmol, 1.0 equiv) was added catalyst 416240 (2.7 g, 14mmol,
0.50 equiv). The reaction mixture was stirred at RT for 16h. H2O was added, and the mixture
was extracted with EtOAc. The organic phases were combined, washed with brine, dried
over Na2SO4, and concentrated in vacuo. Purification by FCC (PE/EtOAc 7:3) afforded pure
compound 417 as a yellow solid (6.0 g, 85% yield). The spectroscopic data of this compound
were in accord with those reported in the literature.200
mp= 67.0-68.2 °C (Toluene / PE).
1H NMR (400MHz, CDCl3): δ 8.23-8.18 (m, 2H, C
2,7−H), 7.65 (t, J = 7.1 Hz, 1H, C4−H), 7.57
(t, J = 7.1 Hz, 1H, C3−H), 7.40 (d, J = 7.1 Hz, 1H, C5−H), 3.87 (s, 3H, C10or12−H), 3.60 (s, 3H,
C10or12−H).
13C NMR (101MHz, CDCl3): δ 165.4 (C
9or11), 163.8 (C9or11), 147.1 (C1), 141.9 (C7), 134.0 (C4),
130.4 (C3), 130.4 (C6), 130.0 (C5), 128.5 (C8), 125.2 (C2), 53.0 (C10or12), 52.6 (C10or12).
IR: 3122 (w), 3005 (w), 2954 (w), 2851 (w), 1718 (s), 1520 (s), 1437 (m), 1341 (s), 1266 (s), 1223
(s), 1070 (s), 977 (m), 939 (m), 843 (m), 793 (m), 744 (s), 697 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C12H11NNaO6+: 288.0479; Found: 288.0483.
Rf (PE/EtOAc 7:3) = 0.35
240Catalyst 416 was prepared by adding dry ice into a solution of piperidine (5.0mL) in Et2O (10mL). The catalyst
precipitated and was filtered off, washed with Et2O and dried.
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2,3-O-Isoheptylidene-D-Erythrolactone 397
1. H2O2, K2CO3
    H2O, then HCl
2. n-Pr2C(OMe)2
    n-Pr2CO
    p-TsOH, EtOAc
62% (2 steps)
2
O1
5
O
OH
O
HO
HO
HO
O
3
4
O
O
6 10
7
8
9
11
12
397
To a solution of 4-heptanone (60mL, 0.43mol) inMeOH (400mL) was added trimethyl ortho-
formate (56mL, 0.52mol, 1.2 equiv) and p-TsOH (0.80g, 4.0mmol, 1.0mol%). A distillation
head was connected to the flask, and the mixture was stirred at 70 °C for 2h, distilling the
methyl formate formed. The reaction mixture was then heated to 100 °C, to distill the MeOH
and the unreacted trimethyl orthoformate. The crude 4,4-dimethoxyheptane thus obtained
was used in the reaction without further purification.
To a solution of erythorbic acid (35g, 0.20mol) in H2O (500mL) at 0 °C was slowly added
K2CO3 (42g, 0.40mol, 2.0 equiv). H2O2 (30% in H2O, 45mL, 0.45mol, 2.3 equiv) was then
added dropwise over 10min. The reaction mixture was stirred for 5 minutes at 0 °C and then
30min at 42 °C. Activated charcoal (8.0 g) was then added. The mixture was stirred at 80 °C
for 30min. The hot mixture was filtered through a plug of Celite and acidified to pH 1 with
6M HCl. Concentration in vacuo afforded a pale yellow solid (84g). AcOEt (180mL) was
added followed by MgSO4 (50g), the freshly prepared 4,4-dimethoxyheptane and p-TsOH
(0.42g, 2.0mmol, 1.0mol%). The suspension was stirred at RT for 16h. The reaction mixture
was cooled down to 0 °C. Et2O (500mL) and triethylamine (62mL, 0.44mol, 2.2 equiv) were
added, and the reaction mixture was filtered and concentrated in vacuo. Purification by FCC
(PE/EtOAc 7:3) afforded pure compound 397 as a colourless oil (27 g, 62% yield).
[α]22D -113.9 (c = 0.49, CHCl3)
1H NMR (400 MHz, CDCl3): δ 4.87 (m, 1H, C
3−H), 4.74 (m, 1H, C4−H), 4.49-4.35 (m, 2H,
C2−H), 1.68-1.55 (m, 4H, C7,10−H), 1.43-1.30 (m, 4H, C8,11−H), 0.97.0.84 (m, 6H, C9,12−H).
13C NMR (101 MHz, CDCl3): δ 174.0 (C
5), 117.8 (C6), 75.8 (C3), 75.0 (C4), 70.5 (C2), 39.7
(C7or10), 39.3 (C7or10), 17.4 (C8or11), 16.6 (C8or11), 14.4 (C9or12), 14.2 (C9or12).
IR: 2961 (m), 2875 (w), 1783 (s), 1466 (w), 1379 (w), 1180 (m), 1111 (w), 1063 (m), 989 (w), 946
(w).
HRMS: (ESI+) m/z: [M+H]+ Calcd for C11H19O4+: 215.1278; Found: 215.1281.
Rf (DCM) = 0.38
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8.6. Experimental Procedures of Chapter 6
methyl (4S,5R)-5-(hydroxymethyl)-2,2-dipropyl-1,3-dioxolane-4-carboxylate 398
MeONa
MeOH, RT
46%, 90% BRSM
2
5
O
3
4
O
O
7
8
11
O
O
O
O nPr
nPr
O6
HO
1
12
13
9
10
397 398
To a solution of lactone 397 (0.86 g, 4.0mmol) in MeOH (40mL) was added MeONa (5.4M
in MeOH, 0.74mL, 4.0mmol, 1.0 equiv). The reaction mixture was stirred at RT for 24h. Sat-
urated aqueous NH4Cl was added, and the mixture was extracted with EtOAc. The organic
phases were combined, washed with brine, dried over Na2SO4, and concentrated in vacuo.
Purification by FCC (PE/EtOAc 7:3) afforded pure compound 398 as a colorless oil (0.45 g,
46% yield, 90% BRSM).
[α]22D -6.7 (c = 0.39, CHCl3)
1H NMR (400 MHz, CDCl3): δ 4.44 (d, J = 8.4 Hz, 1H, C4−H), 4.19 (dt, J = 8.4,3.3 Hz, 1H,
C3−H), 3.97 (dd, J = 12.1,3.3 Hz, 1H, C2−H), 3.80 (s, 3H, C6−H), 3.77 (m, 1H, C2−H), 1.90 (br
s, 1H, C1−H), 1.70-1.62 (m, 4H, C8,11−H), 1.47-1.36 (m, 4H, C9,12−H), 0.92 (t, J = 7.4 Hz, 6H,
C10,13−H).
13C NMR (101MHz, CDCl3): δ 171.2 (C
5), 114.7 (C7), 79.3 (C3), 75.2 (C4), 62.0 (C2), 52.6 (C6),
39.7 (C8or11), 39.7 (C8or11), 17.4 (C9), 16.8 (C12), 14.5 (C10), 14.4 (C13).
IR: 3482 (w), 2960 (m), 2935 (w), 2875 (w), 1758 (m), 1741 (m), 1457 (w), 1438 (w), 1379 (w),
1294 (m), 1197 (m), 1169 (m), 1109 (s), 1050 (m), 957 (m), 907 (m), 840 (m).
HRMS: (ESI+) m/z: [M+Na]+ Calcd for C12H22NaO5+: 269.1359; Found: 269.1358.
Rf (PE/EtOAc 6:4) = 0.50
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